WO1998017810A2 - Multi-functional chimeric hematopoietic receptor agonists - Google Patents

Abstract

Disclosed are novel multi-functional chimeric hematopoietic receptor agonist proteins, DNAs which encode the multi-functional chimeric hematopoietic receptor agonist proteins, methods of making the multi-functional chimeric hematopoietic receptor agonist proteins and methods of using the multi-functional chimeric hematopoietic receptor agonist proteins.

Description

MULTI-FUNCTIONAL CHIMERIC HEMATOPOIETIC RECEPTOR AGONISTS

The present application claims priority under Title 35, United States Code, §119 of United States Provisional application Serial No. 60/029,629, filed October 25, 1996.

Field of the Invention The present invention relates to multi-functional chimeric hematopoietic receptor agonists. These multifunctional chimeric hematopoietic receptor agonists retain one or more activities of individual components of the chimera molecule and may also show improved hematopoietic cell-stimulating activity and/or an improved activity profile which may include reduction of undesirable biological activities associated with individual hematopoietic growth factors and/or have improved physical properties which may include increased solubility, stability and refold efficiency.

Background of the Invention Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells. CSFs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M- CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively, while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. IL- 3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies . U.S. 4,877,729 and U.S. 4,959,455 disclose a gibbon IL-3 cDNA and a deduced human IL-3 DNA sequence and the protein sequences for which they code. The hIL-3 disclosed has serine rather than proline at position 8 in the protein sequence.

International Patent Application (PCT) WO 88/00598 discloses gibbon- and human-like IL-3. The hIL-3 contains a Ser⁸ -> Pro⁸ replacement. Suggestions are made to replace Cys by Ser, thereby breaking the disulfide bridge, and to replace one or more amino acids at the glycosylation sites.

U.S. 4,810,643 discloses a DNA sequence encoding human G-CSF. WO 91/02754 discloses a fusion protein comprised of GM-CSF and IL-3 which has increased biological activity compared to GM-CSF or IL-3 alone. Also disclosed are nonglycosylated IL-3 and GM-CSF analog proteins as components of the multi-functional chimeric hematopoietic receptor agonist.

WO 92/04455 discloses fusion proteins composed of IL-3 fused to a lymphokine selected from the group consisting of IL-3, IL-6, IL-7, IL-9, IL-11, EPO and G- CSF. WO 95/21197 and WO 95/21254 disclose fusion proteins capable of broad multi-functional hematopoietic properties .

GB 2,285,446 relates to the c-mpl ligand ( thrombopoietin) and various forms of thrombopoietin which are shown to influence the replication, differentiation and maturation of megakaryocytes and megakaryocytes progenitors which may be used for the treatment of thrombocytopenia .

EP 675,201 Al relates to the c-mpl ligand (Megakaryocyte growth and development factor (MGDF) , allelic variations of c-mpl ligand and c-mpl ligand attached to water soluble polymers such as polyethylene glycol . WO 95/21920 provides the murine and human c-mpl ligand and polypeptide fragments thereof. The proteins are useful for in vivo and ex vivo therapy for stimulating platelet production. U.S. Patent No. 4,703,008 by Lin, F-K. discloses the a cDNA sequence encoding erythropoietin, methods of production and uses for erythropoietin.

WO 91/05867 discloses analogs of human erythropoietin having a greater number of sites for carbohydrate attachment than human erythropoietin, such as EPO (Asn⁶⁹) , EPO (Asn¹²⁵, Ser¹²⁷) , EPO (Thr¹²⁵) , and EPO

( , _Pro124 , _T,-h!_r125 ,) .

WO 94 /24160 discloses erythropoietin muteins which have enhanced activity, specifically amino acid substitutions at positions 20, 49, 73, 140, 143, 146, 147 and 154.

WO 94/28391 discloses the native flt3 ligand protein sequence and a cDNA sequence encoding the flt3 ligand, methods of expressing flt3 ligand in a host cell transfected with the cDNA and methods of treating patients with a hematopoietic disorder using flt3 ligand.

US Patent No. 5,554,512 is directed to human flt3 ligand as an isolated protein, DNA encoding the flt3 ligand, host cells transfected with cDNAs encoding flt3 ligand and methods for treating patients with flt3 ligand.

WO 94/26891 provides mammalianflt3 ligands, including an isolate that has an insertion of 29 amino acids, and fragments there of.

Rearrangement of Protein Sequences

In evolution, rearrangements of DNA sequences serve an important role in generating a diversity of protein H structure and function. Gene duplication and exon shuffling provide an important mechanism to rapidly generate diversity and thereby provide organisms with a competitive advantage, especially since the basal mutation rate is low (Doolittle, Protein Science 1:191- 200, 1992) .

The development of recombinant DNA methods has made it possible to study the effects of sequence transposition on protein folding, structure and function. The approach used in creating new sequences resembles that of naturally occurring pairs of proteins that are related by linear reorganization of their amino acid sequences (Cunningham, et al . , Proc . Natl . Acad. Sci . U. S. A . 76:3218-3222, 1979; Teather & Erfle, J. Bacteriol . 172: 3837-3841, 1990; Schimming et al . , Eur. J. Biochem . 204: 13-19, 1992; Yamiuchi and Minamikawa, FEBS Let t . 260:127-130, 1991; MacGregor et al . , FEBS Lett . 378:263-266). The first in vitro application of this type of rearrangement to proteins was described by Goldenberg and Creighton (J^". Mol . Biol . 165:407-413,

1983) . A new N-terminus is selected at an internal site (breakpoint) of the original sequence, the new sequence having the same order of amino acids as the original from the breakpoint until it reaches an amino acid that is at or near the original C-terminus. At this point the new sequence is joined, either directly or through an additional portion of sequence (linker), to an amino acid that is at or near the original N-terminus, and the new sequence continues with the same sequence as the original until it reaches a point that is at or near the amino acid that was N-terminal to the breakpoint site of the original sequence, this residue forming the new C- terminus of the chain.

This approach has been applied to proteins which range in size from 58 to 462 amino acids (Goldenberg & Creighton, J. Mol . Biol . 165:407-413, 1983; Li & Coffino, Mol . Cell . Biol . 13:2377-2383, 1993). The proteins examined have represented a broad range of structural classes, including proteins that contain predominantly a-helix (interleukin-4; Kreitman et al . , Cytokine 7:311-318, 1995), b-sheet (interleukin-1; Horlick et al . , Protein Eng. 5:427-431, 1992), or mixtures of the two (yeast phosphoribosyl anthranilate isomerase; Luger et al . , Science 243:206-210, 1989). Broad categories of protein function are represented in these sequence reorganization studies:

Enzymes

T4 lysozyme Zhang et al . , Biochemistry 32:12311-12318, 1993; Zhang et al., Nature Struct . Biol . 1:434-431 (1995)

dihydrofolate Buchwalder et al . , Biochemistry reductase 31:1621-1630, 1994; Protasova et al., Prot . Eng. 7:1373-1377, 1995)

ribonuclease Tl Mullins et al . , J. Am . Chem . Soc . 116:5529-5533, 1994; Garrett et al , Protein Science 5:204-211, 1996)

Bacillus b-glucanse Hahn et al . , Proc . Na tl . Acad. Sci .

U. S. A . 91:10417-10421, 1994)

aspartate Yang & Schachman, Proc . Na tl . Acad . transcarbamoylase Sci . U. S. A . 90:11980-11984, 1993)

phosphoribosyl Luger et al . , Science 243:206-210 anthranilate (1989; Luger et al . , Prot. Eng. isomerase 3:249-258, 1990)

pepsin/pepsinogen Lin et al . , Protein Science 4:159-

166, 1995) <β glyceraldehyde-3- Vignais et al . , Protein Science phosphate dehydro- 4:994-1000, 1995) genase

ornithine Li & Coffino, Mol . Cell . Biol decarboxylase 13:2377-2383, 1993)

yeast Ritco-Vonsovici et al . , Biochemistry phosphoglycerate 34:16543-16551, 1995) dehydrogenase

Enzyme Inhibitor

basic pancreatic Goldenberg & Creighton, J. Mol . trypsin inhibitor Biol . 165:407-413, 1983)

Cytokines

interleukin-lb Horlick et al . , Protein Eng. 5:427- 431, 1992)

interleukin-4 Kreitman et al . , Cytokine 7:311- 318, 1995)

Tyrosine Kinase

Recognition Domain

a-spectrin SH3 Viguera, et al . , J. domain Mol . Biol . 247:670-681, 1995]

Transmembrane Protein

omp A Koebnik & Kramer, J. Mol . Biol . 250:617-626, 1995)

Chimeric Protein interleukin-4— Kreitman et al . , Proc . Natl . Acad. Pseudomonas Sci . U. S. A . 91:6889-6893, 1994). exotoxin

The results of these studies have been highly variable. In many cases substantially lower activity, solubility or thermodynamic stability were observed ( E. coli dihydrofolate reductase, aspartate transcarbamoylase, phosphoribosyl anthranilate isomerase, glyceraldehyde-3 -phosphate dehydrogenase, ornithine decarboxylase, omp A, yeast phosphoglycerate dehydrogenase). In other cases, the sequence rearranged protein appeared to have many nearly identical properties as its natural counterpart (basic pancreatic trypsin inhibitor, T4 lysozyme, ribonuclease Tl, Bacillus b-glucanase, interleukin-lb, a-spectrin SH3 domain, pepsinogen, interleukin-4). In exceptional cases, an unexpected improvement over some properties of the natural sequence was observed, e.g., the solubility and refolding rate for rearranged a-spectrin SH3 domain sequences, and the receptor affinity and anti-tumor activity of transposed interleukin-4—Pseudomonas exotoxin fusion molecule (Kreitman et al . , Proc . Natl . Acad. Sci . U. S. A . 91:6889-6893, 1994; Kreitman et al . , Cancer Res . 55:3357-3363, 1995).

The primary motivation for these types of studies has been to study the role of short-range and long-range interactions in protein folding and stability. Sequence rearrangements of this type convert a subset of interactions that are long-range in the original sequence into short-range interactions in the new sequence, and vice versa. The fact that many of these sequence rearrangements are able to attain a conformation with at least some activity is persuasive evidence that protein folding occurs by multiple folding pathways (Viguera, et al . , J^". Mol . Biol . 247:670-681, 1995) . In the case of the SH3 domain of a-spectrin, choosing new termini at locations that corresponded to b-hairpin turns resulted in proteins with slightly less stability, but which were nevertheless able to fold.

The positions of the internal breakpoints used in the studies cited here are found exclusively on the surface of proteins, and are distributed throughout the linear sequence without any obvious bias towards the ends or the middle (the variation in the relative distance from the original N-terminus to the breakpoint is ca . 10 to 80% of the total sequence length) . The linkers connecting the original N- and C-termini in these studies have ranged from 0 to 9 residues. In one case (Yang & Schachman, Proc . Na tl . Acad . Sci . U. S . A . 90:11980-11984, 1993), a portion of sequence has been deleted from the original C-terminal segment, and the connection made from the truncated C-terminus to the original N-terminus. Flexible hydrophilic residues such as Gly and Ser are frequently used in the linkers. Viguera, et al.(J. Mol . Biol . 247:670-681, 1995) compared joining the original N- and C- termini with 3- or 4-residue linkers; the 3 -residue linker was less thermodynamically stable. Protasova et al . ( Protein Eng. 7:1373-1377, 1994) used 3- or 5-residue linkers in connecting the original N-termini of E. coli dihydrofolate reductase; only the 3 -residue linker produced protein in good yield.

3

Summary of the Invention

A hematopoietic protein comprising; an amino acid sequence of the formula:

^R1 ~ ^L1^{- R}2 ' ^R2~^L1 ~^R1, ^R1^_R2 , °^{r R}2 ^{_ R}1

wherein R and R₂ are independently selected from the group consisting of;

(I) A human EPO receptor agonist polypeptide, comprising a modified EPO amino acid sequence of the Formula:

AlaProProArgLeuIleCysAspSerArgValLeuGluArgTyrLeuLeuGluAlaLys

10 20

GluAlaGluAsnlleThrThrGlyCysAlaGluHisCysSerLeuAsnGluAsnlleThr

30 40

ValProAspThrLysValAsnPheTyrAlaTrpLysArgMetGluValGlyGlnGlnAla

50 60

ValGluValTrpGlnGly euAlaLeuLeuSerGluAlaVal euArgGlyGlnAlaLeu 70 ^' 80

LeuValAsnSerSerGlnProTrpGluProLeuGlnLeuHisValAsp ysAlaValSer

90 100

GlyLeuArgSerLeuThrThrLeu euArgAlaLeuGlyAlaGlnLysGluAlalleSer

110 120

ProProAspAlaAlaSerAlaAlaProLeuArgThrlleThrAlaAspThrPheArgLys

130 140

LeuPheArgValTyrSerAsnPheLeuArgGly ys euLys euTyrThrGlyGl Ala

150 160

CysArgThrGlyAspArg SEQ ID NO: 464 166

wherein optionally 1-6 amino acids from the N-terminus and 1-5 from the C-terminus can be deleted from said EPO receptor agonist polypeptide; wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the

N-terminus to the C-terminus and having new C- and N- termini at amino acids;

23 -24 47-48 109-110 24-25 48-49 110-111 25-26 49-50 111-112 26-27 50-51 112-113 27 -28 51-52 113-114 28-29 52-53 114-115 29-30 53-54 115-116 30-31 54-55 116-117 31-32 55-56 117-118 32 -33 56-57 118-119 33 -34 57-58 119-120 34-35 77-78 120-121 35 -36 78-79 121-122 36 -37 79-80 122-123 37 -38 80-81 123-124 38-39 81-82 124-125 39 -40 82-83 125-126 40 -41 84-85 126-127 41-42 85-86 127-128 42 -43 86-87 128-129 43 -44 87-88 129-130 44-45 88-89 130-131 45-46 108-109 131-132 46-47 respectively; and

(II) A human stem cell factor receptor agonist polypeptide, comprising a modified stem cell factor amino acid sequence of the Formula: //

GluGlylleCysArgAsnArgValThrAsnAsnValLysAspValThr ysLeuValAla

10 20

AsnLeuProLysAspTyrMetlleThrLeuLysTyrValProGlyMetAspValLeuPro 30 40

SerHisCysTrpIleSerGluMetValValGln euSerAspSerLeuThrAspLeuLeu

50 60

AspLysPheSerAsnlleSerGluGlyLeuSerAsnTyrSerllelleAspLys euVal

70 80

AsnlleValAspAspLeuValGluCysValLysGluAsnSerSer ysAspLeuLysLys

90 100

SerPheLysSerProGluProArg euPheThrProGluGluPhePheArgllePheAsn

110 120

ArgSerlleAspAlaPheLysAspPheValValAlaSerGluThrSerAspCysValVal 130 140

SerSerThrLeuSerProGluLysAspSerArgValSerValThr ysProPheMetLeu

150 160 ProProValAlaAla SEQ ID NO: 465

165

wherein optionally 1-23 amino acids can be deleted from the C-terminus of said stem cell factor receptor agonist polypeptide;

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the

N-terminus to the C-terminus and having new C- and N- termini at amino acids;

23 -24 39 -40 96-97

24-25 40 -41 97 -98

25-26 64-65 98-99

26-27 65-66 99-100

27 -28 66-67 100-101 28-29 67-68 101-102 29-30 68-69 102-103 30-31 69-70 103-104 31-32 70-71 104-105 32-33 89-90 105-106 33-34 90-91 106-107 34-35 91-92 107-108 35-36 92-93 108-109 36-37 93-94 109-110 37-38 94-95 110-111 38-39 95-96 respectively; and

(III) A human flt-3 receptor agonist polypeptide, comprising a modified flt-3 ligand amino acid sequence of the Formula:

ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg

10 20

Glu euSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp

30 40

GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg eu

50 60

LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis

70 80

PheValThr ysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 90 100

IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu ysProTrpIleThr

110 120

ArgGlnAsnPheSerArgCysLeuGlu euGlnCysGlnProAspSerSerThr eu

130 SEQ ID NO:466

wherein 1-7 amino acids are optionally deleted from the C-terminus of said flt-3 receptor agonist polypeptide; β wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the

N-terminus to the C-terminus and having new C- and N- termini at amino acids;

28 -29 42 -43 93-94

29-30 64-65 94-95

30-31 65 -66 95-96

31-32 66- 67 96-97

32 -33 86-87 97-98

34 -35 87 -88 98-99

36-37 88-89 99-100

37 -38 89 -90 100-101

38-39 90 -91 101-102

39 -40 91-92 102-103

40 -41 92 -93 respectively; and

41-42

(IV) A polypeptide comprising; a modified human G- CSF amino acid sequence of the formula:

1 10

Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser Xaa

20 Leu Leu Xaa Xaa Xaa Glu Gin Val Xaa Lys Xaa Gin Gly Xaa Gly

30 40

Ala Xaa Leu Gin Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa

50

Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly lie Pro Trp

60 70

Ala Pro Leu Ser Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly

80 Xaa Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

90 100 Leu Gin Ala Leu Glu Gly lie Ser Pro Glu Leu Gly Pro Thr Leu

110 Xaa Thr Leu Gin Xaa Asp Val Ala Asp Phe Ala Xaa Thr lie Trp m

120 130

Gin Gin Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gin Pro Thr

140

Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa Gin Xaa Xaa Ala

150 160

Gly Gly Val Leu Val Ala Ser Xaa Leu Gin Xaa Phe Leu Xaa Xaa

170 Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gin Pro SEQ ID NO: 858

wherein

Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly;

Xaa at position 2 is Pro or Leu;

Xaa at position 3 is Leu, Arg, Tyr or Ser;

Xaa at position 13 is Phe, Ser, His, Thr or Pro; Xaa at position 16 is Lys, Pro, Ser, Thr or His;

Xaa at position 17 is Cys, Ser, Gly, Ala, lie, Tyr or Arg;

Xaa at position 18 is Leu, Thr, Pro, His, lie or Cys;

Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala;

Xaa at position 24 is lie, Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly;

Xaa at position 30 is Ala, lie, Leu or Gly;

Xaa at position 34 is Lys or Ser;

Xaa at position 36 is Cys or Ser;

Xaa at position 42 is Cys or Ser; Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu;

Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin, or Thr;

Xaa at position 46 is Glu, Arg, Phe, Arg, lie or Ala; Xaa at position 47 is Leu or Thr;

Xaa at position 49 is Leu, Phe, Arg or Ser;

Xaa at position 50 is Leu, lie, His, Pro or Tyr;

Xaa at position 54 is Leu or His;

Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gin, Lys, Leu or Cys;

Xaa at position 70 is Gin, Pro, Leu, Arg or Ser;

Xaa at position 74 is Cys or Ser;

Xaa at position 104 is Asp, Gly or Val;

Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gin or Gly; Xaa at position 115 is Thr, His, Leu or Ala; Xaa at position 120 is Gin, Gly, Arg, Lys or His Xaa at position 123 is Glu, Arg, Phe or Thr

Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gin or Glu; Xaa at position 146 is Arg or Gin; Xaa at position 147 is Arg or Gin;

Xaa at position 156 is His, Gly or Ser;

Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa at position 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly, Arg or Ala; Xaa at position 169 is Arg, Ser, Leu, Arg or Cys; Xaa at position 170 is His, Arg or Ser;

wherein optionally 1-11 amino acids from the N-terminus and 1-5 from the C-terminus can optionally be deleted from said modified human G-CSF amino acid sequence; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the

N-terminus to the C-terminus and having new C- and N- termini at amino acids;

38-39 62-63 123-124

39-40 63-64 124-125

40-41 64-65 125-126

41-42 65-66 126-127

42-43 66-67 128-129

43-44 67-68 128-129

45-46 68-69 129-130

48-49 69-70 130-131

49-50 70-71 131-132

52-53 71-72 132-133

53-54 91-92 133-134

54-55 92-93 134-135

55-56 93-94 135-136

56-57 94-95 136-137

57-58 95-96 137-138

58-59 96-97 138-139

59-60 97-98 139-140 %

60 -61 98-99 140-141 61-62 99 -100 141-142 or 142 -143 respectively;

(V) A polypeptide comprising ; a modified human IL-3 amino acid sequence of the formula :

Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa

35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100 105

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

110 115 120

Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala lie Phe SEQ ID NO: 859 125 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg;

Xaa at position 18 is Asn, His, Leu, lie, Phe, Arg, or Gin;

Xaa at position 19 is Met, Phe, lie, Arg, Gly, Ala, or Cys;

Xaa at position 20 is lie, Cys, Gin, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn,

Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin,

Leu, Val or Gly; Xaa at position 23 is lie, Val, Ala, Gly, Trp, Lys, Phe,

Leu, Ser, or Arg;

Xaa at position 24 is lie, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro, or Ala; Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp;

Xaa at position 29 is Gin, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leu, or Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gin;

Xaa at position 32 is Leu, Val, Arg, Gin, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gin, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, lie or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val; Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or lie; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu,

Val, Glu, Phe, Tyr, lie, Met or Ala;

Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp,

Glu, Asn, Gin, Ala or Pro;

Xaa at position 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Lys,

Trp, Asp, Asn, Arg, Ser, Ala, lie, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin,

Lys, His, Ala, Tyr, lie, Val or Gly;

Xaa at position 47 is lie, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, lie. His, Phe, Glu,

Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser,

Ala, lie, Val, His, Phe, Met or Gin;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr; Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or

Met;

Xaa at position 54 is Arg, Asp, lie, Ser, Val, Thr, Gin, Asn,

Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly; Xaa at position 56 is Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 57 is Asn or Gly; Xaa at position 58 is Leu, Ser, Asp, Arg, Gin, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala Ser, Pro Tyr Asn, or Thr; Xaa at position 61 is Phe Asn, Glu Pro Lys, Arg, or Ser; Xaa at position 62 is Asn His, Val Arg Pro, Thr, Asp, or lie; Xaa at position 63 is Arg Tyr, Trp Lys Ser, His, Pro, or Val; Xaa at position 64 is Ala Asn, Pro Ser or Lys ; Xaa at position 65 is Val Thr, Pro His Leu, Phe , or Ser ; Xaa at position 66 is Lys lie, Arg Val Asn, Glu, or Ser ; Xaa at position 67 is Ser Ala, Phe Val Gly, Asn, He, Pro, or

His;

Xaa at position 68 is Leu Val, Trp Ser He, Phe, Thr, or His; Xaa at position 69 is Gin Ala, Pro Thr Glu, Arg, Trp, Gly, or

Leu;

Xaa at position 70 is Asn Leu, Val Trp Pro, or Ala; Xaa at position 71 is Ala Met, Leu Pro Arg, Glu, Thr, Gin,

Trp, or Asn;

Xaa at position 72 is Ser Glu, Met Ala, His, Asn, Arg, or Asp; Xaa at position 73 is Ala Glu, Asp Leu, Ser, Gly, Thr, or Arg; Xaa at position 74 is lie , Met, Thr , Pro, Arg, Gly, Ala; Xaa at position 75 is Glu Lys , Gly Asp, Pro, Trp, Arg, Ser,

Gin, or Leu;

Xaa at position 76 is Ser Val, Ala Asn Trp, Glu, Pro, Gly, or

Asp;

Xaa at position 77 is lie Ser, Arg Thr or Leu; Xaa at position 78 is Leu Ala, Ser Glu Phe, Gly, or Arg; Xaa at position 79 is Lys Thr , Asn Met Arg, He, Gly, or Asp; Xaa at position 80 is Asn Trp, Val Gly Thr, Leu, Glu, or Arg; Xaa at position 81 is Leu Gin, Gly Ala Trp, Arg, Val, or Lys; Xaa at position 82 is Leu Gin, Lys Trp Arg, Asp, Glu, Asn,

His, Thr, Ser, Ala, Tyr , Phe , He, Met or Val;

Xaa at position 83 is Pro Ala, Thr Trp Arg, or Met; Xaa at position 84 is Cys Glu, Gly Arg Met, or Val; Xaa at position 85 is Leu Asn, Val or Gin; Xaa at position 86 is Pro Cys , Arg Ala or Lys ; Xaa at position 87 is Leu Ser, Trp or Gly; Xaa at position 88 is Ala Lys , Arg Val or Trp; Xaa at position 89 is Thr Asp, Cys Leu Val, Glu, His, Asn, or

Ser;

Xaa at position 90 is Ala Pro, Ser Thr Gly, Asp, He, or Met; Xaa at position 91 is Ala Pro, Ser Thr Phe, Leu, Asp, or His; Xaa at position 92 is Pro Phe , Arg Ser Lys, His, Ala, Gly, He or Leu ; 13

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gin, Lys, His,

Ala, or Pro; Xaa at position 95 is His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, He, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, He, or Thr; Xaa at position 97 is He, Val, Lys, Ala, or Asn; Xaa at position 98 is His, He, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is He, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gin, or

Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu, or Gin;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, He, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gin, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu,

Ser, or Trp; Xaa at position 111 is Leu, He, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or lie; Xaa at position 117 is Thr, Ser, Asn, He, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin;

Xaa at position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His,

He, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu; wherein from 1 to 14 amino acids can optionally be deleted from the N-terminus and/or from 1 to 15 amino acids can optionally be deleted from the C-terminus of said modified human IL-3 amino acid sequence; wherein from 0 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 ; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) , capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids;

26-27 49-50 83-84

27-28 50-51 84-85

28-29 51-52 85-86

29-30 52-53 86-87

30-31 53-54 87-88

31-32 54-55 88-89

32-33 64-65 89-90

33-34 65-66 90-91

34-35 66-67 91-92

35-36 67-68 92-93

36-37 68-69 97-98

37-38 69-70 98-99

38-39 70-71 99-100

39-40 71-72 100-101

40-41 72-73 101-102

41-42 82-83 102-103 or 103-104 respectively;

(VI) A polypeptide comprising; a modified human c- mpl ligand amino acid sequence of the formula:

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer 1 5 10 15 2\

HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro 20 25 30 35

ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu 40 45 50 55

ThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla 60 65 70 75

AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly 80 85 90 95

GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa 100 105 110

XaaGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis 115 120 125 130

LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal 135 140 145 150

Arg SEQ ID NO: 860 153

wherein;

Xaa at position 112 is deleted or Leu, Ala, Val, lie,

Pro, Phe, Trp, or Met;

Xaa at position 113 is deleted or Pro, Phe, Ala, Val, Leu, lie, Trp, or Met;

Xaa at position 114 is deleted or Pro, Phe, Ala, Val, Leu, lie, Trp, or Met;

Xaa at position 115 is deleted or Gin, Gly, Ser, Thr, Tyr, or Asn; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

26-27 51-52 108-109 21

27-28 52-53 109-110

28-29 53-54 110-111

29-30 54-55 111-112

30-31 55-56 112-113

32-33 56-57 113-114

33-34 57-58 114-115

34-35 58-59 115-116

36-37 59-60 116-117

37-38 78-79 117-118

38-39 79-80 118-119

40-41 80-81 119-120

41-42 81-82 120-121

42-43 82-83 121-122

43-44 83-84 122-123

44-45 84-85 123-124

46-47 85-86 124-125

47-48 86-87 125-126

48-49 87-88 126-127

50-51 88-89 or 127-128 respectively;

(VII) A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula:

Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 A3

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100 105

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

110 115 120

Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala He Phe SEQ ID NO: 859 125 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg; Xaa at position 18 is Asn, His, Leu, He, Phe, Arg, or Gin;

Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala, or Cys;

Xaa at position 20 is He, Cys, Gin, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser or Val; Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val or Gly;

Xaa at position 23 is He, Val, Ala, Gly, Trp, Lys, Phe,

Leu, Ser, or Arg;

Xaa at position 24 is He, Gly, Val, Arg, Ser, Phe, or Leu; Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp;

Xaa at position 29 is Gin, Asn, Leu, Pro, Arg, or Val; Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leu, or Lys ;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gin;

Xaa at position 32 is Leu, Val, Arg, Gin, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gin, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, He or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val;

Xaa at position 36 is Asp, Leu, or Val; Xaa at position 37 is Phe, Ser, Pro, Trp, or lie; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Ά

Gin, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp,

Glu, Asn, Gin, Ala or Pro;

Xaa at position 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin,

Lys, His, Ala, Tyr, He, Val or Gly;

Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser,

Ala, He, Val, His, Phe, Met or Gin;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or

Met;

Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gin, Asn,

Lys, His, Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gin, Glu, Arg, His,

Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gin, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or lie;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, He, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro, or

His; Xaa at position 68 is Leu, Val, Trp, Ser, He, Phe, Thr, or His;

Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or

Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin, or Leu; Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or

Asp;

Xaa at position 77 is He, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gin, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn,

His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gin;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly; Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or

Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu ,- Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gin, Lys, His,

Ala, or Pro; Xaa at position 95 is His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn,

Lys, Ser, Ala, Trp, Phe, He, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, He, or Thr; Xaa at position 97 is He, Val, Lys, Ala, or Asn; Xaa at position 98 is His, He, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is He, Leu, Arg, Asp, Val, Pro, Gin,

Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gin, or

Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val,

Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu, or Gin; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr,

Leu, Lys, He, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gin, His, Ser, Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu,

Ser, or Trp;

Xaa at position 111 is Leu, He, Arg, Asp, or Met; Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,

Lys, Leu, He, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,

Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or lie;

Xaa at position 117 is Thr, Ser, Asn, He, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin;

Xaa at position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His,

He, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein from 1 to 14 amino acids can optionally be deleted from the N-terminus and/or from 1 to 15 amino acids can optionally be deleted from the C-terminus of said modified human IL-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 ; and

(VIII) a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin; _.

and wherein L_x is a linker capable of linking R_λ to R₂;

with the proviso that at least R₁ or R₂ is selected from the polypeptide of formula (I) , (II), or (III); and ϊ said hematopoietic protein can optionally be immediately preceded by (methionine^-1) , (alanine^-1) or (methionine^-2, alanine^-1) .

The more preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide (I) above are; 23-24, 24-25, 25-26, 27-28, 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 40-41, 41-42, 42-43, 52-53, 53-54, 54-55, 55-56, 77-78, 78-79, 79-80, 80-81, 81-82, 82-83 83 - - 84 , 84 - 85 , 85-86, 86-87, 109-110, 110-111, 110-111, 111 - - 112 , 112 - 113, 113-114, 114-115, 115-116, 116-117, 117 - - 118 , 118 - 119, 119-120, 120-121, 121-122, 122-123, 123 - - 124 , 124 - 125, 125-126, 126-127, 127-128, 128-129, 129 - - 130 , 130 - 131, and 131-132.

The most preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide (I) above are; 23-24, 24-25, 31-32, 32-33, 37-38, 38-39, 82-83, 83-84, 85-86, 86-87, 87-88, 125-126, 126-127 and 131-132.

The EPO receptor agonists of the present invention may contain amino acid substitutions, such as those disclosed in WO 94/24160 or one or more of the

24 83 126 glycosylation sites at Asn , Asn , and Asn are changed to other amino acids such as but not limited to Asp or Glu, deletions and/or insertions. It is also intended that the EPO receptor agonists of the present invention may also have amino acid deletions at either/or both the N- and C- termini of the original protein and or deletions from the new N- and/or C- termini of the sequence rearranged proteins in the formulas shown above.

The more preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide 21

(II) above are; 23-24, 24-25, 25-26, 33-34, 34-35, 35- 36, 36-37, 38-39, 39-40, 40-41, 64-65, 65-66, 66-67, 67- 68, 68-69, 69-70, 70-71, 89-90, 90-91, 91-92, 9-93, 93- 94, 94-95, 95-96, 96-97, 97-98, 98-99, 99-100, 100-101, 101-102, 102-103, 103-104, 104-105 and 105-106 respectively.

The most preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide (II) above are; 64-65, 65-66, 92-93 and 93-94 respectively .

The more preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide (III) above are; 36-37, 37-38, 39-40, 41-42, 42-43, 64- 65, 65-66, 66-67, 86-87, 87-88, 88-89, 89-90, 90-91, 91- 92, 92-93, 93-94, 94-95, 95,-96, 96-97, 97-98, 98-99, 99-100 and 100-101

The most preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide

(III) above are; 39-40, 65-66, 89-90, 99-100 and 100- 101.

The more preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide

(IV) above are; 38-39, 39-40, 40-41, 41-42, 48-49, 53- 54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 60-61, 61- 62, 62-63, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 96- 97, 125-126, 126-127, 127-128, 128-129, 129-130, 130- 131, 131-132, 132-133, 133-134, 134-135, 135-136, 136- 137, 137-138, 138-139, 139-140, 140-141 and 141-142.

The most preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide

(IV) above are; 38-39, 48-49, 96-97, 125-126, 132-133 and 141-142. The more preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide (V) above are; 28-29, 29-30, 30-31, 31-32, 32-33, 33-34, 34-35, 35-36, 36-37, 37-38, 38-39, 39-40, 66-67, 67-68, 68-69, 69-70, 70-71, 84-85, 85-86, 86-87, 87-88, 88-89, 89-90, 90-91, 98-99, 99-100, 100-101 and 101-102.

The most preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide

(V) above are; 34-35, 69-70 and 90-91.

The more preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide (VI) above are; 80-81, 81-82, 82-83, 83-84, 84-85, 85- 86, 86-87, 108-109, 109-110, 110-111, 111-112, 112-113, 113-114, 114-115, 115-116, 116-117, 117-118, 118-119, 119-120, 120-121, 121-122, 122-123, 123-124, 124-125, 125-126 and 126-127.

The most preferred breakpoints at which new C- terminus and N-terminus can be made in the polypeptide

(VI) above are; 81-82, 108-109, 115-116, 119-120, 122- 123 and 125-126.

The multi-functional receptor agonist of the present invention can also be represented by the following formulas:

(T¹) _a- (L -X¹- (L) _C-X²- (L²)_d- (T²)_e or X¹-(L)_c-X²-(L)-Y¹-(L)_c-Y²

in which: X¹ is a peptide comprising an amino acid sequence corresponding to the sequence of residues n+1 through J of the original protein having amino acids residues 3° numbered sequentially 1 through J with an amino terminus at residue 1;

L is an optional linker;

X² is a peptide comprising an amino acid sequence of residues 1 through n of the original protein;

Y¹ is a peptide comprising an amino acid sequence corresponding to the sequence of residues n=l through K of the original protein having amino acids residues numbered sequentially 1 through K with an amino terminus at residue 1;

Y² is a peptide comprising an amino acid sequence of residues 1 through n of the original protein;

L¹ and L² are optional peptide spacers : n is an integer ranging from 1 to J-l; b, c, and d are each independently 0 or 1 ; a and e are either 0 or 1 , provided that both a and e cannot both be 0 ; and

T¹ and T² are proteins .

The multi-functional chimeric hematopoietic receptor agonists of the present invention may contain amino acid substitutions, deletions and/or insertions in the individual protein components of the chimera molecule. It is also intended that the multi-functional chimeric hematopoietic receptor agonists of the present invention may also have amino acid deletions at either/or both the N- and C- termini of the original protein and or deletions from the new N- and/or C- termini of the sequence rearranged proteins in the formulas shown above.

A preferred embodiment of the present invention the linker (L) , (L¹) or (L²) , of the above formulas, joining the N-terminus to the C-terminus is a polypeptide selected from the group consisting of: Ser; J1

Asn ;

Gly;

Thr ;

GlySer; AlaAla;

GlySerGly;

GlyGlyGly

GlyAsnGly

GlyAlaGly GlyThrGly

AlaSerAla;

AlaAlaAla;

GlyGlyGlySer SEQ ID NO: 778;

GlyGlyGlySerGlyGlyGlySer SEQ ID NO: 779; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO: 780;

SerGlyGlySerGlyGlySer SEQ ID NO: 781;

GluPheGlyAsnMet SEQ ID NO: 782;

GluPheGlyGlyAsnMet SEQ ID NO: 783;

GluPheGlyGlyAsnGlyGlyAsnMet SEQ ID NO : 784; GlyGlySerAspMetAlaGly SEQ ID NO : 785;

SerGlyGlyAsnGly SEQ ID NO: 786;

SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO: 787; SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO: 788; SerGlyGlySerGlySerGlyGlySerGly SEQ ID NO: 789; SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly SEQ ID NO: 790;

GlyGlyGlySerGlyGly SEQ ID NO: 791; GlyGlyGlySerGlyGlyGly SEQ ID NO: 792; GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO : 793;

GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO: 794;

GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SEQ ID NO : 795; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGly SEQ ID NO: 796; ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGly GlnProProLeu SEQ ID NO: 797,•

ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr SEQ ID NO: 798; and ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer SEQ ID NO: 799.

Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the multi-functional chimeric hematopoietic receptor agonists, related microbial expression systems, and processes for making the multifunctional chimeric hematopoietic receptor agonists . The invention also relates to pharmaceutical compositions containing the multi-functional chimeric hematopoietic receptor agonists, and methods for using the multifunctional chimeric hematopoietic receptor agonists. In addition to the use of the multi-functional chimeric hematopoietic receptor agonists of the present invention in vivo, it is envisioned that in vitro uses would include the ability to stimulate bone marrow and blood cell activation and growth before infusion into patients . Another intended use is for the production of dendritic cells both in vivo and ex vivo .

It is believed that the reduced affinity of fusion proteins is due, at least in part, to the inability of the individual moieties to achieve their native conformation when incorporated into a chimeric molecule or to steric hindrance between the active site of the individual moieties of the fusion protein. This invention overcomes these limitations providing novel multi-functional chimeric hematopoietic receptor agonists that have a binding affinity comparable to or greater than the individual components of the chimeric molecule .

PAGE INTENTIONALLY LEFT BLANK

Brief Description of the Figures

Figure 1 schematically illustrates the sequence rearrangement of a protein. The N-terminus (N) and the C-terminus (C) of the native protein are joined through a linker, or joined directly. The protein is opened at a breakpoint creating a new N-terminus (new N) and a new C-terminus (new-C) resulting in a protein with a new linear amino acid sequence. A rearranged molecule may be synthesized e novo as linear molecule and not go through the steps of joining the original N-terminus and the C-terminus and opening of the protein at the breakpoint .

Figure 2 shows a schematic of Method I, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a. a. 174) joined to the amino acid 11 (a. a. 1- 10 are deleted) through a linker region and a new C-terminus created at amino acid 96 of the original sequence.

Figure 3 shows a schematic of Method II, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined without a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a. a. 174) joined to the original N-terminus and a new C-terminus created at amino acid 96 of the original sequence. Figure 4 shows a schematic of Method III, for creating new proteins in which the original N-terminus and C-terminus of the native protein are joined with a linker and different N-terminus and C-terminus of the protein are created. In the example shown the sequence rearrangement results in a new gene encoding a protein with a new N-terminus created at amino acid 97 of the original protein, the original C-terminus (a. a. 174) joined to amino acid 1 through a linker region and a new C-terminus created at amino acid 96 of the original sequence .

Figure 5 shows the bioactivity of the multifunctional receptor agonists comprising flt3 receptor agonists pMON32332, pMON32333, pMON32334 and pMON32335 compared to recombinant native flt3 (Genzyme) in the MUTZ-2 cell proliferation assay. MT = mock transfection

Figure 6 shows a DNA sequence encoding human mature EPO based on the sequence of Lin et al . ( PNAS 82:7580- 7584, 1985) .

Figure 7a and 7b shows a DNA sequence encoding native stem cell factor based on the sequence of Martin et al. ( Cell 63:203-211, 1990).

Figure 8 shows a DNA sequence encoding soluble stem cell factor based on the sequence of Langley et al . (Archives of Bichemistry and Biophys ica 311:55-61, 1994) .

Figure 9a and 9b shows the DNA sequence encoding the 209 amino acid mature form of flt3 ligand from Lyman et al. ( Oncogene 11:1165-1172, 1995).

Figure 10 shows the DNA sequence encoding the 134 amino acid soluble form of flt3 ligand from Lyman et al. ( Oncogene 11:1165-1172, 1995). Detailed Description of the Invention

The present invention encompasses multi-functional chimeric hematopoietic receptor agonists formed from covalently linked polypeptides, each of which may act through a different and specific cell receptor to initiate complementary biological activities. Hematopoiesis requires a complex series of cellular events in which stem cells generate continuously into large populations of maturing cells in all major lineages. There are currently at least 20 known regulators with hematopoietic proliferative activity. Most of these proliferative regulators can only stimulate one or another type of colony formation in vitro, the precise pattern of colony formation stimulated by each regulator is quite distinctive. No two regulators stimulate exactly the same pattern of colony formation, as evaluated by colony numbers or, more importantly, by the lineage and maturation pattern of the cells making up the developing colonies.

Proliferative responses can most readily be analyzed in simplified in vitro culture systems. Three quite different parameters can be distinguished: alteration in colony size, alteration in colony numbers and cell lineage. Two or more factors may act on the progenitor cell, inducing the formation of larger number of progeny thereby increasing the colony size. Two or more factors may allow increased number of progenitor cells to proliferate either because distinct subsets of progenitors cells exist that respond exclusively to one factor or because some progenitors require stimulation by two or more factors before being able to respond. Activation of additional receptors on a cell by the use of two or more factors is likely to enhance the mitotic signal because of coalescence of initially differing signal pathways into a common final pathway reaching the nucleus (Metcalf, Nature 339:27, 1989). Other mechanisms could explain synergy. For example, if one signaling pathway is limited by an intermediate activation of an additional signaling pathway which is caused by a second factor, then this may result in a super additive response. In some cases, activation of one receptor type can induce an enhanced expression of other receptors

(Metcalf, Blood 82:3515-3523, 1993). Two or more factors may result in a different pattern of cell lineages than from a single factor. The use of multi-functional chimeric hematopoietic receptor agonists may have a potential clinical advantage resulting from a proliferative response that is not possible by any single factor.

The receptors of hematopoietic and other growth factors can be grouped into two distinct families of related proteins: (1) tyrosine kinase receptors, including those for epidermal growth factor, M-CSF (Sherr, Blood 75:1, 1990) and SCF (Yarden et al . , EMBO J. 6:3341, 1987): and (2) hematopoietic receptors, not containing a tyrosine kinase domain, but exhibiting obvious homology in their extracellular domain (Bazan, PNAS USA 87:6934-6938, 1990). Included in this latter group are erythropoietin (EPO) (D'Andrea et al . , Cell 57:277, 1989), GM-CSF (Gearing et al . , EMBO J. 8:3667, 1989), IL-3 (Kitamura et al . , Cell 66:1165, 1991), G-CSF (Fukunaga et al . , J. Bio . Chem . 265:14008-15, 1990), IL- 4 (Harada et al . , PNAS USA 87:857, 1990), IL-5 (Takaki et al., EMBO J. 9:4367, 1990), IL-6 (Yamasaki et al . , Science 241:825, 1988), IL-7 (Goodwin et al . , Cell 60:941-51, 1990), LIF (Gearing et al . , EMBO J. 10:2839, 1991) and IL-2 (Cosman et al . , Mol-Immunol. 23: 935-94, 1986) . Most of the latter group of receptors exists in a high-affinity form as heterodimers. After ligand binding, the specific a-chains become associated with at least one other receptor chain (b-chain, g-chain) . Many of these factors share a common receptor subunit. The a- chains for GM-CSF, IL-3 and IL-5 share the same b-chain (Kitamura et al . , Cell 66:1165, 1991), Takaki et al . , EMBO J. 10:2833-8, 1991) and receptor complexes for IL- 6, LIF and IL-11 share a common b-chain (gpl30) (Taga et al., Cell 58:573-81, 1989; Gearing et al . , Science 255:1434-7, 1992). The receptor complexes of IL-2, IL- 4, IL-7, IL-9 and IL-15 share a common g-chain (Kondo et al., Science 262:1874, 1993; Russell et al . , Science

266: 1042-1045, 1993; Noguchi et al . , Science 262:1877, 1993; Giri et al . , EMBO J . 13:2822-2830, 1994).

The use of a multiply acting hematopoietic factor may also have a potential advantage by reducing the demands placed on factor-producing cells and their induction systems. If there are limitations in the ability of a cell to produce a factor, then by lowering the required concentrations of each of the factors, and using them in combination may usefully reduce demands on the factor-producing cells. The use of a multiply acting hematopoietic factor may lower the amount of the factors that would be needed, probably reducing the likelihood of adverse side-effects.

Novel compounds of this invention are represented by a formula selected from the group consisting of:

Where R_x and R₂ are as defined above. R₂ is preferably a colony stimulating factor with a different but complementary activity than R₁. By complementary activity is meant activity which enhances or changes the response to another cell modulator. The R_± polypeptide is joined either directly or through a linker segment to the R₂ polypeptide. The term "directly" defines multi-functional chimeric hematopoietic receptor agonists in which the polypeptides are joined without a peptide linker. Thus L₂ represents a chemical bond or polypeptide segment to which both R₁ and R₂ are joined in frame, most commonly L_x is a linear peptide to which Rl and R₂ are joined by amide bonds linking the carboxy terminus of R₁ to the amino terminus of L_x and carboxy terminus of L_x to the amino terminus of R₂. By "joined in frame" is meant that there is no translation termination or disruption between the reading frames of the DNA encoding R₁ and R₂.

A non-exclusive list of other growth factors, i.e. colony stimulating factors (CSFs), are cytokines, lymphokines, interleukins, hematopoietic growth factors which can be joined to (I) , (II) or (III) include GM- CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF) , M- CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12 , IL-13 , IL- 15, LIF, flt3/flk2 ligand, human growth hormone, B-cell growth factor, B-cell differentiation factor, eosinophil differentiation factor and stem cell factor (SCF) also known as steel factor or c-kit ligand. Additionally, this invention encompasses the use of modified R_λ or R₂ molecules or mutated or modified DNA sequences encoding these R₁ or R₂ molecules. The present invention also includes multi-functional chimeric hematopoietic receptor agonists in which R₁ or R₂ is an hIL-3 variant, c-mpl ligand variant, or G-CSF variant. A "hIL-3 variant" is defined as a hIL-3 molecule which has amino acid substitutions and/or portions of hIL-3 deleted as disclosed in WO 94/12638, WO 94/12639 and WO 95/00646, as well as other variants known in the art. A "c-mpl ligand variant" is defined an c-mpl ligand molecule which has amino acid substitutions and/or portions of c- mpl ligand deleted, disclosed in United States Application Serial Number 08/383,035 as well as other variants known in the art. A "G-CSF variant" is defined an G-CSF molecule which has amino acid substitutions and/or portions of G-CSF deleted, as disclosed herein, as well as other variants known in the art. In addition to the list above, IL-3 variants taught in WO 94/12639 and WO 94/12638, G-CSF receptor agonists disclosed in WO 97/12977, c-mpl receptor agonists disclosed in WO 97/12978, IL-3 receptor agonists disclosed in WO 97/12979 can be R₁ or R₂ of the present invention. As ijO used herein "IL-3 variants" refer to IL-3 variants taught in WO 94/12639 and WO 94/12638. As used herein "fusion proteins" refer to fusion protein taught in WO 95/21197, and WO 95/21254. As used herein "G-CSF receptor agonists" refer to G-CSF receptor agonists disclosed in WO 97/12978. As used herein "c-mpl receptor agonists" refer to c-mpl receptor agonists disclosed in WO 97/12978. As used herein "IL-3 receptor agonists" refer to IL-3 receptor agonists disclosed in WO 97/12979. As used herein "multi-functional receptor agonists" refer to multi-functional receptor agonists taught in WO 97/12985.

The linking group (L is generally a polypeptide of between 1 and 500 amino acids in length. The linkers joining the two molecules are preferably designed to (1) allow the two molecules to fold and act independently of each other, (2) not have a propensity for developing an ordered secondary structure which could interfere with the functional domains of the two proteins, (3) have minimal hydrophobic characteristics which could interact with the functional protein domains and (4) provide steric separation of R_χ and R₂ such that R₁ and R₂ could interact simultaneously with their corresponding receptors on a single cell. Typically surface amino acids in flexible protein regions include Gly, Asn and Ser. Virtually any permutation of amino acid sequences containing Gly, Asn and Ser would be expected to satisfy the above criteria for a linker sequence. Other neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. Additional amino acids may also be included in the linkers due to the addition of unique restriction sites in the linker sequence to facilitate construction of the multi-functional chimeric hematopoietic receptor agonists.

Preferred L₁ linkers of the present invention include sequences selected from the group of formulas: Hi

(Gly³Ser)ⁿ (SEQ ID NO:861), (Gly⁴Ser)ⁿ (SEQ ID NO:862), (Gly⁵Ser)ⁿ (SEQ ID NO:863), (GlyⁿSer)ⁿ (SEQ ID NO:864) or (AlaGlySer)" (SEQ ID NO:865).

One example of a highly-flexible linker is the glycine and serine-rich spacer region present within the pill protein of the filamentous bacteriophages , e.g. bacteriophages M13 or fd (Schaller et al . , PNAS USA 72: 737-741, 1975) . This region provides a long, flexible spacer region between two domains of the pill surface protein. The spacer region consists of the amino acid sequence :

GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGluGlyGlyGlySerGlu GlyGlyGlySerGluGlyGlyGlySerGluGlyGlyGlySerGlyGlyGlySer (SEQ ID NO: 800) . The present invention also includes linkers in which an endopeptidase recognition sequence is included. Such a cleavage site may be valuable to separate the individual components of the multi-functional chimeric hematopoietic receptor agonist to determine if they are properly folded and active in vitro. Examples of various endopeptidases include, but are not limited to, plasmin, enterokinase, kallikrein, urokinase, tissue plasminogen activator, clostripain, chymosin, collagenase, Russell's viper venom protease, postproline cleavage enzyme, V8 protease, Thrombin and factor Xa. Peptide linker segments from the hinge region of heavy chain immunoglobulins IgG, IgA, IgM, IgD or IgE provide an angular relationship between the attached polypeptides. Especially useful are those hinge regions where the cysteines are replaced with serines. Preferred linkers of the present invention include sequences derived from murine IgG gamma 2b hinge region in which the cysteines have been changed to serines. These linkers may also include an endopeptidase cleavage site. Examples of such linkers include the following sequences : IleSerGluProSerGlyProIleSerThrlleAsnProSerProProSerLys GluSerHisLysSerPro (SEQ ID NO: 801) and

IleGluGlyArglleSerGluProSerGlyProIleSerThrlleAsnProSer ProProSerLysGluSerHisLysSerPro (SEQ ID NO: 802).

The present invention is, however, not limited by the form, size or number of linker sequences employed and the only requirement of the linker is that functionally it does not interfere with the folding and function of the individual molecules of the multifunctional chimeric hematopoietic receptor agonist.

Determination of the Linker L„

The length of the amino acid sequence of the linker L₂ to be used in R₁ and/or R₂ can be selected empirically or with guidance from structural information, or by using a combination of the two approaches.

When no structural information is available, a small series of linkers can be prepared for testing using a design whose length is varied in order to span a range from 0 to 50 A and whose sequence is chosen in order to be consistent with surface exposure

(hydrophilicity, Hopp & Woods, Mol . Immunol . 20: 483- 489, 1983), Kyte & Doolittle, J. Mol . Biol . 157:105-132; solvent exposed surface area, Lee & Richards, J^". Mol . Biol . 55:379-400, 1971) and the ability to adopt the necessary conformation with out deranging the conformation of R¹ or R² (conformationally flexible; Karplus & Schulz, Naturwissenschaften 72:212-213, 1985). Assuming an average of translation of 2.0 to 3.8 A per residue, this would mean the length to test would be between 0 to 30 residues, with 0 to 15 residues being the preferred range. Exemplary of such an empirical series would be to construct linkers using a cassette sequence such as "Gly-Gly-Gly-Ser" repeated n times, where n is 1, 2, 3 or 4. Those skilled in the art will recognize that there are many such sequences that vary in length or composition that can serve as linkers with the primary consideration being that they be neither excessively long nor short (cf., Sandhu, Cri tical Rev. Biotech . 12: 437-462, 1992); if they are too long, entropy effects will likely destabilize the three- dimensional fold, and may also make folding kinetically impractical, and if they are too short, they will likely destabilize the molecule because of torsional or steric strain.

Those skilled in the analysis of protein structural information will recognize that using the distance between the chain ends, defined as the distance between the c-alpha carbons, can be used to define the length of the sequence to be used, or at least to limit the number of possibilities that must be tested in an empirical selection of linkers. They will also recognize that it is sometimes the case that the positions of the ends of the polypeptide chain are ill-defined in structural models derived from x-ray diffraction or nuclear magnetic resonance spectroscopy data, and that when true, this situation will therefore need to be taken into account in order to properly estimate the length of the linker required. From those residues whose positions are well defined are selected two residues that are close in sequence to the chain ends, and the distance between their c-alpha carbons is used to calculate an approximate length for a linker between them. Using the calculated length as a guide, linkers with a range of number of residues (calculated using 2 to 3.8A per residue) are then selected. These linkers may be composed of the original sequence, shortened or lengthened as necessary, and when lengthened the additional residues may be chosen to be flexible and hydrophilic as described above; or optionally the original sequence may be substituted for using a series of linkers, one example being the "Gly-Gly-Gly-Ser" cassette approach mentioned above; or optionally a combination of the original sequence and new sequence having the appropriate total length may be used.

Determination of the Amino and Carboxyl Termini of R₁ and_R₂

Sequences of R_x and R₂ capable of folding to biologically active states can be prepared by appropriate selection of the beginning (amino terminus) and ending (carboxyl terminus) positions from within the original polypeptide chain while using the linker sequence L₂ as described above. Amino and carboxyl termini are selected from within a common stretch of sequence, referred to as a breakpoint region, using the guidelines described below. A novel amino acid sequence is thus generated by selecting amino and carboxyl termini from within the same breakpoint region. In many cases the selection of the new termini will be such that the original position of the carboxyl terminus immediately preceded that of the amino terminus . However, those skilled in the art will recognize that selections of termini anywhere within the region may function, and that these will effectively lead to either deletions or additions to the amino or carboxyl portions of the new sequence.

It is a central tenet of molecular biology that the primary amino acid sequence of a protein dictates folding to the three-dimensional structure necessary for expression of its biological function. Methods are known to those skilled in the art to obtain and interpret three-dimensional structural information using x-ray diffraction of single protein crystals or nuclear magnetic resonance spectroscopy of protein solutions . Examples of structural information that are relevant to the identification of breakpoint regions include the location and type of protein secondary structure (alpha and 3-10 helices, parallel and anti-parallel beta sheets, chain reversals and turns, and loops; Kabsch & Sander, Biopolymers 22: 2577-2637, 1983), the degree of solvent exposure of amino acid residues, the extent and type of interactions of residues with one another (Chothia, Ann . Rev. Biochem . 53:537-572, 1984) and the static and dynamic distribution of conformations along the polypeptide chain (Alber & Mathews, Methods Enzymol . 154: 511-533, 1987). In some cases additional information is known about solvent exposure of residues; one example is a site of post-translational attachment of carbohydrate which is necessarily on the surface of the protein. When experimental structural information is not available, or is not feasible to obtain, methods are also available to analyze the primary amino acid sequence in order to make predictions of protein tertiary and secondary structure, solvent accessibility and the occurrence of turns and loops. Biochemical methods are also sometimes applicable for empirically determining surface exposure when direct structural methods are not feasible; for example, using the identification of sites of chain scission following limited proteolysis in order to infer surface exposure (Gentile & Salvatore, Eur. J. Biochem . 218:603-621, 1993)

Thus using either the experimentally derived structural information or predictive methods (e.g., Srinivisan & Rose Proteins : Struct . , Funct . & Genetics, 22: 81-99, 1995) the parental amino acid sequence is inspected to classify regions according to whether or not they are integral to the maintenance of secondary and tertiary structure. The occurrence of sequences within regions that are known to be involved in periodic secondary structure (alpha and 3-10 helices, parallel and anti- parallel beta sheets) are regions that should be avoided. Similarly, regions of amino acid sequence that are observed or predicted to have a low degree of solvent exposure are more likely to be part of the so- called hydrophobic core of the protein and should also be avoided for selection of amino and carboxyl termini. In contrast, those regions that are known or predicted to be in surface turns or loops, and especially those regions that are known not to be required for biological activity, are the preferred sites for location of the extremes of the polypeptide chain. Continuous stretches of amino acid sequence that are preferred based on the above criteria are referred to as a breakpoint region.

Additional peptide sequences may also be added to facilitate purification or identification of multifunctional chimeric hematopoietic receptor agonist proteins (e.g., poly-His) . A highly antigenic peptide may also be added that would enable rapid assay and facile purification of the multi-functional chimeric hematopoietic receptor agonist protein by a specific monoclonal antibody.

"Mutant amino acid sequence," "mutant protein", "variant protein", "mutein", or "mutant polypeptide" refers to a polypeptide having an amino acid sequence which varies from a native sequence due to amino acid deletions, substitutions, or both, or is encoded by a nucleotide sequence intentionally made variant from a native sequence.. "Native sequence" refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.

Hematopoietic growth factors can be characterized by their ability to stimulate colony formation by human hematopoietic progenitor cells. The colonies formed include erythroid, granulocyte, megakaryocyte, granulocytic macrophages and mixtures thereof. Many of the hematopoietic growth factors have demonstrated the ability to restore bone marrow function and peripheral blood cell populations to therapeutically beneficial m levels in studies performed initially in primates and subsequently in humans. Many or all of these biological activities of hematopoietic growth factors involve signal transduction and high affinity receptor binding. Multi-functional chimeric hematopoietic receptor agonists of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to a single factor or by having improved half-life or decreased adverse side effects, or a combination of these properties.

Multi-functional chimeric hematopoietic receptor agonists which have little or no agonist activity maybe useful as antagonists, as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful hIL-3 muteins .

Biological activity of the multi-functional chimeric hematopoietic receptor agonist proteins of the present invention can be determined by DNA synthesis in factor-dependent cell lines or by counting the colony forming units in an in vitro bone marrow assay.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may have an improved therapeutic profile as compared to single acting hematopoietic agonists. For example, some multi-functional chimeric hematopoietic receptor agonists of the present invention may have a similar or more potent growth factor activity relative to other hematopoietic agonists without having a similar or corresponding increase in side-effects.

The present invention also includes the DNA sequences which code for the multi-functional chimeric hematopoietic receptor agonist proteins, DNA sequences which are substantially similar and perform substantially the same function, and DNA sequences which differ from the DNAs encoding the multi-functional chimeric hematopoietic receptor agonists of the invention only due to the degeneracy of the genetic code. Also included in the present invention are the oligonucleotide intermediates used to construct the mutant DNAs and the polypeptides coded for by these oligonucleotides .

Genetic engineering techniques now standard in the art (United States Patent 4,935,233 and Sambrook et al . , "Molecular Cloning A Laboratory Manual", Cold Spring Harbor Laboratory, 1989) may be used in the construction of the DNA sequences of the present invention. One such method is cassette mutagenesis (Wells et al . , Gene 34:315-323, 1985) in which a portion of the coding sequence in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites. Pairs of complementary synthetic oligonucleotides encoding the desired gene can be made and annealed to each other. The DNA sequence of the oligonucleotide would encode sequence for amino acids of desired gene with the exception of those substituted and/or deleted from the sequence.

Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent JM101 cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with the desired genes.

Cloning of the DNA sequences of the novel multi- functional hematopoietic agonists wherein at least one of the with the DNA sequence of the other colony stimulating factor may be accomplished by the use of intermediate vectors . Alternatively one gene can be cloned directly into a vector containing the other gene. Linkers and adapters can be used for joining the DNA sequences, as well as replacing lost sequences, where a restriction site was internal to the region of interest. Thus genetic material (DNA) encoding one polypeptide, peptide linker, and the other polypeptide is inserted into a suitable expression vector which is used to transform bacteria, yeast, insect cells or mammalian cells. The transformed organism is grown and the protein isolated by standard techniques. The resulting product is therefore a new protein which has a colony stimulating factor joined by a linker region to a second colony stimulating factor.

Another aspect of the present invention provides plasmid DNA vectors for use in the expression of these novel multi-functional chimeric hematopoietic receptor agonists. These vectors contain the novel DNA sequences described above which code for the novel polypeptides of the invention. Appropriate vectors which can transform microorganisms capable of expressing the multifunctional chimeric hematopoietic receptor agonists include expression vectors comprising nucleotide sequences coding for the multi-functional chimeric hematopoietic receptor agonists joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.

Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the multi-functional chimeric hematopoietic receptor agonist polypeptides.

The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and which are capable of directing the replication and expression thereof in selected host cells.

As another aspect of the present invention, there is provided a method for producing the novel multifunctional chimeric hematopoietic receptor agonists. The method of the present invention involves culturing suitable cells or cell line, which has been transformed with a vector containing a DNA sequence coding for expression of a novel multi-functional chimeric hematopoietic receptor agonist. Suitable cells or cell lines may be bacterial cells. For example, the various strains of E. coli are well-known as host cells in the field of biotechnology. Examples of such strains include E. coli strains JM101 (Yanish-Perron et al . Gene 33: 103-119, 1985) and MON105 (Obukowicz et al . , Applied Environmental Microbiology 58: 1511-1523, 1992). Also included in the present invention is the expression of the multi-functional chimeric hematopoietic receptor agonist protein utilizing a chromosomal expression vector for E. coli based on the bacteriophage Mu

(Weinberg et al . , Gene 126: 25-33, 1993). Various strains of B . subtilis may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention. When expressed in the E. coli cytoplasm, the gene encoding the multi-functional chimeric hematopoietic receptor agonists of the present invention may also be constructed such that at the 5' end of the gene codons are added to encode Met^-2-Ala^-1- or Met^-1 at the N-terminus of the protein. The N termini of proteins made in the cytoplasm of E. coli are affected by post-translational processing by methionine aminopeptidase (Ben Bassat et al., J. Bac . 169:751-757, 1987) and possibly by other peptidases so that upon expression the methionine is cleaved off the N-terminus. The multi-functional chimeric hematopoietic receptor agonists of the present invention may include multi-functional chimeric hematopoietic receptor agonist polypeptides having Met^-1, Ala^-1 or Met^-2-Ala^-1 at the N-terminus. These mutant multi-functional chimeric hematopoietic receptor agonists may also be expressed in E. coli by fusing a secretion signal peptide to the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process. Additional strategies for achieving high-level expression of genes in E. coli can be found in Sawas, CM. (Microbiological Reviews 60; 512-538, 1996) .

Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary cells (CHO) . General methods for expression of foreign genes in mammalian cells are reviewed in Kaufman, R. J., 1987) Genetic Engineering, Principles and Methods, Vol. 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional chimeric hematopoietic receptor agonist. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, California) can be used. The eukaryotic secretion signal peptide coding region can be from the gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al . , Proc . Natl . Acad. Sci . USA 84: 2638-2642, 1987). After construction of the vector containing the gene, the vector DNA is transfected into mammalian cells. Such cells can be, for example, the C0S7 , HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific) . The polypeptide secreted into the media can be recovered by standard biochemical approaches following transient expression for 24 - 72 hours after transfection of the cells or after establishment of stable cell lines following selection for antibiotic resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 293:620- 625, 1981), or alternatively, Kaufman et al, Mol . Cell . Biol . , 5(7) =1750-1759, 1985) or Howley et al . , U.S. Pat. No. 4,419,446. Another suitable mammalian cell line is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.

Where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g., Miller et al . , Genetic Engineering, 8:277-298 (Plenum Press 1986) and references cited therein. In addition, general methods for expression of foreign genes in insect cells using Baculovirus vectors are described in: Summers, M. D. and Smith, G. E., 1987) - A manual of methods for Baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555. An expression vector is constructed comprising a Baculovirus transfer vector, in which a strong Baculovirus promoter (such as the polyhedron promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally joined to the coding region for the multi-functional chimeric hematopoietic receptor agonist polypeptide. For example, the plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, California) can be used. After construction of the vector carrying the gene encoding the multi-functional chimeric hematopoietic receptor agonist polypeptide, two micrograms of this DNA is co-transfected with one microgram of Baculovirus DNA (see Summers & Smith, 1987) into insect cells, strain SF9. Pure recombinant Baculovirus carrying the multi-functional chimeric hematopoietic receptor agonist is used to infect cells cultured, for example, in Excell 401 serum-free medium (JRH Biosciences, Lenexa, Kansas). The multi-functional chimeric hematopoietic receptor agonist secreted into the medium can be recovered by standard biochemical approaches. Supernatants from mammalian or insect cells expressing the multi-functional chimeric hematopoietic β receptor agonist protein can be first concentrated using any of a number of commercial concentration units.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in the treatment of diseases characterized by decreased levels of either myeloid, erythroid, lymphoid, or megakaryocyte cells of the hematopoietic system or combinations thereof. In addition, they may be used to activate mature myeloid and/or lymphoid cells. Among conditions susceptible to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white cells) in the peripheral blood. Leukopenia may be induced by exposure to certain viruses or to radiation. It is often a side effect of various forms of cancer therapy, e.g., exposure to chemotherapeutic drugs, radiation and of infection or hemorrhage. Therapeutic treatment of leukopenia with these multi-functional chimeric hematopoietic receptor agonists of the present invention may avoid undesirable side effects caused by treatment with presently available drugs.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of such conditions as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi syndrome, systemic lupus erythematosus (SLE) , leukemia, myelodysplastic syndrome and myelofibrosis . The multi-functional chimeric hematopoietic receptor agonist of the present invention may be useful in the treatment or prevention of thrombocytopenia. Currently the only therapy for thrombocytopenia is platelet transfusion which are costly and carry the significant risks of infection (HIV, HBV) and alloimunization. The multi-functional chimeric hematopoietic receptor agonist may alleviate or diminish the need for platelet transfusion. Severe thrombocytopenia may result from genetic defects such as Fanconi ' s Anemia, Wiscott-Aldrich, or May Hegglin syndromes. Acquired thrombocytopenia may result from auto- or allo-antibodies as in Immune Thrombocytopenia Purpura, Systemic Lupus Erythromatosis, hemolytic anemia, or fetal maternal incompatibility. In addition, splenomegaly, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, infection or prosthetic heart valves may result in thrombocytopenia. Severe thrombocytopenia may also result from chemotherapy and/or radiation therapy or cancer. Thrombocytopenia may also result from marrow invasion by carcinoma, lymphoma, leukemia or fibrosis.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in the mobilization of hematopoietic progenitors and stem cells in peripheral blood. Peripheral blood derived progenitors have been shown to be effective in reconstituting patients in the setting of autologous marrow transplantation. Hematopoietic growth factors including G-CSF and GM-CSF have been shown to enhance the number of circulating progenitors and stem cells in the peripheral blood. This has simplified the procedure for peripheral stem cell collection and dramatically decreased the cost of the procedure by decreasing the number of pheresis required. The multi-functional chimeric hematopoietic receptor agonist may be useful in mobilization of stem cells and further enhance the efficacy of peripheral stem cell transplantation.

The multi-functional chimeric hematopoietic receptor agonists of the present invention may also be useful in the ex vivo expansion of hematopoietic progenitors and stem cells. Colony stimulating factors

(CSFs), such as hIL-3, have been administered alone, co- administered with other CSFs, or in combination with bone marrow transplants subsequent to high dose chemotherapy to treat the neutropenia and thrombocytopenia which are often the result of such treatment. However the period of severe neutropenia and thrombocytopenia may not be totally eliminated. The myeloid lineage, which is comprised of monocytes

(macrophages), granulocytes (including neutrophils) and megakaryocytes, is critical in preventing infections and bleeding which can be life-threatening. Neutropenia and thrombocytopenia may also be the result of disease, genetic disorders, drugs, toxins, radiation and many therapeutic treatments such as conventional oncology therapy.

Bone marrow transplants have been used to treat this patient population. However, several problems are associated with the use of bone marrow to reconstitute a compromised hematopoietic system including: 1) the number of stem cells in bone marrow, spleen, or peripheral blood is limited, 2) Graft Versus Host Disease, 3) graft rejection and 4) possible contamination with tumor cells. Stem cells make up a very small percentage of the nucleated cells in the bone marrow, spleen and peripheral blood. It is clear that a dose response exists such that a greater number of stem cells will enhance hematopoietic recovery. Therefore, the in vitro expansion of stem cells should enhance hematopoietic recovery and patient survival . Bone marrow from an allogeneic donor has been used to provide bone marrow for transplant. However, Graft Versus Host Disease and graft rejection limit bone marrow transplantation even in recipients with HLA-matched sibling donors. An alternative to allogeneic bone marrow transplants is autologous bone marrow transplants. In autologous bone marrow transplants, some of the patient's own marrow is harvested prior to myeloablative therapy, e.g. high dose chemotherapy, and is transplanted back into the patient afterwards . Autologous transplants eliminate the risk of Graft Versus Host Disease and graft rejection. However, autologous bone marrow transplants still present problems in terms of the limited number of stems cells in the marrow and possible contamination with tumor cells. The limited number of stem cells may be overcome by ex-vivo expansion of the stem cells. In addition, stem cells can be specifically isolated, based on the presence of specific surface antigens such as CD34+ in order to decrease tumor cell contamination of the marrow graft .

The following patents contain further details on separating stem cells, CD34+ cells, culturing the cells with hematopoietic factors, the use of the cells for the treatment of patients with hematopoietic disorders and the use of hematopoietic factors for cell expansion and gene therapy .

5,061,620 relates to compositions comprising human hematopoietic stem cells provided by separating the stem cells from dedicated cells.

5,199,942 describes a method for autologous hematopoietic cell transplantation comprising: (1) obtaining hematopoietic progenitor cells from a patient; (2) ex-vivo expansion of cells with a growth factor selected from the group consisting of IL-3, flt3 ligand, c-kit ligand, GM-CSF, IL-1, GM-CSF/IL-3 fusion protein and combinations thereof; (3) administering cellular preparation to a patient.

5,240,856 relates to a cell separator that includes an apparatus for automatically controlling the cell separation process.

WO 91/16116 describes devices and methods for selectively isolating and separating target cells from a mixture of cells. WO 91/18972 describes methods for in vitro culturing of bone marrow, by incubating suspension of bone marrow cells, using a hollow fiber bioreactor.

WO 92/18615 relates to a process for maintaining and expanding bone marrow cells, in a culture medium containing specific mixtures of cytokines, for use in transplants .

WO 93/08268 describes a method for selectively expanding stem cells, comprising the steps of (a) separating CD34+ stem cells from other cells and (b) incubating the separated cells in a selective medium, such that the stem cells are selectively expanded.

WO 93/18136 describes a process for in vitro support of mammalian cells derived from peripheral blood.

WO 93/18648 relates to a composition comprising human neutrophil precursor cells with a high content of myeloblasts and promyelocytes for treating genetic or acquired neutropenia.

WO 94/08039 describes a method of enrichment for human hematopoietic stem cells by selection for cells which express c-kit protein.

WO 94/11493 describes a stem cell population that are CD34+ and small in size, which are isolated using a counterflow elutriation method.

WO 94/27698 relates to a method combining immunoaffinity separation and continuous flow centrifugal separation for the selective separation of a nucleated heterogeneous cell population from a heterogeneous cell mixture. Si

WO 94/25848 describes a cell separation apparatus for collection and manipulation of target cells.

The long term culturing of highly enriched CD34+ precursors of hematopoietic progenitor cells from human bone marrow in cultures containing IL-la, IL-3, IL-6 or GM-CSF is discussed in Brandt et al J^". Clin . Invest . 86:932-941, 1990) .

One aspect of the present invention provides a method for selective ex-vivo expansion of stem cells. The term "stem cell" refers to the totipotent hematopoietic stem cells as well as early precursors and progenitor cells which can be isolated from bone marrow, spleen or peripheral blood. The term "expansion" refers to the differentiation and proliferation of the cells. The present invention provides a method for selective ex- vivo expansion of stem cells, comprising the steps of: (a) separating stem cells from other cells, (b) culturing said separated stem cells with a selective media which contains multi-functional chimeric hematopoietic receptor agonist protein (s) and (c) harvesting said stems cells. Stem cells, as well as committed progenitor cells destined to become neutrophils, erythrocytes, platelets, etc. may be distinguished from most other cells by the presence or absence of particular progenitor marker antigens, such as CD34, that are present on the surface of these cells and/or by morphological characteristics. The phenotype for a highly enriched human stem cell fraction is reported as CD34+, Thy-1+ and lin-, but it is to be understood that the present invention is not limited to the expansion of this stem cell population. The CD34+ enriched human stem cell fraction can be separated by a number of reported methods, including affinity columns or beads, magnetic beads or flow cytometry using antibodies directed to surface antigens such as the CD34+. Further, physical separation methods such as counterflow elutriation may be used to enrich hematopoietic progenitors. The CD34+ progenitors are heterogeneous, and may be divided into several sub- populations characterized by the presence or absence of co-expression of different lineage associated cell surface associated molecules. The most immature progenitor cells do not express any known lineage associated markers, such as HLA-DR or CD38, but they may express CD90(thy-l). Other surface antigens such as

CD33, CD38, CD41, CD71, HLA-DR or c-kit can also be used to selectively isolate hematopoietic progenitors. The separated cells can be incubated in selected medium in a culture flask, sterile bag or in hollow fibers. Various colony stimulating factors may be utilized in order to selectively expand cells. Representative factors that have been utilized for ex-vivo expansion of bone marrow include, c-kit ligand, IL-3, G-CSF, GM-CSF, IL-1, IL-6, IL-11, flt-3 ligand or combinations thereof. The proliferation of the stem cells can be monitored by enumerating the number of stem cells and other cells, by standard techniques (e.g. hemacytometer, CFU, LTCIC) or by flow cytometry prior and subsequent to incubation.

Several methods for ex-vivo expansion of stem cells have been reported utilizing a number of selection methods and expansion using various colony stimulating factors including c-kit ligand (Brandt et al . , Blood 83:1507-1514 [1994], McKenna et al . , Blood 86:3413-3420 [1995]), IL-3 (Brandt et al . , Blood 83:1507-1514 [1994], Sato et al., Blood 82:3600-3609 [1993]), G-CSF (Sato et al., Blood 82:3600-3609 [1993]), GM-CSF (Sato et al . , Blood 82:3600-3609 [1993]), IL-1 (Muench et al . , Blood 81:3463-3473 [1993]), IL-6 (Sato et al . , Blood 82:3600- 3609 [1993]), IL-11 (Lemoli et al . , Exp . Hem . 21:1668- 1672 [1993], Sato et al . , Blood 82:3600-3609 [1993]), flt-3 ligand (McKenna et al . , Blood 86:3413 3420 [1995]) and/or combinations thereof (Brandt et al . , Blood 83:1507 1514 [1994], Haylock et al . , Blood 80:1405-1412 [1992], Roller et al . , Biotechnology 11:358-363 [1993], (Lemoli et al . , Exp . Hem . 21:1668-1672 [1993]), McKenna et al., Blood 86:3413-3420 [1995], Muench et al . , Blood 81:3463-3473 [1993], Patchen et al . , Bio therapy . - 13 -26 [1994], Sato et al . , Blood 82:3600-3609 [1993], Smith et al., Exp . Hem . 21:870-877 [1993], Steen et al . , Stem Cells 12:214-224 [1994], Tsuj ino et al . , Exp . Hem . 21:1379-1386 [1993]). Among the individual colony stimulating factors, hIL-3 has been shown to be one of the most potent in expanding peripheral blood CD34+ cells (Sato et al . , Blood 82:3600-3609 [1993], Kobayashi et al., Blood 73 :1836-1841 [1989]). However, no single factor has been shown to be as effective as the combination of multiple factors. The present invention provides methods for ex vivo expansion that utilize multi-functional chimeric hematopoietic receptor agonists that are more effective than a single factor alone .

Another aspect of the invention provides methods of sustaining and/or expanding hematopoietic precursor cells which includes inoculating the cells into a culture vessel which contains a culture medium that has been conditioned by exposure to a stromal cell line such as HS-5 (WO 96/02662, Roecklein and Torok-Strob, Blood 85:997-1105, 1995) that has been supplemented with a multi-functional hematopoietic chimeric receptor agonist of the present invention.

It is also envisioned that uses of multi-functional hematopoietic chimeric receptor agonists of the present invention would include blood banking applications, where the EPO receptor agonists are given to a patent to increase the number of blood cells and blood products are removed from the patient, prior to some medical procedure. The blood products stored and transfused back into the patient after the medical procedure. Additionally, it is envisioned that uses of multifunctional hematopoietic chimeric receptor agonists would include giving the multi-functional hematopoietic chimeric receptor agonists to a blood donor prior to blood donation to increase the number of blood cells, thereby allowing the donor to safely give more blood.

Another projected clinical use of growth factors has been in the in vitro activation of hematopoietic progenitors and stem cells for gene therapy. Due to the long life-span of hematopoietic progenitor cells and the distribution of their daughter cells throughout the entire body, hematopoietic progenitor cells are good candidates for ex vivo gene transfection. In order to have the gene of interest incorporated into the genome of the hematopoietic progenitor or stem cell one needs to stimulate cell division and DNA replication. Hematopoietic stem cells cycle at a very low frequency which means that growth factors may be useful to promote gene transduction and thereby enhance the clinical prospects for gene therapy. Potential applications of gene therapy (review Crystal, Science 270:404-410 [1995]) include; 1) the treatment of many congenital metabolic disorders and immunodeficiencies (Kay and Woo, Trends Genet . 10:253-257 [1994]), 2) neurological disorders (Friedmann, Trends Genet . 10:210-214 [1994]), 3) cancer (Culver and Blaese, Trends Genet . 10:174-178 [1994]) and 4) infectious diseases (Gilboa and Smith, Trends Genet . 10:139-144 [1994]).

There are a variety of methods, known to those with skill in the art, for introducing genetic material into a host cell. A number of vectors, both viral and non- viral have been developed for transferring therapeutic genes into primary cells. Viral based vectors include; 1) replication deficient recombinant retrovirus (Boris- Lawrie and Temin, Curr . Opin . Genet . Dev. 3:102-109 [1993], Boris-Lawrie and Temin, Annal . New York Acad . Sci . 716:59-71 [1994], Miller, Current Top . Microbiol . Immunol . 158:1-24 [1992]) and replication-deficient recombinant adenovirus (Berkner, BioTechniques 6:616-629 [1988], Berkner, Current Top . Microbiol . Immunol . 158:39-66 [1992], Brody and Crystal, Annal . New York Acad. Sci . 716:90-103 [1994]). Non-viral based vectors include protein/DNA complexes (Cristiano et al . , PNAS USA . 90:2122-2126 [1993], Curiel et al . , PNAS USA 88:8850-8854 [1991], Curiel, Annal . New York Acad . Sci . 716:36-58 [1994]), electroporation and liposome mediated delivery such as cationic liposomes (Farhood et al., Annal . New York Acad . Sci . 716:23-35 [1994]).

The present invention provides an improvement to the existing methods of expanding hematopoietic cells, which new genetic material has been introduced, in that it provides methods utilizing multi-functional chimeric hematopoietic receptor agonist proteins that have improved biological activity, including an activity not seen by any single colony stimulation factor. Many drugs may cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI, alkylating agents and anti-metabolites used in chemotherapy, antibiotics such as chloramphenicol, penicillin, gancyclovir, daunomycin and sulfa drugs, phenothiazones , tranquilizers such as meprobamate, analgesics such as aminopyrine and dipyrone, anti- convulsants such as phenytoin or carbamazepine, antithyroids such as propylthiouracil and methimazole and diuretics. The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in preventing or treating the bone marrow suppression or hematopoietic deficiencies which often occur in patients treated with these drugs .

Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections, burns and as a result of treatment for renal disease or renal failure, e.g., dialysis. The multi-functional chimeric hematopoietic receptor agonists of the present invention may be useful in treating such hematopoietic deficiencies .

The treatment of hematopoietic deficiency may include administration of a pharmaceutical composition containing the multi-functional chimeric hematopoietic receptor agonists to a patient. The multi-functional chimeric hematopoietic receptor agonists of the present invention may also be useful for the activation and amplification of hematopoietic precursor cells by treating these cells in vitro with the multi-functional chimeric hematopoietic receptor agonist proteins of the present invention prior to injecting the cells into a patient .

Various immunodeficiencies, e.g., in T and/or B lymphocytes, or immune disorders, e.g., rheumatoid arthritis, may also be beneficially affected by treatment with the multi-functional chimeric hematopoietic receptor agonists of the present invention. Immunodeficiencies may be the result of viral infections, e.g., HTLVI, HTLVII, HTLVIII, severe exposure to radiation, cancer therapy or the result of other medical treatment. The multi-functional chimeric hematopoietic receptor agonists of the present invention may also be employed, alone or in combination with other colony stimulating factors, in the treatment of other blood cell deficiencies, including thrombocytopenia (platelet deficiency), or anemia. Other uses for these novel polypeptides are the in vivo and ex vivo treatment of patients recovering from bone marrow transplants, and in the development of monoclonal and polyclonal antibodies generated by standard methods for diagnostic or therapeutic use.

Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the multi-functional chimeric hematopoietic receptor agonists of the present invention in a mixture with a pharmaceutically acceptable carrier. This composition can be administered either parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such a parenterally acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.

Another intended use of the multi-functional chimeric hematopoietic receptor agonists of the present invention is for the generation of larger numbers of dendritic cells, from precursors, to be used as adjuvants for immunization. Dendritic cells play a crucial role in the immune system. They are the professional antigen-presenting cells most efficient in the activation of resting T cells and are the major antigen-presenting cells for activation of naϊve T cells in vivo and, thus, for initiation of primary immune responses. They efficiently internalize, process and present soluble tumor-specific antigens (Ag) . Dendritic cells have the unique capacity to cluster naϊve T cells and to respond to Ag encounter by rapid upregulation of the expression of major histocompatability complex (MHC) and co-stimulatory molecules, the production of cytokines and migration towards lymphatic organs . Since dendritic cells are of central importance for sensitizing the host against a neoantigen for CD4- dependent immune responses, they may also play a crucial role in the generation and regulation of tumor immunity.

Dendritic cells originate from a bone marrow CD34+ precursor common to granulocytes and macrophages, and the existence of a separate dendritic cell colony- forming unit (CFU-DC) that give rise to pure dendritic cell colonies has been established in humans. In addition, a post-CFU CD14+ intermediate has been described with the potential to differentiate along the dendritic cell or the macrophage pathway under distinct cytokine conditions. This bipotential precursor is present in the bone marrow, cord blood and peripheral blood. Dendritic cells can be isolated based on specific cell surface markers, such as CDla+, CD3-, CD4-, CD20-, CD40+, CD80+, and CD83+, to delineate the maturation of cultured dendritic cells.

Dendritic cells based strategies provide a method for enhancing immune response against tumors and infectious agents. AIDS is another disease for which dendritic cell based therapies can be used, since dendritic cells can play a major role in promoting HIV- 1 replication. An immunotherapy requires the generation of dendritic cells from cancer patients, their in vi tro exposure to tumor Ag, derived from surgically removed tumor masses, and reinj ection of these cells into the tumor patients. Relatively crude membrane preparations of tumor cells will suffice as sources of tumor antigen, avoiding the necessity for molecular identification of the tumor antigen. The tumor antigen may also be synthetic peptides, carbohydrates, or nucleic acid sequences. In addition, concomitant administration of cytokines such as the multi-functional chimeric hematopoietic receptor agonists of the present invention may further facilitate the induction of tumor immunity. It is foreseen that the immunotherapy can be in an in vivo setting, wherein the multi-functional chimeric hematopoietic receptor agonists of the present invention is administered to a patient, having a tumor, alone or with other hematopoietic growth factors to increase the number of dendritic cells and endogenous tumor antigen is presented on the dendritic cells. It is also envisioned that in vivo immunotherapy can be with exogenous antigen. It is also envisioned that the immunotherapy treatment may include the mobilization of dendritic cell precursors or mature dendritic, by administering the multi-functional chimeric hematopoietic receptor agonists of the present invention alone or with other hematopoietic growth factors to the patient, removing the dendritic cell precursors or mature dendritic cells from the patient, exposing the dendritic cells to antigen and returning the dendritic cells to the patient. Furthermore, the dendritic cells that have been removed can be cultured ex vivo with the multi-functional chimeric hematopoietic receptor agonists of the present invention alone or with other hematopoietic growth factors to increase the number of dendritic cells prior to exposure to antigen. Dendritic cells based strategies also provide a method for reducing the immune response in auto-immune diseases.

Studies on dendritic cells have been greatly hampered by difficulties in preparing the cells in sufficient numbers and in a reasonably pure form. In an ex-vivo cell expansion setting, granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor- (TNF-α ) cooperate in the ex vivo generation of dendritic cells from hematopoietic progenitors (CD34+ cells) retrieved from bone marrow, cord blood, or peripheral blood and flk-2/flt-3 ligand and c-kit ligand (stem cell factor [SCF] ) synergize to enhance the GM-CSF plus TNF-α induced generation of dendritic cells (Siena, S. et al . Experimental Hematology 23 : 1463-1471 , 1995). Also provide is a method of ex vivo expansion of dendritic cell precursors or mature dendritic cells using the multi-functional chimeric hematopoietic receptor agonists of the present invention to provide sufficient quantities of dendritic cells for immunotherapy .

The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering various factors which modify the action of drugs, e.g., the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be in the range of 0.2 - 150 μg/kg of multifunctional chimeric hematopoietic receptor agonist protein per kilogram of body weight. Dosages would be adjusted relative to the activity of a given multifunctional chimeric hematopoietic receptor agonist protein and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of body weight per day. In addition, there may exist specific circumstances where dosages of multi-functional chimeric hematopoietic receptor agonist would be adjusted higher or lower than the range of 0.2 - 150 micrograms per kilogram of body weight. These include co-administration with other colony stimulating factors or IL-3 variants or growth factors; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated multi-functional chimeric hematopoietic receptor agonist protein; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other appropriate colony stimulating factors (CSFs), cytokines, lymphokines, hematopoietic growth factors and interleukins for simultaneous or serial co-administration with the polypeptides of the present invention includes GM-CSF, G-CSF, c-mpl ligand (also known as TPO or MGDF) , M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-3, IL-5, IL- 6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, LIF, flt3/flk2 ligand, B-cell growth factor, B- cell differentiation factor and eosinophil differentiation factor, stem cell factor (SCF) also known as steel factor or c-kit ligand, or combinations thereof. The dosage recited above would be adjusted to IS compensate for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by periodic assessment of the hematological profile, e.g., differential cell count and the like.

MATERIALS AND METHODS

Unless noted otherwise, all specialty chemicals were obtained from Sigma, Co. (St. Louis, MO) . Restriction endonucleases and T4 DNA ligase were obtained from New England Biolabs (Beverly, MA) or Boehringer Mannheim (Indianapolis, IN).

Transformation of E. coli strains

E. coli strains, such as DH5a™ (Life Technologies, Gaithersburg, MD) and TGI (Amersham Corp., Arlington Heights, IL) are used for transformation of ligation reactions and are the source of plasmid DNA for transfecting mammalian cells. E. coli strains, such as JM101 (Yanisch-Perron, et al . , Gene, 33: 103-119, 1985) and MON105 (Obukowicz, et al . , Appl . and Envir . Micr . , 58: 1511-1523, 1992) can be used for expressing the multi-functional chimeric hematopoietic receptor agonist of the present invention in the cytoplasm or periplasmic space .

MON105 ATCC#55204: F-, lambda- , IN (rrnD, rrE)l, rpoD+ , rpoH358

DH5a™: F-, phi80dlacZdeltaM15 , delta (lacZYA-argF) U169 , deoR, recAl, endAl, hsdR17 (rk- ,mk+) , phoA, supE441amda- , thi-1, gyrA96, relAl

TGI: delta ( lac-pro) , supE, thi-1, hsdD5/F ' ( traD36 , proA+B+, laclq, lacZdeltaM15 ) IS

JM101 ATCC#33876: delta (pro lac), supE, thi , F'(traD36, proA+B+, laclq, lacZdeltaM15 )

DH5a™ Subcloning efficiency cells are purchased as competent cells and are ready for transformation using the manufacturer's protocol, while both E. coli strains TGI and MON105 are rendered competent to take up DNA using a CaCl₂ method. Typically, 20 to 50 mL of cells are grown in LB medium (1% Bacto-tryptone, 0.5% Bacto- yeast extract, 150 mM NaCl) to a density of approximately 1.0 optical density unit at 600 nanometers (OD600) as measured by a Baush & Lomb Spectronic spectrophotometer (Rochester, NY) . The cells are collected by centrifugation and resuspended in one-fifth culture volume of CaCl₂ solution (50 mM CaCl₂, 10 mM

Tris-Cl, pH7.4) and are held at 4°C for 30 minutes. The cells are again collected by centrifugation and resuspended in one-tenth culture volume of CaCl₂ solution. Ligated DNA is added to 0.2 mL of these cells, and the samples are held at 4°C for 30-60 minutes. The samples are shifted to 42°C for two minutes and 1.0 mL of LB is added prior to shaking the samples at 37°C for one hour. Cells from these samples are spread on plates (LB medium plus 1.5% Bacto-agar) containing either ampicillin (100 micrograms/mL, ug/mL) when selecting for ampicillin-resistant transformants, or spectinomycin (75 ug/mL) when selecting for spectinomycin-resistant transformants . The plates are incubated overnight at 37°C. Colonies are picked and inoculated into LB plus appropriate antibiotic (100 ug/mL ampicillin or 75 ug/mL spectinomycin) and are grown at 37°C while shaking.

Methods for creation of genes with new N-terminus/C- terminus lo

Method I. Creation of genes with new N-terminus/C- terminus which contain a linker region (L₂) .

Genes with new N-terminus/C-terminus which contain a linker region (L₂) separating the original C-terminus and N-terminus can be made essentially following the method described in L . S. Mullins, et al (J^". Am . Chem . Soc . 116, 5529-5533, 1994). Multiple steps of polymerase chain reaction (PCR) amplifications are used to rearrange the DNA sequence encoding the primary amino acid sequence of the protein. The steps are illustrated in Figure 2.

In the first step, the first primer set ("new start" and "linker start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein followed by the linker (L₂) that connects the C-terminal and N-terminal ends of the original protein. In the second step, the second primer set ("new stop" and "linker stop") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Stop") that encodes the same linker as used above, followed by the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include the appropriate restriction sites which allow cloning of the new gene into expression plasmids. Typical PCR conditions are one cycle 95°C melting for two minutes; 25 cycles 94°C denaturation for one minute, 50°C annealing for one minute and 72°C extension for one minute; plus one cycle 72 °C extension for seven minutes . A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and one ug of template DNA; and lx

PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl2. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT) .

"Fragment Start" and "Fragment Stop", which have complementary sequence in the linker region and the coding sequence for the two amino acids on both sides of the linker, are joined together in a third PCR step to make the full-length gene encoding the new protein. The DNA fragments "Fragment Start" and "Fragment Stop" are resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen) . These fragments are combined in equimolar quantities, heated at 70°C for ten minutes and slow cooled to allow annealing through their shared sequence in "linker start" and "linker stop". In the third PCR step, primers "new start" and "new stop" are added to the annealed fragments to create and amplify the full-length new N-terminus/C-terminus gene. Typical PCR conditions are one cycle 95°C melting for two minutes; 25 cycles 94°C denaturation for one minute, 60°C annealing for one minute and 72°C extension for one minute; plus one cycle 72°C extension for seven minutes. A Perkin Elmer GeneAmp PCR Core Reagents kit is used. A 100 ul reaction contains 100 pmole of each primer and approximately 0.5 ug of DNA; and lx PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units

AmpliTaq DNA polymerase and 2 mM MgCl₂. PCR reactions are purified using a Wizard PCR Preps kit (Promega) .

Method II. Creation of genes with new N-terminus/C- terminus without a linker region.

New N-terminus/C-terminus genes without a linker joining the original N-terminus and C-terminus can be made using two steps of PCR amplification and a blunt end ligation. The steps are illustrated in Figure 3.

In the first step, the primer set ("new start" and "P-bl start") is used to create and amplify, from the original gene sequence, the DNA fragment ("Fragment Start") that contains the sequence encoding the new N-terminal portion of the new protein. In the second step, the primer set ("new stop" and "P-bl stop") is used to create and amplify, from gene sequence, the DNA fragment ("Fragment Stop") that contains the sequence encoding the new C-terminal portion of the new protein. The "new start" and "new stop" primers are designed to include appropriate restriction sites which allow cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95°C melting for two minutes; 25 cycles 94°C denaturation for one minute, 50°C annealing for 45 seconds and 72 °C extension for 45 seconds. Deep Vent polymerase (New England Biolabs) is used to reduce the occurrence of overhangs in conditions recommended by the manufacturer. The "P-bl start" and "P-bl stop" primers are phosphorylated at the 5 ' end to aid in the subsequent blunt end ligation of "Fragment Start" and "Fragment Stop" to each other. A 100 ul reaction contained 150 pmole of each primer and one ug of template DNA; and lx Vent buffer (New England Biolabs) , 300 uM dGTP, 300 uM dATP, 300 uM dTTP, 300 uM dCTP, and 1 unit Deep Vent polymerase. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin

Elmer Corporation, Norwalk, CT) . PCR reaction products are purified using a Wizard PCR Preps kit (Promega) .

The primers are designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typically "Fragment Start" is designed to create Ncol restriction site , and "Fragment Stop" is designed to create a Hindlll restriction site. Restriction digest reactions are purified using a Magic DNA Clean-up System kit

(Promega) . Fragments Start and Stop are resolved on a 1% TAE gel, stained with ethidium bromide and isolated using a Qiaex Gel Extraction kit (Qiagen) . These fragments are combined with and annealed to the ends of the ~ 3800 base pair Ncol/Hindlll vector fragment of pMON3934 by heating at 50°C for ten minutes and allowed to slow cool. The three fragments are ligated together using T4 DNA ligase (Boehringer Mannheim) . The result is a plasmid containing the full-length new N-terminus/C- terminus gene. A portion of the ligation reaction is used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Plasmid DNA is purified and sequence confirmed as below.

Method III. Creation of new N-terminus/C-terminus genes by tandem-duplication method

New N-terminus/C-terminus genes can be made based on the method described in R. A. Horlick, et al Protein Eng. 5:427-431, 1992). Polymerase chain reaction (PCR) amplification of the new N-terminus/C-terminus genes is performed using a tandemly duplicated template DNA. The steps are illustrated in Figure 3.

The tandemly-duplicated template DNA is created by cloning and contains two copies of the gene separated by DNA sequence encoding a linker connecting the original C- and N-terminal ends of the two copies of the gene. Specific primer sets are used to create and amplify a full-length new N terminus/C-terminus gene from the tandemly-duplicated template DNA. These primers are designed to include appropriate restriction sites which allow for the cloning of the new gene into expression vectors. Typical PCR conditions are one cycle 95°C melting for two minutes; 25 cycles 94°C denaturation for one minute, 50°C annealing for one minute and 72°C extension for one minute; plus one cycle 72 °C extension for seven minutes. A Perkin Elmer GeneAmp PCR Core

Reagents kit (Perkin Elmer Corporation, Norwalk, CT) is used. A 100 ul reaction contains 100 pmole of each primer and one ug of template DNA; and lx PCR buffer, 200 uM dGTP, 200 uM dATP, 200 uM dTTP, 200 uM dCTP, 2.5 units AmpliTaq DNA polymerase and 2 mM MgCl₂. PCR reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT) . PCR reactions are purified using a Wizard PCR Preps kit (Promega) .

Cloning of new N-terminus/C-terminus genes into multi- functional receptor agonist expression vectors.

The new N-terminus/C-terminus gene is digested with restriction endonucleases to create ends that are compatible to insertion into an expression vector containing another colony stimulating factor gene. This expression vector is likewise digested with restriction endonucleases to form compatible ends. After purification, the gene and the vector DNAs are combined and ligated using T4 DNA ligase. A portion of the ligation reaction is used to transform E. coli. Plasmid DNA is purified and sequenced to confirm the correct insert. The correct clones are grown for protein expression.

DNA isolation and characterization

Plasmid DNA can be isolated by a number of different methods and using commercially available kits known to those skilled in the art. A few such methods are shown herein. Plasmid DNA is isolated using the Promega Wizard™ Miniprep kit (Madison, WI) , the Qiagen QIAwe11 Plasmid isolation kits (Chatsworth, CA) or Qiagen Plasmid Midi kit. These kits follow the same general procedure for plasmid DNA isolation. Briefly, cells are pelleted by centrifugation (5000 x g) , plasmid DNA released with sequential NaOH/acid treatment, and cellular debris is removed by centrifugation (10000 x g) . The supernatant (containing the plasmid DNA) is loaded onto a column containing a DNA-binding resin, the column is washed, and plasmid DNA eluted with TE. After screening for the colonies with the plasmid of interest, the E. coli cells are inoculated into 50-100 mLs of LB plus appropriate antibiotic for overnight growth at 37°C in an air incubator while shaking. The purified plasmid DNA is used for DNA sequencing, further restriction enzyme digestion, additional subcloning of DNA fragments and transfection into mammalian, E. coli or other cells.

Sequence confirmation.

Purified plasmid DNA is resuspended in dH₂0 and quantitated by measuring the absorbance at 260/280 nm in a Bausch and Lomb Spectronic 601 UV spectrometer. DNA samples are sequenced using ABI PRISM™ DyeDeoxy™ terminator sequencing chemistry (Applied Biosystems Division of Perkin Elmer Corporation, Lincoln City, CA) kits (Part Number 401388 or 402078) according to the manufacturers suggested protocol usually modified by the addition of 5% DMSO to the sequencing mixture. Sequencing reactions are performed in a Model 480 DNA thermal cycler (Perkin Elmer Corporation, Norwalk, CT) following the recommended amplification conditions. Samples are purified to remove excess dye terminators with Centri-Sep™ spin columns (Princeton Separations, Adelphia, NJ) and lyophilized. Fluorescent dye labeled sequencing reactions are resuspended in deionized formamide, and sequenced on denaturing 4.75% polyacrylamide-8M urea gels using an ABI Model 373A automated DNA sequencer . Overlapping DNA sequence fragments are analyzed and assembled into master DNA contigs using Sequencher DNA analysis software (Gene Codes Corporation, Ann Arbor, MI) . %

Expression of multi-functional receptor agonists in mammalian cells

Mammalian Cell Transfection/Production of Conditioned Media

The BHK-21 cell line can be obtained from the ATCC (Rockville, MD) . The cells are cultured in Dulbecco's modified Eagle media (DMEM/high-glucose) , supplemented to 2 mM (mM) L-glutamine and 10% fetal bovine serum

(FBS) . This formulation is designated BHK growth media. Selective media is BHK growth media supplemented with 453 units/mL hygromycin B (Calbiochem, San Diego, CA) . The BHK-21 cell line was previously stably transfected with the HSV transactivating protein VP16, which transactivates the IE110 promoter found on the plasmid pMON3359 (See Hippenmeyer et al . , Bio /Technology, pp.1037-1041, 1993). The VP16 protein drives expression of genes inserted behind the IE110 promoter. BHK-21 cells expressing the transactivating protein VP16 are designated BHK-VP16. The plasmid pMONlllδ (See Highkin et al., Poul try Sci . , 70: 970-981, 1991) expresses the hygromycin resistance gene from the SV40 promoter. A similar plasmid is available from ATCC, pSV2-hph. BHK-VP16 cells are seeded into a 60 millimeter (mm) tissue culture dish at 3 X 10 cells per dish 24 hours prior to transfection. Cells are transfected for 16 hours in 3 mL of "OPTIMEM"™ (Gibco-BRL, Gaithersburg, MD) containing 10 ug of plasmid DNA containing the gene of interest, 3 ug hygromycin resistance plasmid,

PM0N1118, and 80 ug of Gibco-BRL "LIPOFECTAMINE"™ per dish. The media is subsequently aspirated and replaced with 3 mL of growth media. At 48 hours post- transfection, media from each dish is collected and assayed for activity (transient conditioned media). The cells are removed from the dish by trypsin-EDTA, diluted 1:10 and transferred to 100 mm tissue culture dishes containing 10 mL of selective media. After approximately 7 days in selective media, resistant cells grow into colonies several millimeters in diameter. The colonies are removed from the dish with filter paper (cut to approximately the same size as the colonies and soaked in trypsin/EDTA) and transferred to individual wells of a 24 well plate containing 1 mL of selective media. After the clones are grown to confluence, the conditioned media is re-assayed, and positive clones are expanded into growth media.

Expression of multi-functional receptor agonists in E. coli

E. coli strain MON105 or JM101 harboring the plasmid of interest are grown at 37°C in M9 plus casamino acids medium with shaking in a air incubator Model G25 from New Brunswick Scientific (Edison, New Jersey) . Growth is monitored at OD600 until it reaches a value of 1.0 at which time Nalidixic acid (10 milligrams/mL) in 0.1 N NaOH is added to a final concentration of 50 μg/mL. The cultures are then shaken at 37°C for three to four additional hours. A high degree of aeration is maintained throughout culture period in order to achieve maximal production of the desired gene product. The cells are examined under a light microscope for the presence of inclusion bodies (IB) . One mL aliquots of the culture are removed for analysis of protein content by boiling the pelleted cells, treating them with reducing buffer and electrophoresis via SDS-PAGE (see Maniatis et al . Molecular Cloning: A Laboratory Manual, 1982) . The culture is centrifuged (5000 x g) to pellet the cells.

Inclusion Body preparation. Extraction, Refolding, Dialysis, DEAE Chromatography, and Characterization of the multi-functional chimeric hematopoietic receptor 18 agonists which accumulate as inclusion bodies in E. coli .

Isolation of Inclusion Bodies:

The cell pellet from a 330 mL E. coli culture is resuspended in 15 mL of sonication buffer (10 mM 2- amino-2- (hydroxymethyl) 1, 3-propanediol hydrochloride (Tris-HCl), pH 8.0 + 1 mM ethylenediaminetetraacetic acid (EDTA) . These resuspended cells are sonicated using the microtip probe of a Sonicator Cell Disruptor (Model W-375, Heat Systems-Ultrasonics , Inc., Farmingdale, New York) . Three rounds of sonication in sonication buffer followed by centrifugation are employed to disrupt the cells and wash the inclusion bodies (IB) . The first round of sonication is a 3 minute burst followed by a 1 minute burst, and the final two rounds of sonication are for 1 minute each.

Extraction and refolding of proteins from inclusion body pellets :

Following the final centrifugation step, the IB pellet is resuspended in 10 mL of 50 mM Tris-HCl, pH 9.5, 8 M urea and 5 mM dithiothreitol (DTT) and stirred at room temperature for approximately 45 minutes to allow for denaturation of the expressed protein.

The extraction solution is transferred to a beaker containing 70 mL of 5 mM Tris-HCl, pH 9.5 and 2.3 M urea and gently stirred while exposed to air at 4°C for 18 to 48 hours to allow the proteins to refold. Refolding is monitored by analysis on a Vydac (Hesperia, Ca.) C18 reversed phase high pressure liquid chromatography (RP- HPLC) column (0.46x25 cm). A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid

(TFA) , is employed to monitor the refold. This gradient is developed over 30 minutes at a flow rate of 1.5 mL ? per minute. Denatured proteins generally elute later in the gradient than the refolded proteins.

Purification:

Following the refold, contaminating E. coli proteins are removed by acid precipitation. The pH of the refold solution is titrated to between pH 5.0 and pH 5.2 using 15% (v/v) acetic acid (HOAc) . This solution is stirred at 4°C for 2 hours and then centrifuged for 20 minutes at 12,000 x g to pellet any insoluble protein.

The supernatant from the acid precipitation step is dialyzed using a Spectra/Por 3 membrane with a molecular weight cut off (MWCO) of 3,500 daltons. The dialysis is against 2 changes of 4 liters (a 50-fold excess) of 10 mM Tris-HCl, pH 8.0 for a total of 18 hours. Dialysis lowers the sample conductivity and removes urea prior to DEAE chromatography. The sample is then centrifuged (20 minutes at 12,000 x g) to pellet any insoluble protein following dialysis.

A Bio-Rad Bio-Scale DEAE2 column (7 x 52 mm) is used for ion exchange chromatography. The column is equilibrated in a buffer containing 10 mM Tris-HCl, pH 8.0, and a 0-to-500 mM sodium chloride (NaCl) gradient, in equilibration buffer, over 45 column volumes is used to elute the protein. A flow rate of 1.0 mL per minute is used throughout the run. Column fractions (2.0 mL per fraction) are collected across the gradient and analyzed by RP HPLC on a Vydac (Hesperia, Ca.) C18 column (0.46 x 25 cm) . A linear gradient of 40% to 65% acetonitrile, containing 0.1% trifluoroacetic acid (TFA), is employed. This gradient is developed over 30 minutes at a flow rate of 1.5 mL per minute. Pooled fractions are then dialyzed against 2 changes of 4 liters (50-to-500-fold excess) of 10 mM ammonium acetate (NH4Ac) , pH 4.0 for a total of 18 hours. Dialysis is performed using a Spectra/Por 3 membrane with a MWCO of So

3,500 daltons. Finally, the sample is sterile filtered using a 0.22μm syringe filter (μStar LB syringe filter, Costar, Cambridge, Ma.), and stored at 4°C.

In some cases the folded proteins can be affinity purified using affinity reagents such as mAbs or receptor subunits attached to a suitable matrix. Alternatively, (or in addition) purification can be accomplished using any of a variety of chromatographic methods such as: ion exchange, gel filtration or hydrophobic chromatography or reversed phase HPLC.

These and other protein purification methods are described in detail in Methods in Enzymology, Volume 182 'Guide to Protein Purification' edited by Murray Deutscher, Academic Press, San Diego, CA (1990).

Protein Characterization:

The purified protein is analyzed by RP-HPLC, electrospray mass spectrometry, and SDS-PAGE. The protein quantitation is done by amino acid composition, RP-HPLC, and Bradford protein determination. In some cases tryptic peptide mapping is performed in conjunction with electrospray mass spectrometry to confirm the identity of the protein.

AML Proliferation Assay for Bioactive Human Interleukin- 3

The factor-dependent cell line AML 193 was obtained from the American Type Culture Collection (ATCC,

Rockville, MD) . This cell line, established from a patient with acute myelogenous leukemia, is a growth factor dependent cell line which displayed enhanced growth in GM-CSF supplemented medium (Lange, B., et al . , Blood 70: 192, 1987; Valtieri, M. , et al . , J. Immunol . 138:4042, 1987). The ability of AML 193 cells to proliferate in the presence of human IL-3 has also been documented. (Santoli, D. , et al . , J^". Immunol . 139: 348, 1987) . A cell line variant was used, AML 193 1.3, which was adapted for long term growth in IL-3 by washing out the growth factors and starving the cytokine dependent AML 193 cells for growth factors for 24 hours. The cells are then replated at 1x10 cells/well in a 24 well plate in media containing 100 U/mL IL-3. It took approximately 2 months for the cells to grow rapidly in IL-3. These cells are maintained as AML 193 1.3 thereafter by supplementing tissue culture medium (see below) with human IL-3.

AML 193 1.3 cells are washed 6 times in cold Hanks balanced salt solution (HBSS, Gibco, Grand Island, NY) by centrifuging cell suspensions at 250 x g for 10 minutes followed by decantation of the supernatant. Pelleted cells are resuspended in HBSS and the procedure is repeated until six wash cycles are completed. Cells washed six times by this procedure are resuspended in tissue culture medium at a density ranging from 2 x 10

5 to 5 x 10 viable cells/mL. This medium is prepared by supplementing Iscove's modified Dulbecco ' s Medium (IMDM,

Hazelton, Lenexa, KS) with albumin, transferrin, lipids and 2-mercaptoethanol . Bovine albumin (Boehringer- Mannheim, Indianapolis, IN) is added at 500 μg/mL; human transferrin (Boehringer-Mannheim, Indianapolis, IN) is added at 100 μg/mL; soybean lipid (Boehringer-Mannheim, Indianapolis, IN) is added at 50 μg/mL; and 2- mercaptoethanol (Sigma, St. Louis, MO) is added at 5 x

10^~ M.

Serial dilutions of human interleukin-3 or multi- functional chimeric hematopoietic receptor agonist proteins are made in triplicate series in tissue culture medium supplemented as stated above in 96 well Costar 3596 tissue culture plates. Each well contained 50 μl of medium containing interleukin-3 or multi-functional chimeric hematopoietic receptor agonist proteins once serial dilutions are completed. Control wells contained tissue culture medium alone (negative control) . AML 193 1.3 cell suspensions prepared as above are added to each

4 well by pipetting 50 μl (2.5 x 10 cells) into each well. Tissue culture plates are incubated at 37°C with 5% C0₂ in humidified air for 3 days. On day 3, 0.5 μCi

³H-thymidine (2 Ci/mM, New England Nuclear, Boston, MA) is added in 50 μl of tissue culture medium. Cultures are incubated at 37 °C with 5% C0₂ in humidified air for

18-24 hours. Cellular DNA is harvested onto glass filter mats (Pharmacia LKB, Gaithersburg, MD) using a TOMTEC cell harvester (TOMTEC, Orange, CT) which utilized a water wash cycle followed by a 70% ethanol wash cycle. Filter mats are allowed to air dry and then placed into sample bags to which scintillation fluid (Scintiverse II, Fisher Scientific, St. Louis, MO or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, MD) is added. Beta emissions of samples from individual tissue culture wells are counted in a LKB BetaPlate model 1205 scintillation counter (Pharmacia LKB, Gaithersburg, MD) and data is expressed as counts per minute of ³H-thymidine incorporated into cells from each tissue culture well. Activity of each human interleukin-3 preparation or multi-functional chimeric hematopoietic receptor agonist protein preparation is quantitated by measuring cell proliferation (³H-thymidine incorporation) induced by graded concentrations of interleukin-3 or multifunctional chimeric hematopoietic receptor agonist.

5

Typically, concentration ranges from 0.05 pM - 10 pM are quantitated in these assays. Activity is determined by measuring the dose of interleukin-3 or multifunctional chimeric hematopoietic receptor agonist protein which provides 50% of maximal proliferation (EC₅₀ = 0.5 x (maximum average counts per minute of ³H- thymidine incorporated per well among triplicate cultures of all concentrations of interleukin-3 tested - S3 background proliferation measured by ³H-thymidine incorporation observed in triplicate cultures lacking interleukin-3) . This EC₅₀ value is also equivalent to 1 unit of bioactivity. Every assay is performed with native interleukin-3 as a reference standard so that relative activity levels could be assigned.

Typically, the multi-functional chimeric hematopoietic receptor agonist proteins were tested in a concentration range of 2000 pM to 0.06 pM titrated in serial 2 fold dilutions.

Activity for each sample was determined by the concentration which gave 50% of the maximal response by fitting a four-parameter logistic model to the data. It was observed that the upper plateau (maximal response) for the sample and the standard with which it was compared did not differ. Therefore relative potency calculation for each sample was determined from EC50 estimations for the sample and the standard as indicated above. AML 193.1.3 cells proliferate in response to hIL-3 , hGM-CSF and hG-CSF. Therefore the following additional assays were performed for some samples to demonstrate that the G-CSF receptor agonist portion of the multi-functional chimeric hematopoietic receptor agonist proteins was active. The proliferation assay was performed with the multi-functional chimeric hematopoietic receptor agonist plus and minus neutralizing monoclonal antibodies to the hIL-3 receptor agonist portion. In addition, a fusion molecule with the factor Xa cleavage site was cleaved then purified and the halves of the molecule were assayed for proliferative activity. These experiments showed that both components of the multi-functional chimeric hematopoietic receptor agonist proteins were active.

TFl c-mpl ligand dependent proliferation assay

The c-mpl ligand proliferative activity can be assayed using a subclone of the pluripotential human cell line TFl (Kitamura et al . , J. Cell Physiol 140:323- 334. [1989]). TFl cells are maintained in h-IL3 (100 U/mL) . To establish a sub-clone responsive to c-mpl ligand, cells are maintained in passage media containing 10% supernatant from BHK cells transfected with the gene expressing the 1-153 form of c-mpl ligand (pMON26448). Most of the cells die, but a subset of cells survive. After dilution cloning, a c-mpl ligand responsive clone is selected, and these cells are split into passage

6 media to a density of 0.3 x 10 cells/mL the day prior to assay set-up. Passage media for these cells is the following: RPMI 1640 (Gibco) , 10% FBS (Harlan, Lot #91206) , 10% c-mpl ligand supernatant from transfected BHK cells, 1 mM sodium pyruvate (Gibco), 2 mM glutamine (Gibco) , and 100 ug/mL penicillin-streptomycin (Gibco) . The next day, cells are harvested and washed twice in RPMI or IMDM media with a final wash in the ATL, or assay media. ATL medium consists of the following: IMDM (Gibco) , 500 ug/mL of bovine serum albumin, 100 ug/mL of human transferrin, 50 ug/mL soybean lipids, 4 x 10-8M beta-mercaptoethanol and 2 mL of A9909 (Sigma, antibiotic solution) per 1000 mL of ATL. Cells are

6 diluted m assay media to a final density of 0.25 x 10 cells/mL in a 96-well low evaporation plate (Costar) to a final volume of 50 ul . Transient supernatants

(conditioned media) from transfected clones are added at a volume of 50 ul as duplicate samples at a final concentration of 50% and diluted three-fold to a final dilution of 1.8%. Triplicate samples of a dose curve of IL-3 variant pMON13288 starting at 1 ng/mL and diluted using three-fold dilutions to 0.0014ng/mL is included as a positive control. Plates are incubated at 5% C0₂ and

37° C. At day six of culture, the plate is pulsed with 0.5 Ci of 3H/well (NEN) in a volume of 20 ul/well and allowed to incubate at 5% C0₂ and 37° C for four hours. The plate is harvested and counted on a Betaplate counter.

MUTZ-2 Cell Proliferation Assay

A cell line such as MUTZ-2, which is a human myeloid leukemia cell line (German Collection of Microorganisms and Cell Cultures, DSM ACC 271), can be used to determine the cell proliferative activity of flt3 receptor agonists. MUTZ-2 cultures are maintained with recombinant native flt3 ligand (20-100ng/mL) in the growth medium. Eighteen hours prior to assay set-up, MUTZ-2 cells are washed in IMDM medium (Gibco) three times and are resuspended in IMDM medium alone at a concentration of 0.5-0.7 x 10E6 cells/mL and incubated at 37°C and 5%C0₂ to starve the cells of flt3 ligand.

The day of the assay, standards and flt3 receptor agonists are diluted to two fold above desired final concentration in assay media in sterile tissue culture treated 96 well plates. Flt3 receptor agonists and standards are tested in triplicate. 50μl of assay media is loaded into all wells except row A. 75μl of the flt3 receptor agonists or standards are added to row A and 25μl taken from that row and serial dilutions (1:3) performed on the rest of the plate (rows B through G) . Row H remains as a media only control . The starved MUTZ-2 cells are washed two times in IMDM medium and resuspended in 50μl assay media. 50μl of cells are added to each well resulting in a final concentration of 0.25 x 10E6cells/mL . Assay plates containing cells are incubated at 37°C and 5%C0₂ for 44hrs . Each well is then pulsed with lμCi/well of tritiated thymidine in a volume of 20μl for four hours. Plates are then harvested and counted.

Other in vitro cell based proliferation assays Other in vitro cell based assays, known to those skilled in the art, may also be useful to determine the activity of the multi-functional chimeric hematopoietic receptor agonists depending on the factors that comprise the molecule in a similar manner as described in the AML 193.1.3 cell proliferation assay. The following are examples of other useful assays .

TFl proliferation assay: TFl is a pluripotential human cell line (Kitamura et al . , J. Cell Physiol 140:323-334. [1989]) that responds to hIL-3.

32D proliferation assay: 32D is a murine IL-3 dependent cell line which does not respond to human IL-3 but does respond to human G-CSF which is not species restricted.

Baf/3 proliferation assay: Baf/3 is a murine IL-3 dependent cell line which does not respond to human IL-3 or human c-mpl ligand but does respond to human G-CSF which is not species restricted.

T1165 proliferation assay: T1165 cells are a IL-6 dependent murine cell line (Nordan et al . , 1986) which respond to IL-6 and IL-11.

Human Plasma Clot meg-CSF Assay: Used to assay megakaryocyte colony formation activity (Mazur et al . , 1981) .

Transfected cell lines:

Cell lines such as the murine Baf/3 cell line can be transfected with a colony stimulating factor receptor, such as the human G-CSF receptor or human c- mpl receptor, which the cell line does not have. These transfected cell lines can be used to determine the activity of the ligand for which the receptor has been transfected into the cell line. One such transfected Baf/3 cell line was made by cloning the cDNA encoding c-mpl from a library made from a c-mpl responsive cell line and cloned into the multiple cloning site of the plasmid pcDNA3 (Invitrogen, San Diego Ca.). Baf/3 cells were transfected with the plasmid via electroporation. The cells were grown under G418 selection in the presence of mouse IL-3 in Wehi conditioned media. Clones were established through limited dilution. In a similar manner the human G-CSF receptor can be transfected into the Baf/3 cell line and used to determine the bioactivity of the multi-functional chimeric hematopoietic receptor agonists .

Analysis of c-mpl ligand proliferative activity

Methods

1. Bone marrow proliferation assay a. CD34+ Cell Purification:

Bone marrow aspirates (15-20 mL) were obtained from normal allogeneic marrow donors after informed consent. Cells were diluted 1:3 in phosphate buffered saline (PBS, Gibco-BRL) , 30 mL were layered over 15 mL

Histopaque-1077 (Sigma) and centrifuged for 30 minutes at 300 RCF . The mononuclear interface layer was collected and washed in PBS. CD34+ cells were enriched from the mononuclear cell preparation using an affinity column per manufacturers instructions (CellPro, Inc., Bothell WA) . After enrichment, the purity of CD34+ cells was 70% on average as determined by using flow cytometric analysis using anti-CD34 monoclonal antibody conjugated to fluorescein and anti-CD38 conjugated to phycoerythrin (Becton Dickinson, San Jose CA) .

Cells were resuspended at 40,000 cells/mL in X-Vivo 10 media (Bio-Whittaker, Walkersville, MD) and 1 mL was plated in 12-well tissue culture plates (Costar) . The $$ growth factor rhIL-3 was added at 100 ng/mL (pMON5873) was added to some wells. hIL3 variants were used at 10 ng/mL to 100 ng/mL. Conditioned media from BHK cells transfected with plasmid encoding c-mpl ligand or multi- functional chimeric hematopoietic receptor agonists were tested by addition of 100 μl of supernatant added to 1 mL cultures (approximately a 10% dilution) . Cells were incubated at 37°C for 8-14 days at 5% C0₂ in a 37°C humidified incubator.

b. Cell Harvest and Analysis:

At the end of the culture period a total cell count was obtained for each condition. For fluorescence analysis and ploidy determination cells were washed in megakaryocyte buffer (MK buffer, 13.6 mM sodium citrate, 1 mM theophylline, 2.2 μm PGE1, 11 mM glucose, 3% w/v BSA, in PBS, pH 7.4,) (Tomer et al . , Blood 70: 1735- 1742, 1987) resuspended in 500 μl of MK buffer containing anti-CD41a FITC antibody (1:200, AMAC, Westbrook, ME) and washed in MK buffer. For DNA analysis cells were permeablized in MK buffer containing 0.5% Tween 20 (Fisher, Fair Lawn NJ) for 20 min. on ice followed by fixation in 0.5% Tween-20 and 1% paraformaldehyde (Fisher Chemical) for 30 minutes followed by incubation in propidium iodide (Calbiochem , La Jolla Ca) (50 μg/mL) with RNA-ase (400 U/mL) in 55% v/v MK buffer (200mOsm) for 1-2 hours on ice. Cells were analyzed on a FACScan or Vantage flow cytometer (Becton Dickinson, San Jose, CA) . Green fluorescence (CD41a-FITC) was collected along with linear and log signals for red fluorescence (PI) to determine DNA ploidy. All cells were collected to determine the percent of cells that were CD41+. Data analysis was performed using software by LYSIS (Becton Dickinson, San Jose, CA) . Percent of cells expressing the CD41 antigen was obtained from flow cytometry analysis (Percent) . Absolute (Abs) number of CD41+ cells/mL was calculated by: (Abs) = (Cell Count)* (Percent ) /100.

2. Megakaryocyte fibrin clot assay.

CD34+ enriched population were isolated as described above. Cells were suspended at 25,000 cells/mL with or without cytokine(s) in a media consisting of a base Iscoves IMDM media supplemented with 0.3% BSA, 0.4mg/mL apo-transferrin, 6.67μM FeCl₂, 25μg/mL CaCl₂, 25μg/mL L- asparagine, 500μg/mL e-amino-n-caproic acid and penicillin/streptomycin. Prior to plating into 35mm plates, thrombin was added (0.25 Units/mL) to initiate clot formation. Cells were incubated at 37°C for 13 days at 5% C0₂ in a 37°C humidified incubator.

At the end of the culture period plates were fixed with methanol : acetone (1:3), air dried and stored at -200C until staining. A peroxidase immunocytochemistry staining procedure was used (Zymed, Histostain-SP. San Francisco, CA) using a cocktail of primary monoclonal antibodies consisting of anti-CD41a, CD42 and CD61. Colonies were counted after staining and classified as negative, CFU-MK (small colonies, 1-2 foci and less that approx. 25 cells), BFU-MK (large, multi-foci colonies with > 25 cells) or mixed colonies (mixture of both positive and negative cells.

Methylcellulose Assay

This assay reflects the ability of colony stimulating factors to stimulate normal bone marrow cells to produce different types of hematopoietic colonies in vi tro (Bradley et al . , Aust . Exp Biol . Sci . 44:287-300, 1966), Pluznik et al . , J. Cell Comp . Physio 66:319-324, 1965) . φ

Methods

Approximately 30 mL of fresh, normal, healthy bone marrow aspirate are obtained from individuals following informed consent. Under sterile conditions samples are diluted 1:5 with a IX PBS (#14040.059 Life Technologies, Gaithersburg, MD.) solution in a 50 mL conical tube (#25339-50 Corning, Corning MD) . Ficoll (Histopaque 1077 Sigma H-8889) is layered under the diluted sample and centrifuged, 300 x g for 30 min. The mononuclear cell band is removed and washed two times in IX PBS and once with 1% BSA PBS (CellPro Co., Bothel, WA) . Mononuclear cells are counted and CD34+ cells are selected using the Ceprate LC (CD34) Kit (CellPro Co., Bothel, WA) column. This fractionation is performed since all stem and progenitor cells within the bone marrow display CD34 surface antigen.

Cultures are set up in triplicate with a final volume of 1.0 mL in a 35 X 10 mm petri dish (Nunc#174926) . Culture medium is purchased from Terry Fox Labs. (HCC- 4230 medium (Terry Fox Labs, Vancouver, B.C., Canada) and erythropoietin (Amgen, Thousand Oaks, CA. ) is added to the culture media. 3,000-10,000 CD34+ cells are added per dish. Recombinant IL-3, purified from mammalian cells or E. coli , and multi-functional chimeric hematopoietic receptor agonist proteins, in conditioned media from transfected mammalian cells or purified from conditioned media from transfected mammalian cells or E. coli , are added to give final concentrations ranging from .001 nM to 10 nM.

Recombinant hIL-3, GM-CSF, c-mpl ligand and multifunctional chimeric hematopoietic receptor agonist are supplied in house. G-CSF (Neupogen) is from Amgen (Thousand Oaks Calf.) . Cultures are resuspended using a 3cc syringe and 1.0 mL is dispensed per dish. Control (baseline response) cultures received no colony stimulating factors. Positive control cultures received conditioned media (PHA stimulated human cells: Terry Fox $\

Lab. H2400) . Cultures are incubated at 37°C, 5% C0₂ in humidified air.

Hematopoietic colonies which are defined as greater than 50 cells are counted on the day of peak response (days 10-11) using a Nikon inverted phase microscope with a 40x objective combination. Groups of cells containing fewer than 50 cells are referred to as clusters. Alternatively colonies can be identified by spreading the colonies on a slide and stained or they can be picked, resuspended and spun onto cytospin slides for staining.

Human Cord Blood Hemopoietic Growth Factor Assays

Bone marrow cells are traditionally used for in vitro assays of hematopoietic colony stimulating factor (CSF) activity. However, human bone marrow is not always available, and there is considerable variability between donors. Umbilical cord blood is comparable to bone marrow as a source of hematopoietic stem cells and progenitors (Broxmeyer et al . , PNAS USA 89:4109-113, 1992; Mayani et al . , Blood 81:3252-3258, 1993). In contrast to bone marrow, cord blood is more readily available on a regular basis. There is also a potential to reduce assay variability by pooling cells obtained fresh from several donors, or to create a bank of cryopreserved cells for this purpose. By modifying the culture conditions, and/or analyzing for lineage specific markers, it is be possible to assay specifically for granulocyte / macrophage colonies (CFU- GM) , for megakaryocyte CSF activity, or for high proliferative potential colony forming cell (HPP-CFC) activity.

Methods

Mononuclear cells (MNC) are isolated from cord blood within 24 hr . of collection, using a standard density gradient (1.077 g/mL Histopaque) . Cord blood MNC have been further enriched for stem cells and progenitors by several procedures, including immunomagnetic selection for CD14-, CD34+ cells; panning for SBA- , CD34+ fraction using coated flasks from Applied Immune Science (Santa Clara, CA) ; and CD34+ selection using a CellPro (Bothell, WA) avidin column. Either freshly isolated or cryopreserved CD34+ cell enriched fractions are used for the assay. Duplicate cultures for each serial dilution of sample (concentration range from 1 pM to 1204 pM) are

4 prepared with 1x10 cells m 1ml of 0.9% methylcellulose containing medium without additional growth factors (Methocult H4230 from Stem Cell Technologies, Vancouver, BC . ) . In some experiments, Methocult H4330 containing erythropoietin (EPO) was used instead of Methocult

H4230, or Stem Cell Factor (SCF) , 50 ng/mL (Biosource International, Camarillo, CA) was added. After culturing for 7-9 days, colonies containing >30 cells are counted. In order to rule out subjective bias in scoring, assays are scored blind.

Additional details about recombinant DNA methods which may be used to create the variants, express them in bacteria, mammalian cells or insect cells, purification and refold of the desired proteins and assays for determining the bioactvity of the proteins may be found in co-filed Applications WO 95/00646, WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254 and US 08/383,035 which are hereby incorporated by reference in their entirety. Further details known to those skilled in the art may be found in T. Maniatis, et al . , Molecular Cloning, A Laboratory Manual , Cold Spring Harbor Laboratory, 1982) and references cited therein, incorporated herein by reference; and in J. Sambrook, et al . , Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory, 1989) and references cited therein, incorporated herein by reference. TABLE 1 OLIGONUCLEOTIDES c-mplNcol ACGTCCATGGCNTCNCCNGCNCCNCCTGCTTGTGCACTCCGAGTC SEQ ID NO: 317 N=A,C,G or T

Ecompl ATGCACGAATTCCCTGACGCAGAGGGTGGA SEQ ID NO: 318 c-mplHindlll TGACAAGCTTACCTGACGCAGAGGGTGGACCCT SEQ ID NO: 319

4L-5' AATTCGGCAA SEQ ID NO: 320

4L-3' CATGTTGCCG SEQ ID NO:321

5L-5' AATTCGGCGGCAA SEQ ID NO: 322

5L-3' CATGTTGCCGCCG SEQ ID NO:323 8L-5' AATTCGGCGGCAACGGCGGCAA SEQ ID NO: 324

8L-3' CATGTTGCCGCCGTTGCCGCCG SEQ ID NO: 325

31-5' CGATCCATGGAGGTTCACCCTTTGCCT SEQ ID NO: 3 6

31-3' GATCAAGCTTATGGGCACTGGCTCAGTCT SEQ ID NO: 327

35-5' CGATACATGTTGCCTACACCTGTCCTG SEQ ID NO: 328 35-3' GATCAAGCTTAAGGGTGAACCTCTGGGCA SEQ ID NO:329

39-5' CGATCCATGGTCCTGCTGCCTGCTGTG SEQ ID NO: 330

39-3' GATCAAGCTTAAGGTGTAGGCAAAGGGTG SEQ ID NO: 331

43-5' CGATCCATGGCTGTGGACTTTAGCTTGGGA SEQ ID NO: 332

43-3' GATCAAGCTTAAGGCAGCAGGACAGGTGT SEQ ID NO: 333 45-5' CGATCCATGGACTTTAGCTTGGGAGAA SEQ ID NO: 334

45-3' GATCAAGCTTACACAGCAGGCAGCAGGAC SEQ ID NO: 335

49-5' CGATCCATGGGAGAATGGAAAACCCAG SEQ ID NO: 336

49-3' GATCAAGCTTACAAGCTAAAGTCCACAGC SEQ ID NO: 337

82-5' CGATCCATGGGACCCACTTGCCTCTCA SEQ ID NO: 338 82-3' GATCAAGCTTACAGTTGTCCCCGTGCTGC SEQ ID NO: 339

109-5' CAGTCCATGGGAACCCAGCTTCCTCCA SEQ ID NO: 340

109-3' GATCAAGCTTAAAGGAGGCTCTGCAGGGC SEQ ID NO: 341

116-5' CGATCCATGGGCAGGACCACAGCTCAC SEQ ID NO: 342

116-3' GATCAAGCTTACTGTGGAGGAAGCTGGGTT SEQ ID NO: 343 120-5' CGATCCATGGCTCACAAGGATCCCAATGCC SEQ ID NO: 344

120-3' GATCAAGCTTATGTGGTCCTGCCCTGTGG SEQ ID NO: 345

123-5' CGATCCATGGATCCCAATGCCATCTTCCTG SEQ ID NO: 346

123-3' GATCAAGCTTACTTGTGAGCTGTGGTCCT SEQ ID NO: 347

126-5' CGATCCATGGCCATCTTCCTGAGCTTCCAA SEQ ID NO:348 126-3' GATCAAGCTTAATTGGGATCCTTGTGAGCTGT SEQ ID NO: 349

SYNNOXAl.REQ AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC TCC SEQ ID NO: 350 SYNNOXA2. REQ CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA GATAGAAGGT CAGTTTACGA CGG SEQ ID NO: 351 Llsyn.for GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC TATAATGAT SEQ ID NO: 352

Llsyn.rev CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TCAAGG SEQ ID NO: 353

L3syn.for GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT

CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GAT SEQ ID NO: 354 L3syn.rev CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC

GCCAGAGCCA CCACCCTGTT GTTCCTGCGC TTGCTCAAGG SEQ ID NO: 355

35start.seq GATCGACCAT GGCTCTGGAC CCGAACAACC TC SEQ ID NO:356 34rev.seq CTCGATTACG TACAAAGGTG CAGGTGGT SEQ ID NO: 357

70start.seq GATCGACCAT GGCTAATGCA TCAGGTATTG AG SEQ ID NO: 358

69rev.seq CTCGATTACG TATTCTAAGT TCTTGACA SEQ ID NO: 359

91start.seq GATCGACCAT GGCTGCACCC TCTCGACATC CA SEQ ID NO: 360

90rev.seq CTCGATTACG TAGGCCGTGG CAGAGGGC SEQ ID NO: 361 lOlstart.seq GATCGACCAT GGCTGCAGGT GACTGGCAAG AA SEQ ID NO: 362 lOOrev.seq CTCGATTACG TACTTGATGA TGATTGGA SEQ ID NO:363

L-llstart.seq GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CGCG SEQ ID NO: 364

L-llstop.seq CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG

AGCTTCCTGC TCAAGTCTTT AGAG SEQ ID NO: 365 P-blstart.seqGGGCTGCGCA AGGTGGCG SEQ ID NO:366

P-blstop.seq ACACCATTGG GCCCTGCCAG C SEQ ID NO: 367

39start.seq GATCGACCAT GGCTTACAAG CTGTGCCACC CC SEQ ID NO:368

38stop.Seq CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT SEQ ID NO:369

97start.seq GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC SEQ ID NO: 370 96stop.Seq CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT SEQ ID NO: 371

126start.seq GATCGACCAT GGCTATGGCC CCTGCCCTGC AG SEQ ID NO:372

125stop.Seq CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT SEQ ID NO: 373

133start.seq GATCGACCAT GGCTACCCAG GGTGCCATGC CG SEQ ID NO: 374

132stop.seq CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA SEQ ID NO: 375 142start.seq GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG SEQ ID NO:376

141stop.Seq CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC SEQ ID NO: 377

GLYXA1 GTAGAGGGCG GTGGAGGCTC C SEQ ID NO: 378

GLYXA2 CCGGGGAGCC TCCACCGCCC TCTAC SEQ ID NO: 379 lGGGSfor TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG SEQ ID NO: 380 lGGGSrev CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA SEQ ID NO: 381

NCOFLT CTGACCATGGCNACCCAGGACTGCTCCTTCCAA SEQ ID NO: 807 %

HIND160 ACTGAAGCTTAGGGCTGACACTGCAGCTCCAG SEQ ID NO: 808

HIND165 ACTGAAGCTTACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 809

FL23For GACTGCCATGGCNACYCAGGAYTGYTCYTTYCAACACAGCCCCATC SEQ ID NO: 810

FH3AFor GACTGCCATGGCNACYCAGGAYTGYTCYTTYCAACACAGCCCCATC SEQ ID NO: 811

SCF . REV TGTCCAAACTCATCAATGTATC SEQ ID NO: 812 39FOR CATGGCCATGGCCGACGAGGAGCTCTGCGGGGGCCTCT SEQ ID NO: 813

39REV GCTAGAAGCTTACTGCAGGTTGGAGGCCACGGTGAC SEQ ID NO: 814

65FOR CATGGCCATGGCCTCCAAGATGCAAGGCTTGCTGGAGC SEQ ID NO: 815

65REV GCTAGAAGCTTACCCAGCGACAGTCTTGAGCCGCTC SEQ ID NO: 816

89FOR CATGGCCATGGCCCCCCCCAGCTGTCTTCGCTTCGT SEQ ID NO: 817 89REV GCTAGAAGCTTAGGGCTGAAAGGCACATTTGGTGACA SEQ ID NO: 818

L5A CCCTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 819

L10A GCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO:820

L15A ACGGCAGTGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACT GCTCCTTCCAAC SEQ ID NO: 821

L5B GTGCCGTTGCCGCCAGACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 822 L10B ATTACCTCCACTGCCGTTACCGCCTGACAGGGTTGAGGAGTCGGG CTG SEQ ID NO:823

L15B GCTCCCATTGCCACCACTGCCGTTACCTCCAGACAGGGTTGAGGA GTCGGGCTG SEQ ID NO: 824

L15C GATGAGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGG ACTGCTCCTTCCACC SEQ ID NO: 825

L15D GATGACGGATCCGTTACCTCCAGACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 826

L15E GATGACGGATCCGGAGGTAATGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 827

339FOR2 GACTGCCATGGCCGACGAGGAGCTCTGCG SEQ ID NO: 828

339REV2 GACTCAAGCTTACTGCAGGTTGGAGGCC SEQ ID NO: 829

339-10FOR3 GACTCGGGATCCGGAGGTTCTGGCACCCAGGACTGCTCC SEQ ID NO: 830

339-15FOR2 GACTGGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACC SEQ ID NO: 831

339REV3 GACTTGGGATCCACTACCTCCAGACAGGGTTGAGGA GTC SEQ ID NO: 832

FLN3 ACTGACGGATCCACCGCCCAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 833

FLN7 ACTGACGGATCCACCTCCTGACCCACCGCCCAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 834

FLN11 ACTGACGGATCCACCTCCTGACCCACCTCCTGACCCACCGCCCAG GGTTGAGGAGTCGGGCTG SEQ ID NO: 835

C-term ACGTAAAGCTTACAGGGTTGAGGAGTCG SEQ ID NO: 836 FLC3 GTCAGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAA C SEQ ID NO: 837 FLC4 GTCAGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 838 FLC10 TCAGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAAC SEQ ID NO: 839

N-term TAGTCCATGGCCACCCAGGACTGCTCC SEQ ID NO: 840 134. rev GCATTACGTAGGGCTGACACTGCAGCTCCAG SEQ ID NO: 841 %

139. rev GCATTACGTACAGGGTTGAGGAGTCGGGCTG SEQ ID NO: 842 F129for GTCAGACCATGGCCGATTACCCAGTCACCGTGGCCTC SEQ ID NO : 843; FL29rev TCTGACAAGCTTATTGAAGCAGGTAGTCAGACAGCTCAC SEQ ID NO: 844; FL35for GTCAGCCCATGGCCGCCTCCAACCTGCAGGACGAGGA SEQ ID NO: 845; FL35rev TCTGACAAGCTTACACGGTGACTGGGTAACTTGAAGC SEQ ID NO: 846; FL63for GTCAGACCATGGCCGTCGCTGGGTCCAAGATGCAAGGC SEQ ID NO : 847; FL63rev TCTGACAAGCTTAAGTCTTGAGCCGCTCCATCCAGCG SEQ ID NO: 848; FL95for GTCAGACCATGGCCCGCTTCGTCCAGACCAACATCTCC SEQ ID NO: 849; FL95rev TCTGACAAGCTTAAAGACAGCTGGGGGGGGGCTGAA SEQ ID NO: 850; FL99for GTCAGACCATGGCCACCAACATCTCCCGCCTCCTGCAG SEQ ID NO: 851; FL99rev CTCGACAAGCTTACTGGACGAAGCGAAGACAGCTGGG SEQ ID NO: 852; FLTAFLS1 GATCACATGTCTACAAATCAAGATCTGCCTGTG SEQ ID NO: 853 FLTR1N GATCGAATTCGTTGTCTTGGATGAAAGGGA SEQ ID NO: 854 HGCFOR ACTTGAATTCATCATCCTGGGCCTGTTCGGGC SEQ ID NO: 855 HGCREV ACTCAAGCTTAGAAGCTCCCCAGCGCCTCC SEQ ID NO: 856

F 29FOR GTCAGACCATGGCCGATTACCCAGTCACCGTGGCCTC SEQ ID NO: 382

F 35FOR GTCAGCCCATGGCCGCCTCCAACCTGCAGGACGAGGA SEQ ID NO: 383 FL63FOR GTCAGACCATGGCCGTCGCTGGGTCCAAGATGCAAGGC SEQ ID NO: 384 F 95FOR GTCAGACCATGGCCCGCTTCGTCCAGACCAACATCTCC SEQ ID NO: 385 FL99FOR GTCAGACCATGGCCACCAACATCTCCCGCCTCCTGCAG SEQ ID NO: 386 FL29REV TCTGACAAGCTTATTGAAGCAGGTAGTCAGACAGCTCAC SEQ ID NO: 387

F 35REV TCTGACAAGCTTACACGGTGACTGGGTAATCTTGAAGC SEQ ID NO: 388 F 63REV TCTGACAAGCTTAAGTCTTGAGCCGCTCCATCCAGCG SEQ ID NO: 389 89 REVSTOP GTCAAGAAGCTTACGGCTGAAAGGCACATTTG SEQ ID NO: 390 F 95REV TCTGACAAGCTTAAAGACAGCTGGGGGGGGGCTGAA SEQ ID NO: 391 FL99REV CTCGACAAGCTTACTGGACGAAGCGAAGACAGCTGGG SEQ ID NO: 392 Flt36 GTTGCCATGGCNTCNAAYCTGCARGAYGARGARCTGT GCGGGGGCCTCTGGCGGCTG SEQ ID NO: 393

Flt37 GTTGCCATGGCNAAYCTGCARGAYGARGARCTGTGYG GGGGCCTCTGGCGGCTGGTC SEQ ID NO: 394

Flt38 GTTGCCATGGCNCTGCARGAYGARGARCTGTGYGGYG GCCTCTGGCGGCTGGTCCTG SEQ ID NO: 395

Flt39 GTTGCCATGGCNCARGAYGARGARCTGTGYGGYGGYC 57

TCTGGCGGCTGGTCCTGGCA SEQ ID NO: 396

Flt40 GTTGCCATGGCNGAYGARGARCTGTGYGGYGGYCTCT GGCGGCTGGTCCTGGCACAG SEQ ID NO: 397

Flt41 GTTGCCATGGCNGARGARCTGTGYGGYGGYCTCTGGC GGCTGGTCCTGGCACAGCGC SEQ ID NO: 398

Flt42 GTTGCCATGGCNGARCTGTGYGGYGGYCTGTGGCGYC TGGTCCTGGCACAGCGCTGG SEQ ID NO: 399

Flt43 GTTGCCATGGCNCTGTGYGGYGGYCTGTGGCGYCTGG TCCTGGCACAGCGCTGGATG SEQ ID NO: 400 40 COLI GTTGCCATGGCWGATGAAGAACTGTGTGGNGGNCTGTGGCGG SEQ ID NO:401

36REV TATGCAAGCTTAGGCCACGGTGACTGGGTA SEQ ID NO: 402

37REV TATGCAAGCTTAGGAGGCCACGGTGACTGG SEQ ID NO: 403

38REV TATGCAAGCTTAGTTGGAGGCCACGGTGAC SEQ ID NO: 404

39REV TATGCAAGCTTACAGGTTGGAGGCCACGGT SEQ ID NO: 405

41REV TATGCAAGCTTAGTCCAGGTTGGAGGCCAC SEQ ID NO: 406

42REV TATGCAAGCTTACTCGTCCAGGTTGGAGGC SEQ ID NO: 407

43REV TATGCAAGCTTACTCCTCGTCCAGGTTGGA SEQ ID NO: 408

39N TERM-2 GACTAGCCATGGCNGAYGARGARCTGTGYGGTGGCCTCTGGCGG SEQ ID NO: 409

SNA BICTERM GACTAGTACGTACTGCAGGTTGGAGGCCACGG SEQ ID NO: 410

29SMB1 GCAGGTTACGTATTGAAGCAGGTAGTCAGACAGCTC SEQ ID NO: 411 34SNAB1 GCAGGTTACGTACACGGTGACTGGGTAATCTTGAAG SEQ ID NO: 412

63SNAB1 GCAGGTTACGTAAGTCTTGAGCCGCTCCATCCAGC SEQ ID NO: 413 66SNAB1 GCAGGTTACGTAGCCAGCGACAGTCTTGAGCCGCTC SEQ ID NO:414 M

89N-TERMCSLI GTCAAGCCATGGCNCCRCCRAGCTGTCTRCGCT

TCGTTCAGACCAACTC SEQ ID NO: 415

89SNAB1 GCAGGTTACGTACGGCTGAAAGGCACATTTGGTGACAA SEQ ID NO:416

945 SMB1 GCAGGTTACGTAAAGACAGCTGGGGGGGGG SEQ ID NO: 417

98SUAB1 GCAGGTTACGTACTGGACGAAGCGAAGACAGCTG SEQ ID NO: 418

BAM FOR 1 TCAGTTGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTA SEQ ID NO: 426

BAM REV 1 TCAGTTGGATCCTCCGCCAGAACCACCGCCTGACCCACCTCCTGACCC SEQ ID NO: 427

NAVREV L GTCTGAGGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCC AGGACTGCTCCTTC SEQ ID NO: 428

NAVREV S GTCTGAGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 429

NAVFOR GTCTGAGGCGCCGAGTGGACGCGGGCTCCACGGTGGCGGCAGGGT TGAGGAGTCGGGCTG SEQ ID NO: 430

XBAFOR1 GCTACGTCTAGATCTCCTGACCTCGACCCAGGACTGCTCCTTCCAAC SEQ ID NO: 447 XBAREV1 GCTAGTTCTAGACCATCCTGGCTGACACGGTGAAACACCGTCTCTACG GGCTGACACTGCAGCTCCAG SEQ ID NO: 448

LNK1FOR GTCAGTACTAGTATGGGTGTCCGGGCTCTTCGGCTCCTGCAGG TTGGAGGCCACGG SEQ ID NO: 449

LNK1REV GTCAGTACTAGTCCGCCATCTCCGACACCATTAGGCCCTGCCAGC SEQ ID NO: 450 LNK2FOR GTCAGTTCCGGAGATTTCGGTTCTGCAGAGGGCTGCGCAAGG TGGCGTA SEQ ID NO: 451

LNK2REV GTCAGTTCCGGATACTCATACCAGCCCGCCATCCCCGGGTTCTA ATCTGCAAGATGAAGAGCTG SEQ ID NO: 452

LNK7FOR GTCAGTACTAGTATGGGTGTCCGGGCTCTTCGGAAAGGCACATTT GGTGACAAAGTGTATC SEQ ID NO: 453

LNK7REV GTCAGTACTAGTCCGCCATCTCCGGGTACACCATTAGGCCCTG CCAGC SEQ ID NO: 454

LNK8REV GTCAGTTCCGGATACTCATACCAGCCCGCCATCCCCGGGTAAGGCC TTTCAGCCCCCCCCCAG SEQ ID NO: 455 C1FOR GTCAGACCATGGCCACTCAGGACTCCTCTTTTC SEQ ID NO: 456 59

C3 FOR CACTTTGTCACCAAATCTGCCTTTCAG SEQ ID NO: 457

C3REV CTGAAAGGCAGATTTGGTGACAAAGTG SEQ ID NO: 458 C5FOR GCCCCCCCCCAGCTCTCTTCG SEQ ID NO: 459

C5REV CGAAGAGAGCTGGGGGGGGGC SEQ ID NO: 460

C6REV GTCAGTTACGTACAGGGTTGAAGGAGTCGGGCTGAGACTGC SEQ ID NO:461

GPFOR1 GTCAGTCCATGGCTACTCAAGGTGCTATGC SEQ ID NO: 462

GPREV2 GTAGCATACGTAGGGCTGCAGGGCAGGGGCC SEQ ID NO: 463

(00

TABLE 2

GENE SEQUENCES pMON30304

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGT SEQ ID NO:l

pMON26458

TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGGGAATTC SEQ ID NO : 2 pMON28548

TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTG CTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTG CTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTG GGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACA GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO : 3

PMON28500

TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGC AGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTC CTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO : 4 pMON28501

TCCCCAGCTCCACCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA

TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG

GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC

CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT

GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTG

CTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTG

CTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGA

GCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTG

GGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAG GGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGT

TTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO : 5

PMON28502 b[

TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTC AGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACA CCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGAC ATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCA TCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTT CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO: 6

Syntanl

1 CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA

51 GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC

101 TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT

151 AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC

201 GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT

251 CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC

301 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT

351 CTAACTGCTC TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA

401 CCTGCACCTT TGCTGGACCC GAACAACCTC AATGACGAAG ACGTCTCTAT

451 CCTGATGGAC CGAAACCTTC GACTTCCAAA CCTGGAGAGC TTCGTAAGGG

501 CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TTGAGGCAAT TCTTCGTAAT

551 CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAAT

601 CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT

651 ATCTGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTAC SEQ ID NO: 7

Syntan3

1 CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA

51 GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC 101 TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT

151 AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC

201 GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT

251 CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC

301 GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT 351 CTGGCGGTGG CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA

401 ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG ACCCGAACAA

451 CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC CTTCGACTTC

501 CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA

551 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC 601 GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG

651 AATTCCGGGA AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG

701 GAACAACAGT AC SEQ ID NO : 8

pMON31104

1 ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT

51 GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA

101 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA 151 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT

201 CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG 251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TAACTGCTCT

301 ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT 351 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT 401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC

451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG

501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT

551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC

601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG 651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC

701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT

751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG

801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG

851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT by

951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO : 9 pMON3 1105

1 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG

51 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG

101 CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC

151 CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTAACT GCTCTATAAT

201 GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA CCTTTGCTGG

251 ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC

301 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA

351 ATACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT

401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC

451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG

501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT

551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC

601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG

651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC

701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT

751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG

801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG

851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC

901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT

951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO: 10 pMON3 1106

1 ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA

51 AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC

101 AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT

151 ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT

201 CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA

251 ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT

301 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC

351 CTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT

401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC

451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG

501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT

551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC

601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG

651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC

701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT

751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG

801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG

851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC

901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT

951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO: 11 pMON31107

1 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT 51 GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT

101 CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT

151 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA

201 CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA

251 ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA 301 TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA

351 GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT

401 CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC

451 ATGGCTACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG

501 GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT 551 CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC

601 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG

651 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC

701 ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT

751 CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG 801 CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG

851 AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC

901 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT

951 GGCCCCTGCC CTGCAGCCCT AATAA SEQ ID NO: 12 rø

PMON31108

1 ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT 51 GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA 101 AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA 151 CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC CAATCATCAT 201 CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG TTCTATCTGG 251 TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TGGCGGTGGC 301 AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA 351 CTTAAAGAGA CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA SEQ ID NO :13 pMON31109

1 ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG 51 TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG 101 CAGGTGACTG GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC 151 CTTGAGCAAG CGCAGGAACA ACAGGGTGGT GGCTCTGGCG GTGGCAGCGG 201 CGGCGGTTCT AACTGCTCTA TAATGATCGA TGAAATTATA CATCACTTAA 251 AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TGACGAAGAC 301 GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT 351 CGTAAGGGCT GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA SEQ ID NO :14

PMON31110

1 ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA 51 AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC 101 AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC 151 TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC 201 ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA 251 TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC 301 AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA 351 ACCATGTCTG CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC 401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC 551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT 651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC 701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC 801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA SEQ ID NO :15

PMON31111

1 ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT 51 GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG

101 GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AATTATACAT

151 CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA

201 CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG 251 AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG

301 GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC

351 CTCTCGACAT CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC

401 CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT

451 AAAGAATCTC ATAAATCTCC AAACATGGCT ACCCAGGGTG CCATGCCGGC 501 CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC

551 ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG

601 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT

651 AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC

701 TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 751 CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC

801 CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT 851 ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 901 ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG 951 GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA SEQ ID NO: 16

PMON13182

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC 451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC 501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC 551 TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA

601 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA

651 AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG

701 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC

751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC 801 GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG CTCAAGTCTT

851 TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG

901 CTGTGTGCCA CCTAATAA SEQ ID NO: 17

pMON13183

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG

451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC

501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT

551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG

601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA 651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC

701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 851 CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG 901 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG

951 TGCCACCTAA TAA SEQ ID NO: 18

PMON13184

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC \c$

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC 401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC 551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG 651 CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG 701 GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC 751 CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC 801 TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA 851 GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG 901 GAAGGGATAT CCTAATAA SEQ ID NO: 19

PMON13185

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC 551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 651 CCGCGTTCTA CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC 701 AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT 751 GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC 801 CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC 851 TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA 901 CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG 951 GATATCCTAA TAA SEQ ID NO: 20

pMON13186

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA

401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT

451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG

501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCTCTG

551 GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 601 AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC

651 CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG

701 GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG

751 GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT

801 CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA 851 CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG

901 GAAGAACTGG GATAATAA SEQ ID NO: 21

pMON13187

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC 451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT w

501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC 551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC 601 TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA 651 GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA 701 AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 751 CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG 801 CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC 851 AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG 901 CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA 951 ACTGGGATAA TAA SEQ ID NO: 22

PMON13188 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA 401 CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA 451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG 501 CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC GGCTCTCAGA

551 GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC

601 GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA

651 GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA

701 GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 751 CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT

801 ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG 851 ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 901 GCCCTGCAGC CCTAATAA SEQ ID NO: 23

PMON13189

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG

451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT

501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC

551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC

651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC

701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC

751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG

801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT

901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT

951 GCAGCCCTAA TAA SEQ ID NO: 24

pMON13190

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG

451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCTC

501 TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG

551 TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC

601 ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT 651 GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC 701 TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG 751 CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA

801 CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA 851 TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 901 CCGGCCTTCG CCTAATAA SEQ ID NO: 25

p ON13191

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT 451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG 551 GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA 601 AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA 651 CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA 701 TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 751 GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT 801 GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC 851 TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA 901 GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC 951 CTTCGCCTAA TAA SEQ ID NO: 26

PMON13192

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT 401 ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC 451 ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC 501 AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC 551 TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 601 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA 651 AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG 701 CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC 751 CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC 801 GCAGCCCACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG AGCTTCCTGC 851 TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC 901 CAGGAGAAGC TGTGTGCCAC CTAATAA SEQ ID NO: 27

PMON13193

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTACAAG 451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC 501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT 551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA 651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC 701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT 801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC 851 CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 901 TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA log

951 GAAGCTGTGT GCCACCTAAT AA SEQ ID NO: 28

MON2 15190

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC

401 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT

451 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT

501 GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT TTCCAGCGCC

551 GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG

601 TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC

651 CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA

701 AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC

751 AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT

801 CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG

851 GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG

901 CAGGCCCTGG AAGGGATATC CTAATAA SEQ ID NO: 29

PMON25191

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTCCCGAG 451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC 501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC 551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA

601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA

651 CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT

701 CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC

751 CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT 801 GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT

851 GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC

901 TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC

951 CCTGGAAGGG ATATCCTAAT AA SEQ ID NO: 30

PMON13194

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA

401 TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTCT

451 GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG GTTGCTAGCC ATCTGCAGAG

501 CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG CAGCCCACAC

551 CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 601 GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT

651 GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC

701 ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC

751 CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA

801 CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA 851 CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG

901 CAGCAGATGG AAGAACTGGG ATAATAA SEQ ID NO: 31

PMON13195 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTATGGCC

451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT

501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC

551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CACACCATTG

601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA

651 AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG

701 CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT

751 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA

801 GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG

851 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG

901 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA

951 GATGGAAGAA CTGGGATAAT AA SEQ ID NO: 32

PMON13196 1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA

401 CCCAGGGTGC CATGCCGGCC TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA

451 GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC TTCCTGGAGG TGTCGTACCG 501 CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCT GCCAGCTCCC

551 TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG

601 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG

651 CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG

701 CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG 751 AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT

801 GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG

851 ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA

901 ATGGCCCCTG CCCTGCAGCC CTAATAA SEQ ID NO: 33

PMON13197

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG

451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT

501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC

551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA

651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC

701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC

751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA

801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG 851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC

901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC

951 CCCTGCCCTG CAGCCCTAAT AA SEQ ID NO: 34

pMON13198

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG o

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT

401 CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG

451 AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCAC

501 ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT

551 TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG

601 CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG

651 ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG

701 CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC

751 TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC

801 CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT

851 GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG

901 GGTGCCATGC CGGCCTTCGC CTAATAA SEQ ID NO: 35

PMON13199

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT 101 CTATCCTGAT GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA 151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG 201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC 251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTTCTGCT 451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT 551 TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 601 CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG 651 TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT 701 CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 751 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA 801 GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT 851 TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 901 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC 951 CATGCCGGCC TTCGCCTAAT AA SEQ ID NO: 36

PMON31112

1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG 101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC 251 CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC 551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC 651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC 701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG 801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC 851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT 951 GCAGCCCTAA TAA SEQ ID NO: 37

PMON31113

1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA 51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG 101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC 151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA 201 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC 251 CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG 351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG 451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT 810 PPCCIT/US97/20037

1

501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC

551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC

601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA

651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC

701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC

751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA

801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG

851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC

901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC

951 CCCTGCCCTG CAGCCCTAAT AA SEQ ID NO: 38 pM0N31114

1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA

51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG

101 ATATCCTGAT GGAAAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC

151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA

201 AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC ACGCGACATC

251 CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC

301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG

451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT

501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC

551 TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC

601 CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC

651 GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC

701 TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC

751 TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG

801 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC

851 CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT

901 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT

951 GCAGCCCTAA TAA SEQ ID NO: 39 pM0N31115

1 ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA

51 GCCACCGCTG CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG

101 ATATCCTAAT GGACAATAAC CTTCGTCGTC CAAACCTCGA GGCATTCAAC

151 CGTGCTGTCA AGTCTCTGCA GAATGCATCA GCAATTGAGA GCATTCTTAA

201 AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC ACGCGACATC

251 CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC

301 TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GGCTACCCAG

451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT

501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC

551 TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC

601 CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA

651 TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC

701 CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC

751 CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA

801 ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG

851 GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC

901 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC

951 CCCTGCCCTG CAGCCCTAAT AA SEQ ID NO: 40 p ON28505

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCT TTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAG GCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGA ACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATG GCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGC AGACTGAGCCAGTGCCCA SEQ ID NO: 41 pMON28506

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCT GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT CCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAG GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCT CCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAG TGCCCAGAGGTTCACCCT SEQ ID NO: 42

PMON28507

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG

ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG

CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGG

ACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTG

ATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGT GACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTT

CACCCTTTGCCTACACCT SEQ ID NO: 43 p ON28508 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTT AGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG GTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCAC AAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGA GGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTC CTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCT ACACCTGTCCTGCTGCCT SEQ ID NO: 44 pMON28509

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTG GGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGT CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGT AAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT GTCCTGCTGCCTGCTGTG SEQ ID NO: 45 pMON28510

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGGAACCGTCTGG TCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAACTCCAAACATGGGAGAATGGAAAACC CAGATGGAGGAGACCAAGGCACAGGACATTCTGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGG GACAACTGGGACCCACTTGCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCT GCAGGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCATCTTCCTGA GCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGGGGTCCACCCTCTGCGTCAGGGAATT CGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCAT GTCCTTCACAGCAGACTGACCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACT TTAGTTG SEQ ID NO: 46

PMON28511

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGC CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTC CGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCG TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTG SEQ ID NO: 47 pMON28512

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTT CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA

AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCC

GCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGC

CAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAA

ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG

GCCCTGCAGAGCCTCCTT SEQ ID NO: 48 pMON28513 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACA GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTC CGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCT TTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAG GCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGA ACCCAGCTTCCTCCACAG SEQ ID NO: 49 pMON28514

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGT AAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT CCACAGGGCAGGACCACA SEQ ID NO: 50 pMON28515

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC

AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC GTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGC AGGACCACAGCTCACAAG SEQ ID NO : 51

PMON28516

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTG AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA TTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCC CATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTG GACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTT CTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCT GGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACA GCTCACAAGGATCCCAAT SEQ ID NO: 52

PMON28519

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCT TTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAG

GCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACT

TGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGA

ACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTG

CTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCG TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA

CTGAGCCAGTGCCCA SEQ ID NO: 53

PMON28520 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCT GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT CCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAG GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCG CCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC CCAGAGGTTCACCCT SEQ ID NO: 54

PMON28521

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGG ACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTG ATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGAC CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCAC CCTTTGCCTACACCT SEQ ID NO: 55 pMON28522 llS

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTT AGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG GTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCAC AAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGA GGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTC AGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACA CCTGTCCTGCTGCCT SEQ ID NO: 56 pM0N28523

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTG GGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGT CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTC CTGCTGCCTGCTGTG SEQ ID NO: 57 pMON28524

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAA ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA

CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG

GCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATC

TTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC

AGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGAC TCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCT

GTGGACTTTAGCTTG SEQ ID NO : 58

PMON28525 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGC CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTC CGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCT CCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTG AGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGG AAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCA GCACGGGGACAACTG SEQ ID NO: 59

PMON28526

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTT CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCT CCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAG TGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACC CAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGG GGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCC CTGCAGAGCCTCCTT SEQ ID NO: 60 pM0N28527

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACA GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGA GTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG CCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCA CAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGCTTCCTCCACAG SEQ ID NO: 61

PMON28528

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTC CTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTG GGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTC CTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCA CAGGGCAGGACCACA SEQ ID NO: 62

PMON28529

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC

GTCAGGGAATTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGT

GACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCT

GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG

ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGG

ACCACAGCTCACAAG SEQ ID NO: 63

PMON28530 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTG AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA TTCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCAT GTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGAC TTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTG CTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGA CAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCT CACAAGGATCCCAAT SEQ ID NO: 64

PMON28533

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTGACTTCCAAACCTGGAGAGCTTCGTAAGGG CTGTCAAGAACTTAGAAAATGCATCAGGTATGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCAC GGCCGCACCCTCTCGCATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTAT TGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGTAACCGTCTGGTCCA H 1

ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGAGGTTCACCCTTTGCCT ACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAG GACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTC TCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAG CTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGA GGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAAC ATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCAC AGCAGACTGAGCCAGTGCCCA SEQ ID NO: 65 pMON28534

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGTTGCCTACACCT GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT CCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAG GTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCG TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCT SEQ ID NO: 66 pMON28535

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGTCCTGCTGCCT GCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTG ACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAG CTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGG ACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTG ATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCG CCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGC CCAGAGGTTCACCCTTTGCCTACACCT SEQ ID NO: 67

PMON28536

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGTGGACTTT AGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTG

GAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAG

GTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCAC

AAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGA

GGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGAC CTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCAC

CCTTTGCCTACACCTGTCCTGCTGCCT SEQ ID NO: 68

PMON28537 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGACTTTAGCTTG GGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGA GTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGT CTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGA GTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG CCTACACCTGTCCTGCTGCCTGCTGTG SEQ ID NO: 69

PMON28538 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAGAATGGAAA ACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCA CGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGG GCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATC TTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTC AGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAA CTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTC CTGCTGCCTGCTGTGGACTTTAGCTTG SEQ ID NO: 70 pMON28539

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGACCCACTTGC CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTC CGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGC AACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTT CACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGC TTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAG GGAGTGATGGCAGCACGGGGACAACTG SEQ ID NO: 71

PMON28540

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGAACCCAGCTT CCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGA AAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATG GCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGC AGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGA GAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTG ATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTC CTCCTTGGGGCCCTGCAGAGCCTCCTT SEQ ID NO: 72

PMON28541

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT

GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGGCAGGACCACA GCTCACAAGGATCCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTT

GTAGGAGGGTCCACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCT

TGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAG

GTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAG

GAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTG GGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGC

CTCCTTGGAACCCAGCTTCCTCCACAG SEQ ID NO: 73

PMON28542 GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCACAAGGAT CCCAATGCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCC ACCCTCTGCGTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGA GTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTG CCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCA CAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGC IH

CTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACC CAGCTTCCTCCACAGGGCAGGACCACA SEQ ID NO: 74

PMON28543

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC GTCAGGGAATTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGT AAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCT GTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATT CTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCC CTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCT CCACAGGGCAGGACCACAGCTCACAAG SEQ ID NO: 75 pMON28544

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCATCTTCCTG AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGGGAA TTCGGCGGCAACGGCGGCAACATGGCGTCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGC AGGACCACAGCTCACAAGGATCCCAAT SEQ ID NO: 76

PMON28545

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTGGACCCGAAC AACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCT GGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGATCCCAATGCC ATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGC GTCAGGGAATTCGGCGGCAACATGGCGTCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTT CGTGACTCCCATGTCCTTCACAGCAGACTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTG CCTGCTGTGGACTTTAGCTTGGGAGAATGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCA GTGACCCTTCTGCTGGAGGGAGTGATGGCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGG CAGCTTTCTGGACAGGTCCGTCTCCTCCTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCT CACAAG SEQ ID NO: 77

PMON15981

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTACAAG

451 CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC

501 CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT

551 GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG

601 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA

651 GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC

701 TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC

751 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT

801 GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC

851 CCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CAGCTCCCTG

901 CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG

951 CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAA TAA; SEQ ID NO : 7 tø

PMON15982

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTCCCGAG

451 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC

501 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC

551 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA

601 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA

651 CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA

701 CACCATTAGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT

751 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA

801 GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG

851 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG

901 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT

951 CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA; SEQ ID NC ):79

PMON15965

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTTCTGCT

451 TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT

501 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCGGCGGCG

551 GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC

601 TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC

651 AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG

701 AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC

751 TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA

801 TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT

851 CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC

901 TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC

951 CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA SEQ ID NO: 80

PMON15966

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC

401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTATGGCC

451 CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT

501 CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC

551 TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC

601 TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT

651 CCTGCTCAAG TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG

701 CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG

751 CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC

801 CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA

851 GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC

901 CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT

951 TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA SEQ ID NO: 81

PMON15967

1 ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG

51 ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT

101 CTATCCTGAT GGATCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA

151 AGGGCTGTCA AGAACTTAGA AAATGCATCA GGTATTGAGG CAATTCTTCG W

201 TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC TCTCGACATC

251 CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG

301 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG

351 CGGTGGAGGC TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC 401 CGTCTCCTCC GTCTAAAGAA TCTCATAAAT CTCCAAACAT GTCTACCCAG

451 GGTGCCATGC CGGCCTTCGC CTCTGCTTTC CAGCGCCGGG CAGGAGGGGT

501 CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG TACCGCGTTC

551 TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TACACCATTA

601 GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA 651 AGTGAGGAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG

701 CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT

751 CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA

801 GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG

851 GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG 901 GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA

951 GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA SEQ ID NO: 82 pMON15960 1 ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT

51 CAAGTCTTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC

101 AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG

151 CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC

201 CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC 251 TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG

301 TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC

351 CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC

401 CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA

451 GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 501 CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA

551 CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT

601 TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA

651 GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG

701 GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG 751 GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT

801 CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC

851 CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC

901 TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA

1001 TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT 1051 CTACGCCACC TTGCGCAGCC CTGATAA SEQ ID NO: 83

PMON32132

TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGG SEQ ID NO: 84

PMON32133

TCTCCCGCTCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGGGCAGGACCACAGCTCACAAGGATCCCAATGCCATCTTCCTG AGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTCTGCGTCAGG SEQ ID NO: 85 pMON32134

TCCCCAGCGCCGCCTGCTTGTGACCTCCGAGTCCTCAGTAAACTGCTTCGTGACTCCCATGTCCTTCACAGCAGA CTGAGCCAGTGCCCAGAGGTTCACCCTTTGCCTACACCTGTCCTGCTGCCTGCTGTGGACTTTAGCTTGGGAGAA TGGAAAACCCAGATGGAGGAGACCAAGGCACAGGACATTCTGGGAGCAGTGACCCTTCTGCTGGAGGGAGTGATG GCAGCACGGGGACAACTGGGACCCACTTGCCTCTCATCCCTCCTGGGGCAGCTTTCTGGACAGGTCCGTCTCCTC CTTGGGGCCCTGCAGAGCCTCCTTGGAACCCAGCTTCCTCCACAGGGCAGGACCACAGCTCACAAGGATCCCAAT GCCATCTTCCTGAGCTTCCAACACCTGCTCCGAGGAAAGGTGCGTTTCCTGATGCTTGTAGGAGGGTCCACCCTC TGCGTCAGG SEQ ID NO: 86

Pmonl3181

1 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG 51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT \λ

101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG

151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT

201 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA

251 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 301 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag

351 ggcggtggag gctcCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA

401 CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGTAAGGTA

451 CCGCATGCAA GCTT SEQ ID NO: 87 Pmonl3180.Seg

1 CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG

51 AGACCACCTG CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT

101 CTCTATCCTG ATGGATCGAA ACCTTCGACT TCCAAACCTG GAGAGCTTCG 151 TAAGGGCTGT CAAGAACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT

201 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA

251 TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA

301 CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAgag 351 ggcggtggag gctcCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGTA 401 AGGTACCGCA TGCAAGCTT SEQ ID NO: 88 pMON30237.seq

GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCC SEQ ID NO: 89

pMON30238.seq

GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG SEQ ID NO: 90

pMON30239.seq GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCCGACTCCTCAACCCTG SEQ ID NO: 91

pMON32329.seq

GGAACTCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC

TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC

AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCC SEQ ID NO: 92

pMON32330.seq GGTACCCAGGATTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG SEQ ID NO: 93

pMON32341.seq

GCCACTCAGGACTGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCC SEQ ID NO: 94

pMON32342.seq

GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC AGCCCGACTCCTCAACCCTG SEQ ID NO: 95 pMON32320.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG SEQ ID NO: 96

pMON32321.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 97

pMON32322.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGCGGCAACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 98 Ail

pMON32323 . seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCA ATGGGAGCGGCGGAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCT GCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGG SEQ ID NO: 99 pMON32324.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTA ATGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGT CACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGC GGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 100 pMON32325.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 101

pMON32326.seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGAGGTAACGGCAGTGGTGGCAATGGGAGCGGTGGAAATGGAAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGT CCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGA TGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA TGTGCCTTTCAGCCC SEQ ID NO: 102

p ON32327.seq GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCAGGCGGTAACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 103

pMON32328.seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCAT CTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTC AAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAA GACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGG AGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 104 pMON32348.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC

AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCTGGAGGTAGTGGATCCGGAGGTTCTGGCAACCCAGGACTGCTCCT

TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG

SEQ ID NO: 105 pMON32350.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT

GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC

CTGTCTGGAGGTAGTGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAAC

CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA

AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG

GCCTCCAACCTGCAG SEQ ID NO: 106

FLT3N.seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCC SEQ ID NO: 107

FLT3C.seq

GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT ACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGT CGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC ACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGT GGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGC TGCAGTGTCAGCCCGACTCCTCAACCCTGTAAGCTT SEQ ID NO: 108

FLT7N.seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCC SEQ ID NO: 109

FLT4C.seq

GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC

CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG

ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC

TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA

TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC

TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCT

GGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGG AGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTAAGCTT

SEQ ID NO: 110

FLTllN.seq

CCATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTT TGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCC AGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAG GAGGTGGATCC SEQ ID NO: 111

FLTlOC.seq GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTG GATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGG AGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCA GGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGA ACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG TAAGCTT SEQ ID NO: 112

pMON32365.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 113

pMON32366.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAG CCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACC TGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 114 pMON32367.seq GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTT CCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGT CTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 115 pMON32368.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGA CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC AACCTGCAG SEQ ID NO: 116

pMON32369.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCAC CCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCA AAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAG SEQ ID NO: 117 pMON32370.seq

GCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGCCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCT GCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTC AGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCT CCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA GATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 118 pMON30247.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGAC TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC SEQ ID NO: 119

pMON30248.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC All

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGAC

TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA

ACCTGCAGGACGAGGAGCTCTGCGGGGCGCTCTGGCGGCTGGTCCTGGCA

CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG

CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT

TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC

TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT

CAACCCTG SEQ ID NO: 120

pMON32332.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT

AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 121 pMON32333.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAG SEQ ID NO: 122

pMON32334.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 123 pMON32335.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG

CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 124 pMON32336.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG SEQ ID NO: 125

pMON32337.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC AACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG Ab

TCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 126 pMON32338.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA

TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG

GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT

AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT

CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA

CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 127 pMON32339.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGCAGTGGTGGTAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC SEQ ID NO: 128

pMON32364.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCGACTCAGGAC TGTTCTTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC SEQ ID NO: 129

pMON32377. seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA AW

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAACCCAGGAC TGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCG TGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCA ACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGG CTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCT TTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCAC TCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCT CAACCCTG SEQ ID NO: 130 pMON32392.seq

GCCACTCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA

ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCC

AAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAA AGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC

ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATT

CGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTC

TTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGA

CATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACT GACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 131 pMON32352.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCCAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 132 pMON32353.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG SEQ ID NO: 133 pMON32354.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 134 pMON32355.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 135

pMON32356.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG SEQ ID NO: 136 pMON32357.seq Ab

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC

AACGGCACGCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG

TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG

CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG

GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG

TCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 137

pMON32358.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT

AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA

CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 138

pMON32359.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AACGGCAGTGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG

CCC SEQ ID NO: 139

pMON32360.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCCAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AGTGGATCCGGAGGTTCTGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 140

pMON32362.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AGTGGATCCGGTGGCAGTGGGAGCGGCGGATCTGGAACCCAGGACTGCTC

CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAG SEQ ID NO: 141 pMON32393. seq

GCCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAA

GCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTC

AGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGT

GAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGA

ATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAA TTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAAC

CTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCC

AAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAG

GTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACG

GCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGA ATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGG

AACAACAG SEQ ID NO: 142

pMON32371.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 143

pMON32372.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC

CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT ACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 144 pMON32373.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 145

pMON32374.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA

ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG

ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 146

pMON32375.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAG SEQ ID NO: 147

pMON32376.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG

CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG

GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA

ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG

TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG

CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAG SEQ ID NO: 148 pMON32378.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCC

AACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGA

CGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGA

TGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 149

pMON32379.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCT TCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCA GGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCT GGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 150

pMON32380.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG

CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 151 pMON32381.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTG GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC TGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO: 152 pMON32382.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG GAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG SEQ ID NO: 153 pMON32383.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT

CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG

ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA

CTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCG GAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC

AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTA

CCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGG

AGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAG

CGGCTCAAGACTGTCGCTGGG SEQ ID NO: 154 p ON32384.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGC TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 155

pMON32385.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA TCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTC CGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATT ACCCAGTCACCGTGGCCTCCAACCTGCAGGATGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGT CGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATAC ACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 156

pMON32386.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC

TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT

CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 157 pMON32387.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGA

TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCA

ACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTG

ACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC GAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGAT

GGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGC

GCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 158 pMON32388.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC

GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG

TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC

TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG

CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC

TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC SEQ ID NO: 159

pMON32389.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGG TCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAG TGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCG GCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGT CCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCC SEQ ID NO: 160 hflt3-28291inkl0.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGG AGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCG CTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 161 hflt3-28291inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG AGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCA TCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAA SEQ ID NO: 162

hflt3-34351inkl0.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO: 163 hflt3-34351inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAAGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGG CACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTG TCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC GTG SEQ ID NO: 164 hflt3-62631inkl0.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAG GTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCAC CGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGC TGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 165 hflt3-62631inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG GTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA AGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCG GGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACT SEQ ID NO: 166

hflt3-94951inkl0.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG Ab

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC

GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC

AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCC GGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT

CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG

TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG

CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG

GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 167

hflt3-94951inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC

AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA

GGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCC

CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC

TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT

CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA

CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT

CTT SEQ ID NO: 168 hflt3-98991inkl0.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAAT CCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCA AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTG CCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 169

hflt3-98991inkl5.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGA CTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACC CAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGC TGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACT TTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAG SEQ ID NO: 170

hflt3-28291ink6.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGA CTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCC GTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 171 hflt3-28291ink7.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCA GGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAA TCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 172 hflt3-28291inkl3.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGG GGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCT CCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 173 A k hflt3-28291ink21.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTG GCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTG GGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCA GACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGC TGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGG AGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCT CCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAA SEQ ID NO: 174

hflt3-34351ink6.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGATCCGGAGGTACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCA AGATTACCCAGTCACCGTG SEQ ID NO: 175 hflt3-34351ink7.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGATCCGGAGGTGGCACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAAGATTACCCAGTCACCGTG SEQ ID NO: 176

hflt3-34351inkl3.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA Λ *>

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACTGC TCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGA GCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO: 177 hflt3-34351ink21.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCT CCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTC GCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGG CTCAGGGGGAGGTAGTGGTAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTG SEQ ID NO: 178 hflt3-62631ink6.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACT GCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAA CCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCAC AGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 179

hflt3-62631ink7.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 180

hflt3-62631inkl3.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA

CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG

TCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGG

GAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTA

CCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCC

TCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 181 hflt3-62631ink21.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGG

TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGT

CACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGA

CCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG

AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTG TCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAG

GTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC

TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCT

GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC

AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACT SEQ ID NO: 182 flt3-94951ink6.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC

CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC

AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAG

GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAAT

CCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCT

CCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCA

AGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTG

CCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 183 flt3-94951ink7.seq A 1r

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAA AATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGG CCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGAT GCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAAT GTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 184 hflt3-94951inkl3.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCA GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTC CTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAG ATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGAC TGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGA TACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 185 hflt3-94951ink21.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGC GCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGC AGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTG CTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTG AGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC CTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACA GCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCT TGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 186

hflt3-98991ink6.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT i

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTACCCAGGACTGCTCCTTC CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTC TGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGG ACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGA GCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCC CCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 187

hflt3-98991ink7.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG

GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT

CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG

ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC

TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCT

GTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGC

AGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCT

GGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGC

CCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 188 hflt3-98991inkl3.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC

ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA

TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA

TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC

TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC

TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG

GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG

ACTCCTCAACCCTGGGCGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGC TGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCA

CCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG

CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTC

CAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCA

CCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 189 hflt3-98991ink21.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATA TCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGG GCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTG GATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCG ACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACA CAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACT ACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAG GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGA GCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCG TGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 190 p ON32390

GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGT

CCGCCCCGCCATGTCTACAAATCAAGATCTGCCTGTGATCAAGTGTGTTT

TAATCAATCATAAGAACAATGATTCATCAGTGGGGAAGTCATCATCATAT CCCATGGTATCAGAATCCCCGGAAGACCTCGGGTGTGCGTTGAGACCCCA

GAGCTCAGGGACAGTGTACGAAGCTGCCGCTGTGGAAGTGGATGTATCTG

CTTCCATCACACTGCAAGTGCTGGTCGATGCCCCAGGGAACATTTCCTGT

CTCTGGGTCTTTAAGCACAGCTCCCTGAATTGCCAGCCACATTTTGATTT

ACAAAACAGAGGAGTTGTTTCCATGGTCATTTTGAAAATGACAGAAACCC AAGCTGGAGAATACCTACTTTTTATTCAGAGTGAAGCTACCAATTACACA

ATATTGTTTACAGTGAGTATAAGAAATACCCTGCTTTACACATTAAGAAG

ACCTTACTTTAGAAAAATGGAAAACCAGGACGCCCTGGTCTGCATATCTG

AGAGCGTTCCAGAGCCGATCGTGGAATGGGTGCTTTGCGATTCACAGGGG

GAAAGCTGTAAAGAAGAAAGTCCAGCTGTTGTTAAAAAGGAGGAAAAAGT GCTTCATGAATTATTTGGGATGGACATAAGGTGCTGTGCCAGAAATGAAC

TGGGCAGGGAATGCACCAGGCTGTTCACAATAGATCTAAATCAAACTCCT

CAGACCACATTGCCACAATTATTTCTTAAAGTAGGGGAACCCTTATGGAT

AAGGTGCAAAGCTGTTCATGTGAACCATGGATTCGGGCTCACCTGGGAAT

TAGAAAACAAAGCACTCGAGGAGGGCAACTACTTTGAGATGAGTACCTAT TCAACAAACAGAACTATGATACGGATTCTGTTTGCTTTTGTATCATCAGT

GGCAAGAAACGACACCGGATACTACACTTGTTCCTCTTCAAAGCATCCCA

GTCAATCAGCTTTGGTTACCATCGTAGAAAAGGGATTTATAAATGCTACC

AATTCAAGTGAAGATTATGAAATTGACCAATATGAAGAGTTTTGTTTTTC

TGTCAGGTTTAAAGCCTACCCACAAATCAGATGTACGTGGACCTTCTCTC GAAAATCATTTCCTTGTGAGCAAAAGGGTCTTGATAACGGATACAGCATA

TCCAAGTTTTGCAATCATAAGCACCAGCCAGGAGAATATATATTCCATGC

AGAAAATGATGATGCCCAATTTACCAAAATGTTCACGCTGAATATAAGAA

GGAAACCTCAAGTGCTCGCAGAAGCATCGGCAAGTCAGGCGTCCTGTTTC

TCGGATGGATACCCATTACCATCTTGGACCTGGAAGAAGTGTTCAGACAA GTCTCCCAACTGCACAGAAGAGATCACAGAAGGAGTCTGGAATAGAAAGG

CTAACAGAAAAGTGTTTGGACAGTGGGTGTCGAGCAGTACTCTAAACATG

AGTGAAGCCATAAAAGGGTTCCTGGTCAAGTGCTGTGCATACAATTCCCT

TGGCACATCTTGTGAGACGATCCTTTTAAACTCTCCAGGCCCCTTCCCTT

TCATCCAAGACAACGAATTCATCATCCTGGGCCTGTTCGGCCTCCTGCTG TTGCTCACCTGCCTCTGTGGAACTGCCTGGCTCTGTTGCAGCCCCAACAG

GAAGAATCCCCTCTGGCCAAGTGTCCCAGACCCAGCTCACAGCAGCCTGG

GCTCCTGGGTGCCCACAATCATGGAGGAGGATGCCTTCCAGCTGCCCGGC

CTTGGCACGCCACCCATCACCAAGCTCACAGTGCTGGAGGAGGATGAAAA

GAAGCCGGTGCCCTGGGAGTCCCATAACAGCTCAGAGACCTGTGGCCTCC CCACTCTGGTCCAGACCTATGTGCTCCAGGGGGACCCAAGAGCAGTTTCC

ACCCAGCCCCAATCCCAGTCTGGCACCAGCGATCAGGTCCTTTATGGGCA

GCTGCTGGGCAGCCCCACAAGCCCAGGGCCAGGGCACTATCTCCGCTGTG

ACTCCACTCAGCCCCTCTTGGCGGGCCTCACCCCCAGCCCCAAGTCCTAT

GAGAACCTCTGGTTCCAGGCCAGCCCCTTGGGGACCCTGGTAACCCCAGC CCCAAGCCAGGAGGACGACTGTGTCTTTGGGCCACTGCTCAACTTCCCCC

TCCTGCAGGGGATCCGGGTCCATGGGATGGAGGCGCTGGGGAGCTTC SEQ ID NO : 191 pMON30329.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAG CGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAAC ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 192 pMON32173.seq GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGG GGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG CCCGACTCCTCAACCCTG SEQ ID NO: 193 pMON32175.seq

GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCATGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACA CCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAG ATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAG GAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAG GCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTG CAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACC CAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGC CATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTTTACGCCACCTTGCGCAGCCC SEQ ID NO:194 pMON32204.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACTCAGGACTGCTCTTTTCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAG CGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAAC ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAG GGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCT AAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCC TCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAG ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 195 pMON32205.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTG GACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAAC CTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACTCAGGACTGCTCTTTTCAA CACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGAT TACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAG τ>λ

CGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCT CCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTG AACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID N0:196 pMON32208.seq

GCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGT CCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACA CCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAG ATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAG GAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAG GCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTG CAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCC GACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACC CAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGC CATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTACGTAGAG GGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCT AAAGAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCC TCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAG ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 197

PMON35767. seq/pMON32191. seq

GGCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGA GCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCT CTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTT TCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGG CGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAA GTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCC CCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCT TTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGA CACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAAT GGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGC AGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCA CCTTGCGCAGCCG SEQ ID NO: 198

pMON32397.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATA CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT A&

GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 199 pMON32398.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATA CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT GGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA SEQ ID NO: 200 pMON32399.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAACCTGCAGGACGAG GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO: 201 pMON35700.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAAGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGCCTCCAACCTGCAGGACGAG GAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG SEQ ID NO: 202 pMON35701.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGGTCCAAGATGCAA GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTAC CCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 203 pMON35702.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGTCGCTGGGTCCAAGATGCAA GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGAC TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTAC CTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTC TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT SEQ ID NO: 204 pMON35703.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTCCAGACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT GGATCCGGAGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC GAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT GTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA TGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 205 pMON35704.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCGCTTCGTCCAGACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT GGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATA CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT SEQ ID NO: 206 pMON35705.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAAGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGT ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 207 p ON35706.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAG SEQ ID NO: 208

PMON35733.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTTCTAATCTGCAAGATGAAGAG CTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCC TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC SEQ ID NO: 209 pMON35734.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCAACCTGCAAGATGAAGAGCTG TGTGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGT GGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC SEQ ID NO: 210 pMON35735.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGCAGGATGAGGAACTGTGC GGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCTTTTCAG CCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAG CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT CAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC TCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC SEQ ID NO: 211 pMON35736.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCAAGATGAAGAGCTGTGTGGT GGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG CCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG SEQ ID NO: 212 pMON35738.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAAGAACTGTGTGGTGGTCTG TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAA GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC SEQ ID NO: 213 pMON35739.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAGCTGTGTGGTGGCCTGTGG CGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGC TTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAAAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCC TCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGT AGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAG SEQ ID NO: 214 pMON35740.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGTGCGGTGGTCTGTGGCGT CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG SEQ ID NO: 215 pMON35741.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTTCTAATCTGCAAGATGAAGAG CTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCC TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC TCCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC SEQ ID NO: 216 pMON35742.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCAAGATGAAGAACTGTGCGGT GGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCGGGAGACCTCCGAGCAG CCGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG CCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG SEQ ID NO: 217 pMON35743.seq GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTG GACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAAC CTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGTGCGGTGGTCTGTGGCGT CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCGGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAGATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG SEQ ID NO: 218

pMON32179.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC

ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC

CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG

TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA

GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC

ACCGTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC

CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGAT

GAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAA

GACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTC AAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCT

GCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAA

AAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 219

PMON35707.seq

GCGGATGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGA GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAA GAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTA AAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATG GAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCA TCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCT CGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTG GTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 220 PMON35708.seq

GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 221 pMON35709.seq GCAGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 222 pMON35710.seq

GCGGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCCTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCCTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 223 pMON35711.seq GCGGATGAGGAGCTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGGGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 224 pMON35719.seq

GGCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCG

GCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTT GCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTG TCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCT GAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTC AACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCT TCAATACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCC GTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGA AATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGA CATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAA GCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGC CACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAA ACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 225 pMON35720.seq GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACG GAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCA GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC GTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 226 pMON35721.seq

GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAGGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 227 pMON35722.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCC TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC

TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG

CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA

GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT

GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT

GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG

TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA

ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC

ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC

ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA

CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 228 pMON35723.seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAG CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT CAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 229

PMON35725.seq

GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGT GGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTYGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTG AACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 230

PMON35726.seq GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAACGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT TTTTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 231 pMON35744. seq

GCTTCAAATCTGCAGGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAG ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGA GGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTC CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA GATTACCCAGTCACCGTGGCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 232 pMON35745. seq GCTAATCTGCAAGATGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATA CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT GGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAA CACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGAT TACCCAGTCACCGTGGCCTCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 233 pMON35746.seq

GCGCTGCAGGATGAAGAGCTGTGTGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTTGATGGAG CGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCC CGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTC TCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGG TCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTAC CCAGTCACCGTGGCCTCCAACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 234

PMON35747.seq

GCGCAAGATGAGGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCCCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 235 pMON35748.seq

GCTGAAGAACTGTGTGGTGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC GTGGCCTCCAACCTGCAGGACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 236 pMON35749.seq

GCTCTGTGCGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 37 pMON35750.seq GCACTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 238 pMON35769.seq

GCTCTGTGTGGCGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTGCAGTGTCGGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 239 pMON35771.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCC TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 240 pMON35774.seq

GCTCAAGATGATGAGCTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGCGGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCAT AAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCA CCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAAC CTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATT GAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCA ATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTT GAGCAAGCGCAGGAACAACAG SEQ ID NO: 241 pMON35775.seq

GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG

CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT

GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC A<o^*b

CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCA CTCGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC CTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 242 pMON35776.seq

GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCA CTCGGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGC TCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAAC AACCTCAATTCTGAAGACATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCA TTCGTAAGGGCTGTCAAGCACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAA CCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGG CAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAG SEQ ID NO: 243 pMON32169. seq/pMON40000. seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 244 pMON32188.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAAATCTGCAAGACGAGGAGCTGTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCC CCCAGCTGTCTTCGCTTCGTCCAGATCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC GACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGG GGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCC SEQ ID NO:245 pMON32273.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCA GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO:246 pMON35795.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGCAGGATGAGGAACTGTGCGGCGGCCTC TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAA GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGA GGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC SEQ ID NO: 247 pMON35796.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCAAGATGAAGAGCTGTGTGGTGGTCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGC TTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCG CTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCC TCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGT AGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG SEQ ID NO:248 pMON35797.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC

AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC

GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT

GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC

GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT

CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAAGAACTGTGTGGTGGTCTGTGGCGGCTG

GTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTG GAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTT CGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAG CCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACC CTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGT ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAC SEQ ID NO:249 pMON35798.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGAGCTGTGTGGTGGCCTGTGGCGTCTGGTC CTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAG CGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGC TTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCC TGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG GGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAG SEQ ID NO : 250 pMON35799.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTCTGTGCGGTGGTCTGTGGCGTCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGC GTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGC GGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG SEQ ID NO:251 pMON39914.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGGCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACCACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 252 pMON39915.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG

AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC

CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG Abβ

CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGGCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGCGGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGC GGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC TCCAACCTGCAG SEQ ID NO: 253 pMON39916.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGGCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGCCGCCACCGTGGAGCCCGCGTCCACTCGGCGCCACCGCACCGACCGCTGGACAACCGCCT CTGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:254 pMON35712.seq GCCGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAA SEQ ID NO: 255 p ON35713.seq

GCCGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACG GAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCA GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC GTG SEQ ID NO: 256 pMON35714.seq

GCCGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACT SEQ ID NO: 257 pMON35715.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCC

TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG A (p(p

CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG SEQ ID NO: 258 pMON35716.seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAG CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT CAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC SEQ ID NO: 259 pMON35717.seq GCCCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCC TTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTT CAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTT SEQ ID NO: 260 pMON35718.seq

GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGT GGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTG AACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAG SEQ ID NO: 261 pMON32170.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 262

pMON32187.seq GCAGATGAAGAACTGTGTGGGGGACTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 263 pMON32271.seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTC GGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGC TCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTA GAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAG CTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGC TCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTG CAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCT GCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGG GTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCG CAGCCG SEQ ID NO: 264 pMON32272.seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGC GGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTG CCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTC CAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCT CTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTG AGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCC GAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAG CAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCC TCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTG TCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 265 pMON32274.seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTC GGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCA TTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGRAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 266 pMON35751.seq

GCGGATGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAGGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGA AM

GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAA GAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTC CTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTG TGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCC TGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCAT AGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCC ACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAA CTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAG CGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTT CTACGCCACCTTGCGCAGCCC SEQ ID NO: 267

PMON35752.seq

GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 268

PMON35753.seq

GCAGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTGTACGCCACCTTGCGCAGCCC SEQ ID NO:269 pMON35754.seq

GCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAG CAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGT CAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGC ACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTG TCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGC GGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCC AAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC GTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTATACGCCACCTTGCGCAGCCC SEQ ID NO: 270 pMON35755. seq λtt

GCTTCAAATCTGCAGGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAG ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGA GGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTC CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA GATTACCCAGTCACCGTGGCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCATCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO : 271 pMON35756.seq

GCTAATCTGCAAGATGAGGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATA CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGT GGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAA CACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGAT TACCCAGTCACCGTGGCCTCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTATACGCCACCTTGCGCAGCCC SEQ ID NO: 272 pMON35757.seq

GCGCTGCAGGATGAAGAGCTGTGTGGCGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTTGATGGAG CGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACAC TTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCC CGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTC TCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGG TCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACAC AGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTAC CCAGTCACCGTGGCCTCCAACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:273 pMON35758.seq GCACTGTGCGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTACAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG Mo

CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC

CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG

GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC

TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG

GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT

CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID

NO:274 pMON35759.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCC TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 275 pMON35760.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCC TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTG CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 276 pMON35761.seq

GCGCTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTGCAGTGTCGGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCC GGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC AACTTCGCTGTCAAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATTTTTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 277 pMON35762.seq

GCTGAACTGTGTGGTGGTCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACT

GTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAA

TGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAG GAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTG GAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGA TCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCC TCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTG GCCTCCAACCTGCAGGACGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 278 pMON35763.seq

GCTGAAGAACTGTGTGGTGGCCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAG ACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACC AAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTG CAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGC CTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGT GGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC GTGGCCTCCAACCTGCAGGACTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:279 pMON35764.seq

GCTCAGGACGAGGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:280 pMON35765.seq GCCACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATC ACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGT GGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTTGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCA CAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTG AACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTC CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC V

GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 281 pMON35766.seq/pMON32190. seq/pMON40001. seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTAC AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCC CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT GCGCAGCCG SEQ ID NO: 282 pMON35768.seq

GCTCAAGATGAAGAACTGTGCGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGAGGCGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTCCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 283 pMON35770.seq

GCGCTGTGTGGTGGCCTGTGGCGTCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTC GCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATAT GCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAG ACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAG CTGCAGTGTCGGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAGATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG GACGAGGAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCC AGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGC GCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTC GGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCA GGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGG ATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACC ATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCG GCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTC CTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 284 pMON35772.seq

GCCTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCC TTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACC TCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTTCCGGTGCCTGGAGCTG CAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGA GGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGT GAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC A

CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 285 p ON35773.seq

GCTCAAGACGAAGAACTGTGTGGTGGTCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCA GGCGGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACC CAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCT GACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCAT AAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATG GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC CTTGCGCAGCCC SEQ ID NO: 286 pMON35777. seq

GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCA CTCGGCGCCACCGCACCGACCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTC GCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAAC CTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACAC TCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGC TTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCC CCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGG CAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTC GCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAG GTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO: 287 pMON35778.seq

GCCCAAGATGAAGAACTGTGTGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGG CTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTT GTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGC CTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCC CGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCA CTCGGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGC CCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCA GTCACCGTGGCCTCCAACCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO:288 pMON35779.seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGC GGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCAT AAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATG GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC CTTGCGCAGCCC SEQ ID NO: 289 pMON35780.seq GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCCC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGC GGTGGTTCTGGCGGAGGATCCGGCGGCGGAAGCGGAGGTGGCTCTGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCAT AAATCTCCAAACATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TGCTTAGAGCAAGTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATG GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC CTTGCGCAGCCC SEQ ID NO: 290 pMON35782.seq

GCGGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGCCGCCACCGTGGAGCCCGCGTCCACTC GGCGCCACCGCACCGACCGCTGGACAACCGCCTCTGACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCACCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACACCA TTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAAGTGAGGAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC SEQ ID NO : 291 pMON39908.seq

GCTGATGAGGAGCTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGTAGAGACGGTGTTTCACCGTGTCAGCCAGGATGGTCTAGAT CTCCTGACCTCGACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCATTG GGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAG GGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGGAGCTG GTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTG CAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCC CTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTT GCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGT GCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTG CAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO: 292 pM0N32275.seq

GCTGATGAAGAACTGTGTGGTGGGCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCG GGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCT CCAAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTA GAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAG CTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGC TCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTC TACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTG CAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCT GCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGG GTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCG CAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAACCCAGGACTGCTCTTTTCAA CACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGAT TACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 293 pMON35781.seq

GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGAGCCGAAGAGC CCGGACACCCATACTAGTCCGCCATCTCCGACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGC TTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAG CTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATC CCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTC CATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGC CCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAA GAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTC CAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGC GTTCTACGCCACCTTGCGCAGCCCTCTGCAGAACCGAAATCTCCGGATACTCATACCAGCCCGCCA TCCCCGGGTTCTAATCTGCAAGATGAAGAGCTGTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAG CGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAAC ACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGCCTTCGCTTCGTCCAG ACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACT CGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 294 pMON35783. seq

GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTGGCAGGGGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CCGAAGAGCCCGGACACCCATACTAGTCCGCCATCTCCGGGTACACCATTGGGCCCTGCCAGCTCC CTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCG CTCCAGGAGAAGCTGTGTGCCACTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACT CTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCT TGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCC CCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGC AGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCG CCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGG TGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTCTGCAGAACCGAAATCTCCGGATACTCATA CCAGCCCGCCATCCCCGGGTAAGGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCA ACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCC AGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO:295

pMON32276.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATCTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTCCTCCTTCCAACACAGCCCC A >

ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAAC AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCC CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT GCGCAGCCG SEQ ID NO: 296 pMON32277.seq GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATCTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTCCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGCGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 297 pMON32278.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTCTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTAGAGCTGCAGTCTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAAC AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCC CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT GCGCAGCCG SEQ ID NO: 298 pMON32279.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCAGATGAAGAACTGTGTGGGGGCCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTCT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTCTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO:299 pMON35790.seq A

GCCACTCAGGACTCCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATCTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACT AACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATG GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC CTTGCGCAGCCG SEQ ID NO: 300 pMON35791.seq

GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTCTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATG GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC CTTGCGCAGCCG SEQ ID NO: 301 pMON35792.seq GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGCGGCTCCAACATGGCTACACCA TTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATC CAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACTAACAAGCTGTGCCACCCCGAGGAG CTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCC CTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAG GCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGAC TTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCACCCAG GGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTTGCTAGCCAT CTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCG SEQ ID NO:302 pMON39905.seq

GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACC TACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATG GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC CTTGCGCAGCCG SEQ ID NO: 303 Art pMON39906.seq

GCCACTCAGGACTGTTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGCGCCTGGAGCTGCAG TCTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGC GGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAG TCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACT AACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCC CTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTT TTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGAC ACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATG GCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCA GGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCAC CTTGCGCAGCCG SEQ ID NO: 304 pMON39909.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTACTCAAGGTGCTATGCCAGCTTTTGCTTCTGCTTTTCAACGTCGTGCAGGT GGTGTTCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT GCGCAGCCCTCTGGCGGCTCTGGCGGCTCTCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGA AAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCC GAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGC CAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTC CTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTC GCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCC SEQ ID NO: 305 pMON39910.seq

GCTACTCAAGGTGCTATGCCAGCTTTTGCTTCTGCTTTTCAACGTCGTGCAGGTGGTGTTCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTCT GGCGGCTCTGGCGGCTCTCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTGAGAAAGATCCAGGGC GATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCACCCCGAGGAGCTGGTG CTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCCAGCCAGGCCCTGCAG CTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGGCTCCTGCAGGCCCTG GAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGACGTCGCCGACTTTGCC ACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAGCCCTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAA GAATCTCATAAATCTCCAAACATGGCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGC GTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGC GGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 306 p ON35727.seq

GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAGCTCTGCGGGGGCCTC TGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAA GGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCC AGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTG GCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGAC TCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGAC TGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTAC CTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 307 pMON32168.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCA ATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAAATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGC CTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCC CCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC GACTCCTCAACCCTG SEQ ID NO: 308 pMON32195.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTAC AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCC CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT GCGCAGCCCTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATC AACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGT GGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAG ATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC CCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAG CTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAG CCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCA GGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTC AAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 309 pMON32196.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAA GAATCTCATAAATCTCCAAACATGGCTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCC GACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCC TCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATG GAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATA CACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATC TCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAAC TTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTG SEQ ID NO: 310 pMON32197.seq

GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGC GGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAA GAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTG GCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGC GTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTC GTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGC GGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAG GACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 311 pMON32206.seq

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACCACCTGCACCTTTGCTG GACCCGAACAACCTCAATGACGAAGACGTCTCTATCCTGATGGACCGAAACCTTCGACTTCCAAAC CTGGAGAGCTTCGTAAGGGCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGT AATCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCA GGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAA CAACAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAAC CCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGT CTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCC CCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTG GTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCC GACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGG GGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAA ATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 312 pMON3 207.seq GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGG ATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAG ATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAAC ATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAG AACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGA GGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTC CAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAA GATTACCCAGTCACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAA CCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAAC ATGGCTACACCATTAGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTGCTTAGAGCAA GTGAGGAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGC CACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGC CCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAG GGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTG GACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTG CAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTG GTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCC TGATAAGGATCCGAATTCGGCAGC SEQ ID NO: 313

PMON35728.seq

GCCGACGAGGAGCTGTGCGGTGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCT GTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCG TCTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTAACTGCTCTATAATGATCGATGAA ATTATACATCACTTAAAGAGACCACCTAACCCTTTGCTGGACCCGAACAACCTCAATTCTGAAGAC ATGGATATCCTGATGGAACGAAACCTTCGAACTCCAAACCTGCTCGCATTCGTAAGGGCTGTCAAG CACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAATCTCCAACCATGTCTGCCCTCTGCC ACGGCCGCACCCTCTCGACATCCAATCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAA CTGACGTTCTATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGGTGGAGGC TCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCTCCGTCTAAAGAATCTCAT AAATCTCCAAACATGGCCGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGC TGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACG GAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACC AACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGC CAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCA GGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATC TCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACC GTGGCCTCCAACCTGCAG SEQ ID NO: 314

PMON32183.seq

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGGAATTCAAGCTTGAGCCCAGAGGGCCCACAATCAAGCCCTGTCCT CCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATC AAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGAT GACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACC CATAGAGAGGATTACAACAGTACTCTCCGGGCGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGG ATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACC ATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAG ATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTG GAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGAT GGTTCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTAC TCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCG GGTAAA SEQ ID NO: 315 pMON32184.seq

GCCACCCAGGACTGCTCCTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG TCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTT CAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCC GAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAG TGTCAGCCCGACTCCTCAACCCTGGAATTCAAGCTTGAGCCCAGAGGGCCCACAATCAAGCCCTGT CCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAG A f

ATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAG GATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAA ACCCATAGAGAGGATTACAACAGTACTCTCCGGGCGGTCAGTGCCCTCCCCATCCAGCACCAGGAC TGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGA ACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAA GAGATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTAC GTGGAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCT GATGGTTCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGC TACTCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACT CCGGGTAAA SEQ ID NO: 316

A

TABLE 3

PROTEIN SEQUENCES pMON26458pep

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe SEQ ID NO: 467 p ON28548pep

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGln etGluGluT rLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyVal etAlaAlaArgGlyGln Le GlyProT rCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeu etLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAla SerProAlaProProAlaCysAspLeuArgValLeuΞerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLe LeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspPro AsnAlalleP eLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu etLeu ValGlyGlySerThrLeuCysValArg SEQ ID NO -468

PMON28500

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSer ProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisVal LeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeu ProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGln AspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeu GlyProThrCysLeuSerΞerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeu GlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHis LysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPhe LeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO: 469

PMON28501 SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLe ArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProT rCysLeuSerSerLeuLe GlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAla SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLe LeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO- 470

PMON28502

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrT rAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu ThrLysAlaGlnAspIleLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAla ArgGlyGlnLe GlyProT rCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnVal ArgLeuLeuLeuGlyAlaLe GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArg ThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGly LysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO: 471

13182. Pept

Asn Cys Ser lie Met lie Asp Glu lie lie His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lie Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lie

Glu Ala lie Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro lie lie lie Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys

His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly lie Pro

Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly lie Ser Pro Glu Leu Gly Pro Thr

Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr lie

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly

Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

Arg Lys lie Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

Ala Thr SEQ ID NO: 472

13183.Pept

Asn Cys Ser lie Met lie Asp Glu lie lie His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser lie Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lie

Glu Ala lie Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro lie lie lie Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro lie Ser Thr lie Asn Pro Ser Pro Pro

Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys

His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly lie Pro

Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly

Leu Leu Gin Ala Leu Glu Gly lie Ser Pro Glu Leu Gly Pro Thr

Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr lie

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly

Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

Arg Lys lie Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

Ala Thr SEQ ID NO: 473

13184. Pept

Asn Cys Ser lie Met lie Asp Glu lie lie His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser lie Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly lie

Glu Ala lie Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro lie lie lie Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Ai

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

Thr lie Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser

Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu

Gin Val Arg Lys lie Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu

Leu Gly His Ser Leu Gly lie Pro Trp Ala Pro Leu Ser Ser Cys

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly

He Ser SEQ ID NO: 474

13185. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser SEQ ID NO: 475

13186. Pept Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala

Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu

Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu

His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu

Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly SEQ ID NO: 476

13187. Pept Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp w

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly SEQ ID NO: 477

13188. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val

Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser

Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin

Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly

He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin

Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr

Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu

Gin Pro SEQ ID NO: 478

13189. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala

Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val

Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser

Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys

Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly

He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin

Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr

Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu

Gin Pro SEQ ID NO: 479

13190. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser

Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu

Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly

He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala SEQ ID NO: 480 13191. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro

Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser

Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu

Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp

Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala

Phe Ala SEQ ID NO: 481

13192. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys

His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro

Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr

Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu

Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr SEQ ID NO: 482

13193. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro

Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys

His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro

Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly

Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr

Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu

Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu

Lys Leu Cys Ala Thr SEQ ID NO: 483

25190. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr

Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu G Giinn G Glluu L Lyyss Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu

Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu

Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

Leu Glu Gly He Ser SEQ ID NO: 484

pMON25191. Pep

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser SEQ ID NO: 485

13194. Pept Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala

Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala

Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin

Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr

Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly SEQ ID NO: 486

13195. Pept Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro

Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu

Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin

Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly SEQ ID NO: 487

13196. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val

Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser

Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg

Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro

Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO: 488

13197. Pept Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He lie He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala

Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val

Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser

Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala

Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

Pro Ala Leu Gin Pro SEQ ID NO: 489

13198. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr

Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu

Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu

Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met

Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala

Met Pro Ala Phe Ala SEQ ID NO: 490

13199. Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala SEQ ID NO: 491 31104 . Pep

Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala

Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg

Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He

His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly

Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly

Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO: 492

31105. Pep Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys

Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He

Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr

Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly

Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met

Ala Pro Ala Leu Gin Pro SEQ ID NO: 493

31106.Pep

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin

Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin

Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser He Met He

Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp

Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val

Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly

Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly

Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala w

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO: 494 31107. Pep

Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu

Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn

Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser

Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu

Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

Ala Pro Ser Arg His Pro He He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met

Ala Pro Ala Leu Gin Pro SEQ ID NO: 495

31108. Pep

Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met

Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg

Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin

Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro

Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro

Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu

Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg

His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe

Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly

Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu

Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp

Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO: 496

31109. Pep

Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys

Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr

Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser

Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp

Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp

Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys

Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro

Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu

Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly °

Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu

Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp

Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO: 497

31110. Pep

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin

Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu

Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp

Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser

Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser

Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro

Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu

Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg

His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe

Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp

Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly

Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu

Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO: 498

31111. Pep Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu

Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly

Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu

He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro

Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn

Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin

Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He

He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro

Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg

His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe

Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp

Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly

Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp

Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro SEQ ID NO: 499 pMON15981

MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeu A3

ProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThr SEQ ID NO: 500

PMON15982

MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThrLeuGlnLeu AspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaPro AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeu ArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSer SerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeu ValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGln AlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlylleSer SEQ ID NO: 501

PMON15965

MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln ProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSer PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGln GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAla GlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeu GluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAsp PheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro ThrGlnGlyAlaMetProAlaPheAla SEQ ID NO: 502

PMON15966

MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGly SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylle ProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThr HeTrpGlnGlnMetGluGluLeuGly SEQ ID NO: 503 pMON15967

MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProΞerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProGlyGlyGlySerAspMetAlaThrProLeu GlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys HeGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSer CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeu AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGlu LeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO: 504

pMON31112.pep

MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspHeLeuMetAspAsnAsn LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPhe LeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer LeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu GlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO: 505

PMON31113.pep

MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspHeLeuMetGluAsnAsn LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIlellelleArgAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro SEQ ID NO: 506

pMON31114. ep

MetAlaAsnCysSerAsnMetlleAspGluIleHeThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspHeLeuMetGluAsnAsn LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisPro11e11el1eArgAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGlnSerPhe LeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSer LeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGlu GlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPhe AlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro SEQ ID NO: 507 pMON31115.pep

MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeu ProLeuLeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsn A

LeuArgArgProAsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSer AlalleGluSerlleLeuLysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaPro ThrArgHisProIleHisIleLysAspGlyAspTrpAsnGluPheArgArgLysLeuThr PheTyrLeuLysThrLeuGluAsnAlaGlnAlaGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro SEQ ID NO: 508

PMON28505 AlaAsnCysSerHeMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeu GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaPro ProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSer ArgLeuSerGlnCysPro SEQ ID NO: 509

PMON28506

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePhe LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAsp LeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGln CysProGluValHisPro SEQ ID NO: 510

PMON28507

AlaAsnCysSerlleMe lleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal ArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeu SerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVal HisProLeuProThrPro SEQ ID NO: 511 pMON28508 M

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuPro SEQ ID NO: 512 pMON28509

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsn MetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAsp SerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro ValLeuLeuProAlaVal SEQ ID NO: 513 pMON28510 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp HeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerPro AlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro AlaValAspPheSerLeu SEQ ID NO: 514

PMON28511

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe GlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu LeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeu ProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMet GluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMet AlaAlaArgGlyGlnLeu SEQ ID NO: 515 810 A ,ai<t? PCTYUS97/20037

pMON28512

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMetAlaSerPro AlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeu HisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuPro AlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp HeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeu SEQ ID NO: 516 pMON28513

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGly GluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeu LeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeu LeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGly ThrGlnLeuProProGln SEQ ID NO: 517

PMON28514

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr GlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGly ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro ProGlnGlyArgThrThr SEQ ID NO: 518

PMON28515 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLys SEQ ID NO: 519 PMON28516

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProΞer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys AlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeuGlyProThrCysLeuΞerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu LeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThr AlaHisLysAspProAsn SEQ ID NO: 520

PMON28519

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeu GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProPro AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg LeuSerGlnCysPro SEQ ID NO: 521 pMON28520

AlaAsnCysΞerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePhe LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisPro SEQ ID NO: 522

PMON28521

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal ArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrPro SEQ ID NO: 523 pMON28522 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuPro SEQ ID NO -524

PMON28523

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaVal SEQ ID NO 525

PMON28524

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp HeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAla ProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHis SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAla ValAspPheSer eu SEQ ID NO.526 pMON28525

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu 2o

GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeu SEQ ID NO: 527

PMON28526

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAlaSerProAla ProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHis SerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeuLeuProAla ValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHe LeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyPro ThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAla LeuGlnSerLeuLeu SEQ ID NO: 528 pMON28527 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArg ValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu TrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeu LeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr GlnLeuProProGln SEQ ID NO: 529 pMON28528

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLys LeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisPro LeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGln MetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyVal MetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSer GlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProPro GlnGlyArgThrThr SEQ ID NO: 530 pMON28529

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly AsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArg AspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThr ProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu ThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAla ArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnVal ArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArg ThrThrAlaHisLys SEQ ID NO: 531 pMON28530

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyAsnMetAla SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsn SEQ ID NO: 532

PMON28533

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGluValHisProLeuProThrProValLeuLeuProAlaVal AspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeu GlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThr CysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeu GlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSer ProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisVal LeuHisSerArgLeuSerGlnCysPro SEQ ID NO: 533

PMON28534 AlaAsnCysSerlleMe lleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetLeuProThrProValLeuLeuProAlaValAspPheSerLeu GlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspIleLeuGlyAlaValThr LeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSer LeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeu GlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePhe LeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySer ThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProPro AlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArg LeuSerGlnCysProGluValHisPro SEQ ID NO: 534

PMON28535

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu

ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly

HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer

ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe

TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer

HisLysSerProAsnMetValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys

ThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGlu

GlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGln

LeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeu ProProGlnGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGln HisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal ArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeu ArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCys ProGluValHisProLeuProThrPro SEQ ID NO: 535

PMON28536

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspΞerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrProValLeuLeuPro SEQ ID NO: 536 pMON28537

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThr LysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArg GlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArg LeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThr ThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLys ValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsn GlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeu LeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeu ProThrProValLeuLeuProAlaVal SEQ ID NO: 537 pMON2853£

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAsp HeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGly ProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGly AlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaValAspPheSerLeu SEQ ID NO: 538 pMON28539 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGln GlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeu ArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPhe Zo

GlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeu SerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluVal HisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLys ThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGlu GlyValMetAlaAlaArgGlyGlnLeu SEQ ID NO: 539

PMON28540

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyThrGlnLeuProProGlnGlyArgThrThrAlaHisLys AspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeu MetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMet AlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProVal LeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLys AlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGly GlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeu LeuLeuGlyAlaLeuGlnSerLeuLeu SEQ ID NO: 540

PMON28541

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetGlyArgThrThrAlaHisLysAspProAsnAlallePheLeu SerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThr LeuCysValArgGluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAla CysAspLeuArgValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeu SerGlnCysProGluValHisProLeuProThrProValLeuLeuProAlaValAspPhe SerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAla ValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeu SerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSer LeuLeuGlyThrGlnLeuProProGln SEQ ID NO: 541 pMON28542

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArg GluPheGlyGlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArg ValLeuSerLysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysPro GluValHisProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGlu TrpLysThrGlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeu LeuGluGlyValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeu GlyGlnLeuSerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThr GlnLeuProProGlnGlyArgThrThr SEQ ID NO: 542

PMON28543

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnGlyGlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSer LysLeuLeuArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHis ProLeuProThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThr GlnMetGluGluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGly ValMetAlaAlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeu SerGlyGlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuPro ProGlnGlyArgThrThrAlaHisLys SEQ ID NO: 543

PMON28544 AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysVal ArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGlyGlyAsnGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGly ArgThrThrAlaHisLysAspProAsn SEQ ID NO: 544

PMON28545

AlaAsnCysSerlleMe lleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArg GlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysValArgGluPheGly GlyAsnMetAlaSerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeu ArgAspSerHisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuPro ThrProValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGlu GluThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGln ValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAla HisLys SEQ ID NO: 545

PMON32132

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO: 546

PMON32133

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnGlyArgThrThrAlaHisLysAspPro AsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArgPheLeuMetLeu ValGlyGlySerThrLeuCysValArg SEQ ID NO: 547

PMON32134

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSerHis

ValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrProValLeu LeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGluThrLysAla GlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAlaAlaArgGlyGln LeuGlyProThrCysLeuSerSer euLeuGlyGlnLeuSerGlyGlnValArgLeuLeu LeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnLeuProProGlnGlyArgThrThrAla HisLysAspProAsnAlallePheLeuSerPheGlnHisLeuLeuArgGlyLysValArg PheLeuMetLeuValGlyGlySerThrLeuCysValArg SEQ ID NO: 548 pMON30237.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyAlaLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO: 549 pMON30238.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 550 pMON30239.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrPrOValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeu SEQ ID NO: 551 pMON32329.pep

GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO: 552 pMON32330.pep

GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 553

pMON32341.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro SEQ ID NO: 554 pMON32342.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 555

pMON32320.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 556

pMON32321.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 557 pMON32322.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGln SEQ ID NO: 558

pMON32323.pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly SerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 559

pMON32324.pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly SerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 560

pMON32325.pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys

CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe 2oo

SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGly SEQ ID NO: 561 pMON32326.pep AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn GlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 562 pMON32327.pep

AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsn GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrPrOValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 563 pMON32328.pep

AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnPro SEQ ID NO: 564 pMON32348.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 565

pMON32350.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp IleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlySerGlySerGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 566

FLT3N.pep MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySer SEQ ID NO : 567 FLT3C . pep

GlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPhe ValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeu SEQ ID NO: 568

FLT7N.pep

Me AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySer SEQ ID NO: 569

FLT4C.pep

GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeu SEQ ID NO: 570

FLTHN.pep

MetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer SEQ ID NO: 571

FLTlOC.pep GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 572

pMON32365.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGln SEQ ID NO: 573 ZAP pMON32366.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 574 pMON32367.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 575 pMON32368. pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 576 pMON3 369. pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 577 pMON32370.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO: 578 pMON30247.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu

ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly

HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer

ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe

TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer

HisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSer

AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr

ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyAlaLeuTrpArgLeuValLeuAla

GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys 3,Aλ

LeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln Pro SEQ ID NO: 579

pMON30248.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyAlaLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeu SEQ ID NO: 580 pMON32332.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProΞerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO : 581

pMON32333.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:582

pMON32334.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln uv

ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 583

pMON32335.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:584 pMON32336. pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProΞer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO: 585

PMON32337.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 586

pMON32338.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:587

pMON32339.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln Pro SEQ ID NO: 88

pMON32364.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln Pro SEQ ID NO: 589

pMON32377.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeu SEQ ID NO: 590

pMON32352.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro

LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:591 pMON32353.pep

AlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO: 92 pMON32354.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu IleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 593 pMON32355.ρep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO:594 pMON32356.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla Gly SEQ ID NO: 595

pMON32357.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 596 pMON32358. pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlyΞerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:597

pMON32359.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln Pro SEQ ID NO: 598 pMON32360. pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlySerGlySerGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 599

pMON32362.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlySerGlySerGlyGlySerGlySerGlyGly SerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO: 600

pMON32392.pep AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrPrOValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProTyrValGluGlyGly GlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAsp MetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAla ValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCys LeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrp GlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 601

pMON32393.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln

AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg

LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle

HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr

AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu

TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn

ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMet

HeAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsn

LeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeu AlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArg AsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGlu GlnAlaGlnGluGlnGln SEQ ID NO: 602 pMON32396.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ProHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeu SEQ ID NO: 603 pMON32371.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 604 pMON32372.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 605

pMON32373.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu

ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly

HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer

ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe

TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer

HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu

AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu

GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer

CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO:606 pMON3 374. pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 607

pMON32375.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAs HeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO: 608

pMON32376.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGln SEQ ID NO: 609

pMON32378.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProΞerProProSerLysGluSer % $

HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 610 pMON32379.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 611 pMON32380. pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 612

pMON32381.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO: 613

pMON32382.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro

LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu

ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer 2Zθ

ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla Gly SEQ ID NO: 614

pMON32383.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGly SEQ ID NO: 615 pMON32384.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 616

pMON32385. ep

AlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 617

pMON32386.pep IVΛ

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO:618

pMON32387.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 619 pMON32388.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln Pro SEQ ID NO: 620

pMON3 389.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuTh Phe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr 21%

ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnPro SEQ ID NO: 621 hflt3-28291inkl0.pep

AlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO:622

hflt3-28291inkl5.pep

AlaAsnCysSerHeMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlyΞerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu Gin SEQ ID NO: 623 hflt3-34351inkl0.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO: 624

hflt3-34351inkl5.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr Val SEQ ID NO: 625

hflt3-62631inkl0.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO: 626 hflt3-62631inkl5.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys Thr SEQ ID NO: 627

hflt3-94951inkl0.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO: 628

hflt3-94951inkl5.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro

LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu

ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys Leu SEQ ID NO: 629

hflt3-98991inkl0.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO: 630 hflt3-98991inkl5.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal Gin SEQ ID NO: 631

hflt3-28291ink6.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO: 632

hfIt3-28291ink7.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO: 633 hflt3-28291inkl3.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArg GlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO: 634 hflt3-28291ink21.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAs HeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThr SEQ ID NO: 635

hflt3-34351ink6.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO: 636

hflt3-34351ink7.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAlaSerAs LeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO: 637 hfIt3-34351inkl3.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAs HeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID NO: 638 hflt3-34351ink21.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysΞerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrVal SEQ ID NO: 639

hfIt3-62631ink6.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO: 640 hflt3-62631ink7.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuTh Phe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO: 641 hfIt3-62631inkl3.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO: 642 hflt3-62631ink21.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThr SEQ ID NO: 643

hflt3-94951ink6.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAs IleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGln 22^<?

AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO: 644 hflt3-94951ink7.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO: 645 hfIt3-94951inkl3.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyPro leSerTh lleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO: 646

hflt3-94951ink21.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeu SEQ ID NO: 647

hflt3-98991ink6.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGly LeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysLeuArgPheValGln SEQ ID NO: 648 hflt3-98991ink7.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAs HeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO: 649 hflt3-98991inkl3.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO: 650 hflt3-98991ink21.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnPro LeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeu ArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGln SEQ ID NO: 651

GlySerThrMetSerArgLeuProValLeuLeuLeuLeuGlnLeuLeuValArgProAlaMetSerThrAsnGln AspLeuProVallleLysCysValLeuIleAsnHisLysAsnAsnAspSerSerValGlyLysSerSerSerTyr ProMetValSerGluSerProGluAspLeuGlyCysAlaLeuArgProGlnSerSerGlyThrValTyrGluAla AlaAlaValGluValAspValSerAlaSerlleThrLeuGlnValLeuValAspAlaProGlyAsnlleSerCys LeuTrpValPheLysHisSerSerLeuAsnCysGlnProHisPheAspLeuGlnAsnArgGlyValValSerMet VallleLeuLysMetThrGluThrGlnAlaGlyGluTyrLeuLeuPhelleGlnSerGluAlaThrAsnTyrThr HeLeuPheThrValSerlleArgAsnThrLeuLeuTyrThrLeuArgArgProTyrPheArgLysMetGluAsn GlnAspAlaLeuValCysIleSerGluSerValProGluProIleValGluTrpValLeuCysAspSerGlnGly GluSerCysLysGluGluSerProAlaValValLysLysGluGluLysValLeuHisGluLeuPheGlyMetAsp HeArgCysCysAlaArgAsnGluLeuGlyArgGluCysThrArgLeuPheThrlleAspLeuAsnGlnThrPro GlnThrThrLeuProGlnLeuPheLeuLysValGlyGluProLeuTrpHeArgCysLysAlaValHisValAsn HisGlyPheGlyLeuThrTrpGluLeuGluAsnLysAlaLeuGluGluGlyAsnTyrPheGluMetSerThrTyr SerThrAsnArgThrMetlleArglleLeuPheAlaPheValΞerSerValAlaArgAsnAspThrGlyTyrTyr ThrCysSerSerSerLysHisProSerGlnSerAlaLeuValThrlleValGluLysGlyPhelleAsnAlaThr AsnSerSerGluAspTyrGluIleAspGlnTyrGluGluPheCysPheSerValArgPheLysAlaTyrProGln HeArgCysThrTrpThrPheSerArgLysSerPheProCysGluGlnLysGlyLeuAspAsnGlyTyrSerlle SerLysPheCysAsnHisLysHisGlnProGlyGluTyrllePheHisAlaGluAsnAspAspAlaGlnPheThr LysMetPheThrLeuAsnlleArgArgLysProGlnValLeuAlaGluAlaSerAlaSerGlnAlaSerCysPhe SerAspGlyTyrProLeuProSerTrpThrTrpLysLysCysSerAspLysSerProAsnCysThrGluGluIle ThrGluGlyValTrpAsnArgLysAlaAsnArgLysValPheGlyGlnTrpValSerSerSerThrLeuAsnMet SerGluAlalleLysGlyPheLeuValLysCysCysAlaTyrAsnSerLeuGlyThrSerCysGluThrlleLeu LeuAsnSerProGlyProPheProPhelleGlnAspAsnGluPhellelleLeuGlyLeuPheGlyLeuLeuLeu LeuLeuThrCysLeuCysGlyThrAlaTrpLeuCysCysSerProAsnArgLysAsnProLeuTrpProSerVal ProAspProAlaHisSerSerLeuGlySerTrpValProThrlleMetGluGluAspAlaPheGlnLeuProGly LeuGlyThrProProIleThrLysLeuThrValLeuGluGluAspGluLysLysProValProTrpGluSerHis AsnSerSerGluThrCysGlyLeuProThrLeuValGlnThrTyrValLeuGlnGlyAspProArgAlaValSer ThrGlnProGlnSerGlnSerGlyThrSerAspGlnValLeuTyrGlyGlnLeuLeuGlySerProThrSerPro GlyProGlyHisTyrLeuArgCysAspSerThrGlnProLeuLeuAlaGlyLeuThrProSerProLysSerTyr GluAsnLeuTrpPheGlnAlaSerProLeuGlyThrLeuValThrProAlaProSerGlnGluAspAspCysVal PheGlyProLeuLeuAsnPheProLeuLeuGlnGlylleArgValHisGlyMetGluAlaLeuGlySerPhe SEQ ID NO: 652 pMON30329.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 653

PMON32173.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeu ValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgVal AsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSer ArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 654 pMON32175.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg

LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg

ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr

AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe

SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla

ThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGln

GlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu

GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeu

SerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO 655 pMON32204 pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPhe AlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyr ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLys GluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO 656 pMON32205 pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArg AlaValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLe LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO 657

PMON32208 pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAla ThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGln GlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeu SerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGly ProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGly MetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly ValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProTyr ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLys GluSerHisLysSerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO 658 2*2, pMON35767. pep/pMON32191.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisΞerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 659 pMON32397.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGln HisΞerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln SEQ ID NO : 660 pMON32398. pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu Gin SEQ ID NO: 661 pMON32399.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg

AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla

ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe

TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer

GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr

ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe

GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu

ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer

ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal SEQ ID

NO:662 pMON35700.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAlaSerAsn LeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGl ArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr Val SEQ ID NO: 663 pMON35701.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr SEQ ID NO:664 pMON35702. pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLys Thr SEQ ID NO: 665 pMON35703.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaArgPheVal GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeu SEQ ID NO:666

pMON35704.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnΞerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaArgPheVal GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys Leu SEQ ID NO: 667 pMON35705.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlySerSerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln SEQ ID NO:668 pMON35706.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal Gin SEQ ID NO: 669 pMON35733. pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAla SEQ ID NO: 670 pMON35734.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg

AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla

ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe

TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer

GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla

GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro

ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla

LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu

GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp

TyrProValThrValAlaSer SEQ ID NO: 671 pMON35735.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsn SEQ ID NO: 672 pMON35736.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeu SEQ ID NO- 673 pMON35738.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlyΞerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAsp SEQ ID NO: 674 pMON35739.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeu ArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHe ThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGlu SEQ ID NO: 675 pMON35740.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspIleLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg

AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla

ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe

TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer

GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly

LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg

PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr

ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGly

GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla

SerAsnLeuGlnAspGluGlu SEQ ID NO- 676 pMON35741.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspSerAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAla SEQ ID NO: 677 pMON35742.pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaGlnAspGlu GluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuArgGluThrSerGluGlnProValAlaLeuLys ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeu SEQ ID NO: 678 pMON35743. pep

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsn AsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArg AlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGlu SEQ ID NO: 679 pMON32179.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln

ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal

AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr

LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp

CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlle

AsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIle

HeHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeu

MetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly

HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGlu

GlnGln SEQ ID NO: 680 pMON35707.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuArgProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArg ProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArg ThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArg AsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrp GlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO : 681 pMON35708.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlyΞerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 682 pMON35709.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspΞerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 683 pMON35710.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgLeuValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 684 pMON35711.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlyArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln

ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal

AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr

LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp

CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly

ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle

MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu

AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu

GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu

GluGlnAlaGlnGluGlnGln SEQ ID NO: 685 pMON35719.pep MetAlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlle AsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIle HeHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeu MetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlelle HeLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGlu GlnGln SEQ ID NO: 686 pMON35720.pep

AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 687 pMON35721.pep

AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 688

PMON35722. pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuΞerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 689 pMON35723.pep

AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr

LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer

ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal

AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg

LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn

ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle

HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet

GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle

GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln

Gin SEQ ID NO: 690 pMON35725 . pep AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProI leSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys 2S3

LeuArgPheValGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 691 pMON35726.pep

AlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysPheTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 692 pMON35744. pep

AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 693 pMON35745. pep

AlaAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGlu GlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 694 pMON35746.pep

AlaLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgLeuMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla

PheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln

LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer

SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr

GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly

ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle

MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu

AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu

GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu

GluGlnAlaGlnGluGlnGln SEQ ID NO: 695 pMON35747.pep P

AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetHeAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 696 pMON35748.pep

AlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 697 pMON35749.pep

AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysΞerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 698 pMON35750.pep

AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro

SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys

ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly

GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe

GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly

ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle

MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu

AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu

GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu

GluGlnAlaGlnGluGlnGln SEQ ID NO: 699 pMON35769.pep AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle MetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu GluGlnAlaGlnGluGlnGln SEQ ID NO: 700 pMON35771. ep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMe HeAspGluIlelle HisHlsLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspIleLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO:701 pMON35774. pep

AlaGlnAspAspGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGly GlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSer ProAsnMetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeu AspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAla PheValArgAlaValLysHisLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeu ProSerAlaThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLys LeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGln SEQ ID NO: 702 pMON35775.pep

AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln Gin SEQ ID NO: 703 pMON35776.pep

AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe

GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu

ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer

ThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGln

AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly

ProHeSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlle

MetHeAspGluIlelleHisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGlu

AspMetAspHeLeuMetGluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeu

GluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeu

GluGlnAlaGlnGluGlnGln SEQ ID NO: 704

PMON32169.pep/pMON40000.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly IMl

GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysΞerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 705 pMON32188.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuVal LeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsn ThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnlleAsnlle SerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAla ValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer SEQ ID NO: 706 pMON32273. pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerTh lleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCys GlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGln GlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO: 707 pMON35795.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaVal LysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn SEQ ID NO:708 pMON35796.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer lnS

LysGluSerHisLysSerProAsnMetAlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu SEQ ID NO:709

PMON35797.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArg TrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeu GlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeu GlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp SEQ ID NO: 710 pMON35798.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrp MetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPhe ValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGln GluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGln CysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGlu SEQ ID NO: 711 pMON35799.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGlu SEQ ID NO: 712 pMON39914.pep AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu 2

LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThr ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrPrOValThrValAlaSerAsnLeuGln SEQ ID NO: 713 pMON39915.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGln SEQ ID NO: 714 pMON39916.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThr AlaGlyGlnProProLeuThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 715

pMON35712.pep

AlaAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThr GluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCys LeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly GlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGln SEQ ID NO: 716 pMON35713.pep

AlaAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrVal SEQ ID NO: 717 pMON35714.pep

AlaValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThr SEQ ID NO: 718 pMON35715.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla

SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGly SEQ ID NO : 719 pMON35716 . pep

AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnPro SEQ ID NO: 720 pMON35717.pep

AlaArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln AspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeu SEQ ID NO: 721 ρMON35718.pep

AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGln SEQ ID NO: 722 pMON32170.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 723 pMON32187.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 724 1M pMON32271.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGly GlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGln ValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGlu GluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln LeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylle SerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGln MetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGln ArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnPro SEQ ID NO:725 pMON32272.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGly GlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGln SerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeu SerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGln GlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAla AspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAla MetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeu GluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 726 pMON32274.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThr ProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGly AspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGly HisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSer GlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyPro ThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMet AlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVal LeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 727 pMON35751.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuArgProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPrOValThrValAlaSerAsnLeuGln TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 728 pMON35752.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:729 pMON35753. pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValValArgHisLeuAlaGlnPro SEQ ID NO: 730 pMON35754.pep

AlaProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerValPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgVallleArgHisLeuAlaGlnPro SEQ ID NO: 731 pMON35755.pep AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerHisProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 732 pMON35756.pep

AlaAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu

LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCys AlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGlu GlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsp SerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly ThrGlriAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyr LeuLeuGlnAspTyrProValThrValAlaSerTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgVallleArgHisLeuAlaGlnPro SEQ ID NO:733 pMON35757.pep

AlaLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgLeuMetGluArgLeuLys ThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAla PheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGln LeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSer SerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThr GlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu LeuGlnAspTyrProValThrValAlaSerAsnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:734 pMON35758.pep

AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 735 pMON35759.pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 736 pMON35760.pep AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 737 pMON35761.pep

AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProPro SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPhe GlnHisSerProIleSerSerAsnPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrPro ValThrValAlaSerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIlePheThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 738 pMON35762.pep

AlaGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGlnAspGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 739 pMON35763.pep

AlaGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAla GlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCys SerPheGlnHisSerProHeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 740 pMON35764.pep

AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 741 pMON35765.ρep AlaThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 742

PMON35766.pep/pMON32190.pep/pMON40001.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu GlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisPro GluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGly HeSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArg HisLeuAlaGlnPro SEQ ID NO: 743 pMON35768.pep

AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGln AspCysSerPheGlnHisSerProIleSerSerAspSerAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 744 pMON35770.pep

AlaLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySer LysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysTyrAlaPheGlnProProPro

SerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLys

ProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysArgProAspSerSerThrLeuGlyGly

GlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro

HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr

HeAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSer

LeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu

LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrp

AlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeu I

AspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThr GlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGln SerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 745 pMON35772.pep

AlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro ProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAla LeuLysProTrpHeThrArgGlnAsnPhePheArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerPro HeSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAla SerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlyTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 746

PMON35773.pep AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGly GlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSer ProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVal ArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGlu LeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeu AlaGlnPro SEQ ID NO: 747 pMON35777.pep

AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThrThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuPro GlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGly AlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 748 pMON35778.pep

AlaGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThr ValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPhe GlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGln AspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeu GlnAspTyrProValThrValAlaSerAsnLeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 749 pMON35779.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGly GlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSer ProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVal ArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGlu LeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeu AlaGlnPro SEQ ID NO: 750 pMON35780.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgProLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGly GlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSer ProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnVal ArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGlu LeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeu AlaGlnPro SEQ ID NO: 751

PMON35782.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGlyGlnProProLeuThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlyThrProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrProLeuGly ProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIleGlnGlyAspGlyAla AlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeu GlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHis SerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAsp ThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAla LeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAla SerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 752 pMON39908.ρep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProValGluThrVal PheHisArgValSerGlnAspGlyLeuAspLeuLeuThrSerThrGlnAspCysSerPheGlnHisSerProIle SerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSer AsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsnMetAlaThrPro LeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThr LeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAla ProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeu ValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SEQ ID NO:753 pMON32275.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeu LeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyr LysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCys ProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeu GlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAla ThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAla PheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyPro HeSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCysSer PheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyr ProValThrValAlaSerAsnLeuGln SEQ ID NO: 754 pMON35781.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnGluProLysSerProAspThrHisThrSer ProProSerProThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVal ArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGlu LeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeu AlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArg ArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeu AlaGlnProSerAlaGluProLysSerProAspThrHisThrSerProProSerProGlySerAsnLeuGlnAsp GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProPro ProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 755 pMON35783.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyTrpGlnGlyArg ValAsnThrGluIleHisPheValThrLysCysAlaPheProLysSerProAspThrHisThrSerProProSer ProGlyThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys HeGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro SerAlaGluProLysSerProAspThrHisThrSerProProSerProGlyLysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO:756

pMON32276.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysSerAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp SerSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu GlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisPro GluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGly HeSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArg HisLeuAlaGlnPro SEQ ID NO: 757

PMON32277.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysSerAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspSerSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 758 pMON32278.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerSerLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnSerGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu GlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisPro GluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGly HeSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArg HisLeuAlaGlnPro SEQ ID NO: 759 pMON32279.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerSerLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnP eSerArgCysLeuGlu LeuGlnSerGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 760 pMON35790.pep AlaThrGlnAspSerSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysSerAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 761 pMON35791.pep 2#

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerSerLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 762 pMON35792.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg

LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg

ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr

AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe

SerArgCysLeuGluLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGlyGlySerAsn MetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLys

HeGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLysLeuCysHisProGluGluLeuVal

LeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGly

CysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGlu

LeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGlu LeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla

GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGln

Pro SEQ ID NO: 763 pMON39905.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPro SEQ ID NO: 764 pMON3 906. pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPhe SerArgArgLeuGluLeuGlnSerGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGly GlyGlySerGlyGlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeu LysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrAsnLys LeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGln AlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThr ThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPhe AlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyr ArgValLeuArgHisLeuAlaGlnPr SEQ ID NO: 765 pMON39909.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp lS<o

CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyVal LeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGly GlySerGlyGlySerGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGly HeProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSer GlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThr LeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnPro SEQ ID NO: 766 pMON39910.pep

AlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHis LeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySer GlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeu CysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro LeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyr GlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProTyrValGlu GlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMet GluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGlu ThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeu SerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 767 pMON35727.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 768 pMON32168.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGly ProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnAspCys SerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsn TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 769

pMON32195.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGlu GlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisPro GluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeu GlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGly HeSerProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrTh lleTrpGln GlnMetGluGluLeuGlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArg HisLeuAlaGlnProTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 770 pMON32196.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerTh lleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGly GlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLys SerProAsnMetAlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGly GlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGly LeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArg PheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu SEQ ID NO: 771 pMON32197.pep

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro TyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer LysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIle HisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGlu LeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIle ArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGly GlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLys SerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg LeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLys CysAlaPheGlnProProProΞerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnPro AspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 772 pMON32206.pep AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaProLeuLeuAspProAsn AsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeuArgLeuProAsnLeuGluSerPheValArg AlaValLysAsnLeuGluAsnAlaSerGlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAla ThrAlaAlaProSerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSer GlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGlu 2.5%

LeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLys MetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysPro TrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGly SerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGln HisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThr HeAsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeu TrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheVal GlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySer GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerProIleSer SerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsn LeuGln SEQ ID NO: 773 pMON32207.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlyΞerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThr LysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThr SerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGln ProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SerGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerPro GlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSerHisLysSerProAsnMet AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysCysLeuGluGlnValArgLysIle GlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeu LeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeu GlyMetAlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnPro STPSTPGlySerGluPheGlySer SEQ ID NO: 774 pMON35728.pep AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsn ProSerProProSerLysGluSerHisLysSerProAsnMetAlaAsnCysSerlleMetlleAspGluIlelle HisHisLeuLysArgProProAsnProLeuLeuAspProAsnAsnLeuAsnSerGluAspMetAspHeLeuMet GluArgAsnLeuArgThrProAsnLeuLeuAlaPheValArgAlaValLysHisLeuGluAsnAlaSerGlylle GluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSerArgHisProIlellelle LysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPheTyrLeuValThrLeuGluGlnAlaGlnGluGln GlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerProPro SerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArg LeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeu GluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 775

pMON32183.pep

AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrVal AlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln ProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuVal AlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnGluPheLysLeuGluProArgGlyProTh lleLysProCys ProProCysLysCysProAlaProAsnLeuLeuGlyGlyProSerValPhellePheProProLysIleLysAsp ValLeuMetlleSerLeuSerProIleValThrCysValValValAspValSerGluAspAspProAspValGln HeSerTrpPheValAsnAsnValGluValHisThrAlaGlnThrGlnThrHisArgGluAspTyrAsnSerThr LeuArgAlaValSerAlaLeuProIleGlnHisGlnAspTrpMetSerGlyLysGluPheLysCysLysValAsn AsnLysAspLeuProAlaProIleGluArgThrlleSerLysProLysGlySerValArgAlaProGlnValTyr ValLeuProProProGluGluGluMetThrLysLysGlnValThrLeuThrCysMetValThrAspPheMetPro GluAspIleTyrValGluTrpThrAsnAsnGlyLysThrGluLeuAsnTyrLysAsnThrGluProValLeuAsp SerAspGlySerTyrPheMetTyrSerLysLeuArgValGluLysLysAsnTrpValGluArgAsnSerTyrSer CysSerValValHisGluGlyLeuHisAsnHisHisThrThrLysSerPheSerArgThrProGlyLys SEQ ID NO:776 pMON32184.pep

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAsp TyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArg ValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThr AsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGlnAsnPhe SerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGluPheLysLeuGluProArgGlyProThr HeLysProCysProProCysLysCysProAlaProAsnLeuLeuGlyGlyProSerValPhellePheProPro LysIleLysAspValLeuMetlleSerLeuSerProIleValThrCysValValValAspValSerGluAspAsp ProAspValGlnlleSerTrpPheValAsnAsnValGluValHisThrAlaGlnThrGlnThrHisArgGluAsp TyrAsnSerThrLeuArgAlaValSerAlaLeuProIleGlnHisGlnAspTrpMetSerGlyLysGluPheLys CysLysValAsnAsnLysAspLeuProAlaProIleGluArgThrlleSerLysProLysGlySerValArgAla ProGlnValTyrValLeuProProProGluGluGluMetThrLysLysGlnValThrLeuThrCysMetValThr AspPheMetProGluAspHeTyrValGluTrpThrAsnAsnGlyLysThrGluLeuAsnTyrLysAsnThrGlu ProValLeuAspSerAspGlySerTyrPheMetTyrSerLysLeuArgValGluLysLysAsnTrpValGluArg AsnSerTyrSerCysSerValValHisGluGlyLeuHisAsnHisHisThrThrLysSerPheSerArgThrPro GlyLys SEQ ID NO: 777

The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples.

EXAMPLE 1

Construction of parental BHK expression vector

A. Removal of Afllll site from mammalian expression plasmid.

A new mammalian expression vector was constructed to accept Ncol-Hindlll or AfIIII-Hindlll gene fragments in-frame and 3' to the hIL-3 receptor agonist pMON13146 (WO 94/12638) gene and a mouse IgG2b linker fragment. First, the single Afllll site was removed from pM0N3934 , which is a derivative of pMON3359. pMON3359 is a pUC18- based vector containing a mammalian expression cassette. The cassette includes a herpes simplex viral promoter IE110 (-800 to +120) followed by a modified human IL-3 signal peptide sequence and an SV40 late poly- adenylation (poly-A) signal which has been subcloned into the pUC18 polylinker (See Hippenmeyer et al . , Bio/Technology, 1993, pp.1037-1041) . The modified human IL-3 signal sequence, which facilitates secretion of gene products outside of the cell, is flanked by a BamHl site on the 5' end and a unique Ncol site on the 3' end. A unique Hindlll site is 3 ' to the Ncol site and 5' to the poly-A sequence. The DNA sequence encoding the signal peptide is shown below (restriction enzyme sites are indicated above) . The ATG (methionine) codon within the Ncol site is in-frame with the initiator ATG of the signal peptide (underlined) ; BamHl Ncol

5 ' GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACTCCTGGTCCGCCCCGCCATGG ( SEQ ID NO : 857 )

The single Afllll site was removed from pMON3934 by digestion with Afllll followed by filling in the overhangs by addition of a DNA polymerase and nucleotides. The digested DNA fragment was purified via Magic PCR Clean up kit (Promega) and ligated with T4 DNA ligase. The ligation reaction was transformed into DH5oc ™ and the cells were plated onto LB-agar plus ampicillin. Individual colonies were screened for the loss of the Afllll site by restriction analysis with Afllll and Hindlll which results in a single fragment if the Afllll site was removed. The resulting plasmid was designated pMON30275.

B. Transfer of hIL-3 receptor agonist pMONl3416/IgG2b cassette into pMON30275.

The Ncol-Hindlll fragment (ca. 425 bp) from pMON30245 was ligated to the Ncol-Hindlll fragment (ca. 3800 bp) of the pMON30275. pMON30245 (WO 94/12638) contains the gene coding for hIL-3 receptor agonist pMON13416 joined to a mouse IgG2b hinge fragment. Immediately 3' to the IgG2b hinge and 5' to the Hindlll site is an Afllll site. Genes can be cloned into the Afllll-Hindlll sites as Ncol-Hindlll or Afllll-Hindlll fragments in frame with the hIL-3 variant pMON13416/IgG2b hinge to create novel chimeras. The Ncol site and the Afllll site have compatible overhangs and will ligate but both recognition sites are lost. The plasmid, pMON30304 containing the DNA sequence of (SEQ ID N0:1), coding for hIL-3 variant pMONl3416 joined with a mouse IgG2b hinge region, was a result of this cloning. EXAMPLE 2

Construction of an intermediate plasmid containing one copy of the c-mpl ligand (1-153) gene of the dimer template

In order to generate a plasmid DNA with the coding sequence of c-mpl (1-153) ligand followed by a unique EcoRI restriction site, the gene is isolated via reverse transcriptase/polymerase chain reaction (RT/PCR) . Human fetal (lot #38130) and adult liver (lot #46018) A+ RNA are obtained from Clontech (Palo Alto, CA) for source of c-mpl ligand messenger RNA (mRNA) . The first strand cDNA reactions are carried out using a cDNA Cycle™ Kit obtained from Invitrogen (San Diego, CA) . In the RT reaction, random primers and oligo dT primer are used to generate cDNA from a combination of human and fetal liver mRNA. For amplification of c-mpl ligand gene fragment encoding amino acids 1-153, the RT product serves as the template for PCR with a combination of the primers, Forward primer: c-mplNcol (SEQ ID NO: 317) and Reverse primer: Ecompl . The c-mplNcol primer anneals to the c-mpl ligand gene (bases #279-311 based on c-mpl ligand sequence from Gene bank accession #L33410 or de Sauvage et al . , Nature 369: 533-538 (1994)) and encodes a Ncol restriction enzyme site immediately 5' to the first codon (Ser+1) of c-mpl ligand. The Ncol restriction enzyme site codes for methionine and alanine codons prior to Ser+1 and includes codon degeneracy for the Ala codon and the first four codons (Ser, Pro, Ala, & Pro) of c-mpl ligand. The Ecompl primer anneals to bases #720-737 of c-mpl ligand and encodes an EcoRI site (GAATTC) in-frame with the c-mpl ligand gene immediately following Arg-153. The EcoRI site creates Glu and Phe codons following Arg-153. The ca . 480 bp PCR product was purified, digested with Ncol and EcoRI and ligated to the NcoI-EcoRI vector fragment of pMON3993 (ca. 4550 bp . ) . pMON3993 was a derivative of pMON3359 (described in Example 1) . The human IL-3 signal peptide sequence, which had been subcloned as a BamHl fragment into the unique BamHl site between the IE110 promoter and poly-A signal, contains an Ncol site at its 3' end and is followed by a unique EcoRI site. The plasmid, pMON26458 containing the DNA sequence of (SEQ ID NO:2), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO: 467) , was the result of this cloning.

EXAMPLE 3

Construction of the parental plasmids containing the second genes of the dimer templates

For amplification of c-mpl ligand gene fragments starting at amino acid 1 (Ser) with a termination codon following amino acid 153 (Arg) , the RT reaction from Example 2 serves as the template for PCR with a combination of the following primers; c-mplNcol (SEQ ID NO: 317) (forward primer) and c-mplHindlll (SEQ ID NO:319) (reverse primer) . The c-mplNcol (SEQ ID NO:317) primer is described in Example 2. The c-mplHindlll (SEQ ID NO: 319) primer, which anneals to bases #716-737 of c- mpl ligand, adds both a termination codon and a Hindlll restriction enzyme site immediately following the final codon, Arg¹⁵³.

Two types of PCR products are generated from the RT cDNA samples, one with a deletion of the codons for amino acids 112-115 and one without the deletion of these codons. The c-mpl ligand PCR products (ca. 480 bp) are digested with Ncol and Hindlll restriction enzymes for transfer to a mammalian expression vector, pMON3934. pMON3934 is digested with Ncol and Hindlll (ca. 3800 bp) and will accept the PCR products. Plasmid, pMON32132 (SEQ ID NO:84), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO: 546) was a result of this cloning. Plasmid, pMON32134 (SEQ ID NO:86), coding for c-mpl ligand amino acids 1-153 (SEQ ID NO: 548) was a result of this cloning. Plasmid, pMON32133 (SEQ ID

NO:85), coding for c-mpl ligand amino acids 1-153 with a deletion of codons 112-115 (Δ112-115) (SEQ ID NO: 547) was also a result of this cloning.

EXAMPLE 4

Generation of PCR dimer template 5L with a 112-115 deletion in the second c-mpl ligand gene

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32133 (containing a deletion of amino acids 112-115) along with the EcoRI/Afllll 5L synthetic oligonucleotide linker 5L-5' (SEQ ID NO:322) and 5L-3 ' (SEQ ID NO:323).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The Afllll end of the linker will ligate to the Ncol site of pMON32133, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32133 will ligate as well. Plasmid, pMON28548, is a result of the cloning and contains the DNA sequence of (SEQ ID NO: 3) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnMet (SEQ ID NO: 783) linker to amino acids 1-153 c-mpl ligand that contains a deletion of amino acids 112-115 (SEQ ID NO:468) .

EXAMPLE 5

Generation of PCR dimer template 4L A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32132 along with the EcoRI/Afllll 4L synthetic oligonucleotide linker 4L-5' (SEQ ID NO:320) and 4L-3 ' (SEQ ID NO: 321).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The Afllll end of the linker will ligate to the Ncol site of pMON32132, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32132 will ligate as well. The plasmid, pMON28500, is a result of the cloning and contains the DNA sequence of (SEQ ID NO: 4) which encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyAsnMetAla (SEQ ID NO: 223) linker (4L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:469).

EXAMPLE 6 Generation of PCR dimer template 5L

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp NcoI/BstXI fragment from pMON32132 along with the

EcoRI/Afllll 5L synthetic oligonucleotide linker 5L-5' (SEQ ID NO:322) and 5L-3 ' (SEQ ID NO:323).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The Afllll end of the linker will ligate to the Ncol site of pMON32132, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32132 will ligate as well. Plasmid, pMON28501 is a result of the cloning and contains the DNA sequence of (SEQ ID NO: 4) which encodes amino acids 1-153 c-mpl ligand fused via a

GluPheGlyGlyAsnMet (SEQ ID NO: 783) linker (5L) to amino acids 1-153 c-mpl ligand (SEQ ID NO:470). EXAMPLE 7 Generation of PCR dimer templates 8L

A PCR template for generating novel forms of c-mpl ligand is constructed by ligating the 3.7 Kbp BstXI/EcoRI fragment of pMON26458 to the 1 Kbp Ncol/BstXI fragment from pMON32134 along with the EcoRI/Afllll 8L synthetic oligonucleotide linker 8L-5' (SEQ ID NO:324) and 8L-3 ' (SEQ ID NO:325).

The EcoRI end of the linker will ligate to the EcoRI end of pMON26458. The Afllll end of the linker will ligate to the Ncol site of pMON32134, and neither restriction site will be retained upon ligation. The BstXI sites of pMON26458 and pMON32134 will ligate as well. Plasmid, pMON28502 is a result of the cloning which contains the DNA sequence of (SEQ ID NO : 6 ) and encodes amino acids 1-153 c-mpl ligand fused via a GluPheGlyGlyAsnGlyGlyAsnMetAla (SEQ ID NO: 224) linker

(8L) to amino acids 1-153 c-mpl ligand (SEQ ID NO: 471) .

EXAMPLES 8-44 Generation of novel c-mpl ligand genes with new N- terminus and C-terminus

A. PCR generation of genes encoding novel c-mpl ligand receptor agonists.

Genes encoding novel c-mpl ligand receptor agonists were generated using Method III (Horlick et al . , Prot.

Eng. 5:427-433, 1992 ). The PCR reactions were carried out using dimer templates, pMONs 28500, 28501, 28502 or 28548 and one of the sets of synthetic primer sets below

(The first number refers to the position of the first amino acid in the original sequence. For example, the 31-5' and 31-3' refers to the 5' and 3' oligo primers, receptively, for the sequence beginning at the codon corresponding to residue 31 of the original sequence.).

31-5' (SEQ ID NO:326) and 31-3' (SEQ ID NO:327), 35-5'

(SEQ ID NO:328) and 35-3' (SEQ ID NO:329), 39-5' (SEQ ID NO:330) and 39-3' (SEQ ID NO:331), 43-5' (SEQ ID NO:332) and 43-3' (SEQ ID NO:333), 45-5' (SEQ ID NO:334) and 45- 3' (SEQ ID NO:335), 49-5' (SEQ ID NO:336) and 49-3' (SEQ ID NO:337), 82-5' (SEQ ID NO:338) and 82-3' (SEQ ID NO:339), 109-5' (SEQ ID NO:340) and 109-3' (SEQ ID

NO: 341) 115-5' (SEQ ID NO: 342) and 115-3' (SEQ ID

NO: 343) 120-5' (SEQ ID NO:344) and 120-3' (SEQ ID

NO: 345) 123-5' (SEQ ID NO:346) and 123-3' (SEQ ID NO:347) 126-5' (SEQ ID NO:348) and 126-3' (SEQ ID

NO:349) .

The templates and oligonucleotide sets used in the PCR reactions are shown in Table 4. The products that were generated were about 480 bp and were purified via Magic PCR Clean up kits (Promega) .

B. Subcloning of novel c-mpl receptor agonist gene products into mammalian expression vector for generation of chimeras.

The c-mpl receptor agonist gene PCR products were digested with Ncol and Hindlll or Afllll and Hindlll restriction enzymes (ca. 470 bp) for transfer to a mammalian expression vector. The expression vector,

PMON30304, was digested with Ncol and Hindlll (ca. 4200 bp) and accepts the PCR products as Ncol-Hindlll or Afllll-Hindlll fragments. The restriction digest of the PCR product and the resulting plasmids are shown in Table 4. 2.£tf

TABLE 4

PCR PCR Product Resulting Breakpoint

Example # PCR Product Restriction Linker Plasmid in c-mpl template Primer Digest pMON ligand set

Example 8 PMON28501 31 Ncol/Hindlll 5L 28505 30- -31

Example 9 pMON28501 35 AflHI/Hindl 5L 28506 34- -35 II

Example 10 PMON28501 39 Ncol/Hindlll 5L 28507 38- -39

Example 11 PMON28501 43 Ncol/Hindlll 5L 28508 42- -43

Examp1e 12 PMON28501 45 Ncol/Hindlll 5L 28509 44- -45

Example 13 pMON28501 49 Ncol/Hindlll 5L 28510 48- -49

Example 14 PMON28501 82 Ncol/Hindlll 5L 28511 81- -82

Example 15 pMON28501 109 Ncol/Hindlll 5L 28512 108- -109

Example 16 pMON28501 116 Ncol/Hindlll 5L 28513 115- -116

Example 17 PMON28501 120 Ncol/Hindlll 5L 28514 119- -120

Example 18 pMON28501 123 Ncol/Hindlll 5L 28515 122- -123

Example 19 pMON28501 126 Ncol/Hindlll 5L 28516 125- -126

Example 20 PMON28500 31 Ncol/Hindlll 4L 28519 30- -31

Example 21 pMON28500 35 AflHI/Hindl 4L 28520 34- -35 II

Example 22 pMON28500 39 Ncol/Hindlll 4L 28521 38- -39

Example 23 pMON28500 43 Ncol/Hindlll 4L 28522 42- -43

Example 24 PMON28500 45 Ncol/Hindlll 4L 28523 44- -45

Example 25 PMON28500 49 Ncol/Hindlll 4L 28524 48- -49

Example 26 PMON 8500 82 Ncol/Hindlll 4L 28525 81- -82

Example 27 PMON28500 109 Ncol/Hindlll 4L 28526 108- -109

Example 28 PMON28500 116 Ncol/Hindlll 4L 28527 115- -116

Example 29 pMON28500 120 Ncol/Hindlll 4L 28528 119- -120

Example 30 pMON28500 123 Ncol/Hindlll 4L 28529 122- -123

Example 31 pMON28500 126 Ncol/Hindlll 4L 28530 125- -126

Example 32 PMON28502 31 Ncol/Hindlll 8L 28533 30- -31

Example 33 pMON 8502 35 AflHI/Hindl 8L 28534 34- -35 II

Example 34 pMON28502 39 Ncol/Hindlll 8L 28535 38- -39

Exam le 35 pMON28502 43 Ncol/Hindlll 8L 28536 42- -43 2^5

TABLE 4 cont .

PCR PCR Product Resulting Breakpoint

Example # PCR Product Restriction Linker Plasmid in c-mpl template Primer Digest pMON ligand set

Example 36 PMON28502 45 Ncol/Hindlll 8L 28537 44-45

Exam 1e 37 pMON28502 49 Ncol/Hindlll 8L 28538 48-49

Example 38 pMON28502 82 Ncol/Hindlll 8L 28539 81-82

Example 39 pMON28502 109 Ncol/Hindlll 8L 28540 108-109

Exam 1e 40 pMON28502 116 Ncol/Hindlll 8L 28541 115-116

EXAMPLE 41 PMON28502 120 Ncol/Hindlll 8L 28542 119-120

Example 42 pMON28502 123 Ncol/Hindlll 8L 28543 122-123

Examp1e 43 pMON28502 126 Ncol/Hindlll 8L 28544 125-126

Example 44 pMON28548 123 Ncol/Hindlll 5L 28545 122-123

EXAMPLE 45 Construction of pMON15960

Construction of pMON15960, an intermediate plasmid used for constructing plasmids containing DNA sequences encoding G-CSF Ser¹⁷ with a new N-terminus and C- terminus. Plasmid pACYC177 (Chang, A.C.Y. and Cohen, S.N. J. Bacteriol . 134:1141-1156, 1978) DNA was digested with restriction enzymes Hindlll and BamHl, resulting in a 3092 base pair Hindlll, BamHl fragment. Plasmid, pMONl3037 (WO 95/21254), DNA was digested with Bglll and Fspl, resulting in a 616 base pair Bglll, Fspl fragment. A second sample of plasmid, pMONl3037, DNA was digested with Ncol and Hindlll, resulting in a 556 base pair Ncol, Hindlll fragment. The synthetic DNA oligonucleotides lGGGSfor (SEQ ID NO:380) and lGGGSrev (SEQ ID NO: 381) were annealed to each other, and then digested with Afllll and Fspl, resulting in a 21 base pair Afllll, Fspl fragment. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and analyzed by restriction analysis to confirm the correct insert.

EXAMPLE 46 Construction of PMON15981

Construction of pMONl5981, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMON15960, DNA was digested with restriction enzyme Smal and used as template in a PCR reaction using synthetic DNA oligonucleotides 38 stop (SEQ ID NO: 369) and 39 start (SEQ ID NO: 368) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes Hindlll and Ncol, resulting in a Hindlll, Ncol fragment of 558 base pairs. Plasmid, pMONl3181, DNA was digested with Hindlll and

Afllll, resulting in a Hindlll, Afllll fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, PMON15981, contains the DNA sequence of (SEQ ID NO: 78) which encodes the following amino acid sequence:

MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeu ysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle euMetAspArgAsn LeuArg euProAsn euGluSerPheValArgAlaVal ysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCys euProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGlu ysLeuThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer ysGlu SerHisLysSerProAsnMetAlaTyrLys euCysHisProGluGluLeuValLeuLeu GlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGln euAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe euTyrGlnGlyLeuLeuGln Ala euGluGlylleSerProGlu euGlyProThr euAspThrLeuGlnLeuAspVal AlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeu GlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGly Val euValAlaSerHis euGlnSerPhe euGluValSerTyrArgValLeuArgHis LeuAlaGlnProGlyGlyGlySerAspMetAlaThrPro euGlyProAlaSerSerLeu ProGlnSerPheLeu euLysSerLeuGluGlnValArg ysIleGlnGlyAspGlyAla Ala euGlnGluLys euCysAlaThr (SEQ ID NO: 500)

EXAMPLE 47 Construction of PMON15982

Construction of pMON15982 , a plasmid containing DNA sequences encoding a multi- functional hematopoietic receptor agonist . Plasmid, pMON15960 , DNA was digested with restriction enzyme Smal and used as template in a PCR reaction using synthetic DNA oligonucleotides 96 stop ( SEQ ID NO : 371 ) and 97 start ( SEQ ID NO : 370 ) as primers , resulting in the amplif ication of a DNA fragment of 576 base pairs . The amplified fragment was digested with restriction enzymes Hindlll and Ncol , resulting in a Hindlll , Ncol fragment of 558 base pairs . Plasmid, pMON13181 , DNA was digested with Hindlll and Afllll , resulting in a Hindlll , Afllll fragment of 4068 base pairs . The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101 . Transf ormant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated, analyzed by restriction analysis , and sequenced to conf irm the correct insert . The plasmid, PMON15982 , contains the DNA sequence of ( SEQ ID NO : 79 ) which encodes the following amino acid sequence :

MetAlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn euArgLeuProAsn euGluSerPheValArgAlaValLysAsn euGluAsnAlaSer GlylleGluAlalle euArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThr euGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaProGluLeuGlyProThrLeuAspThr euGln eu AspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaPro AlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla GlyGlyValLeuValAlaSerHis euGlnSerPheLeuGluValSerTyrArgValLeu ArgHis euAlaGlnProGlyGlyGlySerAspMetAlaThrPro euGlyProAlaSer SerLeuProGlnSerPheLeuLeuLysSer euGluGlnValArgLysIleGlnGlyAsp GlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLys euCysHisProGluGlu eu ValLeuLeuGlyHisSerLeuGlylleProTrpAlaProLeuSerSerCysProSerGln Ala euGlnLeuAlaGlyCys euSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAla euGluGlylleSer (SEQ ID NO: 501)

EXAMPLE 48 Construction of PMON15965

Construction of pMON15965, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMONl5960, DNA was digested with restriction enzyme Smal and used as template in a PCR reaction using synthetic DNA oligonucleotides 142 stop (SEQ ID NO:377) and 141 start (SEQ ID NO:376) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes Hindlll and Ncol, resulting in a Hindlll, Ncol fragment of 558 base pairs. Plasmid, pMONl3181, DNA was digested with Hindlll and

Afllll, resulting in a Hindlll, Afllll fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, PMON15965, contains the DNA sequence of (SEQ ID NO: 80) which encodes the following amino acid sequence:

Me AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeu ysArgProProAla Pro eu euAspProAsnAsnLeuAsnAspGluAspValSerlle euMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaVal ysAsn euGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGlu ys euThr PheTyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer ysGlu SerHisLysSerProAsnMetAlaSerAlaPheGlnArgArgAlaGlyGlyVal euVal AlaSerHisLeuGlnSerPheLeuGluValSerTyrArgVal euArgHisLeuAlaGln ProGlyGlyGlySerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSer PheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla euGln GluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuVal euLeuGlyHis SerLeuGlylleProTrpAlaPro euSerSerCysProSerGlnAlaLeuGlnLeuAla GlyCys euSerGlnLeuHisSerGly euPheLeuTyrGlnGlyLeuLeuGlnAla eu GluGlylleSerProGluLeuGlyProThr euAspThrLeuGlnLeuAspValAlaAsp PheAlaThrThrlleTrpGlnGlnMetGluGlu euGlyMetAlaProAlaLeuGlnPro ThrGlnGlyAlaMetProAlaPheAla (SEQ ID NO: 502)

EXAMPLE 49 Construction of PMON15966

Construction of pMONl5966, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMONl5960, DNA was digested with restriction enzyme Smal and used as template in a PCR reaction using synthetic DNA oligonucleotides 126 stop (SEQ ID NO:372) and 125 start (SEQ ID NO:373) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes Hindlll and Ncol, resulting in a Hindlll, Ncol fragment of 558 base pairs. Plasmid, pMONl3181, DNA was digested with Hindlll and

Afllll, resulting in a Hindlll, Afllll fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid, PMON15966, contains the DNA sequence of (SEQ ID NO: 81) which encodes the following amino acid sequence:

etAlaAsnCysSerlleMetlleAspGluIlelleHisHis eu ysArgProProAla ProLeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlle euMetAspArgAsn LeuArgLeuProAsn euGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSer GlylleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelle ysAlaGlyAspTrpGlnGluPheArgGluLysLeuThr PheTyrLeuValThr euGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSer ysGlu SerHis ysSerProAsnMetAlaMetAlaProAlaLeuGlnProThrGlnGlyAlaMet ProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeu GlnSerPheLeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProGlyGlyGly SerAspMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla euGlnGluLysLeuCys AlaThrTyrLysLeuCysHisProGluGluLeuValLeu euGlyHisSer euGlylle ProTrpAlaPro euSerSerCysProSerGlnAla euGlnLeuAlaGlyCysLeuSer GlnLeuHisSerGlyLeuPhe euTyrGlnGlyLeu euGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGln euAspValAlaAspPheAlaThrThr IleTrpGlnGlnMetGluGluLeuGly (SEQ ID NO: 503)

EXAMPLE 50 Construction of PMON15967

Construction of pMONl5967, a plasmid containing DNA sequences encoding a multi-functional hematopoietic receptor agonist. Plasmid, pMONl5960, DNA was digested with restriction enzyme Smal and used as template in a PCR reaction using synthetic DNA oligonucleotides 132 stop (SEQ ID NO:375) and 133 start (SEQ ID NO:374) as primers, resulting in the amplification of a DNA fragment of 576 base pairs. The amplified fragment was digested with restriction enzymes Hindlll and Ncol, resulting in a Hindlll, Ncol fragment of 558 base pairs. Plasmid, pMON13181, DNA was digested with Hindlll and

Afllll, resulting in a Hindlll, Afllll fragment of 4068 base pairs. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis, and sequenced to confirm the correct insert. The plasmid,

PMON15967, contains the DNA sequence of (SEQ ID NO: 82) which encodes the following amino acid sequence:

MetAlaAsnCysSerlleMetlleAspGluIlelleHisHis eu ysArgProProAla Pro eu euAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsn LeuArgLeuProAsnLeuGluSerPheValArgAlaVal ysAsnLeuGluAsnAlaSer GlylleGluAlalle euArgAsn euGlnProCysLeuProSerAlaThrAlaAlaPro SerArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGlu ys euThr

PheTyr euValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGly SerProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGlu SerHisLysSerProAsnMetAlaThrGlnGlyAlaMetProAlaPheAlaSerAlaPhe GlnArgArgAlaGlyGlyVal euValAlaSerHisLeuGlnSerPheLeuGluValSer TyrArgValLeuArgHis euAlaGlnProGlyGlyGlySerAspMetAlaThrPro eu GlyProAlaSerSerLeuProGlnSerPhe eu euLysSerLeuGluGlnValArg ys IleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHis ProGluGluLeuVal eu euGlyHisSerLeuGlylleProTrpAlaPro euSerSer CysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln euHisSerGly euPhe LeuTyrGlnGly eu euGlnAlaLeuGluGlylleSerProGluLeuGlyProThr eu AspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGlu LeuGlyMetAlaProAla euGlnPro SEQ ID NO: 504

EXAMPLE 51

Construction of pMONl3180, an intermediate plasmid used for constructing plasmids that contain DNA sequence encoding multi-functional hematopoietic receptor agonists .

Plasmid, pMONl3046 (WO 95/21254), DNA was digested with restriction endonucleases Xmal and SnaBI, resulting in a 4018 base pair vector fragment. The 4018 base pair Xmal-SnaBI fragment was purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) in which the 25 base pair Xmal-SnaBI insert fragment is not retained. The complimentary pair of synthetic oligonucleotides, glyxal (SEQ ID NO: 378) and glyxa2 (SEQ ID NO: 379), were designed to remove sequence encoding a factor Xa cleavage site. When properly assembled these oligonucleotides also result in Xmal and SnaBI ends . The primers, Glyxal and glyxa2 , were annealed in annealing buffer (20mM Tris-HCl pH7.5 , 10 mM MgCl₂, 50 mM NaCl) by heating at 70°C for ten minutes and allowed to slow cool. The 4018 base pair Xmal-SnaBI fragment from pMON13046 was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from the transformants and analyzed using a PCR based assay. Plasmid DNA from selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid was designated pMONl3180 (SEQ ID NO: 88) . EXAMPLE 52 Construction of PMON13181, an intermediate plasmid used for constructing plasmids that contain DNA sequences encoding multi-functional hematopoietic receptor agonists .

Plasmid, pMONl3047 (WO 95/21254), DNA was digested with restriction endonucleases Xmal and SnaBI, resulting in a 4063 base pair vector fragment. The 4063 base pair Xmal-SnaBI fragment was purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) in which the 25 base pair Xmal-SnaBI insert fragment is not retained. The complimentary pair of synthetic oligonucleotides, glyxal (SEQ ID NO:378) and glyxa2 (SEQ ID NO:379), were designed to remove sequence encoding the factor Xa cleavage site. When properly assembled these oligonucleotides also result in Xmal and SnaBI ends. Glyxal and glyxa2 were annealed in annealing buffer by heating at 70°C for ten minutes and allowed to slow cool. The 4063 base pair Xmal-SnaBI fragment from pMON13047 was ligated with the assembled oligonucleotides using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated from the transformants and analyzed using a PCR based assay. Plasmid DNA from selected transformants was sequenced to confirm the correct insertion of the oligonucleotides. The resulting plasmid was designated pMONl3181 (SEQ ID NO: 87) .

EXAMPLE 53 Construction of PMON13182

The new N-terminus/C-terminus gene in pMONl3182 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 39 start (SEQ ID NO:368) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 38 stop (SEQ ID NO:369) and L-ll stop (SEQ ID NO:365). The full- length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using primers 39 start and 38 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMONl3180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic

DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMONl3182. E. coli strain JM101 was transformed with pMONl3182 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13182, contains the DNA sequence of (SEQ ID NO: 17) which encodes the following amino acid sequence:

Asn Cys Ser lie Met lie Asp Glu lie lie His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys

His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro

Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly

Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr

Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly

Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

Ala Thr (SEQ ID NO: 472)

EXAMPLE 54

Construction of pMONl3183

The new N-terminus/C-terminus gene in pMON13183 was created using Method I as described in Materials and Methods. "Fragment Start" was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 39 start (SEQ ID NO: 368) and L-ll start (SEQ ID NO: 364) . Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 38 stop (SEQ ID NO: 369) and L-ll stop (SEQ ID NO:365). The full-length new N terminus/C- terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 39 start and 38 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMONl3181, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4068 base pair vector fragment, and purified using a Magic &$

DNA Clean-up System kit ( Promega , Madison, WI ) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis , IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells ( Life Technologies , Gaithersburg , MD) . Transf ormant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated and sequenced to conf irm the correct insert . The resulting plasmid was designated pMONl3183 . E. coli strain JM101 was transformed with pMONl3183 for protein expression and protein isolation from inclusion bodies .

The plasmid, pMONl3183 , contains the DNA sequence of ( SEQ ID NO : 18 ) which encodes the following amino acid sequence :

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr

Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr ( SEQ ID NO : 473 )

EXAMPLE 55

Construction of PMON13184

The new N-terminus/C-terminus gene in pMON13184 was created using Method I as described in Materials and

Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 97 start (SEQ ID NO:370) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:371) and L-ll stop (SEQ ID NO:365). The full- length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 97 start and 96 stop. The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMONl3180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMONl3184.

E. coli strain JM101 was transformed with pMONl3184 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13184, contains the DNA sequence of (SEQ ID NO: 19) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser

Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu

Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly

He Ser (SEQ ID NO:474)

EXAMPLE 56

Construction of pMONl3185

The new N-terminus/C-terminus gene in pMONl3185 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 97 start (SEQ ID NO:370) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 96 stop (SEQ ID NO:371) and L-ll stop (SEQ ID NO:365). The full- length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 97 start and 96 stop.

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMON13181, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg , MD) . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated and sequenced to conf irm the correct insert . The resulting plasmid was designated pMON13185 . E. coli strain JM101 was transformed with pMONl3185 for protein expression and protein isolation from inclusion bodies .

The plasmid, pMON13185 , contains the DNA sequence of ( SEQ ID NO : 20 ) which encodes the following amino acid sequence :

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu

Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser ( SEQ ID N0 : 475 )

EXAMPLE 57

Construction of PMON13186

The new N-terminus/C-terminus gene in pMON13186 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 126 start (SEQ ID NO: 372) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 125 stop (SEQ ID NO:373) and L-ll stop (SEQ ID NO:365). The full-length new N terminus /C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 126 start and 125 stop. The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMONl3180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13186.

E. coli strain JM101 was transformed with pMON13186 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13186, contains the DNA sequence of (SEQ ID NO: 21) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu

Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu

His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu

Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO: 476)

EXAMPLE 58

Construction of pMON13187

The new N-terminus/C-terminus gene in pMONl3187 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 126 start (SEQ ID NO:372) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 125 stop (SEQ ID NO:373) and L-ll stop (SEQ ID NO:365). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 126 start and 125 stop. The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The intermediate plasmid, pMON13181, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMONl3187. E. coli strain JM101 was transformed with pMONl3187 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13187, contains the DNA sequence of (SEQ ID NO: 22) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro

Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala

Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu

Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu

His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu

Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO: 477)

EXAMPLE 59

Construction of PMON13188

The new N-terminus/C-terminus gene in pMON13188 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 133 start (SEQ ID NO: 374) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:375) and L-ll stop (SEQ ID NO:365). The full-length new N terminus /C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 133 start and 132 stop. The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMONl3180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5 cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13188.

E. coli strain JM101 was transformed with pMON13188 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMONl3188, contains the DNA sequence of (SEQ ID NO: 23) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO: 478)

EXAMPLE 60

Construction of PMON13189

The new N-terminus/C-terminus gene in pMONl3189 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 133 start (SEQ ID NO: 374) and L-ll start (SEQ ID

NO: 364) . Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:375) and L-ll stop (SEQ ID NO:365). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed

Fragments Start and Stop using 133 start and 132 stop. The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMONl3181, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMONl3189.

E. coli strain JM101 was transformed with pMONl3189 for protein expression and protein isolation from inclusion bodies. The plasmid, pMON13189, contains the DNA sequence of (SEQ ID NO: 24) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO: 479)

EXAMPLE 61

Construction of pMONl3190

The new N-terminus/C-terminus gene in pMONl3190 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 142 start (SEQ ID NO: 376) and L-ll start (SEQ ID

NO:364). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:377) and L-ll stop (SEQ ID NO:365). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed

Fragments Start and Stop using 142 start and 141 stop. The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMON13180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMONl3190.

E. coli strain JM101 was transformed with pMONl3190 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMONl3190, contains the DNA sequence of (SEQ ID NO: 25) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala (SEQ ID NO: 480)

EXAMPLE 62 Construction of PMON13191

The new N-terminus/C-terminus gene in pMONl3191 was created using Method I as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 142 start (SEQ ID NO: 376) and L-ll start (SEQ ID NO:364). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 141 stop (SEQ ID NO:377) and L-ll stop (SEQ ID NO:365). The full-length new N terminus/C-terminus G-CSF Ser¹⁷ gene was created and amplified from the annealed Fragments Start and Stop using 142 start and 141 stop. The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and Hindlll and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The intermediate plasmid, pMONl3181, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI). The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON13191. E. coli strain JM101 was transformed with pMONl3191 for protein expression and protein isolation from inclusion bodies .

The plasmid, pMONl3191, contains the DNA sequence of (SEQ ID NO: 26) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro

Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser

Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly

He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp

Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala

Phe Ala (SEQ ID NO: 481)

EXAMPLE 63

Construction of PMON13192

The new N-terminus/C-terminus gene in pMONl3192 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMONl3037 using the primer set, 39 start (SEQ ID NO:368) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 38 stop (SEQ ID NO: 369) and P-bl stop (SEQ ID NO: 367) . Fragment Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol-Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved on a 1% 2 2

TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The intermediate plasmid, pMONl3180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13192.

E. coli strain JM101 was transformed with pMONl3192 for protein expression and protein isolation from inclusion bodies. The plasmid, pMONl3192, contains the DNA sequence of (SEQ ID NO: 27) which encodes the following amino acid sequence:

13192.Pept

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr ( SEQ ID NO : 482 )

EXAMPLE 64

Construction of PMON13193

The new N-terminus/C-terminus gene in pMONl3193 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set,

39 start (SEQ ID NO:368) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 38 stop (SEQ ID NO:369) and P-bl stop (SEQ ID NO:367). Fragment Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol-Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The intermediate plasmid, pMON13181, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5 cells (Life

Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMONl3193.

E. coli strain JM101 was transformed with pMON13193 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMONl3193, contains the DNA sequence of (SEQ ID NO: 28) encodes the following amino acid sequence :

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Tyr Lys Leu Cys

His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro

Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly

Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr (SEQ ID NO: 483)

EXAMPLE 65

Construction of pMON25190

The new N-terminus/C-terminus gene in pMON25190 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMONl3037 using the primer set, 97 start (SEQ ID NO:370) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 96 stop (SEQ ID NO:371) and P-bl stop (SEQ ID NO:367). Fragment Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol-Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The intermediate plasmid, pMONl3180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON25190.

E. coli strain JM101 was transformed with pMON25190 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON25190 , contains the DNA sequence of ( SEQ ID NO : 29 ) which encodes the following amino acid sequence :

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu

Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu

Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

Leu Glu Gly He Ser (SEQ ID NO: 484)

EXAMPLE 66

Construction of PMON25191

The new N-terminus/C-terminus gene in pMON25191 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 97 start (SEQ ID NO:370) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 96 stop (SEQ ID NO: 371) and P-bl stop (SEQ ID NO: 367) . Fragment

Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol-Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The 25Ϊ intermediate plasmid, pMON13181 , was digested with restriction endonucleases Hindlll and Afllll , resulting in a 4068 base pair vector fragment , and purified using a Magic DNA Clean-up System kit ( Promega, Madison, WI ) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis , IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells ( Life Technologies , Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene . The resulting plasmid was designated pMON25191 .

E. coli strain JM101 was transformed with pMON25191 for protein expression and protein isolation from inclusion bodies .

The plasmid, pMON25191 , contains the DNA sequence of ( SEQ ID NO : 30 ) which encodes the following amino acid sequence :

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro

Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser ( SEQ ID NO : 485 ) EXAMPLE 67

Construction of pMONl3194

The new N-terminus/C-terminus gene in pMONl3194 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 126 start (SEQ ID NO:372) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 125 stop (SEQ ID NO: 371) and P-bl stop (SEQ ID NO: 367) . Fragment Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol- Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The intermediate plasmid, pMON13180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct Z 3

insertion of the new gene. The resulting plasmid was designated pMON13194.

E. coli strain JM101 was transformed with pMONl3194 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMONl3194, contains the DNA sequence of (SEQ ID NO: 31) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Met Ala Pro Ala

Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala

Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu

Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin

Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr

Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin

Met Glu Glu Leu Gly (SEQ ID N0:486)

EXAMPLE 68

Construction of PMON13195

The new N-terminus/C-terminus gene in pMON13195 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set,

126 start (SEQ ID NO:372 and P-bl start (SEQ ID NO:366) . Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 125 stop (SEQ ID NO: 373) and P-bl stop (SEQ ID NO: 367) . Fragment 0O

Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol-Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The intermediate plasmid, pMON13181, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5 cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13195.

E. coli strain JM101 was transformed with pMON13195 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMONl3195 , contains the DNA sequence of ( SEQ ID NO : 32 ) which encodes the following amino acid sequence :

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He- Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Met Ala Pro Ala

Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala

Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu

Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr

Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly (SEQ ID NO: 487)

EXAMPLE 69

Construction of PMON13196

The new N-terminus/C-terminus gene in pMONl3196 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:374) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 132 stop (SEQ ID NO:375) and P-bl stop (SEQ ID NO:367) . Fragment Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol-Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The intermediate plasmid, pMON13180 , was digested with restriction endonucleases Hindlll and Afllll , resulting in a 4023 base pair vector fragment , and purified using a Magic DNA Clean-up System kit ( Promega , Madison , WI ) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis , IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies , Gaithersburg , MD) . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene . The resulting plasmid was designated pMON13196 .

E. coli strain JM101 was transformed with pMONl3196 for protein expression and protein isolation from inclusion bodies .

The plasmid, pMONl3196 , contains the DNA sequence of ( SEQ ID NO : 33 ) which encodes the following amino acid sequence :

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Gin Gly Ala

Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val

Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser

Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala

Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

Pro Ala Leu Gin Pro ( SEQ ID NO : 488 ) EXAMPLE 70

Construction of PMON13197

The new N-terminus/C-terminus gene in pMONl3197 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set, 133 start (SEQ ID NO:374) and P-bl start (SEQ ID NO:366). Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 132 stop (SEQ ID NO:375) and P-bl stop (SEQ ID NO:367). Fragment Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol- Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The intermediate plasmid, pMONl3181, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4068 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm the correct % insertion of the new gene. The resulting plasmid was designated pMON13197.

E. coli strain JM101 was transformed with pMONl3197 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON13197, contains the DNA sequence of (SEQ ID NO: 34) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro

Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Tyr Lys Leu Cys

His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro

Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly

Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr

Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu

Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu

Lys Leu Cys Ala Thr (SEQ ID N0:489)

EXAMPLE 71

Construction of pMONl3198

The new N-terminus/C-terminus gene in pMONl3198 was created using Method II as described in Materials and Methods. Fragment Start was created and amplified from G-CSF sequence in pMONl3037 using the primer set, 142 start (SEQ ID NO: 376) and P-bl start (SEQ ID NO: 366) . Fragment Stop was created and amplified from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set, 141 stop (SEQ ID NO:377) and P-bl stop (SEQ ID NO:367). Fragment Start was digested with restriction endonuclease Ncol, and Fragment Stop was digested with restriction endonuclease Hindlll. After purification, the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol-Hindlll vector fragment of pMON3934.

The intermediate plasmid described above contained the full length new N-terminus/C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases

Ncol and Hindlll. The digested DNA was resolved on a 1% TAE gel, stained with ethidium bromide and the full- length new N-terminus/C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean (BiolOl, Vista, CA) . The intermediate plasmid, pMONl3180, was digested with restriction endonucleases Hindlll and Afllll, resulting in a 4023 base pair vector fragment, and purified using a Magic DNA Clean-up System kit (Promega, Madison, WI) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim,

Indianapolis, IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene. The resulting plasmid was designated pMON13198.

E. coli strain JM101 was transformed with pMONl3198 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMONl3198, contains the DNA sequence of (SEQ ID NO: 35) which encodes the following amino acid sequence:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He S t

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr

Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu

Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu

Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met

Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala

Met Pro Ala Phe Ala ( SEQ ID NO : 490 )

EXAMPLE 72

Construction of PMON13199

The new N-terminus /C-terminus gene in pMONl3199 was created using Method II as described in Materials and Methods . Fragment Start was created and amplif ied from G-CSF Ser¹⁷ sequence in pMONl3037 using the primer set , 142 start ( SEQ ID NO : 376 ) and P-bl start ( SEQ ID NO : 366 ) . Fragment Stop was created and amplif ied from G-CSF Ser¹⁷ sequence in pMON13037 using the primer set , 141 stop ( SEQ ID NO : 377 ) and P-bl stop ( SEQ ID NO : 367 ) . Fragment Start was digested with restriction endonuclease Ncol , and Fragment Stop was digested with restriction endonuclease Hindlll . After purif ication , the digested Fragments Start and Stop were combined with and ligated to the approximately 3800 base pair Ncol - Hindlll vector fragment of pMON3934 .

The intermediate plasmid described above contained the full length new N-terminus /C-terminus G-CSF Ser¹⁷ gene and was digested with restriction endonucleases Ncol and Hindlll . The digested DNA was resolved on a 1% TAE gel , stained with ethidium bromide and the full- length new N-terminus /C-terminus G-CSF Ser¹⁷ gene was isolated using Geneclean ( Biol Ol , Vista , CA) . The intermediate plasmid, pMON13181 , was digested with restriction endonucleases Hindlll and Afllll , resulting in a 4068 base pair vector fragment , and purified using a Magic DNA Clean-up System kit ( Promega, Madison , WI ) . The purified restriction fragments were combined and ligated using T4 DNA ligase (Boehringer Mannheim, Indianapolis , IN) . A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies , Gaithersburg , MD) . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated and sequenced to confirm the correct insertion of the new gene . The resulting plasmid was designated pMONl3199 .

E. coli strain JM101 was transformed with pMONl3199 for protein expression and protein isolation from inclusion bodies .

The plasmid, pMON13199 , contains the DNA sequence of ( SEQ ID NO : 36 ) which encodes the following amino acid sequence :

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro

Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Ser Ala Phe Gin

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr

Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu

Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu

Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu

Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met

Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala ( SEQ ID NO : 491 ) EXAMPLE 73

Construction of tandemly-duplicated plasmid template, Svntanl

To create the tandemly-duplicated hIL-3 receptor agonist pMONl3416 template, Syntanl , three DNAs were joined by means of ligation using T4 DNA ligase (Boehringer Mannheim) . The three DNAs are: 1) pMONl3046, containing hIL-3 receptor agonist pMON13416, digested with BstEII and SnaBI; 2) the annealed complimentary pair of synthetic oligonucleotides, Llsyn.for (SEQ ID NO:352) and Llsyn.rev (SEQ ID NO:353), which contain sequence encoding the linker that connects the C-terminal and N-terminal ends of the original protein and a small amount of surrounding pMON13416 sequence and which when properly assembled result in BstEII and Clal ends; and 3) a portion of hIL-3 receptor agonist pMONl3416 digested from pMONl3046 with Clal (DNA had been grown in the dam- cells, DM1 (Life

Technologies)) and SnaBI. The digested DNAs were resolved on a 0.9% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl) .

A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Miniprep DNA was isolated from the transformants, and the transformants were screened using a PCR based assay. Plasmid DNA from selected transformants was sequenced to obtain the correct template. The resulting plasmid was designated syntanl and contains the DNA sequence of (SEQ ID NO : 7 ) .

EXAMPLE 74

Construction of tandemly-duplicated template, svntan3. To create the tandemly-duplicated hIL-3 receptor agonist pMON13416 template, syntan3 , three DNAs were joined by means of ligation using T4 DNA ligase (Boehringer Mannheim) . The three DNAs are: 1) pMONl3046, containing hIL-3 receptor agonist pMONl3416, digested with BstEII and SnaBI; 2) the annealed complimentary pair of synthetic oligonucleotides, L3syn.for (SEQ ID NO: 354) and L3syn.rev (SEQ ID NO: 355), which contain sequence encoding the linker that connects the C-terminal and N-terminal ends of the original protein and a small amount of surrounding pMONl3416 sequence and which when properly assembled result in BstEII and SnaBI ends; and 3) a portion of hIL-3 receptor agonist pMON13416 digested from pMON13046 with Clal (DNA had been grown in the dam- cells, DMl (Life Technologies)) and SnaBI. The digested DNAs were resolved on a 0.9% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl) .

A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Miniprep DNA was isolated from the transformants, and the transformants were screened using a PCR based assay. Plasmid DNA from selected transformants was sequenced to obtain the correct template. The resulting plasmid was designated syntan3 and contains the DNA sequence of (SEQ ID NO: 8) .

EXAMPLE 75

Construction of PMON31104

The new N-terminus/C-terminus gene in pMON31104 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntanl, using Iλo the primer set 35 start (SEQ ID NO: 356) and 34 rev (SEQ ID NO: 357) .

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and SnaBI . The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA) . The purified digested DNA fragment was ligated into the expression vector, MON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . The pMONl3189 DNA had been previously digested with Ncol and SnaBI to remove the hIL3 receptor agonist pMONl3416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5 cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin- containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31104.

E. coli strain JM101 was transformed with pMON31104 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31104, contains the DNA sequence of (SEQ ID NO: 9) which encodes the following amino acid sequence :

Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met

Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly M

Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO: 492)

EXAMPLE 76

Construction of pMON31105

The new N-terminus/C-terminus gene in pMON31105 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntanl, using the primer set 70 start (SEQ ID NO: 358) and 69 rev (SEQ ID NO:359) .

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA) . The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . The pMON13189 DNA had been previously digested with Ncol and SnaBI to remove the hIL3 receptor agonist pMONl3416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5 cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin- containing plates . Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31105. E. coli strain JM101 was transformed with pMON31105 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31105, contains the DNA sequence of (SEQ ID NO: 10) which encodes the protein with the following amino acid sequence:

Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO: 493)

EXAMPLE 77

Construction of PMON31106

The new N-terminus/C-terminus gene in pMON31106 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntanl, using the primer set 91 start (SEQ ID NO: 360) and 90 rev (SEQ ID NO: 361) .

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA) . The purified digested DNA fragment was ligated into the expression vector pMONl3189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . The pMONl3189 DNA had been previously digested with Ncol and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin- containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31106.

E. coli strain JM101 was transformed with pMON31106 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31106, contains the DNA sequence of (SEQ ID NO: 11) which encodes the protein with the following amino acid sequence:

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin

Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin

Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser He Met He

Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu

Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val

Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro ( SEQ ID NO ; 494 )

EXAMPLE 78

Construction of pMON31107

The new N-terminus /C-terminus gene in pMON31107 was created using Method III as described in Materials and

Methods . The full length new N-terminus /C-terminus gene of hIL-3 receptor agonist pMONl3416 was created and ampli f ied from the intermediate plasmid, Syntanl , using the primer set 101 start ( SEQ ID NO : 362 ) and 100 rev ( SEQ ID NO : 363 ) .

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and SnaBI. The digested The DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA) . The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN). The pMONl3189 DNA had been previously digested with Ncol and SnaBI to remove the hIL3 receptor agonist pMONl3416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31107. E. coli strain JM101 was transformed with pMON31107 for protein expression and protein isolation from inclusion bodies. The plasmid, pMON31107, contains the DNA sequence of (SEQ ID NO: 12) which encodes the following amino acid sequence :

Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO: 495)

EXAMPLE 79

Construction of PMON31108

The new N-terminus/C-terminus gene in pMON31108 was created using Method III as described in Materials and Methods. The full length new N- terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3 , using the primer set 35 start (SEQ ID NO:356) and 34 rev (SEQ ID NO:357). The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and SnaBI . The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA) . The purified digested DNA fragment was ligated into the expression vector pMONl3189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . The pMONl3189 DNA had been previously digested with Ncol and SnaBI to remove the hIL3 receptor agonist pMONl3416 coding sequence and the 4254 base pair vector fragment was isolated using

Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin- containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31108.

E. coli strain JM101 was transformed with pMON31108 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31108, contains the DNA sequence of (SEQ ID NO: 13) which encodes the following amino acid sequence:

Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met

Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala

Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin

Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro

Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu

Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe

Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp

Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu

Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp

Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO: 496) IΛl

EXAMPLE 80

Construction of PMON31109

The new N-terminus/C-terminus gene in pMON31109 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMONl3416 was created and amplified from the intermediate plasmid, Syntan3 , using the primer set 70 start (SEQ ID NO: 358) and 69 rev (SEQ ID NO:359) .

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA) . The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer

Mannheim, Indianapolis, IN) . The pMONl3189 DNA had been previously digested with Ncol and SnaBI to remove the hIL3 receptor agonist pMONl3416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin- containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31109.

E. coli strain JM101 was transformed with pMON31109 for protein expression and protein isolation from inclusion bodies. The plasmid, pMON31109, contains the DNA sequence of (SEQ ID NO: 14) which encodes the following amino acid sequence :

Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp

Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID NO: 497)

EXAMPLE 81

Construction of PMON31110

The new N-terminus/C-terminus gene in pMON31110 was created using Method III as described in Materials and

Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMONl3416 was created and amplified from the intermediate plasmid, Syntan3 , using the primer set 91 start (SEQ ID NO: 360) and 90 rev (SEQ ID NO:361) .

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA) . The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN) . The pMONl3189 DNA had been previously digested with Ncol and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5α cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin- containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31110. E. coli strain JM101 was transformed with pMON31110 for protein expression and protein isolation from inclusion bodies.

The plasmid, pMON31110, contains the DNA sequence of (SEQ ID NO: 15) which encodes the following amino acid sequence :

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser

Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID N0:498) $2o

EXAMPLE 82

Construction of pMON31111

The new N-terminus/C-terminus gene in pM0N31111 was created using Method III as described in Materials and Methods. The full length new N-terminus/C-terminus gene of hIL-3 receptor agonist pMON13416 was created and amplified from the intermediate plasmid, Syntan3 , using the primer set 101 start (SEQ ID NO: 362) and 100 rev (SEQ ID NO: 363) .

The resulting DNA fragment which contains the new gene was digested with restriction endonucleases Ncol and SnaBI. The digested DNA fragment was resolved on a 1% TAE gel, stained with ethidium bromide and isolated using Geneclean (BiolOl, Vista, CA) . The purified digested DNA fragment was ligated into the expression vector pMON13189, using T4 DNA ligase (Boehringer

Mannheim, Indianapolis, IN) . The pMON13189 DNA had been previously digested with Ncol and SnaBI to remove the hIL3 receptor agonist pMON13416 coding sequence and the 4254 base pair vector fragment was isolated using Geneclean (BiolOl, Vista, CA) after resolution on a 0.8% TAE gel and staining with ethidium bromide. A portion of the ligation reaction was used to transform E. coli strain DH5 cells (Life Technologies, Gaithersburg, MD) . Transformant bacteria were selected on ampicillin- containing plates. Plasmid DNA was isolated and sequenced to confirm the correct insert. The resulting plasmid was designated pMON31111.

E. coli strain JM101 was transformed with pMON31111 for protein expression and protein isolation from inclusion bodies. 2

The plasmid, pMON31111, contains the DNA sequence of (SEQ ID NO: 16) which encodes the following amino acid sequence :

Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu

Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly

Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu

He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro

Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn

Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn

Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin

Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He

He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro

Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu

Ser His Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg

His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe

Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp

Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly

Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu

Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp

Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro (SEQ ID

NO:' 199)

EXAMPLE 83

Construction of PMON31112

Construction of pMON31112, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13189 DNA was digested with restriction enzymes Ncol and Xmal resulting in an Ncol, Xmal vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMONl3222 (WO 94/12639, US serial # 08/411,796) was digested with Ncol and EcoRI resulting in a 281 base pair Ncol, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXAl.REQ (SEQ ID NO: 350) and SYNNOXA2 . REQ ( SEQ ID NO : 351 ) were annealed and ligated with the 281 base pair DNA fragment from pMON13222 to the DNA vector fragment from pMON13189 . A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101 . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment , and sequenced to confirm the correct inserts .

The plasmid, pMON31112 , contains the DNA sequence of ( SEQ ID NO : 37 ) which encodes the following amino acid sequence :

MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeuProLeu LeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspHeLeuMetAspAsnAsnLeuArgArgPro AsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlalleGluSerlleLeu LysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLys

AspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGln AlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlle AsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetPro AlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGln SerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGly HeProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet

GluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO: 505)

Construction of PMON31113

Construction of pMON31113, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMON13197 DNA was digested with restriction enzymes Ncol and Xmal resulting in an Ncol, Xmal vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMON13239 (WO 94/12639, US serial # 08/411,796) was digested with Ncol and EcoRI resulting in a 281 base pair Ncol , EcoRI fragment . This fragment was isolated and purified from a 1 . 0% agarose gel . Two oligonucleotides SYNNOXAl . REQ ( SEQ ID NO : 350 ) and SYNNOXA2 . REQ ( SEQ ID NO : 351 ) were annealed and ligated with the 281 base pair DNA fragment from pMON13239 to the DNA vector fragment from pMONl3197 . A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101 . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment , and sequenced to conf irm the correct inserts .

The plasmid, pMON31113 , contains the DNA sequence of ( SEQ ID NO : 38 ) which encodes the following amino acid sequence :

MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeuProLeu LeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspHeLeuMetGluAsnAsnLeuArgArgPro AsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlalleGluSerlleLeu

LysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIlellelleArg AspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGln AlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlle AsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetPro AlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer

ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrp GlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO: 506)

EXAMPLE 85

Construction of pMON31114

Construction of pMON31114, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMONl3189 DNA was digested with restriction enzymes Ncol and Xmal resulting in an Ncol, Xmal vector fragment that was isolated and purified from a 0 . 8% agarose gel . The DNA from a second plasmid, pM0N13239 (WO 94 / 12639 , US serial # 08 /411 , 796 ) , was digested with Ncol and EcoRI resulting in a 281 base pair Ncol , EcoRI fragment . This fragment was isolated and purif ied from a 1 . 0% agarose gel . Two oligonucleotides SYNNOXAl . REQ ( SEQ ID NO : 350 ) and SYNNOXA2 . REQ ( SEQ ID NO : 351 ) were annealed and ligated with the 281 base pair DNA fragment from pMONl3239 to the DNA vector fragment from pMONl3189 . A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101 . Transformant bacteria were selected on ampicillin-containing plates . Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment , and sequenced to confirm the correct inserts .

The plasmid, pMON31114 , contains the DNA sequence of ( SEQ ID NO : 39 ) which encodes the following amino acid sequence :

MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeuProLeu LeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetGluAsnAsnLeuArgArgPro AsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlalleGluSerlleLeu LysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIlellelleArg AspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGln AlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlle AsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetPro AlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProSerGlyGlySerGlyGlySerGln SerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGlu LysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGly HeProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGln LeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeu GlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMet GluGluLeuGlyMetAlaProAlaLeuGlnPro ( SEQ ID NO : 507 )

EXAMPLE 86

Construction of PMON31115 Construction of pMON31115, a plasmid containing DNA sequence encoding a multi-functional hematopoietic receptor agonist which activates the hIL-3 receptor and G-CSF receptor. Plasmid, pMONl3197 DNA was digested with restriction enzymes Ncol and Xmal resulting in an Ncol, Xmal vector fragment that was isolated and purified from a 0.8% agarose gel. The DNA from a second plasmid, pMONl3222, was digested with Ncol and EcoRI resulting in a 281 base pair Ncol, EcoRI fragment. This fragment was isolated and purified from a 1.0% agarose gel. Two oligonucleotides SYNNOXAl.REQ (SEQ ID NO: 350) and SYNNOXA2.REQ (SEQ ID NO:351) were annealed and ligated with the 281 base pair DNA fragment from PMON13222 to the DNA vector fragment from pMON13197. A portion of the ligation mixture was then transformed into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated, analyzed by restriction analysis to show the presence of an EcoRV fragment, and sequenced to confirm the correct inserts.

The plasmid, pMON31115, contains the DNA sequence of (SEQ ID NO: 40) which encodes the following amino acid sequence :

MetAlaAsnCysSerAsnMetlleAspGluIlelleThrHisLeuLysGlnProProLeuProLeu LeuAspPheAsnAsnLeuAsnGlyGluAspGlnAspIleLeuMetAspAsnAsnLeuArgArgPro AsnLeuGluAlaPheAsnArgAlaValLysSerLeuGlnAsnAlaSerAlalleGluSerlleLeu LysAsnLeuLeuProCysLeuProLeuAlaThrAlaAlaProThrArgHisProIleHisIleLys AspGlyAspTrpAsnGluPheArgArgLysLeuThrPheTyrLeuLysThrLeuGluAsnAlaGln AlaGlnGlnTyrValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlle AsnProSerProProSerLysGluSerHisLysSerProAsnMetAlaThrGlnGlyAlaMetPro AlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuValAlaSerHisLeuGlnSerPhe LeuGluValSerTyrArgValLeuArgHisLeuAlaGlnProThrProLeuGlyProAlaSerSer LeuProGlnSerPheLeuLeuLysSerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla LeuGlnGluLysLeuCysAlaThrTyrLysLeuCysHisProGluGluLeuValLeuLeuGlyHis SerLeuGlylleProTrpAlaProLeuSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCys LeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSer ProGluLeuGlyProThrLeuAspThrLeuGlnLeuAspValAlaAspPheAlaThrThrlleTrp GlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGlnPro (SEQ ID NO:508) EXAMPLE 87

Determination of the in vitro activity of multifunctional hematopoietic receptor agonist proteins

The protein concentration of the multi-functional hematopoietic receptor agonist protein can be determined using a sandwich ELISA based on an affinity purified polyclonal antibody. Alternatively the protein concentration can be determined by amino acid composition analysis. The bioactivity of the multifunctional hematopoietic receptor agonist can be determined in a number of in vitro assays . For example a multi-functional hematopoietic receptor agonist which binds the hIL-3 receptor and G-CSF receptor can be assayed in cell proliferation assays using cell lines expressing the hIL-3 and/or G-CSF receptors. One such assay is the AML-193 cell proliferation assay. AML-193 cells respond to IL-3 and G-CSF which allows for the combined bioactivity of the IL-3 /G-CSF multi-functional hematopoietic receptor agonist to be determined. Another such assay is the TFl cell proliferation assay.

In addition other factor dependent cell lines, such as M-NFS-60 (ATCC. CRL 1838) or 32D which are murine IL- 3 dependent cell line, may be used. The activity of IL-3 is species specific whereas G-CSF is not, therefore the bioactivity of the G-CSF component of the IL-3 /G-CSF multi-functional hematopoietic receptor agonist can be determined independently. Cell lines, such as BHK or murine Baf/3, which do not express the receptor for a given ligand can be transfected with a plasmid containing a gene encoding the desired receptor. An example of such a cell line is BaF3 transfected with the hG-CSF receptor (BaF3 /hG-CSF) . The activity of the multi-functional hematopoietic receptor agonist in these cell lines can be compared with hIL-3 or G-CSF alone or together. The bioactivity of examples of multi- functional hematopoietic receptor agonists of the present invention assayed in the BaF3 /hG-CSF cell proliferation and TFl cell proliferation assays is shown in Table 5 and Table 6. The bioactivity of the ulti- functional hematopoietic receptor agonist is expressed as relative activity compared with a standard protein PMON13056 (WO 95/21254) which has IL-3 and G-CSF receptor binding activity. The bioactivity of examples of multi-functional hematopoietic receptor agonists of the present invention assayed in the BaF3 /c-mpl cell proliferation and TFl cell proliferation assays is shown in Table 7 and Table 8.

$lt

TABLE 5 CELL PROLIFERATIVE ACTIVITY OF DUAL IL-3 /G-CSF RECEPTOR AGONISTS

nd = not determined

* The bioactivity of the multi-functional hematopoietic receptor agonist is expressed as relative activity compared with a standard protein pMONl3056. n=3 or greater

323

TABLE 6 CELL PROLIFERATIVE ACTIVITY OF DUAL IL-3 /G-CSF RECEPTOR AGONISTS

nd = not determined t The bioactivity (n=l or 2 ) of the multi-functional hematopoietic receptor agonist is expressed as relative activity compared with a standard protein pMONl3056. "+" indicates that the molecule was comparable to PMON13056.

Sfc

TABLE 7 CELL PROLIFERATION ACTIVITY

* Activity measured in the Baf3 ce 11 line transfected with the c--mpl receptor, relative to c-mpl ligand (1- 153) . t Activity measured relative to pMON13056.

In a similar manner other factor dependent cell lines known to those skilled in the art can be used to measure the bioactivity of the desired multi-functional hematopoietic receptor agonist. The methylcellulose assay can be used to determine the effect of the multifunctional hematopoietic receptor agonists on the expansion of the hematopoietic progenitor cells and the pattern of the different types of hematopoietic colonies in vi tro . The methylcellulose assay can provide an estimate of precursor frequency since one measures the frequency of progenitors per 100,000 input cells. Long term, stromal dependent cultures have been used to delineate primitive hematopoietic progenitors and stem cells. This assay can be used to determine whether the multi-functional hematopoietic receptor agonist stimulates the expansion of very primitive progenitors and/or stem cells. In addition, limiting dilution cultures can be performed which will indicate the frequency of primitive progenitors stimulated by the multi-functional hematopoietic receptor agonist.

Vfr

Table 8

Table 8 (cont)

EXAMPLE 88

G-CSF variants which contain single or multiple amino acid substitutions were made using PCR mutagenesis techniques as described in WO 94/12639 and WO 94/12638. These and other variants (i.e. amino acid substitutions, insertions or deletions and N-terminal or C-terminal extensions) could also be made, by one skilled in the art, using a variety of other methods including synthetic gene assembly or site-directed mutagenesis (see Taylor et al . , Nucl . Acids Res . , 13: 7864-8785 [1985]; Kunkel et al . , Proc . Natl . Acad. Sci . USA, 82: 488-492 [1985]; Sambrook et al . , Molecular Cloning: A Laboratory Manual, 2nd ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, [1989], (WO 94/12639) and (WO 94/12638)). These substitutions can be made one at a time or in combination with other amino acid substitutions, and/or deletions, and/or insertions and/or extensions. After sequence verification of the changes, the plasmid DNA can be transfected into an appropriate mammalian cell, insect cell or bacterial strain such as E. coli for production. Known variants of G-CSF, which are active, include substitutions at positions 1 (Thr to Ser, Arg or Gly, 2 (Pro to Leu) , 3 (Leu to Arg or Ser) and 17 (Cys to Ser) and deletions of amino acids 1-11 (Kuga et al . Biochemicla and Biophysical Research Comm . 159:103-111 (1989)). These G- CSF amino acid substitution variants can be used as the template to create the G-CSF receptor agonists in which a new N-terminus and new C-terminys are created. Examples of G-CSF amino acid substitution variants are shown in Table 9.

EXAMPLE 89 Bioactivity determination of G-CSF amino acid substitution variants

The G-CSF amino acid substitution variants can be assayed for cell proliferation activity using the Baf/3 cell line transfected with the human G-CSF receptor. The bioactvity of examples of G-CSF amino acid substitution variants is shown in Table 9 relative to native human G- CSF . A "+" indicates a comparable activity to native and a "-" indicates significantly reduced or no measurable activity.

TABLE 9

CELL PROLIFERATION ACTIVITY OF G-CSF VARIANTS IN BAF3

CELL LINE TRANSFECTED WITH THE HUMAN G-CSF RECEPTOR

3> &

TABLE 9 cont ,

aa position native aa mutant aa activity

27 Asp Gly +

30 Ala He +

30 Ala Leu +

34 Lys Ser +

43 His Gly +

43 His Thr +

43 His Val +

43 His Lys +

43 His Trp +

43 His Ala +

43 His Arg +

43 His Cys +

43 His Leu +

44 Pro Arg +

44 Pro Asp +

44 Pro Val +

44 Pro Ala +

44 Pro His +

44 Pro Gin +

44 Pro Trp +

44 Pro Gly +

44 Pro Thr +

46 Glu Ala +

46 Glu Arg +

47 Leu Thr +

49 Leu Phe +

49 Leu Arg +

49 Leu Ser +

50 Leu His +

54 Leu His + * -

TABLE 8 cont

^

TABLE 8 cont .

aa position native aa mutant aa activity

159 Ser Arg +

159 Ser Thr +

159 Ser Tyr +

159 Ser Val +

159 Ser Gly +

162 Glu Gly -

162 Glu Trp +

162 Glu Leu +

163 Val Arg +

163 Val Ala +

163 Val Gly +

165 Tyr Cys nd

169 Ser Leu +

169 Ser Cys +

169 Ser Arg +

170 His Arg +

170 His Ser +

* activity relative to native hG-CSF nd = not determined

3

EXAMPLE 90

Isolation of cDNA encoding flt3 ligand

Three flt3 ligand clones were amplified from human bone morrow poly A+ RNA (Clontech) using NCOFLT, HIND160, and HIND165 PCR primers (according to the manufacturer's suggested conditions) . These amplified PCR products were gel purified and cloned into the BHK expression vector pMON5723 generating pMON30237 (NCOFLT + HIND160), PMON30238 (NCOFLT + HIND165), and a deletion clone PMON30239 (NCOFLT + HIND165) . The deletion in pMON30239 is of amino acid residues 89 through 106.

EXAMPLE 91

Sequence rearranged flt3 receptor agonists were constructed using several methods and linker types. The first set of constructs containing the linker peptide ( SerGlyGlyAsnGly) X (where X = 1, 2 , or 3 ) with the breakpoints 39/40, 65/66, and 89/90 were made using a two step PCR process described by Mullins et al . in which the front half and the back half of each final sequence rearranged molecule is made separately in the first PCR step, then the paired products of the first reaction step are combined in a second PCR step and extended in the absence of exogenous primers . For example, to make the three 89/90 breakpoint precursor molecules with SerGlyGlyAsnGly SEQ ID NO:786, SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO: 787, and SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO: 788 amino acid linkers (pMON32326, pMON32327 and pMON32328 respectively) , six initial PCR products were generated. The following primer pairs were used in the first step PCR reaction: a) 89For/L5B; b) 89For/LlOB; c) 89For/L15B; d) 89Rev/L5A; e) 89Rev/LlOA; and f) 89Rev/Ll5A. The identical approach was used to make PMON32321 (39/40 breakpoint, primer pairs 39For/LlOB and 39Rev/LlOA) and pMON32325 (65/66 breakpoint, primer pairs 65For/L5B and 65Rev/L5A) precursors. Except as noted below, all subsequent PCR reactions utilized the components of the PCR Optimizer Kit (Invitrogen) and amplification conditions according to the manufacturers suggested protocol. Reactions were set up as follows: 50 pmol of each primer, 10 ul of 5X Buffer B [300 mM Tris-HCl (pH 8.5), 10 mM MgCl₂, 75 mM (NH₄)2S0₄], 5 U Taq polymerase, and 100 ng of heat denatured DNA (in this example pMON30238) template were combined, and brought to 45 ul final volume with dH₂0. Reactions were preincubated for 1-5 minute at 80°C, then 5 ul of 10 mM dNTP added to each reaction, and heat denatured for 2 minutes at 94°C prior to amplification in a Perkin Elmer model 480 DNA thermal cycler. Seven DNA amplification cycles were done under the following conditions: heat denature for one minute at 94°C, two minutes annealing at 65°C, followed by a three minute extension at 72°C. Twenty three additional cycles consisting of a one minute heat denaturation at 94°C followed by a four minute annealing/extension at 72 °C were done, followed by a final 7 minute extension cycle at 72 °C. With the exception of pMON32328, the PCR amplification products were run out on a 1.2% TAE agarose gel, and the appropriate size bands (the major amplification product) were excised and purified using Geneclean II (Bio 101) . Samples were resuspended in 10 ul dH₂0. The amplication products for pMON32328 were purifed directly using a

Wizard PCR Clean UP kit (Promega) , and DNA eluted in 50 ul dH₂0.

The method to construct the precursors of pMON32322 (39/40 breakpoint, primer pairs 39For/L5B and 39Rev/L5A) was modified by increasing the amount of template to 1 ug, and by changing the PCR amplification conditions as follows: six cycles of 94°C, 1 minute, 65°C for 2 minute, and 72°C for 2 1/2 minutes, followed by 15 cycles of 94°C for 1 minute, 70°C for 2 minutes, and 72 °C for 2 minutes, followed by a single 72 °C extension cycle for seven minutes . The second PCR step utilized the gel-purified precursors from the first PCR step as a combination of primer/template as follows: 5 ul each of each precursor molecule (i.e. for pMON32328 the PCR products from primer pairs 89For/L5B and 89Rev/L5A) , 10 ul of 5X Buffer B, 5 U of Taq polymerase, and 24 ul dH₂0. The reactions were heated for five minutes at 80°C, 5 ul of 10 mM dNTP was added, and the reactions heat denatured for 94°C for two minutes. DNA amplification conditions were as follows: 15 cycles of 94°C for one minute, 69°C for two minutes, followed then by a three minute extension at 72°C. To allow for complete extension, the last cycle was followed by a single extension step at 72 °C for seven minutes. The 80 deg incubation time was reduced to two minutes and the number of cycles was decreased to ten cycles for pMON32325 (PCR products

65For/L5B and 65Rev/L5A) . PCR reaction products of the appropriate size were gel purified on a 1.2 % TAE agarose gel using Geneclean II. For pMON32322 (39For/L5B and 39Rev/L5A) the annealing temperature was reduced to 68°C, and the extension time reduced to two minutes. In addition, the PCR product was purified using a Wizard PCR Clean Up kit (Promega) according to the suppliers suggested protocol. The second PCR step was modified for pMON32326 (PCR products of 89For/Ll5B and 89Rev/Ll5A) as follows. Three sets of PCR reactions were set up identically as above, except for the sample buffer type (either 5X buffer B, D, or J - PCR Optimizer Kit) . Composition of buffers D and J differ from buffer B only by pH or [MgCl₂] . The [MgCl₂] for buffer D is 3.5 mM, whereas the pH of buffer J is 9.5. The protocol was modified by increasing the number of PCR cycles 20, and 15 ul aliquots were withdrawn at the end of cycles 10, 15 and 20. Five uls of each aliquot timepoint were analyzed for the presence of amplfied material on a 1.2% TBE agarose gel. The remainder of the buffer B, D, and J PCR reaction mixtures were pooled and subsequently purified using the Wizard PCR Clean Up Kit protocol. The DNA was eluted in 50 ul dH₂0.

The purified samples from the second step PCR reaction were digested with Ncol/Hindlll using one of two standardized digestion conditions. For Geneclean II purified samples, 10 ul of DNA were digested in a 20 ul reaction with 7.5 U each of Ncol/Hindlll for two hours at 37°C, and gel purified on a 1.1% TAE agarose gel again with Geneclean II. Ligation-ready samples were resuspended in 10 ul dH₂0. For pMON32322, 20 ul of sample was digested in a 50 ul reaction volume with 20U each of Ncol and Hindlll for 3 hour at 37°C. 0.1 volume 3M NaOAc (pH 5.5) and 2.5 volume of EtOH were added, mixed, and stored at -20°C overnight. The DNA was recovered by pelleting for 20 minutes at 13,000 rpm @ 4°C in a Sigma Mk 202 microfuge. The DNA pellet was rinsed with chilled 70% EtOH, lyophilized, and resuspended in 10 ul dH₂0.

EXAMPLE 92

An alternate approach was used to construct pMON32320 (39/40 breakpoint, fifteen amino acid linker) , pMON32323 (65/66 breakpoint, fifteen AA linker) , and pMON32324 (65/66 breakpoint, ten amino acid linker). New primers (L15C, L15D, L15E) were designed to incorporate BamHl restriction site in the primer that was inframe to allow cloninng into the BamHl site and maintain the proper reading frame. PCR reaction conditions for the first step were performed identically to that described for pMON32322, except that the following set of primer pairs were used: 65For/L15D and 65Rev/Ll5E (pMON32324); 39For/L15D and 39Rev/Ll5C (pMON32320) ; and 65For/Ll5D and 65Rev/L15C (pMON32323) . The PCR reaction products were purified using a Wizard PCR Clean Up kit as described, and eluted in 50 ul dH₂0. Samples were digested with either NcoI/Ba HI (39For/Ll5D and

65For/Ll5D) or BamHI/Hindlll (39Rev/Ll5C, 65Rev/Ll5C, and 65Rev/Ll5E) . Restriction digests were performed as follows: 10 ul of purified PCR reaction products, 3 ul of 10X universal restriction buffer, 15 U of either Ncol or Hindlll, 15 U of BamHl, in a final reaction volume of 30 ul . Reactions were incubated for 90 minutes at 37°C, and the PCR products gel purified on a 1.1% TAE agarose gel using Geneclean II. Ligation-ready DNA was resuspended in 10 ul dH₂0.

Inserts were ligated to Ncol/ Hindlll digested pMON3977 (BHK mammalian expression vector) that had been treated with shrimp alkaline phosphatase (SAP) either in a three way (pMON32320, pMON32323, or pMON32324) or a two way (pMON32321, pMON32322, pMON32325, pMON32326, pMON32327 and pMON32328) ligation reaction as follows: 2.5 ul of insert (2 ul of each primer pair amplicon for pMON32320, PMON32323, and pMON32324) was added to 50 ng of vector in a ten ul reaction using standard ligation conditions. Two ul of each reaction was transformed with 100 ul of chemically competent DH5α cells (Gibco/BRL) following the manufacturers suggested protocol. Twenty five ul and 200 ul aliquots were plated out on LB plates containing 50 ug/ml ampicillin and incubated overnight. Isolated colonies were picked and DNA prepared from 50 ml overnight cultures using Qiagen DNA midiprep kits. DNA was quantitated by absorbance at A260/A280, and verified for correct insert size by agarose gel electrophoresis following digestion of 1 ug template with Ncol/Hindlll restriction endonucleases. Samples containing inserts of the predicted size were sequenced in both orientations using vector-specific primers using an automated fluorescent DNA sequencer model 373A (Perkin Elmer ABI) . Sequencing reactions were done in 20 ul reaction volumes using a Perkin Elmer model 480 DNA thermal cycler as follows: one ug of template, 3.2 pmol primer, 1 ul DMSO, 9.5 ul Taq terminator dyedeoxy premix ( Perkin Elmer ABI) were combined, and subjected to 25 cycles of sequencing amplification as follows: 30 seconds at 94°C, 15 second annealing at 50°C, followed by a four minute extension cycle at 60°C. Samples were purified using Centri-Sep spin columns (Princeton Separations) following the manufacturers suggested protocol, lyophized, and submitted for sequence analysis. Samples containing the predicted amino acid sequence were selected for analysis and assigned pMONnumbers .

EXAMPLE 93

A similar approach used to construct pMON32320, pMON32323, and pMON32324 was utilized to introduce the second linker type (SerGlyGlySerGly) X where x = 2 or 3 , into two sequence rearranged sequences containing the 39/40 breakpoint (pMON32348 and 32350) . The primer pairs were as follows: for pMON32348 the combinations of 339For2/339Rev3 and 339Rev2/339-10For3 and for pMON32350 the combinations of 339For2/339Rev3 and 339Rev2/339- 15For3 were used to create three PCR amplification products. Each PCR amplification was set up as follows: to 100 ng of heat denatured pMON32320, 50 pmol of each primer pair, 10 ul of 5X Buffer B, 5 U of Taq polymerase and dH₂0 was added to a final volume of 45 ul . Reactions were preincubated as described before. Fifteen amplification cycles were done under the following conditions: heat denature at 94°C, one minute, followed by a two minute annealing step at 70°C, and a three minute extension at 72°C. After the last cycle, a single 72 deg extension step of 7 minutes was done. The PCR amplification products of primer pairs 339For2/339Rev3, 339Rev2 /339-10For3 , and 339Rev2/339- 15For2 were purified using a Wizard PCR Clean Up kit (Promega), and eluted in 50 ul dH₂0. NcoI/BamHI digests for the 339For2/339Rev3 primer pair as follows: 8 ul of DNA template was mixed with 2 ul universal restriction buffer and 10 U each of Ncol and BamHl in a 20 ul reaction volume, and incubated for 90 minutes at 37°C. The digestion products was purified using the Geneclean II direct purification protocol, and ligation ready DNA resuspended in 10 ul dH₂0. The restriction digests and subsequent purification for the 339Rev2/339- 10For3 and 339Rev2/339-15For2 amplification products were done identically as described for the 339For2/339Rev3 amplicon, except that 10 U of Hindlll was substituted for Ncol. Standard ligations were done by adding to 50 ng NcoI/Hindlll/SAP-treated, gel purified pMON3977, 0.5 ul 339For2/Rev3 amplicon, 1 ul of either 339Rev2/339-10For3 (pMON32348) or 339Rev2/339- 15For3 (pMON32350) amplicons, 5U T4 DNA ligase, and 1 ul 10 X ligase buffer in a 10 ul reaction volume for 60 minutes at ambient temperature. Subsequent steps leading to final DNA sequence confirmation were done as described above.

EXAMPLE 94

A third type of linker, with a variable (GlyGlyGlySer)X repeat motif, was incorporated into another set of sequence rearranged flt3 receptor agonists from modularly constructed templates. These linker lengths were; 6 AA linker (GlyGlyGlySerGlyGly SEQ ID NO:792), 7 AA linker (GlyGlyGlySerGlyGlyGly SEQ ID NO: 793), 10 AA linker (GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO:794) , 13 AA linker (GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO:795), 15 AA linker (GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SEQ ID NO: 796) ; and 21 AA linker

(GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGly GlySerGly SEQ ID NO: 797) amino acid residues. These modular templates, each comprising a dimer of hflt3 ligand separated by a BamHI-containing linker of unique length, were constructed as follows. Six intermediate PLASMID templates, FL3N, FL7N, FL11N, FL3C, FL4C, and FL10C, were constructed by PCR using paired primers and pMON30238 as template using cycling conditions similar to those employed for pMON32322. Per reaction, 50 pmol of each primer was added to 100 ng of heat-denatured template and the reactions assembled as described for pMON32322. Cycle conditions were as follows: seven cycles of 94°C, one minute; two minutes at 65°C, and 2.5 minutes at 72 °C; followed by ten cycles of one minute at 94°C, two minutes at 70°C, and 2.5 minutes at 72°C. A single seven minute extension at 72 °C completed the cycling reactions. The primer pairs used to construct each intermediate were; N-term/FLN3 (FL3N) ; N-term/FLN7 (FL7N) ; N-term/FLNll (FL11N) ; C term/FLC3 (FL3C) ; C- term/FLC4 (FL4C) ; and C-term/FLCIO (FL10C) . The PCR amplification products were purified with Wizard PCR Clean Up kits (Promega) and eluted in 50 ul dH₂0.

Purified DNA for the first subset, FL3N, FL7N, and FLllN, were digested with NcoI/BamHI, gel purified as described previously, and ligated to Ncol/BamHl/Sap- treated pSE420 vector DNA (Invitrogen) . Intermediate templates of the second subset, FL3C, FL4C, and FL10C, were constructed in an identical manner except Hindlll was utilized instead of Ncol. Subsequent steps leading to final DNA sequence confirmation were done as described above .

EXAMPLE 95 To make the final six templates, the two subsets of intermediates in pSE420 were digested with either NcoI/BamHI (FL3N, FL7N, FLllN-subset 1) or BamHI/Hindlll

(FL3C, FL4C, FLlOC-subset 2) and gel purified using Geneclean II as described previously. One intermediate amplicon from each subset were ligated to NcoI/Hindlll/SAP-treated pMON3977 per reaction and transformed in DH5α cells as described previously using the following combinations to generate specific linker lengths: six AA linker (FL3N and FL3C) , seven AA linker

(FL3N and FL4C) , ten AA linker (FL7N and FL3C) , thirteen AA linker (FL3N and FLlOC) , fifteen AA linker (FLllN and FL4C) , and 21 AA linker (FLllN and FLlOC) . DNA was prepared 50 ml overnight cultures from single colonies from each of the six combination as described above, analyzed for correct insert size by Ncol/Hindlll restriction analysis, and used as template. Primer pairs 39For/39Rev (39/40 breakpoint) ; 65For/65Rev

(65/66 breakpoint) and 89For/89Rev (89/90 breakpoint) were used to PCR amplify each templates as described for pMON32322, except 75 pmol of each primer was used. Amplification conditions were modified as follows: six cycles of 94°C for one minute, 2 minutes at 70°C, 2.5 minutes at 72°C; followed by nine cycles of 94°C for one minute, and three minutes at 72°C. After the last cycle, a final extension of six minutes at 72 °C allowed ample time for full extension of products. Samples were purified using a Wizard PCR Clean Up kit as described, and double digested with Ncol/Hindlll . These amplification products were purified again using a

Wizard PCR Clean Up kit. In addition, all six different linker length molecules for the 39/40 breakpoint were cloned into NcoI/Hindlll/SAP-treated pMON3977 as single proteins (pMON32365, pMON32366, pMON32367, pMON32368, pMON32369 and 32370) . Subsequent steps leading to final DNA sequence confirmation were done as described above. EXAMPLE 96

Genes encoding multi-functional chimeric receptor agonist molecules consisting of an IL-3 receptor agonist, of pMONl3416 (WO 94/12638) joined via an IgG2b linker to either native flt3 ligand or sequence rearranged flt3 receptor agonists, Examples 91-93, were constructed. Inserts containing the desired sequence rearranged flt3 receptor agonists molecule were isolated from the parental plasmid as a Ncol/Hindlll restriction fragment and ligated to pMON30304 digested with Afllll/Hind Ill/SAP Subsequent steps leading to final DNA sequence confirmation were done as described above. The resulting plasmids, containing the DNA sequences encoding multi-functional chimeric molecules comprising an IL-3 receptor agonist (from pMONl3416) and a sequence rearranged flt3 receptor agonist are indicated in Table 9.

Table 9

Resulting Plasmid hflt3 ligand permutein precursors

pMON30247 pMON30237

PMON30248 pMON30238 pMON32332 pMON32321

PMON32333 pMON32320

PMON32334 pMON32325 pMON32335 pMON32324

PMON32336 pMON32323 pMON32337 pMON32328

PMON32338 pMON32327

PMON32339 pMON32326

EXAMPLE 97 Genes encoding multi-functional chimeric receptor agonist molecules consisting of an IL-3 receptor agonist, of pMON13288 (WO 94/12638) joined via an IgG2b linker to either native flt3 ligand or sequence rearranged flt3 receptor agonists, Examples 91-93, were constructed. Inserts containing the desired sequence rearranged flt3 receptor agonists molecule were isolated from the parental plasmid as a Ncol/Hindlll restriction fragment and ligated to pMON30311 digested with Afllll/Hind Ill/SAP Subsequent steps leading to final DNA sequence confirmation were done as described above. The resulting plasmids, containing the DNA sequences encoding multi-functional chimeric molecules comprising an IL-3 receptor agonist (from pMONl3288) and a sequence rearranged flt3 receptor agonist are indicated in Table 10.

Table 10 Resulting Plasmid Flt3 ligand precursors

pMON32364 PMON30237 PMON32377 pMON30238 pMON32352 PMON32321 PMON32353 pMON32320 PMON32354 pMON32325 PMON32355 pMON32324 PMON32356 PMON32323 PMON32357 PMON32328 PMON32358 pMON32327 PMON32359 pMON32326 PMON32360 pMON32348 pMON32362 PMON32350 PMON32396 pMON30239

EXAMPLE 98 3

Two chimeric molecules with the sequence rearranged hflt3 receptor agonist component at the N-terminus of the chimeric molecule were constructed via PCR using pMON32360 and pMON32362 plasmid DNA as the template and primer pairs N-term/134rev and N-term/139 rev to replace the stop codon at the C terminus of the native flt3 ligand molecules with an inframe SnaBI restriction site. Reaction mixtures were set up as described previously for pMON32322. Cycle conditions and were as follows: seven cycles of 94°C, one minute, 65°C, two minutes, and 72°C 2 1/2 minutes and an additional 10 amplification cycles were performed in which the annealing temperature was elevated from 65°C to 70°C. Samples were purified using the Wizard PCR Purification kit and protocol, and eluted in 50 ul dH₂0, 20 ul of each sample was digested with Ncol and SnaBI. Plasmid, pMON26431, DNA was digested with Ncol and SnaBI and ligated with the NcoI/SnaBI digested PCR reactions. Transformation of competent DH5α cells and subsequent steps leading to final DNA sequence confirmation were done as described above .

EXAMPLE 99

Five additional hflt3 ligand breakpoints were made using the indicated primers 28/29 (28For/28Rev) , 34/35 (34For/34Rev) , 62/63 (62For/62Rev) , 94/95 (94For/94Rev) , and 98/99 (98For/98Rev) to amplify the ten and fifteen amino acid linker (GlyGlyGlySer) x as described above. The resulting PCR products were digested with Ncol/Hindlll and ligated into pMON30311, digested with Afllll/Hindlll/SAP as described previously. Transformation of competent DH5 cells and subsequent steps leading to final DNA sequence confirmation were done as described above. λ

EXAMPLE 100

For enhanced expression of sequence rearranged hflt3 receptor agonists in E. coli, N-terminal specific primers coding for degenerate codons were used to re- engineer both the 1-134 and 1-139 forms of native hflt3 ligand in the E. coli expression vector pMON5723. Primer pairs FH3AFor/SCF . rev (Ala2) and Flt23For/SCF (Gly2) were used to PCR amplify a N-terminal degenerate mixture of sequences encoding native flt3 ligand using reaction conditions as described for pMON23222, except that the number of amplification cycles was reduced to fifteen cycles of 1 minute at 95°C, 2 minutes at 55°C, and 2 1/2 minutes at 72°C. Amplicons were purified using Wizard PCR Clean up kit (Promega) , and eluted in 50 ul dH₂0. Restriction digestion with Ncol/Hindlll and subsequent gel purification using Geneclean II was performed as previously described. Inserts were ligated to NcoI/Hindlll/SAP-treated, gel-purified pMON5723 plasmid DNA, and transformed into competent DH5α cells as previously described. Aliquots of transformed cells were plated out on LB agarose media plates containing 75 ug/mL spectinomycin, incubated for 14-16 hours at 37°C, and colonies counted. After confirmation of colonies, the remainder of each transformation mixture was incubated overnight (14-16hr) at 37°C in 2 x 5 mL of LB media containing 75 ug/mL spectinomycin. Miniprep DNA was prepared using a Wizard DNA 373A Miniprep kit (Promega) following the recommended protocol. Purified miniprep DNA was eluted in 50 ul dH₂0, and 1-2 ul used to transform chemically competent MON207 cells. 25 and 200 ul aliquots were plated out on LB media plates containing 75 ug/mL spectinomycin, and incubated for 12-15 hours at 37°C. 40-50 well-isolated colonies representing each original primer pair were selected and streaked out on LB/spectinomycin master plates, and incubated an additional 4-6 hours at 37°C.

Individual sequence rearranged hflt3 receptor agonist clones were screened for E. coli expression in a 96 well microtiter format to select for improved expression levels. Per well, 100 ul of minimal M9 media (including 1% casamino acids) was inoculated by a single colony (40 - 50 isolates were analyzed for each hflt3 PCR primer pair), and incubated at 37°C at 200 rpm for 3-4 hr (1=0) and induced by addition of 5 ul/well of lmg/mL freshly prepared Nalidixic acid (in 0.1 N NaOH) . After an additional four hours incubation at 37°C (1=4), approximately 5-10 ul aliquots were withdrawn from each well, and analyzed by light microscopy for the presence of refractile bodies, and the results scored as a approximate percentage of cells containing refractile bodies to the total number of cells. The clones having the highest expression levels were selected for 10 mL benchtop scale expression studies as follows. Five mL overnight cultures were grown in LB media in the presence of 75ug/mL spectinomycin at 37°C. To 10 mL freshly prepared minimal M9 (with 1% casamino acids) in 125 mL shake flasks, inoculation with sufficient overnight cells to achieve an initial reading of 20 Klett units was done, and then incubated for - 3-4 hours at 37°C with shaking until a density of -110-150 Klett units was reached (1=0) and induced with 50 ul of freshly prepared Nalidixic acid (10 mg/mL in 0.1 N NaOH) . One mL aliquots were removed and the cells pelleted for one minute in a microf ge. The supernatants were removed by aspiration and the pellets stored at -20°C until ready for SDS-PAGE analysis. The remainder of the induced cells were incubated for an additional four hours at 37°C with shaking, after this time point (1=4) cell density (in Klett units) was measured. A one mL aliquot was removed from each sample, pelleted and stored as described above. Another 5-10 ul aliquot was removed from each flask and analyzed by light microscopy for the presence of refractile bodies. Pelleted samples were resuspended in a volume (in ul) of 2X loading buffer (including 1% B-mercaptoethanol) equal to the 1=4 Klett value, boiled for 5 minutes, and 6-7 ul loaded on a 12% or 14% Tris-Glycine SDS polyacrylamide gel (Novex) and electrophoresed for 90 minutes at 90 volts. Gels were fixed, stained and prepared for drying according the suggested protocol (Novex) . Clones were selected at this point for scale up fermentation based upon enhanced expression levels of a single induced protein band (1=4) corresponding to the predicted size when compared to the 1=0 samples. Midiprep DNA was also prepared from selected clones expressing high level of induced protein as described previously and steps leading to final DNA sequence confirmation were done exactly as described above. These clones were designated pMON32329, pMON32330, PMON32341, and pMON32342

EXAMPLE 101

A set of multi-functional receptor agonist chimeric molecules comprising an IL-3 receptor agonist (from pMONl3288) and native flt3 ligand were also constructed for expression in E. coli. The genes encoding the multi-functional receptor agonist chimeric molecules from pMON32364 and pMON32377 were released from the parental vector by digestion with Ncol/Hind III and ligated to pMON5677 vector, transformed into MON207 cells, and single isolates picked, as described above. These constructs were designated pMON32394 (insert from PMON32364) and pMON32395 (insert from pMON32377) .

EXAMPLE 102 7810 l 2.$k. PCT/US97/20037

A truncated Flt3 receptor was isolated as a 1.4Kb PCR product using 50pmol of the primers FLTAFLS1 and FLTR1N with approximately lOng of the plasmid pMON27184 as the template. The primers were designed to produce an Afllll restriction site just 5' to the first Asn codon of the mature coding sequence, as well as an EcoRI restriction site just 5' to the putative transmembrane region. The reaction was digested with Afllll and EcoRI using standard reaction conditions and ligated into the NcoI/EcoRI digested plasmid pMON26458. This plasmid contains the following DNA sequence: 5' - GGATCCACCATGAGCCGCCTGCCCGTCCTGCTCCTGCTCCAACT CCTGGTCCGCCCCGCCATGGCTAAAGCTT - 3' SEQ ID NO: 857, encoding the IL-3 signal sequence. This sequence contains a BamHl restriction site on the 5' end, and includes the ATG methionine as the first amino acid of the signal sequence 3' to the BamHl site. This signal sequence is cleaved by the cell, leaving a 5' Met/Ala generated by fusing the Ncol site from the signal sequence fused to the Afllll site of the receptor produced in the PCR reaction. The entire truncated form of the receptor along with the IL-3 signal sequence could be cut back out of the vector as a BamHl/EcoRI digest (hIL3L/hFflt3R) . The catalytic domain of pMON30298 (hG-CSFR) was reengineered to create an in frame EcoRI restriction site at the transmembrane/cytoplasmic bound via PCR as follows. To 0.5 ug of heat denatured pMON30298, 100 pmole each of primers HGCFfor and HGCFrev, 10 ul of 5X buffer J, 5U of Taq polymerase, and dH₂0 were added to a final volume of 45 ul as described. PCR amplification was done as follows: six cycles (one minute at 94°C, two minutes at 64°C, and three minutes at 70°C) , followed by nine cycles (one minute at 94°C, four minutes at 70°C) . A final one minute extension of seven minutes at 70°C was done. Ten ul of each PCR reaction were gel purified using Geneclean II as described previously, and eluted in 10 ul dH₂0. Samples were digested with 10U each of EcoRI and Hindlll in 20 ul reactions for 90 minutes at 37°C. Samples were gel purified again (Geneclean II) as described previously, and eluted in 10 ul dH₂0. Two ul of insert were ligated to 50 ng of

NcoI/Hindlll/phosphatased pSE420 vector in a 10 ul reaction as described previously. Transformation of competent DH5α cells and subsequent steps leading to final DNA sequence confirmation were done exactly as described above. Selected clones were then sequenced to verify the presence of the in frame EcoRI site as well as confirmation of the correct G-CSFR catalytic domain DNA sequence. Clones containing the predicted sequence were digested with EcoRI/Hindlll as described previously and gel purified. Purified inserts of the hG-SCFR (EcoRI/Hindlll) and hIL3L/hFlt3R (BamHI/EcoRI) fragments were ligated to BamHl/Hindlll/phosphatased pcDNA 3.1 (-) vector (Invitrogen). Transformation of competent DH5 cells and subsequent steps leading to final DNA sequence confirmation were done as described above .

EXAMPLE 103

Additional genes encoding sequence rearranged Flt3 ligands were constructed using the dimer template intermediates previously described. For sequence rearranged flt3 receptor agonists having the fifteen amino acid linker (GlyGlyGlySer) ₃GlyGlyGly SEQ ID NO: 795, the dimer intermediates Flt4C.seq and FltllN.seq were used as template. Breakpoints corresponding to Flt3 3 ligand amino acid residues 28/29, 34/35, 62/63, 94/95, and 98/99, were constructed using a PCR based approach using a PCR Optimizer kit (Invitrogen) and the following primer pairs; FL29For/FL29Rev, FL35For/FL35Rev, FL63For/FL63Rev, FL95For/FL95Rev, FL99For/FL99Rev as described IN Example 94. Amplification conditions were as follows: seven cycles of 94 °C for 1 min, 62 °C for 2 min, and 2.5 min at 70 °C; twelve cycles of 94 °C for 1 min, 68 °C for 2 min, and 70 °C for 2.5 min; followed by a final cycle of 7 min at 72 °C. PCR products corresponding to the predicted insert size were digested with Ncol and Hindlll, and gel purified as described previously using Gene Clean II (Bio 101) following the manufacturer's suggested protocol. Samples were resuspended in 10 ul final volume with dH₂0. Inserts were cloned as single genes into the mammalian expression vector pMON3934 (NcoI/Hindlll/SAP treated) and designated pMON35712, pMON35713, pMON35714, pMON35715, pMON35716, pMON35717 and pMON35718 respectively.

Genes encoding chimeric proteins comprising an IL-3 receptor agonist encoded by pMON13288 (WO 94/12638) herein referred to as "IL-3 receptor agonist I", and sequence rearranged Flt3 ligand were prepared by cloning the purified, restriction-digested PCR products of the 28/29, 34/35, 62/63, 94/95, and 98/99 breakpoint primer pairs into Afllll/Hindlll/SAP-treated pMON30311. The resulting plasmids were designated pMON32398, pMON35700, pMON35702, pMON35704, and pMON35706 respectively. In addition, the same primer pairs were used in conjunction with the dimer template intermediates Flt7N.seq and Flt3C.seq to construct the ten amino acid linker (GlyGlyGlySer) ₂GlyGly SEQ ID NO: 793, forms of these IL-3 receptor agonist I/Flt3L chimeric proteins; pMON32397, PMON32399, pMON35701, pMON35703, and pMON35705 respectively.

EXAMPLE 104

Genes encoding IL-3 receptor agonist I/Flt3L chimeric proteins containing the 21 amino acid residue linker (GlyGlyGlySer) ₅Gly SEQ ID NO: 796 were constructed using a similar PCR approach using the dimer template intermediates FltllN.seq and FltlOC.seq and the following primer pairs; Flt36/36Rev, Flt37/37Rev, Flt38/38Rev, Flt39/39Rev, Flt41/4lRev, Flt42/42^"Rev, and Flt43/43Rev. These primer pairs correspond to the following Flt3 ligand breakpoints 35/36; 36/37; 37/38; 38/39; 40/41; 41/42; and 42/43 (the 39/40 breakpoint was previously constructed as pMON32376) and were used for PCR amplification using the following cycle conditions: seven cycles of 94 °C for 1 min, 66 °C for 2 min, and 2.5 min at 70 ° C; fifteen cycles of 94 °C for 1 min, and 70 °C for 4 min; followed by a final cycle of 7 min at 72 °C using the Invitrogen PCR Optimizer kit (Buffer B) . Following DNA sequence confirmation these constructs were designated pMON35733, pMON35734, PMON35735, pMON35736, pMON35738, pMON35739, pMON35740, pMON35741, pMON35742 and pMON35743 respectively. PCR incorporation errors resulted in two single amino acid substitutions of the sequence rearranged Flt3 chimeric partner (pMON35741, 35/36 breakpoint; and pMON35743, 42/43 breakpoint) and one construct (pMON35742, 38/39

133 breakpoint) containing two ammo acid substitutions Q

133 100 112 112 to R and Q to R¹⁰⁰ and L to P in the Flt3L moiety, constructed and tested as part of this series.

Additional Flt3L/IL-3 receptor agonist I chimeric proteins in which the alternate Flt3L breakpoints corresponding to Flt3 ligand amino acid residues 28/29, 34/35, 62/63, 65/66, 89/90, 94/95, and 98/99 previously described were also constructed with the fifteen amino acid linker (GlyGlyGlySer) ₃GlyGlyGly templates FLt4C and FLtllN. PCR reaction mixtures were similar to those described in Example 103, except that reverse primers encoding the C-terminus of the sequence rearranged Flt3 moieties were modified by replacing the Hindlll restriction site with a SnaBI recognition sequence. PCR amplification cycle parameters were as follows: seven cycles of 94 °C for 1 min, 66 °C for 2 min, and 2.5 min at 70 °C; fourteen cycles of 94 °C for 1 min, and 70 °C for 4 min; followed by a final cycle of 7 min at 72 °C . PCR clean up, restriction digestion and purification were done as described previously. Inserts were ligated to NcoI/SnaBI/SAP-treated pMON26431 (a BHK expression vector containing an IgG2b linker/IL-3 receptor agonist I moiety) as follows: 50ng treated vector, insert (10:1 insert :vector) , 1 unit of T4 DNA ligase (Gibco BRL), and 1 ul 10X ligase buffer in a 10 ul reaction volume. Ligations were incubated for one hour at ambient temperature, then 2 ul of each ligation were removed and used to transform 100 ul of chemically competent DH10B (alternatively, DH5 ) cells (Gibco BRL) following the manufacturer's suggested protocol. One fifth and l/25th volumes of each transformation mixture were plated out on LB agar plates supplemented with the appropriate antibiotic markers and incubated overnight (14-16 hours) at 37 °C. Isolated colonies were picked, and DNA prepared using the Qiagen midiprep protocol as described previously.

Sequence analysis of selected clones were confirmed for 28/29 breakpoint (pMON35719) , 34/35 breakpoint

(pMON35720), 62/63 breakpoint (pMON35721) , 65/66 breakpoint (pMON35722), 89/90 breakpoint (pMON35723), and 98/99 breakpoint (pMON35725) . pMON35726 contains a single amino acid substitution (Leu94 to Phe94) for the 94/95 breakpoin. Flt3L/IL-3 receptor agonist I chimeric constructs with a Flt3L breakpoint of 39/40 and varying amino acid linker lengths of 10, 15, and 21 AA are represented by pMON35707, pMON35708, pMON35709, pMON35710 and pMON35711. These constructs were generated by PCR amplification of one of the following templates; PMON32373, pMON32375, or pMON32376, and the Flt3L- specific primer pair 39N TERM-1/SNABlC TERM. Standard PCR reaction mixtures were set up as previously described, and DNA product amplified using the following parameters: seven cycles of 94 °C for 1 min, 62 °C for 2 min, and 2.5 min at 70 °C; twelve cycles of 94 °C for 1 min, 68 °C for 2 min, and 70 °C for 2.5 min; followed by a final cycle of 7 min at 72 °C . PCR products corresponding to the predicted insert size were digested to completion with Ncol and SnaBI, gel purified, and cloned as described previously into the mammalian expression vector pMON26431 (NcoI/SnaBI/SAP treated) as Flt3L/IgG2b/IL-3 receptor agonist I chimeric proteins. Two of these constructs contained PCR incorporation errors in the sequence rearranged Flt3 chimeric partner

96 which resulted in single ammo acid substitutions F to L , and E to G⁵⁸ (pMON35710 and pMON35711) .

EXAMPLE 105

Another series of chimeric proteins, sequence rearranged Flt3L/IL-3 receptor agonist I with the breakpoints corresponding to Flt3 ligand amino acid residues 35/36, 36/37, 38/39, 40/41, 41/42, 42/43 and 65/66 previously described and a 21 amino acid linker were also constructed using selected IL-3 receptor agonist I/sequence rearranged Flt3L constructs as template (see Table 11 below) . One exception was that a fifteen amino acid linker template (pMON35715) was used to construct the 65/66 breakpoint, pMON35771. 3 o

Table 11 Flt3L/IL-3 receptor agonist I IL-3 receptor agonist I/Flt3L

Construct template Flt3L Primer Pair breakpoint pMON35744 PMON35733 35/36 Flt36/36Rev'

PMON35745 pMON35734 36/37 Flt37/37ReV

PMON35746 pMON35735 37/38 Flt38/38Rev' pMON35747 PMON35736 38/39 Flt39/39Rev'

PMON35748 pMON35738 40/41 Flt41/4lRev' pMON35749 PMON35739 41/42 Flt42/42Rev'

PMON35750 pMON35740 42/43 Flt43/43Rev'

PMON35769 PMON35743 42/43 Flt43/43Rev'

PMON35771 PMON35715 65/66 65For/66SnaBI

Primer pairs encoding the same restriction sites as those used to construct pMON35719-35725 were utilized. The reverse primers 36Rev' , 37 Rev' , 38 Rev' , 39 Rev' , 41 Rev' , 42 Rev' , and 43 Rev' , were used to create the in frame SnaBI site. The same forward primers Flt36, Flt37, Flt38, Flt39, Flt41, Flt42 and Flt43 were used. PCR reaction mixtures were identical to those described previously, however, with the exception of pMON35771, amplification conditions were modified as follows: 18 cycles of 94 °C for 1 min, 68 °C for 2 min, and 70 °C for 2.5 min; followed by a single extension cycle at 70 °C for 7 minutes. For pMON35771, amplification conditions were as follows: six cycles of 94 °C for 1 min, 66 °C for 2 min, and 2.5 min at 70 °C; fifteen cycles of 94 °C for 1 min, and 70 °C for 4 min; followed by a final cycle of 7 min at 72 °C . Flt3-specific PCR amplification products were restriction digested, purified, and cloned into pMON26431 (a BHK expression vector containing an IgG2b linker/IL-3 receptor agonist I moiety) as described in Example 104. One variant, pMON32179, was constructed as a 34/40 breakpoint using the PCR primer pair Flt40/34Rev and dimer template intermediates FltllN.seq and FltlOC.seq. PCR amplification conditions and subsequent cloning were identical to that used to clone pMON35771.

Three additional Flt3L/IL-3 receptor agonist I chimera (38/39 breakpoint) were designed and constructed to test the effects of alternate linker lengths and composition. Using pMON35709 as template, the GlySer linker length was expanded to encompass 29 amino acid residues with the motif (GlyGlyGlySer) ₇Gly using the primer pairs BamForl/38Rev (reaction product referred to as PCR A) and Flt38/BamRevl (reaction product referred to as PCR B) . The amplification conditions were as follows: six cycles of 94 °C for 1 min, 66 °C for 2 min, and 2.5 min at 70 °C; fifteen cycles of 94 °C for 1 min, and 70 °C for 4 min; followed by a final cycle of 7 min at 72 °C. The resulting PCR products were cleaned up using a Promega PCR clean up kit, and digested with either NcoI/BamHI (PCR A) or BamHI/SnaBI (PCR B) , gel purified and ligated to pMON26431 (a BHK expression vector containing an IgG2b linker/IL-3 receptor agonist I moiety) as described previously. The resulting construct was sequenced confirmed and designated pMON35774. In comparison, pMON35775 and 35776 different in that the GlySer linker was replaced by native Flt3L amino acid residues 140-154 (pMON35775) or 140-160 (pMON35776) containing a single amino acid substitution. PCR reaction conditions were identical as described for pMON35774, except the following primer pairs were used: 38For/Navfor and 38Rev/NavRevS (pMON35775) ; and 38For/Navfor and 38Rev/NavRevL (pMON35776) . Kasl was substituted for BamHl, otherwise the cloning steps of these PCR amplification products were identical to those employed for pMON35774. Sequence analysis revealed PCR induced errors in multiple isolates for both pMON35775 and 35776. To obtain the final correct sequences, it was necessary to redigest selected subclones with 3ζV

Narl/SnaBI and Ncol/Narl, and use these gel purified fragments to redone the desired constructs. Several Flt3L dimer chimeric molecules were also constructed for testing as BHK transients. pMON32173, consisting of two native Flt3L molecules linked by an IgG2b linker, was assembled from two pre-existing molecules as follows: the NcoI/SnaBI Flt3L-containing insert from pMON32393 was ligated to gel purified, NcoI/SnaBI cut, pMON32377 in which the IL-3 receptor agonist I chimeric partner had been released.

Similarly, pMON35727 (39/40 breakpoint, fifteen amino acid linker) was assembled using the Flt3L insert from PMON35708 (as an NcoI/SnaBI insert) to gel purified pMON32375 in which the IL-3 receptor agonist I chimeric partner had been excised. The third Flt3L dimer,

PMON32168, (39/40 breakpoint, 21 amino acid linker) was assembled as follows: the NcoI/SnaBI insert from PMON32165 (E. coli equivalent of pMON35709, assembled by subcloning the NcoI/BamHI fragment from pMON32163 and the BamHl/Hindlll fragment of pMON35709 into

NcoI/Hindlll-digested pMON5723). The NcoI/SnaBI insert from pMON32165 (Flt3L 1-139 (39/40) L21) and the SnaBI/Hindlll insert (IgG2b/Flt3L 1-139 (39/40)L21) from pMON32376 were subcloned into the E. coli production vector pMON5723, creating pMON32167. The Ncol/Hindlll insert from pMON32167 was then subcloned into pMON30304, and designated pMON32168.

EXAMPLE 106

A series of trimeric molecules, each consisting of two Flt3L moieties and a single copy of IL-3 receptor agonist I or IL-3 receptor agonist II (an IL-3 receptor agonist encoded by pMONl3416 (WO 94/12638) herein referred to as "IL-3 receptor agonist II"), were also constructed from pre-existing molecules using restriction digested, gel purified fragments. pMON3572£ was assembled using the NcoI/EcoRI (Flt3L/IgG2b/IL-3 receptor agonist I) insert from pMON32375 and the EcoRI/Hindlll (IL-3 receptor agonist I/IgG2b/Flt3L) insert from pMON35708. The two fragments were then religated to NcoI/Hindlll/SAP-treated mammalian expression vector pMON3934 and subcloned as described previously. pMON32205 (IL-3 receptor agonist II/IgG2B/Flt3 l-139/IgG2B/Flt3 1-139) was assembled by ligating the Ncol/Hindlll fragment from pMON32173 into the Afllll/Hindlll site of pMON30304. A similar approach was used to construct pMON32206 (IL-3 receptor agonist II/IgG2b/Flt3L (39/40) L21/IgG2b/Flt3L (39/40) L21) . The Ncol/Hindlll fragment from pMON32167 was gel and subcloned into the Afllll/Hind Ill-digested pMON30304 (which contains the IL-3 receptor agonist II/IgG2b-moiety) . The plasmid pMON32207 (Flt3L (39/40)L21/IgG2b/Flt3L (39/40 ) L21) /G-CSF) was assembled by subcloning the gel purified Ncol/Hindlll insert from PMON32170 into the intermediate pMON32198 (Afllll/Hindlll) .

PMON32208 (Flt3L l-139/IgG2b/G-CSF/IgG2b/Flt3Ll-139 ) was assembled by subcloning the gel purified SnaBI insert from pMON30320 (as IgG2b/G-CSF) into SnaBI- digested/SAP-treated pMON32173. pMON32204 was assembled by subcloning the Ncol/Hindlll insert from pMON32173 into Afllll/Hindlll-digested pMON30309 (which contains G-CSF/IgG2b) . pMON32195 (Flt3L 1-139 (39/40 ) L21/IgG2b/G- CSF/Flt3L 1-139 (39/40) L21) was constructed by subcloning the Ncol/Sacl insert from pMON32190 and the Sacl/Hindlll fragment from pMON32171 into NcoI/Hindlll-digested PMON30304. pMON32196 (G-CSF/IgG2b/Flt3L 1- 139 (39/40)L21/IgG2b/Flt3L 1-139) was assembled by subcloning the Ncol/Afllll fragment from pMON30309 (as G-CSF/IgG2b) into NcoI/SAP-treated pMON32168 (Flt3L 1- 139 (39/40)L21/IgG2b/Flt3L 1-139), and confirming orientation by DNA sequence and restriction analysis. PMON32197 (G-CSF/IgG2b/Flt3L 1-139 (39/40 ) L21/IgG2b/Flt3L 1-139 (39/40) L21) was constructed by subcloning the Ncol/Hindlll insert of pMON32167 (Flt3L 1-

139 (39/40)L21/IgG2b/Flt3L 1-139 (39/40)L21) into the

Afllll/Hindlll site of pMON30309 (G-CSF/IgG2b) .

EXAMPLE 108

A series of Flt3L containing molecules was constructed as BHK transients by replacing IL-3 receptor agonist I or IL-3 receptor agonist II with G-CSF as the chimeric partner. For chimeric proteins expressed transiently and made using the BHK vector pMON3934, the G-CSF moiety could either encode Ser or Cys at position 17. For molecules used for either E. coli expression or expressed non-transiently in mammalian expression systems, position 17 of the G-CSF partner encoded Ser exclusively. Chimera of native Flt3L and G-CSF were made as BHK expression constructs in both orientations: G-CSF/IgG2b/Flt3L (pMON30329) and Flt3L/IgG2b/G-CSF (pMON32175) . pMON30329 was assembled by subcloning the Flt3L 1-139 insert from pMON30238 (as a Ncol/Hind III digest) into pMON30309 (which contains G-CSF/IgG2b) digested with Afllll/Hindlll, whereas pMON32175 was constructed using the gel-purified NcoI/SnaBI insert from pMON32393 to NcoI/SnaBI-digested pMON26420 (which contains the IgG2b/G-CSF gene) . A third native G- CSF/Flt3L chimeric molecule, pMON32191, differs from pMON32175 in that it has a GlySer linker in place of the IgG2b chimeric linker and was designed for E.coli expression. pMON32191 was assembled using the same gel- purified NcoI/SnaBI insert from pMON32393 into NcoI/SnaBI-digested pMON31123 (which contains the GlySer/G-CSF gene) . The BHK equivalent, pMON35767, was assembled by subcloning the gel-purified Ncol/Hindlll chimeric gene from pMON32191 into the BHK vector PMON3934. 3£5

EXAMPLE 109

Two series of sequence rearranged Flt3L chimera were constructed by replacing the IL-3 receptor agonist I component with G-CSF. The first set, with the orientation G-CSF/IgG2B/ sequence rearranged Flt3L, were essentially assembled as follows: pMON30329 (G- CSF/IgG2B/Flt3L 1-139) was digested with SnaBI/Hindlll, and the vector-containing G-CSF moiety gel-purified as described above. SnaBI/Hindlll-digested inserts from the appropriate IL-3 receptor agonist I/Flt3L constructs shown below in Table ! 2were then subcloned into PMON30329 (SnaBI/Hindlll) .

Table 12

G-CSF/IgG2b/Flt3L constructs and their IL-3 receptor agonist I analogues

Flt3L breakpoint pMON (G-CSF) pMON(IL-3 receptor agonist I)

35/36L21 pMON32188 pMON35733

89/90L21 pMON32273 pMON32389

37/38L21 p ON35795 pMON35735

38/39L21 pMON35796 pMON35736 40/41L21 pMON35797 pMON35738

41/42L21 pMON35798 pMON35739

42/43L21 pMON35799 pMON35740

PMON32169 (G-CSF/IgG2b/Flt3L 1-139 (39/40)L21) was assembled using the NcoI/BamHI insert from pMON32163 and the BamHI/Hindlll insert from pMON32370 subcloned into the Afllll/Hindlll-digested pMON30309. Three molecules in this series have no direct IL-3 receptor agonist I counterparts. The first, pMON39914, was assembled using the BHK expression vector pMON30309 (which contains G-

CSF/IgG2b) digested with Afllll/Hindlll, and the Flt3 1- 139 (39/40)L29 insert from pMON32243 (as Ncol/Hindlll) . For pMON39915, the Flt3L 1-154 (39/40) gene from pMON32242 (as a Ncol/Hindlll insert) was subcloned into the parental vector pMON30309. pMON39916 was assembled exactly as for pMON39915, except that the Flt3L 1-160 (39/40) insert from pMON32252 was utilized. pMONs 32242, 32243, and 32252 are E. coli expression constructs containing a nonchimeric, sequence rearranged Flt3L gene (as Ncol/Hindlll) . Finally, the insert from pMON35799 was subcloned into pMON5723 (as an Ncol /Hindlll fragment) for expression in E. coli. This E. coli production plasmid was designated pMON39904.

EXAMPLE 110

Many of the second series of G-CSF chimera with the orientation Flt3L/IgG2b/G-CSF were also constructed from their IL-3 receptor agonist I analogues as indicated below in Table 13.

Table 13 Flt3L /IgG2b/G-CSF constructs and their IL-3 receptor agonist I analogues

Flt3L breakpoint pMON (G-CSF) pMON(IL-3 receptor agonist I)

39/40L10 pMON35751 pMON35707

39/40L15 pMON35752 pMON35708

39/40L21 pMON35753 pMON35709

89/90L15 pMON35754 pMON35723 35/36L21 pMON35755 pMON35744

36/37L21 pMON35756 pMON35745

37/38L21 pMON35757 pMON35746

34/35L15 pMON35759 pMON35720

65/66L15 pMON35760 pMON35722 98/99L15 pMON35765 pMON35725

These constructs were assembled using NcoI/SnaBI- digested pMON36113 (a BHK vector containing the IgG2b/G- CSF gene) and specific NcoI/SnaBI-digested sequence rearranged Flt3L inserts from the Flt3L/IL-3 receptor agonist I chimeric proteins in Table above. The resulting plasmids were designated pMON32170, pMON32871, pMON32271, pMON32172, pMON32174, pMON35751, pMON35752, PMON35753, pMON35754, pMON35755, pMON35756, pMON35757, PMON35758, pMON35759, pMON35760, pMON35761, pMON35762, PMON35763, pMON35764, pMON35765, pMON35766, pMON35767, PMON35768, pMON35770, pMON35772, pMON35773, pMON35777, pMON35778, pMON35779, pMON35780, pMON35782 and pMON39908

PMON35777 and pMON35778 were constructed by PCR and assembled from the same Ncol/Narl and Narl/SnaBI inserts as described for pMON35775 and pMON35776, except that NcoI/SnaBI-digested pMON35751 was used as the parental vector containing the IgG2b/G-CSF gene. To construct the 39/40 breakpoint equivalent of pMON35778, the primer pair Flt40/SnaBI C-term was used to re-amplify pMON35778 template. Amplification conditions were done as described previously for pMON35771, except the initial

Tanneal. was lowered from 66 to 55 °C. The resulting³ construct was designated pMON35782 (Flt3 1-160 (39/40) /IgG2b/G-CSF) .

pMON32170 (Flt3L 1-139 (39/40 ) L21/IgG2B/G-CSF) was assembled using the NcoI/SnaBI insert from pMON32165 ligated into NcoI/SnaBI-digested pMON26430 (which contains IgG2B/G-CSF) . pMON35764 (Flt3L (38/39) L21/IgG2b/G-CSF) was cloned as follows: the sequence rearranged Flt3L insert was PCR amplified using as template pMON35736 and the primer pair Flt39/39Rev. Amplification conditions were identical to those employed for pMON35771, except the initial T_anne was lowered from 66 to 56 °C. The NcoI/SnaBI digested PCR amplification was subcloned into NcoI/SnaBI-digested pMON35754 containing the IgG2b/G-CSF gene. pMON35768 (Flt3L (38/39)L21/IgG2b/G-CSF) has a mutation at residue 15 (Ser to Phe) of the Flt3 chimeric partner. pMON35762 (Flt3 template pMON35739 ) , pMON35763 (Flt3 template 35738), pMON35758 (Flt3 template 35740), pMON35770 (pMON35743 as Flt3L template were constructed exactly as described for pMON35764. pMON35772 , a S

125 to F mutant of the sequence rearranged Flt3 gene in PMON35760, was cloned by PCR using pMON35715 as Flt3 template and the primer pairs 65For/65SnaBI . PCR cycle conditions were identical to that used to amplify the Flt3 genes from pMON35733, pMON35734, pMON35735 and pMON35736 described previously. pMON35761 is a Q to

133

R mutant of the sequence rearranged Flt3L gene m

PMON35758. pMON35773 (Flt3L 1-139 (38/39 ) L29/IgG2B/G- CSF) was cloned as described previously for pMON35774, except pMON26430 (NcoI/SnaBI/SAP-treated) containing the IgG2b/G-CSF gene was used as parental vector.

To construct the 39/40 breakpoint equivalent, pMON35773 was used as template in a PCR amplification reaction with the primer pair Flt40/SnaBI C-term. Amplification was done exactly as described previously for pMON35771. The NcoI/SnaBI-digested amplification product was subcloned into pMON26430 (NcoI/SnaBI/SAP-treated), resulting in pMON35779 (Flt3L 1-139 (39/40 ) L29/IgG2B/G- CSF) . pMON35780 is a variant of pMON35779 and encodes a

60 60 single ammo acid mutation (L to P ) in the sequence rearranged Flt3 chimeric partner. pMON32190 (Flt3L 1- 139 (39/40) L21/GS/G-CSF) contains an alternate GlySer chimeric linker which replaces the IgG2b linker of pMON32170. The NcoI/SnaBI fragment Flt3L gene from pMON32165 (Flt3L 1-139 (39/40 ) L21/IgG2b/IL-3 receptor agonist I in the E. coli expression vector pMON5723) was subcloned into NcoI/SnaBI-digested pMON31123. The BHK expression equivalent, pMON35766, was constructed by subcloning the entire Flt3L/GlySer/G-CSF chimeric insert as an Ncol/Hindlll fragment into pMON3934. PMON39908 is similar to pMON35779, except the Flt3L amino acid residues 133-160 have been replaced by the amino acid sequence, VETVFHRVSQDGLDLLTS SEQ ID NO: 798, which is homologous to an alternate splice variant of Flt3L (Genbank accession number HSU29874) . pMON32190 was used as a PCR template with the following sets of primer pairs Flt40/XbaRev and SnaBICterm/XbaFor. Amplification conditions were done as described previously for pMON35771, except the initial T_anneal was lowered from 66 to 64 °C. Both gel-purified PCR amplification products were digested with either Ncol/Xbal (Flt40/XbaRev PCR product) or Xbal/SnaBI (SnaBICterm/XbaFor PCR product) and subcloned into pMON26430 (NcoI/SnaBI/SAP-treated) . pMON32273 (Flt3L 1- 139 (39/40) L21/IgG2b/G-CSF) was constructed by PCR of pMON35777 with the primer pairs FltConNco/Grev to re- amplify the 38/39 Flt3L moiety as 39/40. The purified amplicon was digested with NcoI/SnaBI, and subcloned into the NcoI/SnaBI-digested pMON32191, and designated pMON32259 (for E. coli production) . For BHK expression, the Ncol/Hindlll insert from pMON32259 was subcloned into pMON3934 (Ncol/Hindlll) .

EXAMPLE 103

Another series of chimeric proteins were constructed in which the Flt3L partner contained one or two Cys mutations (Table XIA and XIB) . pMON35790 (Flt3L 1- 139 (C⁴ → S⁴, C⁸⁵ → S⁸⁵) /GS/G-CSF (Serl7)), was constructed by PCR using pMON32191 as template and the primer pairs ClFor/C3Rev and C3For/139Rev in two reactions. pMON35791 (Flt3L 1-139(C³→ S , c"² →

S ) /GS/G-CSF (Serl7)), was also constructed by PCR using pMON32191 as template and the primer pairs

C5For/C6Rev and C5Rev/N-term. Amplification conditions were done as described previously for pMON35771, except the initial Tannea.l was lowered from 66 to 64 °C. A second round of PCR was done using the amplicons (10 ul each) from the first round, and the PCR products were then purified, digested with NcoI/SnaBI, and subcloned into NcoI/SnaBI -digested pMON32191. PCR amplification conditions for the second round were modified as follows: the initial T_anneal was increased to 68°C, and the number of cycles increased from 6 to 15. No additional amplification was required. These constructs, pMON35787 (C⁴ → s\ C⁸⁵ → S⁸ ) and pMON35788

93 93 132 132

(C → S , C —> S ) were used for E. coli expression.

The BHK expression equivalents, pMON35790 and 35791, were constructed by subcloning the correctly mutated Flt3L/GlySer/G-CSF chimeric inserts as Ncol/Hindlll fragments into pMON3934. pMON35792 (Flt3L 1-132 (C →

S ) /GlySer/G-CSF (Serl7)) was constructed by PCR using pMON32191 as template and the primer pair FLDlRev/FltNTerm. pMON39905 (Flt3L 1-139 (c"² → s"²) /GlySer/G-CSF (Serl7)) was constructed by PCR using pMON32191 as template and the primer pair FLMlRev/FltNTerm. pMON39906 (Flt3L 1-

127 127 32 132

139 (C → S / C → S ) /GlySer/G-CSF (Serl7)) contains a single amino acid substitution at residue 127 of the sequence rearranged Flt3L partner, a result of a PCR induced error during the PCR amplification of pMON39905.

PMON32276 (Flt3L 1-139 (39/40 ) L21 (C⁴ → S*/ C⁸⁵ →

85

S ) /GlySer/G-CSF (Serl7)) was constructed by two rounds of PCR. Three initial amplicons were generated: PCRl (pMON32190 template and primer pairs G10L/85N) ; PCR 7

(pMON32190 template and primer pairs 4N/85S) ; and PCR 4 (pMON32198 template and primer pairs 4S/3605Rev) . For the second round, PCRl, 4 and 7 were re-amplified in a combined mixture, resulting in PCR A. PCR A was purified, digested with NcoI/SnaBI, and subcloned in PMON30277 (GlySer/G-CSF) . The next three constructs were generated in a similar manner. pMON32277 (G-CSF

(Serl7) /IgG2B/Flt3L 1-139 (39/40 ) L21 (C⁴ → s C ^ → S⁸⁵) ) first round PCR generated three initial amplicons: PCRl (pMON32190 template and primer pairs G10L/85N) ; PCR 7 (pMON32190 template and primer pairs 4N/85S) ; and PCR 6 (pMON32169 template and primer pairs 4S/3605Rev) . For the second round, PCRl, 6 and 7 were re-amplified in a combined mixture, resulting in PCR B. PCR B was purified, digested with Ncol/Hindlll , and subcloned into NcoI/Hindlll-digested pMON30309 (G-CSF (Serl7 ) /IgG2B) .

PMON32278 (Flt3L 1-139 (39/40 ) L21 (c" → s"/ c"² →

S ) /GlySer/G-CSF (Serl7)) first round PCR generated three initial amplicons: PCR2 (pMON32190 template and primer pairs G10L/93N) ; PCR 8 (pMON32190 template and primer pairs 132N/93S) ; and PCR 3 (pMON32198 template and primer pairs 132S/3605Rev) . For the second round, PCR2 , 3 and 8 were re-amplified in a combined mixture, resulting in PCR C. PCR C was purified, digested with NcoI/SnaBI, and subcloned in pMON30277 (GlySer/G-CSF) .

PMON32279 G-CSF (Serl7 ) /IgG2B/Flt3L 1-139 (39/40 ) L21 (c"

93 132 132

—> S / C → S ) ) first round PCR generated three initial amplicons: PCR2 (pMON32190 template and primer pairs G10L/93N) ; PCR 8 (pMON32190 template and primer pairs 132N/93S) ; and PCR 5 (pMON32169 template and primer pairs 132S/3605Rev) . For the second round, PCR2 , 5 and 8 were re-amplified in a combined mixture, resulting in PCR D. PCR D was purified, digested with Ncol/Hindlll, and subcloned into NcoI/Hindlll-digested PMON30309 (G-CSF (Serl7) /IgG2B) .

EXAMPLE 112

pMON39909 (Flt3L 1-139 (39/40 ) L21/GS/G-

CSF(Serl7) (133/132) ) is one of two Flt3/G-CSF chimeric proteins in which both proteins the sequenced are rearranged. The Ncol/Afllll fragment from pMON32198 comprising the Flt3L 1-139 (39/40 ) L21/GlySer gene was subcloned into NcoI/SAP-treated pMON25187 (E. coli production plasmid containing a single copy of G- CSF(Serl7) (133/132) ) . Following DNA sequence confirmation, the chimeric insert was subcloned into pMON3934 as an Ncol/Hindlll fragment and designated PMON39909. pMON39910 (G-CSF (Serl7 )( 133 /132 / IgG2B/Flt3L 1-139 (39/40) L21) was constructed by PCR using pMON25187 as template and the primer pair GPForl/GPRev2. Amplification conditions were identical to those utilized for pMON39908. NcoI/SnaBI-digested G- CSF(Serl7) (133/132) was subcloned into the NcoI/SnaBI site of pMON32376 containing the IgG2B/Flt3L 1-139 (39/40)L21 gene.

EXAMPLE 113

pMON40000 is the production plasmid modified from pClneo (Promega) containing G-CSF (Serl7 ) /GlySer/Flt3L 1-139 (39/40) L21 for expression in NSO cells (pMON32169 is the BHK equivalent) . pMON40000 contains the CMV IE promoter/enhancer element, an IL-3 leader sequence immediately upstream of CSF (Serl7 ) /GlySer/Flt3L 1-139 (39/40) L21, truncated thymidine kinase promoter, SV40 late poly A signal sequence, and several DNAse 1 hypersensitive regions (part of IgH 3 min LCR) .

EXAMPLE 114 Bioactivity of multi-functional chimeric hematopoietic receptor agonists Table 14

IN VITRO MULTI-FUNCTIONAL CHIMERIC HEMATOPOIETIC RECEPTOR AGONISTS BIOASSAY

Legend:

+: Decreased potency (right shifted) compared to control

++: Equivalent potency to control (within 2 fold)

+++: Increased potency (left shifted) compared to control

Compared to control: pMON30247

Compared to control: pMON32352

Compared to appropriate coaddition control

Analyzed in pool of clones pMON40000 and pMON40002 s%

EXAMPLE 115 Bioactivity determination

Tablelδ EX VIVO MULTI-FUNCTIONAL CHIMERIC HEMATOPOIETIC

RECEPTOR AGONISTS BIOASSAY

&5

Legend: +: Decreased activity compared to IL-3, IL-6, SCF,G-CΞF (literature control)

++: Equivalent activity to IL-3, IL-6, SCF,G-CSF ((literature control) (within 20%))

+++: Increased activity compared to IL-3, IL-6, SCF,G-CSF (literature control) Culture Condition: X-Vivo 10 Media, 37°C, 5% C0₂ , 11 day incubation

Legend: +: Decreased activity compared to GM-CSF, TNFa, SCF (literature control)

++: Equivalent activity to GM-CSF, TNFa, SCF ((literature control) (within 20%))

+++: Increased activity compared to GM-CSF, TNFa, SCF (literature control)

Culture Condition: IMDM-20 Media supplemented with 100 ng/ml GM-CSF, 100 ng/ml TNFa, 20 ng/ml SCF, at 37°C/5% C0₂ for 18-22 days MFR agonist I = pMON31140 (WO 95/21197) MFR agonist II = pMON28571 (WO 97/12985)

Hematopoietic Ex Vivo Expansion Assay

CD34⁺ enriched progenitor cells from human bone marrow were isolated and cultured at 5x10" cells/ml in X-Vivo 10 + 1% HSA with test cytokines and controls to assess cytokine expansion potential. Cells were expanded and replated at 5xl0⁴ cells/ml with new media and cytokines around day 5 depending on cell growth. On day 10 cells were harvested and characterized. Cells were collected from the plates and diluted to a concentration of lxlO⁶ cells/ml. Total cell expansion was determined and cells were characterized for hematopoietic progenitor cells by CFU Pre- and Post Expansion in methylcellulose (Stem Cell Technologies, MethocultHCC3534) . Expanded cells were also characterized by flow cytometry for lineage specific phenotyping: CDllb (PE) /CD15 (FITC) , CD34 (FITC) , CD41a (FITC) .

Dendritic Cell Ex Vivo Expansion Assay

CD34^* enriched progenitor cells from human bone marrow were isolated and cultured at 2xl0⁵ cells/ml in IMDM/20% FCS with test cytokines and controls to assess expansion potential. Cells were expanded and replated at 5xl0⁴ cells/ml with new media and cytokines around day 5 depending on cell growth. On day 18-22 cells were harvested and characterized. Total cell expansion was determined expanded cells were characterized by flow cytometry for lineage specific phenotyping: HLA-DR+ (PE) /CDla+ (FITC) , CD86+ (PE) /CDla-f-(FITC) , CD19- (FITC) . Dendritic cell fold expansion was determined as the total cellular expansion x % H A-DR+/CDla+ . The functional activity of the cells was determined using a 1-way mixed lymphocyte reaction. Washed, irradiated cultured dendritic cells were added in graded doses to allogeneic responder peripheral blood mononuclear cells in 96-well microtiter plates. The ability of the dendritic cells to serve as antigen presenting cells was determined by the degree of proliferation stimulated in the responding cell preparations, as measured by ³H thymidine incorporation.

3#

EXAMPLE 116 Receptor Binding

Table 16 Receptor Binding Analyses :

Data are expressed as the mean " SEM from at least three experiments determined in triplicate, except pMON 32360 where only (2) experiments have been completed.

The affinity of the Flt-3 agonist containing chimeric molecules was evaluated in receptor binding assays. BIACORE analysis was performed by directly immobilizing Flt3-Fc and the K_d value computed from determining the association and dissociation rate constants. Competitive binding assays were utilized for evaluating the interactions of the chimeric molecules with either the G-CSF receptor transfected in BaF3 cells or the " subunit of the IL-3 receptor expressed in BHK cells. The competition assays using these cells employed an agonist-specific radioligand and IC₅₀ values were generated for the competing chimeras using logit-log analysis of dose-response curves . w

EXAMPLE 117 In vivo bioactivity

Tablel7 MURINE IN VIVO MULTI-FUNCTIONAL CHIMERIC HEMATOPOIETIC

RECEPTOR AGONISTS ASSAY DATA

C57BL/6 mice were injected s.c. with pMON30247, PMON32342 or pMON32360 (150 ug/day) or PMON32191 (200ug/day) or Mouse Serum Albumin (MSA, 200 ug/day) for 10 days. On Day 11 terminal bleeds were done via cardiac puncture. Leucocytes counts were obtained on whole blood. Peripheral blood leucocytes were obtained by gradient centrifugation (Histopaque) followed by ammonium chloride lysis to further remove erythrocytes. Cells were stained for flow cytometery using direct fluorescein or phycoerythrin conjugated monoclonal antibodies (Pharmingen) . Prior to staining non-specific Fc receptor binding was blocked using FcBlock (Pharmingen) . Cells were analyzed on a FacScan flow cytometer (Becton/Dickinson) . Percent postive cells were determined by integration and phenotype enumeration was calculated based on WBC count. Spleens from treated animals were removed aseptically, teased apart, in RPMI media with needles. A cell suspension was obtained using the flat end of a 5cc syringe plunger followed by filtration through a cotton plug to remove clumps. Erythrocytes were removed by ammonium chloride lysis, cells were washed, resuspended and counted using a Coulter counter (Coulter Electronics) . Cells were prepared for flow cytometry as described above. Phenotype was expressed as number of cells/spleen based on the percent of cells with a postive phenotype and total spleen WBC count. CFU cultures were obtained by plating 1.5 x 10⁵ splenic cells/lml in triplicate wells of methylcellulose with murine cytokines w/o erythropoietin (Stem Cell

Technologies). Cultures were incubated for 10 days at 37°C and counted on an inverted microscope. A CFU was defined as a colony of cells with >50 cells. The fold increase of CFU/spleen was determined (total number of CFU/Spleen of test compound/total number of CFU/Spleen of MSA control) . MSA control values for peripheral blood were 15 and 347 cells/ul for I- A^b7CDllc⁺ and I-A^b+/CD8⁺ respectively. MSA control values for the splenic leucocytes were 2 and 1 x 10⁶ cells/spleen for I-A^b7CDllc⁺ and I-A^b+/CD8⁺ respectively .

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

More details concerning the molecular biology techniques, protein purification and bioassays can be found in WO 94/12639, WO 94/12638, WO 95/20976, WO 95/21197, WO 95/20977, WO 95/21254 and WO 96/23888, are hereby incorporated by reference in their entirety. 0

All references, patents or applications cited herein are incorporated by reference in their entirety as if written herein.

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: G. D. Searle

(ii) TITLE OF THE INVENTION: Multi-functional Chimeric Hematopoietic Receptor Agonists

(iii) NUMBER OF SEQUENCES: 865

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: G. D. Searle & Co.

(B) STREET: P.O. Box 5110

(C) CITY: Chicago

(D) STATE: IL

(E) COUNTRY: U. S. A.

(F) ZIP: 60680

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: DOS

(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE: 22-OCT-1997

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 60/029,629

(B) FILING DATE: 25-OCT-1996

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Bennett, Dennis A

(B) REGISTRATION NUMBER: 34,547

(C) REFERENCE/DOCKET NUMBER: C-2994

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 314-737-6986

(B) TELEFAX: 314-737-6972

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO : 1 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 439 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGT 439

(2) INFORMATION FOR SEQ ID NO : 2 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360

CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420

TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTC 465

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 600

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 660

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 720

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 780

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360

CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420

TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACATGGCG 480

TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 540

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 600

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 660

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 720

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 780

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CAAGGATCCC 840

AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT 900

GTAGGAGGGT CCACCCTCTG CGTCAGG 927

(2) INFORMATION FOR SEQ ID NO : 4 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 936 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360

CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420

TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCAA CATGGCGTCT 480

CCCGCTCCGC CTGCTTGTGA CCTCCGAGTC CTCAGTAAAC TGCTTCGTGA CTCCCATGTC 540

CTTCACAGCA GACTGAGCCA GTGCCCAGAG GTTCACCCTT TGCCTACACC TGTCCTGCTG 600

CCTGCTGTGG ACTTTAGCTT GGGAGAATGG AAAACCCAGA TGGAGGAGAC CAAGGCACAG 660

GACATTCTGG GAGCAGTGAC CCTTCTGCTG GAGGGAGTGA TGGCAGCACG GGGACAACTG 720

GGACCCACTT GCCTCTCATC CCTCCTGGGG CAGCTTTCTG GACAGGTCCG TCTCCTCCTT 780

GGGGCCCTGC AGAGCCTCCT TGGAACCCAG CTTCCTCCAC AGGGCAGGAC CACAGCTCAC 840

AAGGATCCCA ATGCCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTC 900

CTGATGCTTG TAGGAGGGTC CACCCTCTGC GTCAGG 936

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 939 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5 :

TCCCCAGCTC CACCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 600

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 660

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 720

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 780

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 840

CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 900

TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 93 G AATTCGGCGG CAACATGGCG 480 TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 540 GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 600 CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 660 CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 720 CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 780 CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 840 CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 900 TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 939

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 948 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 :

TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360

CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420

TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGGG AATTCGGCGG CAACGGCGGC 480

AACATGGCGT CCCCAGCGCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT 540

GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA 600

CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GATGGAGGAG 660

ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGCA 720

CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC 780

CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAGG 840

ACCACAGCTC ACAAGGATCC CAATGCCATC TTCCTGAGCT TCCAACACCT GCTCCGAGGA 900

AAGGTGCGTT TCCTGATGCT TGTAGGAGGG TCCACCCTCT GCGTCAGG 948

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 688 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7 :

CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC 60

ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA 120

CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC 180

AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC 240

CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC 300

GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC 360

TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA CCTGCACCTT TGCTGGACCC 420

GAACAACCTC AATGACGAAG ACGTCTCTAT CCTGATGGAC CGAAACCTTC GACTTCCAAA 480

CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGTA TTGAGGCAAT 540

TCTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC GCACCCTCTC GACATCCAAT 600

CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA CTGACGTTCT ATCTGGTTAC 660

CCTTGAGCAA GCGCAGGAAC AACAGTAC 688

(2) INFORMATION FOR SEQ ID NO : 8 :

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 712 base pairs

(B) TYPE: nucleic acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8 :

CATGGCTAAC TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC 60

ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA 120

CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC 180

AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC 240

CTCTCGACAT CCAATCATCA TCAAGGCAGG TGACTGGCAA GAATTCCGGG AAAAACTGAC 300

GTTCTATCTG GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG 360

CAGCGGCGGC GGTTCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG 420

ACCACCTGCA CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT 480

GGACCGAAAC CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA 540

AAATGCATCA GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC 600

GGCCGCACCC TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA 660

AAAACTGACG TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT AC 712

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 975 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO : :

ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 60

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 120

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 180

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 240

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TAACTGCTCT 300

ATAATGATCG ATGAAATTAT ACATCACTTA AAGAGACCAC CTGCACCTTT GTACGTAGAG 360

GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 420

CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 480

GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 540

CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 600

TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 660

GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 720

CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 780

CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 840

CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 900

GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC 960

CTGCAGCCCT AATAA 975

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 975 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT 60

GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GCAAGAATTC 120

CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA ACAGGGTGGT 180

GGCTCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 240

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 300

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA ATACGTAGAG 360

GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 420

CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 480

GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 540

CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 600

TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 660

GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 720

CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 780

CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 840

CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 900

GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC 960

CTGCAGCCCT AATAA 975 ( 2 ) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 975 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG 60 GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC 120 TCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 180 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 240 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 300 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CTACGTAGAG 360 GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 420 CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 480 GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 540 CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 600 TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 660 GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 720 CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 780 CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 840 CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 900 GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC 960 CTGCAGCCCT AATAA 975

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 975 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 60

GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTAACTGCT CTATAATGAT CGATGAAATT 120

ATACATCACT TAAAGAGACC ACCTGCACCT TTGCTGGACC CGAACAACCT CAATGACGAA 180

GACGTCTCTA TCCTGATGGA CCGAAACCTT CGACTTCCAA ACCTGGAGAG CTTCGTAAGG 240

GCTGTCAAGA ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA 300

TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GTACGTAGAG 360

GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 420

CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACCC AGGGTGCCAT GCCGGCCTTC 480

GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 540

CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC 600

TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 660

GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 720

CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 780

CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 840

CAGGCCCTGG AAGGGATATC CCCCGAGTTG GGTCCCACCT TGGACACACT GCAGCTGGAC 900

GTCGCCGACT TTGCCACCAC CATCTGGCAG CAGATGGAAG AACTGGGAAT GGCCCCTGCC 960

CTGCAGCCCT AATAA 975

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 999 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

ATGGCTCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 60 CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 120 GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 180 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 240 TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGG GTGGTGGCTC TGGCGGTGGC 300 AGCGGCGGCG GTTCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CTTAAAGAGA 360 CCACCTGCAC CTTTGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 420 ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 480 ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 540

GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 600

CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 660

AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 720

TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG 780

AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 840

CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 900

ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 960

GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 999 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

ATGGCTAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT 60

GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG GCAAGAATTC 120

CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA ACAGGGTGGT 180

GGCTCTGGCG GTGGCAGCGG CGGCGGTTCT AACTGCTCTA TAATGATCGA TGAAATTATA 240

CATCACTTAA AGAGACCACC TGCACCTTTG CTGGACCCGA ACAACCTCAA TGACGAAGAC 300

GTCTCTATCC TGATGGACCG AAACCTTCGA CTTCCAAACC TGGAGAGCTT CGTAAGGGCT 360

GTCAAGAACT TAGAATACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 420

ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 480

ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 540

GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 600

CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 660

AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 720

TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG 780

AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 840

CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 900

ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 960

GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 999 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

ATGGCTGCAC CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG 60

GAAAAACTGA CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GGGTGGTGGC 120

TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC TGCTCTATAA TGATCGATGA AATTATACAT 180

CACTTAAAGA GACCACCTGC ACCTTTGCTG GACCCGAACA ACCTCAATGA CGAAGACGTC 240

TCTATCCTGA TGGACCGAAA CCTTCGACTT CCAAACCTGG AGAGCTTCGT AAGGGCTGTC 300

AAGAACTTAG AAAATGCATC AGGTATTGAG GCAATTCTTC GTAATCTCCA ACCATGTCTG 360

CCCTCTGCCA CGGCCTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 420

ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 480

ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 540

GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 600

CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 660

AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 720

TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG 780

AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 840

CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 900

ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 960

GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 999 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

ATGGCTGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 60

GAGCAAGCGC AGGAACAACA GGGTGGTGGC TCTGGCGGTG GCAGCGGCGG CGGTTCTAAC 120

TGCTCTATAA TGATCGATGA AATTATACAT CACTTAAAGA GACCACCTGC ACCTTTGCTG 180

GACCCGAACA ACCTCAATGA CGAAGACGTC TCTATCCTGA TGGACCGAAA CCTTCGACTT 240

CCAAACCTGG AGAGCTTCGT AAGGGCTGTC AAGAACTTAG AAAATGCATC AGGTATTGAG 300

GCAATTCTTC GTAATCTCCA ACCATGTCTG CCCTCTGCCA CGGCCGCACC CTCTCGACAT 360

CCAATCATCA TCAAGTACGT AGAGGGCGGT GGAGGCTCCC CGGGTGAACC GTCTGGTCCA 420

ATCTCTACTA TCAACCCGTC TCCTCCGTCT AAAGAATCTC ATAAATCTCC AAACATGGCT 480

ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 540

GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 600

CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 660

AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 720

TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG 780

AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 840

CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 900

ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 960

GAAGAACTGG GAATGGCCCC TGCCCTGCAG CCCTAATAA 999

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 17 :

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CCACCCCGAG 420

GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 480

AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 540

CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 600

CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 660

ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 720

CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 780

CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GGCGGCTCTG GCGGCTCTCA GAGCTTCCTG 840

CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 900

CTGTGTGCCA CCTAATAA 918

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 963 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 480

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 540

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 600

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 660

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 720

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 780

GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 840

CTTGCGCAGC CCTCTGGCGG CTCTGGCGGC TCTCAGAGCT TCCTGCTCAA GTCTTTAGAG 900

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAA 960

TAA 963 (2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TCCCACCTTG 420

GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA 480

CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT 540

TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 600

TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCTCTGGCG GCTCTGGCGG CTCTCAGAGC 660

TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA AAGATCCAGG GCGATGGCGC AGCGCTCCAG 720

GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC 780

TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 840

GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG 900

GAAGGGATAT CCTAATAA 918

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 963 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 480

GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 540

GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 600

GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 660

CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT 720

TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 780

ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC 840

TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA 900

CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCTAA 960

TAA 963

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CCTGCAGCCC 420

ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 480

GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 540 CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG 600

AGAAAGATCC AGGGCGATGG CGCAGCGCTC CAGGAGAAGC TGTGTGCCAC CTACAAGCTG 660

TGCCACCCCG AGGAGCTGGT GCTGCTCGGA CACTCTCTGG GCATCCCCTG GGCTCCCCTG 720

AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG GCAGGCTGCT TGAGCCAACT CCATAGCGGC 780

CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC CTGGAAGGGA TATCCCCCGA GTTGGGTCCC 840

ACCTTGGACA CACTGCAGCT GGACGTCGCC GACTTTGCCA CCACCATCTG GCAGCAGATG 900

GAAGAACTGG GATAATAA 918

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 963 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 480

CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG 540

CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CTCTGGCGGC 600

TCTGGCGGCT CTCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GATCCAGGGC 660

GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG 720

CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC 780

CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG 840

GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG 900

CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGATAA 960

TAA 963

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTCTGG CGGCTCTGGC 540

GGCTCTCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC 600

GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG 660

CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC 720

CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC 780

CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 840

GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 900

GCCCTGCAGC CCTAATAA 918

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 963 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60 CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 540

TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 600

CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG 660

AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 720

CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC 780

TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA 840

GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 900

GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA 960

TAA 963

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GCGCCGGGCA 420

GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 480

CGCCACCTTG CGCAGCCCTC TGGCGGCTCT GGCGGCTCTC AGAGCTTCCT GCTCAAGTCT 540

TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 600

ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC 660

TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA 720

CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC 780

GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC 840

TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 900

CCGGCCTTCG CCTAATAA 918

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 963 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT 480

GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG 540

CCCTCTGGCG GCTCTGGCGG CTCTCAGAGC TTCCTGCTCA AGTCTTTAGA GCAAGTGAGA 600

AAGATCCAGG GCGATGGCGC AGCGCTCCAG GAGAAGCTGT GTGCCACCTA CAAGCTGTGC 660

CACCCCGAGG AGCTGGTGCT GCTCGGACAC TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC 720

TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA GGCTGCTTGA GCCAACTCCA TAGCGGCCTT 780

TTCCTCTACC AGGGGCTCCT GCAGGCCCTG GAAGGGATAT CCCCCGAGTT GGGTCCCACC 840

TTGGACACAC TGCAGCTGGA CGTCGCCGAC TTTGCCACCA CCATCTGGCA GCAGATGGAA 900

GAACTGGGAA TGGCCCCTGC CCTGCAGCCC ACCCAGGGTG CCATGCCGGC CTTCGCCTAA 960

TAA 963

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT ACAAGCTGTG CCACCCCGAG 420

GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 480

AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 540

CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 600

CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 660

ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 720

CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 780

CGCGTTCTAC GCCACCTTGC GCAGCCCACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG 840

AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGAAAGATCC AGGGCGATGG CGCAGCGCTC 900

CAGGAGAAGC TGTGTGCCAC CTAATAA 927

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 972 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 480

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 540

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 600

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 660

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 720

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 780

GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 840

CTTGCGCAGC CCACACCATT GGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 900

TCTTTAGAGC AAGTGAGAAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 960

GCCACCTAAT AA 972

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTC CCGAGTTGGG TCCCACCTTG 420

GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA 480

CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT CGCCTCTGCT 540

TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT CCTGGAGGTG 600

TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCCACACCAT TGGGCCCTGC CAGCTCCCTG 660

CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGAA AGATCCAGGG CGATGGCGCA 720 GCGCTCCAGG AGAAGCTGTG TGCCACCTAC AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG 780

CTCGGACACT CTCTGGGCAT CCCCTGGGCT CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG 840

CAGCTGGCAG GCTGCTTGAG CCAACTCCAT AGCGGCCTTT TCCTCTACCA GGGGCTCCTG 900

CAGGCCCTGG AAGGGATATC CTAATAA 927

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 972 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 480

GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 540

GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 600

GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 660

CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG 720

CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 780

CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG 840

GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC 900

TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG 960

ATATCCTAAT AA 972

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA TGGCCCCTGC CCTGCAGCCC 420

ACCCAGGGTG CCATGCCGGC CTTCGCCTCT GCTTTCCAGC GCCGGGCAGG AGGGGTCCTG 480

GTTGCTAGCC ATCTGCAGAG CTTCCTGGAG GTGTCGTACC GCGTTCTACG CCACCTTGCG 540

CAGCCCACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 600

GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 660

TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 720

GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 780

CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 840

TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 900

CAGCAGATGG AAGAACTGGG ATAATAA 927

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 972 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240 TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 480

CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG 540

CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CACACCATTG 600

GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG 660

ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC 720

CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 780

TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC 840

CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG 900

GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA 960

CTGGGATAAT AA 972

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCACACC ATTGGGCCCT 540

GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG 600

GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG 660

GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 720

AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 780

CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 840

CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 900

ATGGCCCCTG CCCTGCAGCC CTAATAA 927

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 972 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 540

TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 600

CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG 660

CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960

CAGCCCTAAT AA 972

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTT CTGCTTTCCA GCGCCGGGCA 420

GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 480

CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG 540

CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT CCAGGAGAAG 600

CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG ACACTCTCTG 660

GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC 720

TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC CCTGGAAGGG 780

ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC CGACTTTGCC 840

ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA GCCCACCCAG 900

GGTGCCATGC CGGCCTTCGC CTAATAA 927

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 972 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGACCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT 480

GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG 540

CCCACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 600

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 660

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 720

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 780

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 840

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 900

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 960

TTCGCCTAAT AA 972

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 963 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60

CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GGACAATAAC 120

CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180

GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC 240

ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300

TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 540

TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 600

CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG 660

AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 720

CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC 780

TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA 840

GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 900 GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA 960

TAA 963

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 972 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60

CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC 120

CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180

GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240

ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300

TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 540

TACCGCGTTC TACGCCACCT TGCGCAGCCC ACACCATTGG GCCCTGCCAG CTCCCTGCCC 600

CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG 660

CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960

CAGCCCTAAT AA 972

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 963 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60

CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC 120

CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180

GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240

ACGCGACATC CAATCATCAT CCGTGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300

TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GGCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 540

TACCGCGTTC TACGCCACCT TGCGCAGCCC TCTGGCGGCT CTGGCGGCTC TCAGAGCTTC 600

CTGCTCAAGT CTTTAGAGCA AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG 660

AAGCTGTGTG CCACCTACAA GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT 720

CTGGGCATCC CCTGGGCTCC CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC 780

TGCTTGAGCC AACTCCATAG CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA 840

GGGATATCCC CCGAGTTGGG TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT 900

GCCACCACCA TCTGGCAGCA GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCTAA 960

TAA 963

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 970 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60

CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTAAT GGACAATAAC 120

CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180

GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CGCTAGCCAC GGCCGCACCC 240

GCGACATCCA ATCCATATCA AGGACGGTGA CTGGAATGAA TTCCGTCGTA AACTGACCTT 300 CTATCTGAAA ACCTTGGAGA ACGCGCAGGC TCAACAGTAC GTAGAGGGCG GTGGAGGCTC 360 CCCGGGTGAA CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC 420 TCATAAATCT CCAAACATGG CTACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA 480 GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA 540 CCGCGTTCTA CGCCACCTTG CGCAGCCCAC ACCATTGGGC CCTGCCAGCT CCCTGCCCCA 600 GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC CAGGGCGATG GCGCAGCGCT 660 CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC GAGGAGCTGG TGCTGCTCGG 720 ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC CCCAGCCAGG CCCTGCAGCT 780 GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC TACCAGGGGC TCCTGCAGGC 840 CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC ACACTGCAGC TGGACGTCGC 900 CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG GGAATGGCCC CTGCCCTGCA 960 GCCCTAATAA 970

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGTG 480

GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GGACATTCTG 540

GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GGGACCCACT 600

TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TGGGGCCCTG 660

CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCCC 720

AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT 780

GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCGGCA ACATGGCGTC TCCCGCTCCG 840

CCTGCTTGTG ACCTCCGAGT CCTCAGTAAA CTGCTTCGTG ACTCCCATGT CCTTCACAGC 900

AGACTGAGCC AGTGCCCA 918

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG 480

GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC 540

CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC 600

CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT 660

GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC 720

CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC 780

ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CCGCTCCGCC TGCTTGTGAC 840

CTCCGAGTCC TCAGTAAACT GCTTCGTGAC TCCCATGTCC TTCACAGCAG ACTGAGCCAG 900

TGCCCAGAGG TTCACCCT 918

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 480

ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 540

GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG 600

CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCTT 660

CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA 720

CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC 780

AGGGAATTCG GCGGCAACAT GGCGTCTCCC GCTCCGCCTG CTTGTGACCT CCGAGTCCTC 840

AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CCCAGAGGTT 900

CACCCTTTGC CTACACCT 918

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 480

GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 540

GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 600

GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC 660

AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 720

GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 780

GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 840

CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT 900

ACACCTGTCC TGCTGCCT 918

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC 480

AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG 540

GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT 600

CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC 660

ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG 720

GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC 780

ATGGCGTCTC CCGCTCCGCC TGCTTGTGAC CTCCGAGTCC TCAGTAAACT GCTTCGTGAC 840

TCCCATGTCC TTCACAGCAG ACTGAGCCAG TGCCCAGAGG TTCACCCTTT GCCTACACCT 900

GTCCTGCTGC CTGCTGTG 918

(2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 907 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCGGTTAC CCTTGAGCAA GCGCAGGAAC AACAGTACGT AGAGGGCGGT GGAGGCTCCC 360

CGGGGAACCG TCTGGTCCAA TCTCTACTAT CAACCCGTCT CCTCCGTCTA AAGAATCTCA 420

TAAACTCCAA ACATGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGC ACAGGACATT 480

CTGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA 540

CTTGCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC CGTCTCCTCC TTGGGGCCCT 600

GCAGGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCCC 660

AATGCATCTT CCTGAGCTTC CAACACCTGC TCCGAGGAAA GGTGCGTTTC CTGATGCTTG 720

TAGGGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC ATGGCGTCTC CCGCTCCGCC 780

TGCTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA 840

CTGACCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT 900

TTAGTTG 907

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 917 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA 480

CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG 540

GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 600

CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC 660

GGCGGCAACA TGGCGTCTCC CGCTCCGCCT GCTTGTGACC TCCGAGTCCT CAGTAAACTG 720

CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TCACCCTTTG 780

CCTACACCTG TCCTGCTGCC TGCTGTGGAC TTTAGCTTGG GAGAATGGAA AACCCAGATG 840

GAGGAGACCA AGGCACAGGA CATTCTGGGA GCAGTGACCC TTCTGCTGGA GGGAGTGATG 900

GCAGCACGGG GACAACT 917

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG 480

GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG 540

ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACAT GGCGTCTCCC 600

GCTCCGCCTG CTTGTGACCT CCGAGTCCTC AGTAAACTGC TTCGTGACTC CCATGTCCTT 660 CACAGCAGAC TGAGCCAGTG CCCAGAGGTT CACCCTTTGC CTACACCTGT CCTGCTGCCT 720

GCTGTGGACT TTAGCTTGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC 780

ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA 840

CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG 900

GCCCTGCAGA GCCTCCTT 918

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG 480

AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC 540

CTCTGCGTCA GGGAATTCGG CGGCAACATG GCGTCTCCCG CTCCGCCTGC TTGTGACCTC 600

CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC 660

CCAGAGGTTC ACCCTTTGCC TACACCTGTC CTGCTGCCTG CTGTGGACTT TAGCTTGGGA 720

GAATGGAAAA CCCAGATGGA GGAGACCAAG GCACAGGACA TTCTGGGAGC AGTGACCCTT 780

CTGCTGGAGG GAGTGATGGC AGCACGGGGA CAACTGGGAC CCACTTGCCT CTCATCCCTC 840

CTGGGGCAGC TTTCTGGACA GGTCCGTCTC CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA 900

ACCCAGCTTC CTCCACAG 918

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC 480

CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG 540

GAATTCGGCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT 600

AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC 660

CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC 720

CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GCTGGAGGGA 780

GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GGGGCAGCTT 840

TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT 900

CCACAGGGCA GGACCACA 918

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 480

GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 540

GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 600

CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT 660

ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 720

GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 780

GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 840

GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC 900

AGGACCACAG CTCACAAG 918

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 918 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG 480

CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACATG 540

GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 600

CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 660

CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GGAGACCAAG 720

GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AGCACGGGGA 780

CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GGTCCGTCTC 840

CTCCTTGGGG CCCTGCAGAG CCTCCTTGGA ACCCAGCTTC CTCCACAGGG CAGGACCACA 900

GCTCACAAGG ATCCCAAT 918

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA GGTTCACCCT TTGCCTACAC CTGTCCTGCT GCCTGCTGTG 480

GACTTTAGCT TGGGAGAATG GAAAACCCAG ATGGAGGAGA CCAAGGCACA GGACATTCTG 540

GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG ATGGCAGCAC GGGGACAACT GGGACCCACT 600

TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT GGACAGGTCC GTCTCCTCCT TGGGGCCCTG 660

CAGAGCCTCC TTGGAACCCA GCTTCCTCCA CAGGGCAGGA CCACAGCTCA CAAGGATCCC 720

AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT 780

GTAGGAGGGT CCACCCTCTG CGTCAGGGAA TTCGGCAACA TGGCGTCTCC CGCTCCGCCT 840

GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA 900

CTGAGCCAGT GCCCA 915

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG 480

GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC 540

CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC 600

CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT 660

GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC 720

CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC 780

ACCCTCTGCG TCAGGGAATT CGGCAACATG GCGTCTCCCG CTCCGCCTGC TTGTGACCTC 840

CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC 900

CCAGAGGTTC ACCCT 915

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 480

ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 540

GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG 600

CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCTT 660

CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA 720

CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC 780

AGGGAATTCG GCAACATGGC GTCTCCCGCT CCGCCTGCTT GTGACCTCCG AGTCCTCAGT 840

AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC 900

CCTTTGCCTA CACCT 915

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 480

GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 540

GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 600

GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC 660

AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 720

GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 780

AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT 840

GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA 900

CCTGTCCTGC TGCCT 915

(2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC 480

AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG 540

GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT 600

CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC 660

ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG 720

GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCAACATG 780

GCGTCTCCCG CTCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 840

CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 900

CTGCTGCCTG CTGTG 915

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC 480

ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA 540

CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG 600

GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG 660

GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG 720

ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GTCTCCCGCT 780

CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC 840

AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCTGCT 900

GTGGACTTTA GCTTG 915

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA 480

CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG 540

GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 600

CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC 660 GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 720

CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT 780

ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 840

GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 900

GCACGGGGAC AACTG 915

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG 480

GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG 540

ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCAACATGGC GTCTCCCGCT 600

CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC 660

AGCAGACTGA GCCAGTGCCC AGAGGTTCAC CCTTTGCCTA CACCTGTCCT GCTGCCTGCT 720

GTGGACTTTA GCTTGGGAGA ATGGAAAACC CAGATGGAGG AGACCAAGGC ACAGGACATT 780

CTGGGAGCAG TGACCCTTCT GCTGGAGGGA GTGATGGCAG CACGGGGACA ACTGGGACCC 840

ACTTGCCTCT CATCCCTCCT GGGGCAGCTT TCTGGACAGG TCCGTCTCCT CCTTGGGGCC 900

CTGCAGAGCC TCCTT 915

(2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG 480

AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC 540

CTCTGCGTCA GGGAATTCGG CAACATGGCG TCTCCCGCTC CGCCTGCTTG TGACCTCCGA 600

GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA 660

GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA 720

TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG 780

CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG 840

GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC 900

CAGCTTCCTC CACAG 915

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC 480

CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG 540

GAATTCGGCA ACATGGCGTC TCCCGCTCCG CCTGCTTGTG ACCTCCGAGT CCTCAGTAAA 600

CTGCTTCGTG ACTCCCATGT CCTTCACAGC AGACTGAGCC AGTGCCCAGA GGTTCACCCT 660

TTGCCTACAC CTGTCCTGCT GCCTGCTGTG GACTTTAGCT TGGGAGAATG GAAAACCCAG 720

ATGGAGGAGA CCAAGGCACA GGACATTCTG GGAGCAGTGA CCCTTCTGCT GGAGGGAGTG 780

ATGGCAGCAC GGGGACAACT GGGACCCACT TGCCTCTCAT CCCTCCTGGG GCAGCTTTCT 840

GGACAGGTCC GTCTCCTCCT TGGGGCCCTG CAGAGCCTCC TTGGAACCCA GCTTCCTCCA 900

CAGGGCAGGA CCACA 915

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 480

GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 540

AACATGGCGT CTCCCGCTCC GCCTGCTTGT GACCTCCGAG TCCTCAGTAA ACTGCTTCGT 600

GACTCCCATG TCCTTCACAG CAGACTGAGC CAGTGCCCAG AGGTTCACCC TTTGCCTACA 660

CCTGTCCTGC TGCCTGCTGT GGACTTTAGC TTGGGAGAAT GGAAAACCCA GATGGAGGAG 720

ACCAAGGCAC AGGACATTCT GGGAGCAGTG ACCCTTCTGC TGGAGGGAGT GATGGCAGCA 780

CGGGGACAAC TGGGACCCAC TTGCCTCTCA TCCCTCCTGG GGCAGCTTTC TGGACAGGTC 840

CGTCTCCTCC TTGGGGCCCT GCAGAGCCTC CTTGGAACCC AGCTTCCTCC ACAGGGCAGG 900

ACCACAGCTC ACAAG 915

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 915 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG 480

CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CAACATGGCG 540

TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 600

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 660

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 720

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 780

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 840

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 900

CACAAGGATC CCAAT 915

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

GACTTCCAAA CCTGGAGAGC TTCGTAAGGG CTGTCAAGAA CTTAGAAAAT GCATCAGGTA 180

TGAGGCAATT CTTCGTAATC TCCAACCATG TCTGCCCTCT GCCACGGCCG CACCCTCTCG 240

CATCCAATCA TCATCAAGGC AGGTGACTGG CAAGAATTCC GGGAAAAACT GACGTTCTAT 300

TGGTTACCCT TGAGCAAGCG CAGGAACAAC AGTACGTAGA GGGCGGTGGA GGCTCCCCGG 360

TAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 420

TCTCCAAACA TGGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT 480

AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA 540

GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC 600

TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC 660

CTCCTTGGAA CCCAGCTTCC TCCACAGGGC AGGACCACAG CTCACAAGGA TCCCAATGCC 720

ATCTTCCTGA GCTTCCAACA CCTGCTCCGA GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA 780

GGGTCCACCC TCTGCGTCAG GGAATTCGGC GGCAACGGCG GCAACATGGC GTCCCCAGCG 840

CCGCCTGCTT GTGACCTCCG AGTCCTCAGT AAACTGCTTC GTGACTCCCA TGTCCTTCAC 900

AGCAGACTGA GCCAGTGCCC A 921

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGTT GCCTACACCT GTCCTGCTGC CTGCTGTGGA CTTTAGCTTG 480

GGAGAATGGA AAACCCAGAT GGAGGAGACC AAGGCACAGG ACATTCTGGG AGCAGTGACC 540

CTTCTGCTGG AGGGAGTGAT GGCAGCACGG GGACAACTGG GACCCACTTG CCTCTCATCC 600

CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT 660

GGAACCCAGC TTCCTCCACA GGGCAGGACC ACAGCTCACA AGGATCCCAA TGCCATCTTC 720

CTGAGCTTCC AACACCTGCT CCGAGGAAAG GTGCGTTTCC TGATGCTTGT AGGAGGGTCC 780

ACCCTCTGCG TCAGGGAATT CGGCGGCAAC GGCGGCAACA TGGCGTCCCC AGCGCCGCCT 840

GCTTGTGACC TCCGAGTCCT CAGTAAACTG CTTCGTGACT CCCATGTCCT TCACAGCAGA 900

CTGAGCCAGT GCCCAGAGGT TCACCCT 927

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 480

ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 540

GGAGTGATGG CAGCACGGGG ACAACTGGGA CCCACTTGCC TCTCATCCCT CCTGGGGCAG 600

CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG GCCCTGCAGA GCCTCCTTGG AACCCAGCTT 660

CCTCCACAGG GCAGGACCAC AGCTCACAAG GATCCCAATG CCATCTTCCT GAGCTTCCAA 720

CACCTGCTCC GAGGAAAGGT GCGTTTCCTG ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC 780

AGGGAATTCG GCGGCAACGG CGGCAACATG GCGTCCCCAG CGCCGCCTGC TTGTGACCTC 840

CGAGTCCTCA GTAAACTGCT TCGTGACTCC CATGTCCTTC ACAGCAGACT GAGCCAGTGC 900

CCAGAGGTTC ACCCTTTGCC TACACCT 927

(2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 480

GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 540

GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 600

GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC 660

AGGACCACAG CTCACAAGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 720

GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 780

GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AGTCCTCAGT 840

AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC 900

CCTTTGCCTA CACCTGTCCT GCTGCCT 927

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA CTTTAGCTTG GGAGAATGGA AAACCCAGAT GGAGGAGACC 480

AAGGCACAGG ACATTCTGGG AGCAGTGACC CTTCTGCTGG AGGGAGTGAT GGCAGCACGG 540

GGACAACTGG GACCCACTTG CCTCTCATCC CTCCTGGGGC AGCTTTCTGG ACAGGTCCGT 600

CTCCTCCTTG GGGCCCTGCA GAGCCTCCTT GGAACCCAGC TTCCTCCACA GGGCAGGACC 660

ACAGCTCACA AGGATCCCAA TGCCATCTTC CTGAGCTTCC AACACCTGCT CCGAGGAAAG 720

GTGCGTTTCC TGATGCTTGT AGGAGGGTCC ACCCTCTGCG TCAGGGAATT CGGCGGCAAC 780

GGCGGCAACA TGGCGTCCCC AGCGCCGCCT GCTTGTGACC TCCGAGTCCT CAGTAAACTG 840

CTTCGTGACT CCCATGTCCT TCACAGCAGA CTGAGCCAGT GCCCAGAGGT TCACCCTTTG 900

CCTACACCTG TCCTGCTGCC TGCTGTG 927

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG AGAATGGAAA ACCCAGATGG AGGAGACCAA GGCACAGGAC 480

ATTCTGGGAG CAGTGACCCT TCTGCTGGAG GGAGTGATGG CAGCACGGGG ACAACTGGGA 540

CCCACTTGCC TCTCATCCCT CCTGGGGCAG CTTTCTGGAC AGGTCCGTCT CCTCCTTGGG 600

GCCCTGCAGA GCCTCCTTGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG 660 GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG 720

ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG 780

GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 840

CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 900

CTGCTGCCTG CTGTGGACTT TAGCTTG 927

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG ACCCACTTGC CTCTCATCCC TCCTGGGGCA GCTTTCTGGA 480

CAGGTCCGTC TCCTCCTTGG GGCCCTGCAG AGCCTCCTTG GAACCCAGCT TCCTCCACAG 540

GGCAGGACCA CAGCTCACAA GGATCCCAAT GCCATCTTCC TGAGCTTCCA ACACCTGCTC 600

CGAGGAAAGG TGCGTTTCCT GATGCTTGTA GGAGGGTCCA CCCTCTGCGT CAGGGAATTC 660

GGCGGCAACG GCGGCAACAT GGCGTCCCCA GCGCCGCCTG CTTGTGACCT CCGAGTCCTC 720

AGTAAACTGC TTCGTGACTC CCATGTCCTT CACAGCAGAC TGAGCCAGTG CCCAGAGGTT 780

CACCCTTTGC CTACACCTGT CCTGCTGCCT GCTGTGGACT TTAGCTTGGG AGAATGGAAA 840

ACCCAGATGG AGGAGACCAA GGCACAGGAC ATTCTGGGAG CAGTGACCCT TCTGCTGGAG 900

GGAGTGATGG CAGCACGGGG ACAACTG 927

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG AACCCAGCTT CCTCCACAGG GCAGGACCAC AGCTCACAAG 480

GATCCCAATG CCATCTTCCT GAGCTTCCAA CACCTGCTCC GAGGAAAGGT GCGTTTCCTG 540

ATGCTTGTAG GAGGGTCCAC CCTCTGCGTC AGGGAATTCG GCGGCAACGG CGGCAACATG 600

GCGTCCCCAG CGCCGCCTGC TTGTGACCTC CGAGTCCTCA GTAAACTGCT TCGTGACTCC 660

CATGTCCTTC ACAGCAGACT GAGCCAGTGC CCAGAGGTTC ACCCTTTGCC TACACCTGTC 720

CTGCTGCCTG CTGTGGACTT TAGCTTGGGA GAATGGAAAA CCCAGATGGA GGAGACCAAG 780

GCACAGGACA TTCTGGGAGC AGTGACCCTT CTGCTGGAGG GAGTGATGGC AGCACGGGGA 840

CAACTGGGAC CCACTTGCCT CTCATCCCTC CTGGGGCAGC TTTCTGGACA GGTCCGTCTC 900

CTCCTTGGGG CCCTGCAGAG CCTCCTT 927

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGG CAGGACCACA GCTCACAAGG ATCCCAATGC CATCTTCCTG 480

AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG CGTTTCCTGA TGCTTGTAGG AGGGTCCACC 540

CTCTGCGTCA GGGAATTCGG CGGCAACGGC GGCAACATGG CGTCCCCAGC GCCGCCTGCT 600

TGTGACCTCC GAGTCCTCAG TAAACTGCTT CGTGACTCCC ATGTCCTTCA CAGCAGACTG 660

AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT ACACCTGTCC TGCTGCCTGC TGTGGACTTT 720

AGCTTGGGAG AATGGAAAAC CCAGATGGAG GAGACCAAGG CACAGGACAT TCTGGGAGCA 780

GTGACCCTTC TGCTGGAGGG AGTGATGGCA GCACGGGGAC AACTGGGACC CACTTGCCTC 840

TCATCCCTCC TGGGGCAGCT TTCTGGACAG GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC 900

CTCCTTGGAA CCCAGCTTCC TCCACAG 927

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TCACAAGGAT CCCAATGCCA TCTTCCTGAG CTTCCAACAC 480

CTGCTCCGAG GAAAGGTGCG TTTCCTGATG CTTGTAGGAG GGTCCACCCT CTGCGTCAGG 540

GAATTCGGCG GCAACGGCGG CAACATGGCG TCCCCAGCGC CGCCTGCTTG TGACCTCCGA 600

GTCCTCAGTA AACTGCTTCG TGACTCCCAT GTCCTTCACA GCAGACTGAG CCAGTGCCCA 660

GAGGTTCACC CTTTGCCTAC ACCTGTCCTG CTGCCTGCTG TGGACTTTAG CTTGGGAGAA 720

TGGAAAACCC AGATGGAGGA GACCAAGGCA CAGGACATTC TGGGAGCAGT GACCCTTCTG 780

CTGGAGGGAG TGATGGCAGC ACGGGGACAA CTGGGACCCA CTTGCCTCTC ATCCCTCCTG 840

GGGCAGCTTT CTGGACAGGT CCGTCTCCTC CTTGGGGCCC TGCAGAGCCT CCTTGGAACC 900

CAGCTTCCTC CACAGGGCAG GACCACA 927

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 480

GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 540

GGCAACGGCG GCAACATGGC GTCCCCAGCG CCGCCTGCTT GTGACCTCCG AGTCCTCAGT 600

AAACTGCTTC GTGACTCCCA TGTCCTTCAC AGCAGACTGA GCCAGTGCCC AGAGGTTCAC 660

CCTTTGCCTA CACCTGTCCT GCTGCCTGCT GTGGACTTTA GCTTGGGAGA ATGGAAAACC 720

CAGATGGAGG AGACCAAGGC ACAGGACATT CTGGGAGCAG TGACCCTTCT GCTGGAGGGA 780

GTGATGGCAG CACGGGGACA ACTGGGACCC ACTTGCCTCT CATCCCTCCT GGGGCAGCTT 840

TCTGGACAGG TCCGTCTCCT CCTTGGGGCC CTGCAGAGCC TCCTTGGAAC CCAGCTTCCT 900

CCACAGGGCA GGACCACAGC TCACAAG 927

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 927 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60 TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CATCTTCCTG AGCTTCCAAC ACCTGCTCCG AGGAAAGGTG 480 CGTTTCCTGA TGCTTGTAGG AGGGTCCACC CTCTGCGTCA GGGAATTCGG CGGCAACGGC 540 GGCAACATGG CGTCCCCAGC GCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 600 CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT 660 ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 720 GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 780 GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 840 GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGCTTCC TCCACAGGGC 900 AGGACCACAG CTCACAAGGA TCCCAAT 927

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 906 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGA TCCCAATGCC ATCTTCCTGA GCTTCCAACA CCTGCTCCGA 480

GGAAAGGTGC GTTTCCTGAT GCTTGTAGGA GGGTCCACCC TCTGCGTCAG GGAATTCGGC 540

GGCAACATGG CGTCTCCCGC TCCGCCTGCT TGTGACCTCC GAGTCCTCAG TAAACTGCTT 600

CGTGACTCCC ATGTCCTTCA CAGCAGACTG AGCCAGTGCC CAGAGGTTCA CCCTTTGCCT 660

ACACCTGTCC TGCTGCCTGC TGTGGACTTT AGCTTGGGAG AATGGAAAAC CCAGATGGAG 720

GAGACCAAGG CACAGGACAT TCTGGGAGCA GTGACCCTTC TGCTGGAGGG AGTGATGGCA 780

GCACGGGGAC AACTGGGACC CACTTGCCTC TCATCCCTCC TGGGGCAGCT TTCTGGACAG 840

GTCCGTCTCC TCCTTGGGGC CCTGCAGAGC CTCCTTGGAA CCCAGGGCAG GACCACAGCT 900

CACAAG 906

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 993 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GTCTTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 480

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 540

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 600

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 660

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 720

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 780

GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 840

CTTGCGCAGC CCGGCGGCGG CTCTGACATG GCTACACCAT TAGGCCCTGC CAGCTCCCTG 900

CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG CAAGTGAGGA AGATCCAGGG CGATGGCGCA 960

GCGCTCCAGG AGAAGCTGTG TGCCACCTAA TAA 993 (2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 993 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GTCTCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 480

GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 540

GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 600

GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 660

CGCCACCTTG CGCAGCCCGG CGGCGGCTCT GACATGGCTA CACCATTAGG CCCTGCCAGC 720

TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT 780

GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACCTACAAGC TGTGCCACCC CGAGGAGCTG 840

GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG 900

GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG 960

CTCCTGCAGG CCCTGGAAGG GATATCCTAA TAA 993

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 993 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GTCTTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT 480

GCTAGCCATC TGCAGAGCTT CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG 540

CCCGGCGGCG GCTCTGACAT GGCTACACCA TTAGGCCCTG CCAGCTCCCT GCCCCAGAGC 600

TTCCTGCTCA AGTCTTTAGA GCAAGTGAGG AAGATCCAGG GCGATGGCGC AGCGCTCCAG 660

GAGAAGCTGT GTGCCACCTA CAAGCTGTGC CACCCCGAGG AGCTGGTGCT GCTCGGACAC 720

TCTCTGGGCA TCCCCTGGGC TCCCCTGAGC TCCTGCCCCA GCCAGGCCCT GCAGCTGGCA 780

GGCTGCTTGA GCCAACTCCA TAGCGGCCTT TTCCTCTACC AGGGGCTCCT GCAGGCCCTG 840

GAAGGGATAT CCCCCGAGTT GGGTCCCACC TTGGACACAC TGCAGCTGGA CGTCGCCGAC 900

TTTGCCACCA CCATCTGGCA GCAGATGGAA GAACTGGGAA TGGCCCCTGC CCTGCAGCCC 960

ACCCAGGGTG CCATGCCGGC CTTCGCCTAA TAA 993

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 993 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GTCTATGGCC CCTGCCCTGC AGCCCACCCA GGGTGCCATG 480 CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG GCAGGAGGGG TCCTGGTTGC TAGCCATCTG 540

CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC CGGCGGCGGC 600

TCTGACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660

TCTTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720

GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780

CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840

CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900

CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960

ATCTGGCAGC AGATGGAAGA ACTGGGATAA TAA 993

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 993 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

ATGGCTAACT GCTCTATAAT GATCGATGAA ATTATACATC ACTTAAAGAG ACCACCTGCA 60

CCTTTGCTGG ACCCGAACAA CCTCAATGAC GAAGACGTCT CTATCCTGAT GGATCGAAAC 120

CTTCGACTTC CAAACCTGGA GAGCTTCGTA AGGGCTGTCA AGAACTTAGA AAATGCATCA 180

GGTATTGAGG CAATTCTTCG TAATCTCCAA CCATGTCTGC CCTCTGCCAC GGCCGCACCC 240

TCTCGACATC CAATCATCAT CAAGGCAGGT GACTGGCAAG AATTCCGGGA AAAACTGACG 300

TTCTATCTGG TTACCCTTGA GCAAGCGCAG GAACAACAGT ACGTAGAGGG CGGTGGAGGC 360

TCCCCGGGTG AACCGTCTGG TCCAATCTCT ACTATCAACC CGTCTCCTCC GTCTAAAGAA 420

TCTCATAAAT CTCCAAACAT GTCTACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 480

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 540

TACCGCGTTC TACGCCACCT TGCGCAGCCC GGCGGCGGCT CTGACATGGC TACACCATTA 600

GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA AGTGAGGAAG 660

ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA GCTGTGCCAC 720

CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC CCTGAGCTCC 780

TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG CGGCCTTTTC 840

CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG TCCCACCTTG 900

GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA GATGGAAGAA 960

CTGGGAATGG CCCCTGCCCT GCAGCCCTAA TAA 993

(2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1027 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:

ATGGCTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 60

GAGCAAGTGA GGAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACC 120

TACAAGCTGT GCCACCCCGA GGAGCTGGTG CTGCTCGGAC ACTCTCTGGG CATCCCCTGG 180

GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC CTGCAGCTGG CAGGCTGCTT GAGCCAACTC 240

CATAGCGGCC TTTTCCTCTA CCAGGGGCTC CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG 300

TTGGGTCCCA CCTTGGACAC ACTGCAGCTG GACGTCGCCG ACTTTGCCAC CACCATCTGG 360

CAGCAGATGG AAGAACTGGG AATGGCCCCT GCCCTGCAGC CCACCCAGGG TGCCATGCCG 420

GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA GGAGGGGTCC TGGTTGCTAG CCATCTGCAG 480

AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA CGCCACCTTG CGCAGCCCGG CGGCGGCTCT 540

GACATGGCTA CACCATTGGG CCCTGCCAGC TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT 600

TTAGAGCAAG TGAGGAAGAT CCAGGGCGAT GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC 660

ACCTACAAGC TGTGCCACCC CGAGGAGCTG GTGCTGCTCG GACACTCTCT GGGCATCCCC 720

TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA 780

CTCCATAGCG GCCTTTTCCT CTACCAGGGG CTCCTGCAGG CCCTGGAAGG GATATCCCCC 840

GAGTTGGGTC CCACCTTGGA CACACTGCAG CTGGACGTCG CCGACTTTGC CACCACCATC 900

TGGCAGCAGA TGGAAGAACT GGGAATGGCC CCTGCCCTGC AGCCCACCCA TCCTGGTTGC 960

TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT CTACGCCACC TTGCGCAGCC 1020

CTGATAA 1027

(2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 459 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear Lt lλ>

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360

CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420

TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 459

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 447 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

TCTCCCGCTC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGGGCAGGA CCACAGCTCA CAAGGATCCC 360

AATGCCATCT TCCTGAGCTT CCAACACCTG CTCCGAGGAA AGGTGCGTTT CCTGATGCTT 420

GTAGGAGGGT CCACCCTCTG CGTCAGG 447

(2) INFORMATION FOR SEQ ID NO: 86:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 459 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

TCCCCAGCGC CGCCTGCTTG TGACCTCCGA GTCCTCAGTA AACTGCTTCG TGACTCCCAT 60

GTCCTTCACA GCAGACTGAG CCAGTGCCCA GAGGTTCACC CTTTGCCTAC ACCTGTCCTG 120

CTGCCTGCTG TGGACTTTAG CTTGGGAGAA TGGAAAACCC AGATGGAGGA GACCAAGGCA 180

CAGGACATTC TGGGAGCAGT GACCCTTCTG CTGGAGGGAG TGATGGCAGC ACGGGGACAA 240

CTGGGACCCA CTTGCCTCTC ATCCCTCCTG GGGCAGCTTT CTGGACAGGT CCGTCTCCTC 300

CTTGGGGCCC TGCAGAGCCT CCTTGGAACC CAGCTTCCTC CACAGGGCAG GACCACAGCT 360

CACAAGGATC CCAATGCCAT CTTCCTGAGC TTCCAACACC TGCTCCGAGG AAAGGTGCGT 420

TTCCTGATGC TTGTAGGAGG GTCCACCCTC TGCGTCAGG 459

(2) INFORMATION FOR SEQ ID NO: 87:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 464 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG 60

CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGATCGAA 120

ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT 180

CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC 240

CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 300

CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAGAG GGCGGTGGAG 360

GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG 420

AATCTCATAA ATCTCCAAAC ATGTAAGGTA CCGCATGCAA GCTT 464

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 419 base pairs

(B) TYPE: nucleic acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

CCATGGCTAA CTGCTCTATA ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTG 60

CACCTTTGCT GGACCCGAAC AACCTCAATG ACGAAGACGT CTCTATCCTG ATGGATCGAA 120

ACCTTCGACT TCCAAACCTG GAGAGCTTCG TAAGGGCTGT CAAGAACTTA GAAAATGCAT 180

CAGGTATTGA GGCAATTCTT CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC 240

CCTCTCGACA TCCAATCATC ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA 300

CGTTCTATCT GGTTACCCTT GAGCAAGCGC AGGAACAACA GTACGTAGAG GGCGGTGGAG 360

GCTCCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGTA AGGTACCGCA TGCAAGCTT 419

(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 405 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGC GCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCC 405

(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 420 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420

(2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 366 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 300

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 360

ACCCTG 366

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 405 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single It 11,

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

GGAACTCAGG ATTGTTCTTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCC 405

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 420 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

GGTACCCAGG ATTGTTCTTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 405 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:! 34:

GCCACTCAGG ACTGTTCTTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCC 405

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 420 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:! 35:

GCCACTCAGG ACTGCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420

(2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear b/5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO : ! 36:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGTCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC 360 TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420 TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG 465

(2) INFORMATION FOR SEQ ID NO: 97:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 450 base pairs

(B) TYPE: nucleic acid (C) ^• STRANDEDNESS: single (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:! 37:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGTCAGGCG GTAACGGCAG TGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC 360 CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 420 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 450

(2) INFORMATION FOR SEQ ID NO: 98:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 435 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120 ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240 ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300 CTGTCTGGCG GCAACGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 360 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 420 GCCTCCAACC TGCAG 435

(2) INFORMATION FOR SEQ ID NO: 99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG AGGTAACGGA 240 TCCGGTGGCA ATGGGAGCGG CGGAAATGGA ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGG 465

(2) INFORMATION FOR SEQ ID NO: 100:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 450 base pairs (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60

TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120

CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180

TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG AGGTAACGGA 240

TCCGGAGGTA ATGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 300

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 360

TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 420 TGGATGGAGC GGCTCAAGAC TGTCGCTGGG 450

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 435 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60

TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120

CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180

TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGTCTGG CGGCAACGGC 240

ACGCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT 300

GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC 360

GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC 420

AAGACTGTCG CTGGG 435

(2) INFORMATION FOR SEQ ID NO: 102:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60

TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGAG GTAACGGCAG TGGTGGCAAT 180

GGGAGCGGTG GAAATGGAAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 240

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 300

GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 360

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 420

GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCC 465

(2) INFORMATION FOR SEQ ID NO: 103:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 450 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60

TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCAGGCG GTAACGGCAG TGGAGGTAAT 180

GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 240

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 300

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 360

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 420

CACTTTGTCA CCAAATGTGC CTTTCAGCCC 450

(2) INFORMATION FOR SEQ ID NO: 104: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 435 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60

TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGTCTGGCG GCAACGGCAC GCAGGACTGC 180

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 240

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 300

GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 360

GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 420

TGTGCCTTTC AGCCC 435

(2) INFORMATION FOR SEQ ID NO: 105:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 451 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:: L05:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGTCTGGAG GTAGTGGATC CGGAGGTTCT GGCAACCCAG GACTGCTCCT TCCAACACAG 360

CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA 420

TTACCCAGTC ACCGTGGCCT CCAACCTGCA G 451

(2) INFORMATION FOR SEQ ID NO: 106:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGTCTGGAG GTAGTGGATC CGGTGGCAGT GGGAGCGGCG GATCTGGAAC CCAGGACTGC 360

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG 465

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 437 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 60

AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 120

TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG 180

AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG 240

AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300

AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360

GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 420 CCCTGGGCGG TGGATCC 437

(2) INFORMATION FOR SEQ ID NO: 108:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 436 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

GGATCCGGAG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 60

GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 120

AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 180

ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 240

ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 300

GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 360

CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 420

TCAACCCTGT AAGCTT 436

(2) INFORMATION FOR SEQ ID NO: 109:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 449 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 60

AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 120

TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG 180

AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG 240

AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300

AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360

GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 420

CCCTGGGCGG TGGGTCAGGA GGTGGATCC 449

(2) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 439 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110:

GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 60

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 120

TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 180

TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 240

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 300

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 360

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 420

TCCTCAACCC TGTAAGCTT 439

(2) INFORMATION FOR SEQ ID NO: 111:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 461 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111:

CCATGGCCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 60

AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC 120

TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG 180

AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG 240 AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC 300

AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT 360

GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA 420

CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC C 461

(2) INFORMATION FOR SEQ ID NO: 112:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 457 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 60

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 120

TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 180

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 240

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 300

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 360

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 420

CTGCAGTGTC AGCCCGACTC CTCAACCCTG TAAGCTT 457

(2) INFORMATION FOR SEQ ID NO: 113:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 438 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 360

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 420

GTGGCCTCCA ACCTGCAG 438

(2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 441 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GATCCGGAGG TGGCACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 360

TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 420

ACCGTGGCCT CCAACCTGCA G 441

(2) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 450 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115: GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG ACTGCTCCTT CCAACACAGC 360

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 420

TACCCAGTCA CCGTGGCCTC CAACCTGCAG 450

(2) INFORMATION FOR SEQ ID NO: 116:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 459 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC 360

CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 420

CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAG 459

(2) INFORMATION FOR SEQ ID NO: 117:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC 360

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAG 465

(2) INFORMATION FOR SEQ ID NO: 118:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 483 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

GCCGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGCCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAG 483

(2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 843 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 480

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 540

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGCGC TCTGGCGGCT GGTCCTGGCA 600

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 660

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 720

CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 780

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840

CCC 843

(2) INFORMATION FOR SEQ ID NO: 120:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 858 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 480

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 540

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGCGC TCTGGCGGCT GGTCCTGGCA 600

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 660

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 720

CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 780

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840

CCCGACTCCT CAACCCTG 858

(2) INFORMATION FOR SEQ ID NO: 121:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GTCAGGCGGT AACGGCAGTG GAGGTAATGG CACCCAGGAC 780

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 840

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 888

(2) INFORMATION FOR SEQ ID NO: 122:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 903 base pairs (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GTCTGGAGGT AACGGATCCG GTGGCAATGG GAGCGGCGGA 780

AATGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 123:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 873 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGTCTGGCG GCAACGGCAC GCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 720

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 780

GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 840

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG 873

(2) INFORMATION FOR SEQ ID NO: 124:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGTCTGGAG GTAACGGATC CGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC 720

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 780

TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 840

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG 888 (2) INFORMATION FOR SEQ ID NO: 125:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGTCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC 720

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 780

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 840

GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 900

GGG 903

(2) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 873 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGCGGC 600

AACGGCACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 660

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 720

CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 780

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 840

ATACACTTTG TCACCAAATG TGCCTTTCAG CCC 873

(2) INFORMATION FOR SEQ ID NO: 127:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCAGGCGGT 600 AACGGCAGTG GAGGTAATGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 660

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 720

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 780

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC 888

(2) INFORMATION FOR SEQ ID NO: 128:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT 600

AACGGCAGTG GTGGTAATGG GAGCGGCGGA AATGGAACCC AGGACTGCTC CTTCCAACAC 660

AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 720

GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG 780

CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 840

CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 900

CCC 903

(2) INFORMATION FOR SEQ ID NO: 129:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 843 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC GACTCAGGAC TGTTCTTTCC AACACAGCCC CATCTCCTCC 480

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 540

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 600

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 660

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 720

CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 780

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840

CCC 843

(2) INFORMATION FOR SEQ ID NO: 130:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 858 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC AACCCAGGAC TGCTCTTTTC AACACAGCCC CATCTCCTCC 480

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 540

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 600

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 660

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 720

CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 780

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840

CCCGACTCCT CAACCCTG 858

(2) INFORMATION FOR SEQ ID NO: 131:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 843 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131:

GCCACTCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCTACGT AGAGGGCGGT 420

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 480

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 540

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 600

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 660

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 720

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 780

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 840

CAG 843

(2) INFORMATION FOR SEQ ID NO: 132:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CCAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GTCAGGCGGT AACGGCAGTG GAGGTAATGG CACCCAGGAC 780

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 840

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 888

(2) INFORMATION FOR SEQ ID NO: 133:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GTCTGGAGGT AACGGATCCG GTGGCAATGG GAGCGGCGGA 780

AATGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 134:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 873 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGTCTGGCG GCAACGGCAC GCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 720

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 780

GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 840

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGG 873

(2) INFORMATION FOR SEQ ID NO: 135:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGTCTGGAG GTAACGGATC CGGAGGTAAT GGCACCCAGG ACTGCTCCTT CCAACACAGC 720

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 780

TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 840

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG 888

(2) INFORMATION FOR SEQ ID NO: 136:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGTCTGGAG GTAACGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC 720

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 780

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 840

GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 900

GGG 903

(2) INFORMATION FOR SEQ ID NO: 137:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 873 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGCGGC 600

AACGGCACGC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 660

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 720

CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 780

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 840

ATACACTTTG TCACCAAATG TGCCTTTCAG CCC 873

(2) INFORMATION FOR SEQ ID NO: 138:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCAGGCGGT 600

AACGGCAGTG GAGGTAATGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 660

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 720

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 780

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC 888

(2) INFORMATION FOR SEQ ID NO: 139: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GTCTGGAGGT 600

AACGGCAGTG GTGGCAATGG GAGCGGCGGA AATGGAACCC AGGACTGCTC CTTCCAACAC 660

AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 720

GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG 780

CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 840

CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 900

CCC 903

(2) INFORMATION FOR SEQ ID NO: 140:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CCAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GTCTGGAGGT AGTGGATCCG GAGGTTCTGG CACCCAGGAC 780

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 840

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 888

(2) INFORMATION FOR SEQ ID NO: 141:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GTCTGGAGGT AGTGGATCCG GTGGCAGTGG GAGCGGCGGA 780 TCTGGAACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 142:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 858 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142:

GCCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420

TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC 480

CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTAACTG CTCTATAATG 540

ATCGATGAAA TTATACATCA CTTAAAGAGA CCACCTAACC CTTTGCTGGA CCCGAACAAC 600

CTCAATTCTG AAGACATGGA TATCCTGATG GAACGAAACC TTCGAACTCC AAACCTGCTC 660

GCATTCGTAA GGGCTGTCAA GCACTTAGAA AATGCATCAG GTATTGAGGC AATTCTTCGT 720

AATCTCCAAC CATGTCTGCC CTCTGCCACG GCCGCACCCT CTCGACATCC AATCATCATC 780

AAGGCAGGTG ACTGGCAAGA ATTCCGGGAA AAACTGACGT TCTATCTGGT TACCCTTGAG 840

CAAGCGCAGG AACAACAG 858

(2) INFORMATION FOR SEQ ID NO: 143:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTA CCCAGGACTG CTCCTTCCAA 780

CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 840

CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAG 876

(2) INFORMATION FOR SEQ ID NO: 144:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 879 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480 GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTG GCACCCAGGA CTGCTCCTTC 780

CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 840

CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAG 879

(2) INFORMATION FOR SEQ ID NO: 145:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GATCCGGAGG TACCCAGGAC 780

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 840

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAG 888

(2) INFORMATION FOR SEQ ID NO: 146:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 897 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GGGCGGTGGA TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT 780

ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT 840

GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAG 897

(2) INFORMATION FOR SEQ ID NO: 147:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 780

GGTGGCACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 148:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 780

GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 840

TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 900

ACCGTGGCCT CCAACCTGCA G 921

(2) INFORMATION FOR SEQ ID NO: 149:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGGGCGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 720

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 780

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 840

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGG 876

(2) INFORMATION FOR SEQ ID NO: 150:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 879 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGGGCGGTG GATCCGGAGG TGGCACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 720

TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 780

ACCGTGGCCT CCAACCTGCA GGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 840

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGG 879

(2) INFORMATION FOR SEQ ID NO: 151:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 151:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG ACTGCTCCTT CCAACACAGC 720

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 780

TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 840

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGG 888

(2) INFORMATION FOR SEQ ID NO: 152:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 897 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGGGCGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC 720

CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 780

CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC 840

CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGG 897

(2) INFORMATION FOR SEQ ID NO: 153:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC 720

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 780

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 840

GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 900

GGG 903

(2) INFORMATION FOR SEQ ID NO: 154:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 480

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 540

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 600

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 660

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 720

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 780

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 840

CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 900

CGGCTCAAGA CTGTCGCTGG G 921

(2) INFORMATION FOR SEQ ID NO: 155:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA 600

TCCGGAGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 660

AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 720

CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 780

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 840

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCC 876 (2) INFORMATION FOR SEQ ID NO: 156:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 879 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA 600

TCCGGAGGTG GCACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 660

GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 720

AACCTGCAGG ATGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 780

ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 840

ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCC 879

(2) INFORMATION FOR SEQ ID NO: 157:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG 600

TCAGGAGGTG GATCCGGAGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 660

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 720

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 780

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCC 888

(2) INFORMATION FOR SEQ ID NO: 158:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 897 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGA 600

TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 660 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 720

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 780

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840

TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCC 897

(2) INFORMATION FOR SEQ ID NO: 159:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG 600

TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCACCC AGGACTGCTC CTTCCAACAC 660

AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 720

GATTACCCAG TCACCGTGGC CTCCAACCTG CAGGACGAGG AGCTCTGCGG GGGCCTCTGG 780

CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 840

CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 900

CCC 903

(2) INFORMATION FOR SEQ ID NO: 160:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC CAACATCTCC 480

CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT CACTCGCCAG 540

AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT GGGCGGTGGG 600

TCAGGAGGTG GGTCAGGAGG TGGATCCGGA GGTGGCTCAG GGGGAGGTAG TGGTACCCAG 660

GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG 720

TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 780

CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT 840

GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC 900

ACCAAATGTG CCTTTCAGCC C 921

(2) INFORMATION FOR SEQ ID NO: 161:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 161:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780

GGGTCAGGAG GTGGATCCGG AGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 840

TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAA 888

(2) INFORMATION FOR SEQ ID NO: 162:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA 840

CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 900

CAA 903

(2) INFORMATION FOR SEQ ID NO: 163:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC 780

GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTG 888

(2) INFORMATION FOR SEQ ID NO: 164:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAAGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 780

GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 840

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 900

GTG 903

(2) INFORMATION FOR SEQ ID NO: 165:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC 720

CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 780

CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC 840

CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACT 888

(2) INFORMATION FOR SEQ ID NO: 166:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCACC 720

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 780

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 840

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 900

ACT 903

(2) INFORMATION FOR SEQ ID NO: 167:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC 600

GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 660

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 720

CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 780

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 840

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTT 888

(2) INFORMATION FOR SEQ ID NO: 168:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 600

GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 660

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 720

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 780

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 900

CTT 903

(2) INFORMATION FOR SEQ ID NO: 169:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTACCCAG 600

GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG 660

TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 720

CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT 780

GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC 840

ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAG 888 (2) INFORMATION FOR SEQ ID NO: 170:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 600

GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 660

AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 720

CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 780

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 840

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 171:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780

GGATCCGGAG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 840

GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAA 876

(2) INFORMATION FOR SEQ ID NO: 172:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 879 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780

GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 840

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAA 879

(2) INFORMATION FOR SEQ ID NO: 173:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 897 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 840

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAA 897

(2) INFORMATION FOR SEQ ID NO: 174:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 840

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 900

CTGTCTGACT ACCTGCTTCA A 921

(2) INFORMATION FOR SEQ ID NO: 175:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 869 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTACTGCT 780

CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT 840

ACCTGCTTCA AGATTACCCA GTCACCGTG 869

(2) INFORMATION FOR SEQ ID NO: 176:

[i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 872 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 176:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCACT 780

GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG 840

ACTACCTGCT TCAAGATTAC CCAGTCACCG TG 872

(2) INFORMATION FOR SEQ ID NO: 177:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 890 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 177:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCTCA 780

GGGGGAGGTA GTGGTACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA 840

AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 890

(2) INFORMATION FOR SEQ ID NO: 178:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 917 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 780

GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA GGACTGCTCC TTCCAACACA 840

GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG 900

ATTACCCAGT CACCGTG 917

(2) INFORMATION FOR SEQ ID NO: 179:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660

TCCTCAACCC TGGGCGGTGG ATCCGGAGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 720

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 780

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 840

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACT 876

(2) INFORMATION FOR SEQ ID NO: 180:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 879 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 180:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660

TCCTCAACCC TGGGCGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC 720

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 780

TACCCAGTCA CCGTGGCCTC CAACCTGCAG GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 840

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACT 879

(2) INFORMATION FOR SEQ ID NO: 181:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 897 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660

TCCTCAACCC TGGGCGGTGG ATCCGGAGGT GGCTCAGGGG GAGGTAGTGG TACCCAGGAC 720

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 780

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC 840

TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACT 897

(2) INFORMATION FOR SEQ ID NO: 182:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 182:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA 720

GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 780

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 840

TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 900

TGGATGGAGC GGCTCAAGAC T 921

(2) INFORMATION FOR SEQ ID NO: 183:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTACCCAG 600

GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG 660

TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 720

CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT 780

GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC 840

ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTT 876

(2) INFORMATION FOR SEQ ID NO: 184:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 879 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 184:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCACC 600

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 660

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 720

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 780

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 840

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTT 879

(2) INFORMATION FOR SEQ ID NO: 185:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 897 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 185:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGATCCGG AGGTGGCTCA 600

GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 660

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 720

TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 780

TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 840

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTT 897

(2) INFORMATION FOR SEQ ID NO: 186:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 600

GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA 660

CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 720

CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 780

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 840

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 900 CAGCCCCCCC CCAGCTGTCT T 921

(2) INFORMATION FOR SEQ ID NO: 187:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 187:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120 CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180 ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300 TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360 CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420 CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480 CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540 TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC 600 CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 660 CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC 720 CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC 780 AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC 840 TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAG 876

(2) INFORMATION FOR SEQ ID NO: 188:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 879 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTGGCACCCA GGACTGCTCC 600

TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC 660

CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GCTCTGCGGG 720

GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG 780

TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT 840

GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAG 879

(2) INFORMATION FOR SEQ ID NO: 189:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 897 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 189:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT 600 98/17810 fl_j fc PCT/US97/20037

GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 660

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 720

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 780

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 840

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAG 897

(2) INFORMATION FOR SEQ ID NO: 190:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 190:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 600

GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC 660

TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA 720

GTCACCGTGG CCTCCAACCT GCAGGACGAG GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC 780

CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 840

CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 900

AGCTGTCTTC GCTTCGTCCA G 921

(2) INFORMATION FOR SEQ ID NO: 191:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2247 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 191:

GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CCGCCCCGCC 60

ATGTCTACAA ATCAAGATCT GCCTGTGATC AAGTGTGTTT TAATCAATCA TAAGAACAAT 120

GATTCATCAG TGGGGAAGTC ATCATCATAT CCCATGGTAT CAGAATCCCC GGAAGACCTC 180

GGGTGTGCGT TGAGACCCCA GAGCTCAGGG ACAGTGTACG AAGCTGCCGC TGTGGAAGTG 240

GATGTATCTG CTTCCATCAC ACTGCAAGTG CTGGTCGATG CCCCAGGGAA CATTTCCTGT 300

CTCTGGGTCT TTAAGCACAG CTCCCTGAAT TGCCAGCCAC ATTTTGATTT ACAAAACAGA 360

GGAGTTGTTT CCATGGTCAT TTTGAAAATG ACAGAAACCC AAGCTGGAGA ATACCTACTT 420

TTTATTCAGA GTGAAGCTAC CAATTACACA ATATTGTTTA CAGTGAGTAT AAGAAATACC 480

CTGCTTTACA CATTAAGAAG ACCTTACTTT AGAAAAATGG AAAACCAGGA CGCCCTGGTC 540

TGCATATCTG AGAGCGTTCC AGAGCCGATC GTGGAATGGG TGCTTTGCGA TTCACAGGGG 600

GAAAGCTGTA AAGAAGAAAG TCCAGCTGTT GTTAAAAAGG AGGAAAAAGT GCTTCATGAA 660

TTATTTGGGA TGGACATAAG GTGCTGTGCC AGAAATGAAC TGGGCAGGGA ATGCACCAGG 720

CTGTTCACAA TAGATCTAAA TCAAACTCCT CAGACCACAT TGCCACAATT ATTTCTTAAA 780

GTAGGGGAAC CCTTATGGAT AAGGTGCAAA GCTGTTCATG TGAACCATGG ATTCGGGCTC 840

ACCTGGGAAT TAGAAAACAA AGCACTCGAG GAGGGCAACT ACTTTGAGAT GAGTACCTAT 900

TCAACAAACA GAACTATGAT ACGGATTCTG TTTGCTTTTG TATCATCAGT GGCAAGAAAC 960

GACACCGGAT ACTACACTTG TTCCTCTTCA AAGCATCCCA GTCAATCAGC TTTGGTTACC 1020

ATCGTAGAAA AGGGATTTAT AAATGCTACC AATTCAAGTG AAGATTATGA AATTGACCAA 1080

TATGAAGAGT TTTGTTTTTC TGTCAGGTTT AAAGCCTACC CACAAATCAG ATGTACGTGG 1140

ACCTTCTCTC GAAAATCATT TCCTTGTGAG CAAAAGGGTC TTGATAACGG ATACAGCATA 1200

TCCAAGTTTT GCAATCATAA GCACCAGCCA GGAGAATATA TATTCCATGC AGAAAATGAT 1260

GATGCCCAAT TTACCAAAAT GTTCACGCTG AATATAAGAA GGAAACCTCA AGTGCTCGCA 1320

GAAGCATCGG CAAGTCAGGC GTCCTGTTTC TCGGATGGAT ACCCATTACC ATCTTGGACC 1380

TGGAAGAAGT GTTCAGACAA GTCTCCCAAC TGCACAGAAG AGATCACAGA AGGAGTCTGG 1440

AATAGAAAGG CTAACAGAAA AGTGTTTGGA CAGTGGGTGT CGAGCAGTAC TCTAAACATG 1500

AGTGAAGCCA TAAAAGGGTT CCTGGTCAAG TGCTGTGCAT ACAATTCCCT TGGCACATCT 1560

TGTGAGACGA TCCTTTTAAA CTCTCCAGGC CCCTTCCCTT TCATCCAAGA CAACGAATTC 1620

ATCATCCTGG GCCTGTTCGG CCTCCTGCTG TTGCTCACCT GCCTCTGTGG AACTGCCTGG 1680

CTCTGTTGCA GCCCCAACAG GAAGAATCCC CTCTGGCCAA GTGTCCCAGA CCCAGCTCAC 1740

AGCAGCCTGG GCTCCTGGGT GCCCACAATC ATGGAGGAGG ATGCCTTCCA GCTGCCCGGC 1800

CTTGGCACGC CACCCATCAC CAAGCTCACA GTGCTGGAGG AGGATGAAAA GAAGCCGGTG 1860

CCCTGGGAGT CCCATAACAG CTCAGAGACC TGTGGCCTCC CCACTCTGGT CCAGACCTAT 1920 GTGCTCCAGG GGGACCCAAG AGCAGTTTCC ACCCAGCCCC AATCCCAGTC TGGCACCAGC 1980

GATCAGGTCC TTTATGGGCA GCTGCTGGGC AGCCCCACAA GCCCAGGGCC AGGGCACTAT 2040

CTCCGCTGTG ACTCCACTCA GCCCCTCTTG GCGGGCCTCA CCCCCAGCCC CAAGTCCTAT 2100

GAGAACCTCT GGTTCCAGGC CAGCCCCTTG GGGACCCTGG TAACCCCAGC CCCAAGCCAG 2160

GAGGACGACT GTGTCTTTGG GCCACTGCTC AACTTCCCCC TCCTGCAGGG GATCCGGGTC 2220

CATGGGATGG AGGCGCTGGG GAGCTTC 2247

(2) INFORMATION FOR SEQ ID NO: 192:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1047 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 660

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 720

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 780

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840

TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 900

CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 960

CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 1020

CAGTGTCAGC CCGACTCCTC AACCCTG 1047

(2) INFORMATION FOR SEQ ID NO: 193:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 942 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

GCCACTCAGG ACTGCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420

TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC 480

CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACCCA GGACTGCTCC 540

TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAAA TCCGTGAGCT GTCTGACTAC 600

CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GCTCTGCGGG 660

GGCCTCTGGC GGCTGGTCCT GGCACAGCGC TGGATGGAGC GGCTCAAGAC TGTCGCTGGG 720

TCCAAGATGC AAGGCTTGCT GGAGCGCGTG AACACGGAGA TACACTTTGT CACCAAATGT 780

GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC TTCGTCCAGA CCAACATCTC CCGCCTCCTG 840

CAGGAGACCT CCGAGCAGCT GGTGGCGCTG AAGCCCTGGA TCACTCGCCA GAACTTCTCC 900

CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC TCCTCAACCC TG 942

(2) INFORMATION FOR SEQ ID NO: 194:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1047 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 194:

GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCATGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420

TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC 480

CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACACC ATTAGGCCCT 540

GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTGCTTAG AGCAAGTGAG GAAGATCCAG 600

GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG 660

GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 720

AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 780

CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 840

CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 900

ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 960

CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 1020

CGCGTTTTAC GCCACCTTGC GCAGCCC 1047

(2) INFORMATION FOR SEQ ID NO: 195:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1569 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCC ACTCAGGACT GCTCTTTTCA ACACAGCCCC 660

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 720

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 780

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840

TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 900

CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 960

CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 1020

CAGTGTCAGC CCGACTCCTC AACCCTGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 1080

CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 1140

CCAAACATGG CTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 1200

GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 1260

AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 1320

ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 1380

ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 1440

GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 1500

CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 1560

TCAACCCTG 1569

(2) INFORMATION FOR SEQ ID NO: 196:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1380 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 196:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120

CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCTGTCAAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACTCAGGAC TGCTCTTTTC AACACAGCCC CATCTCCTCC 480

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 540 GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 600

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 660

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 720

CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 780

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 840

CCCGACTCCT CAACCCTGTA CGTAGAGGGC GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT 900

CCAATCTCTA CTATCAACCC GTCTCCTCCG TCTAAAGAAT CTCATAAATC TCCAAACATG 960

GCTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 1020

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1080

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 1140

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 1200

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 1260

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 1320

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 1380

(2) INFORMATION FOR SEQ ID NO: 197:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1569 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 197:

GCCACTCAGG ACTGCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120 GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240 CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300 AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360 ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 1569 420 TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GAACCGTCTG GTCCAATCTC TACTATCAAC 480 CCGTCTCCTC CGTCTAAAGA ATCTCATAAA TCTCCAAACA TGGCTACACC ATTGGGCCCT 540 GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC AAGTCTTTAG AGCAAGTGAG AAAGATCCAG 600 GGCGATGGCG CAGCGCTCCA GGAGAAGCTG TGTGCCACCT ACAAGCTGTG CCACCCCGAG 660 GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC 720 AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC ATAGCGGCCT TTTCCTCTAC 780 CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT TGGGTCCCAC CTTGGACACA 840 CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC AGCAGATGGA AGAACTGGGA 900 ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG CCTTCGCCTC TGCTTTCCAG 960 CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA GCTTCCTGGA GGTGTCGTAC 1020 CGCGTTCTAC GCCACCTTGC GCAGCCCTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 1080 CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 1140 CCAAACATGG CTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 1200 GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 1260 AACCTGCAGG ACGAGGAGCT CTGCGGGGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG 1320 ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 1380 ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 1440 GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 1500 CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 1560 TCAACCCTG 1569

(2) INFORMATION FOR SEQ ID NO: 198:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1003 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 198:

GGCCACTCAG GACTGCTCTT TTCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT 60

CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA 120

GGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG 180

GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT 240

ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAGAC 300

CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG GTGGCGCTGA AGCCCTGGAT 360

CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT CAGCCCGACT CCTCAACCCT 420

GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGGTGGTTCT GGCGGCGGCT CCAACATGGC 480

TACACCATTG GGCCCTGCCA GCTCCCTGCC CCAGAGCTTC CTGCTCAAGT CTTTAGAGCA 540

AGTGAGAAAG ATCCAGGGCG ATGGCGCAGC GCTCCAGGAG AAGCTGTGTG CCACCTACAA 600

GCTGTGCCAC CCCGAGGAGC TGGTGCTGCT CGGACACTCT CTGGGCATCC CCTGGGCTCC 660 βo

CCTGAGCTCC TGCCCCAGCC AGGCCCTGCA GCTGGCAGGC TGCTTGAGCC AACTCCATAG 720 CGGCCTTTTC CTCTACCAGG GGCTCCTGCA GGCCCTGGAA GGGATATCCC CCGAGTTGGG 780 TCCCACCTTG GACACACTGC AGCTGGACGT CGCCGACTTT GCCACCACCA TCTGGCAGCA 840 GATGGAAGAA CTGGGAATGG CCCCTGCCCT GCAGCCCACC CAGGGTGCCA TGCCGGCCTT 900 CGCCTCTGCT TTCCAGCGCC GGGCAGGAGG GGTCCTGGTT GCTAGCCATC TGCAGAGCTT 960 CCTGGAGGTG TCGTACCGCG TTCTACGCCA CCTTGCGCAG CCG 1003

(2) INFORMATION FOR SEQ ID NO: 199:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780

GGGTCAGGAG GTGGATCCGG AGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 840

TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAA 888

(2) INFORMATION FOR SEQ ID NO: 200:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 200:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 540

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 600

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 660

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 720

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 780

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA 840

CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 900

CAA 903

(2) INFORMATION FOR SEQ ID NO: 201:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240 CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC 780

GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 840

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTG 888

(2) INFORMATION FOR SEQ ID NO: 202:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 202:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAAGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 480

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 540

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 600

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 660

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 720

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 780

GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 840

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 900

GTG 903

(2) INFORMATION FOR SEQ ID NO: 203:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 203:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGATCCGGAG GTACCCAGGA CTGCTCCTTC 720

CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 780

CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGG ACGAGGAGCT CTGCGGGGGC 840

CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACT 888

(2) INFORMATION FOR SEQ ID NO: 204:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 204: £2>

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 480

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 540

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 600

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 660

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCACC 720

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 780

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 840

GAGCTCTGCG GGGGCCTCTG GCGGCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 900

ACT 903

(2) INFORMATION FOR SEQ ID NO: 205:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGATCC 600

GGAGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 660

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 720

CAGGACGAGG AGCTCTGCGG GGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 780

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 840

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTT 888

(2) INFORMATION FOR SEQ ID NO: 206:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 206:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 480

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 540

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 600

GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 660

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 720

GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 780

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 840

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 900

CTT 903

(2) INFORMATION FOR SEQ ID NO: 207:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 888 base pairs (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 207:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAAGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGATCCGG AGGTACCCAG 600

GACTGCTCCT TCCAACACAG CCCCATCTCC TCCGACTTCG CTGTCAAAAT CCGTGAGCTG 660

TCTGACTACC TGCTTCAAGA TTACCCAGTC ACCGTGGCCT CCAACCTGCA GGACGAGGAG 720

CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG GCACAGCGCT GGATGGAGCG GCTCAAGACT 780

GTCGCTGGGT CCAAGATGCA AGGCTTGCTG GAGCGCGTGA ACACGGAGAT ACACTTTGTC 840

ACCAAATGTG CCTTTCAGCC CCCCCCCAGC TGTCTTCGCT TCGTCCAG 888

(2) INFORMATION FOR SEQ ID NO: 208:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 208:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 480

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 540

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 600

GGAGGTGGCA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 660

AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 720

CTGCAGGACG AGGAGCTCTG CGGGGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 780

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 840

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 209:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TTCTAATCTG CAAGATGAAG AGCTGTGCGG GGGCCTCTGG 480

CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 540

CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 600

CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 660

TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 720

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 780

GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC 840

AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 900 GATTACCCAG TCACCGTGGC C 921 (2) INFORMATION FOR SEQ ID NO: 210:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC CAACCTGCAA GATGAAGAGC TGTGTGGGGG CCTCTGGCGG 480

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 540

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 600

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 660

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 720

CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 780

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 840

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 900

TACCCAGTCA CCGTGGCCTC C 921

(2) INFORMATION FOR SEQ ID NO: 211:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 211:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TCTGCAGGAT GAGGAACTGT GCGGCGGCCT CTGGCGGCTG 480

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 540

TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCTTT TCAGCCCCCC 600

CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 660

CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 720

CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC AGGAGGTGGA 780

TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 840

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 900

CCAGTCACCG TGGCCTCCAA C 921

(2) INFORMATION FOR SEQ ID NO: 212:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 212:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TCAAGATGAA GAGCTGTGTG GTGGTCTCTG GCGGCTGGTC 480 CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 540

CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 600

AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 660

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 720

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 780

GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC 840

TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA 900

GTCACCGTGG CCTCCAACCT G 921

(2) INFORMATION FOR SEQ ID NO: 213:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TGAAGAACTG TGTGGTGGTC TGTGGCGGCT GGTCCTGGCA 480

CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 540

CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 600

CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 660

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 720

CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT 780

GGCTCAGGGG GAGGTAGTGG TACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 840

GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAAGATTA CCCAGTCACC 900

GTGGCCTCCA ACCTGCAGGA C 921

(2) INFORMATION FOR SEQ ID NO: 214:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 214:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TGAGCTGTGT GGTGGCCTGT GGCGTCTGGT CCTGGCACAG 480

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 540

GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 600

CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 660

CTGAAGCCCT GGATCACTCG CCAAAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 720

GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC 780

TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 840

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 900

GCCTCCAACC TGCAGGACGA G 921

(2) INFORMATION FOR SEQ ID NO: 215:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215: GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60 TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TCTGTGCGGT GGTCTGTGGC GTCTGGTCCT GGCACAGCGC 480

TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 540

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 600

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 660

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 720

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA 780

GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 840

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 900

TCCAACCTGC AGGACGAGGA G 921

(2) INFORMATION FOR SEQ ID NO: 216:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TTCTAATCTG CAAGATGAAG AGCTGTGCGG GGGCCTCTGG 480

CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 540

CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 600

CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 660

TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 720

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 780

GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC 840

AGCCCCATCT CCTCCGACTC CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 900

GATTACCCAG TCACCGTGGC C 921

(2) INFORMATION FOR SEQ ID NO: 217:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 217:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TCAAGATGAA GAACTGTGCG GTGGTCTCTG GCGGCTGGTC 480

CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 540

CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 600

AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCGGGAGAC CTCCGAGCAG 660

CCGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 720

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 780

GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC 840

TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA 900

GTCACCGTGG CCTCCAACCT G 921

(2) INFORMATION FOR SEQ ID NO: 218:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid Li ≤

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTAACCCT 60

TTGCTGGACC CGAACAACCT CAATTCTGAA GACATGGATA TCCTGATGGA ACGAAACCTT 120

CGAACTCCAA ACCTGCTCGC ATTCGTAAGG GCTGTCAAGC ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TCTGTGCGGT GGTCTGTGGC GTCTGGTCCT GGCACAGCGC 480

TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 540

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 600

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 660

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCGGCCCGAC 720

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA 780

GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 840

GCTGTCAAGA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 900

TCCAACCTGC AGGACGAGGA G 921

(2) INFORMATION FOR SEQ ID NO: 219:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 906 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGTA CGTAGAGGGC 480

GGTGGAGGCT CCCCGGGTGA ACCGTCTGGT CCAATCTCTA CTATCAACCC GTCTCCTCCG 540

TCTAAAGAAT CTCATAAATC TCCAAACATG GCTAACTGCT CTATAATGAT CGATGAAATT 600

ATACATCACT TAAAGAGACC ACCTAACCCT TTGCTGGACC CGAACAACCT CAATTCTGAA 660

GACATGGATA TCCTGATGGA ACGAAACCTT CGAACTCCAA ACCTGCTCGC ATTCGTAAGG 720

GCTGTCAAGC ACTTAGAAAA TGCATCAGGT ATTGAGGCAA TTCTTCGTAA TCTCCAACCA 780

TGTCTGCCCT CTGCCACGGC CGCACCCTCT CGACATCCAA TCATCATCAA GGCAGGTGAC 840

TGGCAAGAAT TCCGGGAAAA ACTGACGTTC TATCTGGTTA CCCTTGAGCA AGCGCAGGAA 900

CAACAG 906

(2) INFORMATION FOR SEQ ID NO: 220:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 888 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 220:

GCGGATGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAGGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG ACTGCTCCTT CCAACACAGC 360

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 420

TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 480

GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 540

TCTCCAAACA TGGCTAACTG CTCTATAATG ATCGATGAAA TTATACATCA CTTAAAGAGA 600

CCACCTAACC CTTTGCTGGA CCCGAACAAC CTCAATTCTG AAGACATGGA TATCCTGATG 660

GAACGAAACC TTCGAACTCC AAACCTGCTC GCATTCGTAA GGGCTGTCAA GCACTTAGAA 720

AATGCATCAG GTATTGAGGC AATTCTTCGT AATCTCCAAC CATGTCTGCC CTCTGCCACG 780

GCCGCACCCT CTCGACATCC AATCATCATC AAGGCAGGTG ACTGGCAAGA ATTCCGGGAA 840

AAACTGACGT TCTATCTGGT TACCCTTGAG CAAGCGCAGG AACAACAG 888 (2) INFORMATION FOR SEQ ID NO: 221:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 222:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 222:

GCAGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 223:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 223:

GCGGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCCTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CCTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CA.TCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 224:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 224:

GCGGATGAGG AGCTGTGTGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGGG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 225:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 904 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:

GGCCGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT 60

CTGGCGGCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA 120

GATGCAAGGC TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT 180

TCAGCCCCCC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA 240

GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG 300

CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC 360

AGGAGGTGGA TCCGGAGGTG GCACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC 420

CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAATACG TAGAGGGCGG 480

TGGAGGCTCC CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC 540

TAAAGAATCT CATAAATCTC CAAACATGGC TAACTGCTCT ATAATGATCG ATGAAATTAT 600

ACATCACTTA AAGAGACCAC CTAACCCTTT GCTGGACCCG AACAACCTCA ATTCTGAAGA 660

CATGGATATC CTGATGGAAC GAAACCTTCG AACTCCAAAC CTGCTCGCAT TCGTAAGGGC 720

TGTCAAGCAC TTAGAAAATG CATCAGGTAT TGAGGCAATT CTTCGTAATC TCCAACCATG 780

TCTGCCCTCT GCCACGGCCG CACCCTCTCG ACATCCAATC ATCATCAAGG CAGGTGACTG 840

GCAAGAATTC CGGGAAAAAC TGACGTTCTA TCTGGTTACC CTTGAGCAAG CGCAGGAACA 900

ACAG 904

(2) INFORMATION FOR SEQ ID NO: 226:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

GCCGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 60 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 120 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 180

CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 240

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 300

CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT 360

GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 420

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 227:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 227:

GCCGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 60

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 120

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 180

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 240

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA 300

CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 360

CAGGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 420

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 228:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60

TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120

CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180

TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240

GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 229:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 229:

GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60

TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 180

GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 240

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 300

GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 360

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 420

GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 230:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

GCCACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 60 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 120 ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC 180 TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTYGCTG TCAAAATCCG TGAGCTGTCT 240 GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC 300 TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC 360 GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC 420 AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600 CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660 ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720 GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780 CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840 CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900 CAG 903

(2) INFORMATION FOR SEQ ID NO: 231:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 231:

GCCCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 60

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 120

CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT 180

GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 240

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 300

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 360

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AACGCGTGAA CACGGAGATA 420

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTTTTTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903 (2) INFORMATION FOR SEQ ID NO: 232:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

GCTTCAAATC TGCAGGATGA AGAGCTGTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 60

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 120

GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 180

CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 240

CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 300

GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC 360

TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 420

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 480

GCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 233:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:

GCTAATCTGC AAGATGAGGA GCTGTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 60

TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 120

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 180

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 240

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 300

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA 360

GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 420

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 480

TCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

GCGCTGCAGG ATGAAGAGCT GTGTGGCGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTTG 60

ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 120

ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 180

GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 240

CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 300

TCAACCCTGG GCGGTGGGTC AGGAGGTGGG TCAGGAGGTG GATCCGGAGG TGGCTCAGGG 360

GGAGGTAGTG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 420

GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 480

AACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 235:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 235:

GCGCAAGATG AGGAACTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300

ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA 360

GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420

AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480

CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CCCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 236:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 236:

GCTGAAGAAC TGTGTGGTGG CCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 60

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 120

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 180

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 240

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 300

GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT 360

GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 420

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 480

GACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 237:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

GCTCTGTGCG GTGGCCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120 έ4

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 300

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 420

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 238:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 238:

GCACTGTGTG GTGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 300

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 420

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 239:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

GCTCTGTGTG GCGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT 300

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA GATCCGTGAG 420

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600

ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660

AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720

CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780

CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840

ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900

GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 240:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 240:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60

TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120

CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180

TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240

GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903

(2) INFORMATION FOR SEQ ID NO: 241:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 945 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 241:

GCTCAAGATG ATGAGCTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300

ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGCGGTGGTT CTGGCGGAGG ATCCGGCGGC 360

GGAAGCGGAG GTGGCTCTGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 420

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 480

TACCCAGTCA CCGTGGCCTC CAACCTGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540

CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600

CCAAACATGG CTAACTGCTC TATAATGATC GATGAAATTA TACATCACTT AAAGAGACCA 660

CCTAACCCTT TGCTGGACCC GAACAACCTC AATTCTGAAG ACATGGATAT CCTGATGGAA 720

CGAAACCTTC GAACTCCAAA CCTGCTCGCA TTCGTAAGGG CTGTCAAGCA CTTAGAAAAT 780

GCATCAGGTA TTGAGGCAAT TCTTCGTAAT CTCCAACCAT GTCTGCCCTC TGCCACGGCC 840

GCACCCTCTC GACATCCAAT CATCATCAAG GCAGGTGACT GGCAAGAATT CCGGGAAAAA 900

CTGACGTTCT ATCTGGTTAC CCTTGAGCAA GCGCAGGAAC AACAG 945

(2) INFORMATION FOR SEQ ID NO: 242:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 903 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:242:

GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300

ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CACCCAGGAC 360

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 420

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAG 903 (2) INFORMATION FOR SEQ ID NO:243:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 921 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 243:

GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60 GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180 CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240 TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300 ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CGCTGGACAA 360 CCGCCTCTGA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420 AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480 CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540 AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAA CTGCTCTATA 600 ATGATCGATG AAATTATACA TCACTTAAAG AGACCACCTA ACCCTTTGCT GGACCCGAAC 660 AACCTCAATT CTGAAGACAT GGATATCCTG ATGGAACGAA ACCTTCGAAC TCCAAACCTG 720 CTCGCATTCG TAAGGGCTGT CAAGCACTTA GAAAATGCAT CAGGTATTGA GGCAATTCTT 780 CGTAATCTCC AACCATGTCT GCCCTCTGCC ACGGCCGCAC CCTCTCGACA TCCAATCATC 840 ATCAAGGCAG GTGACTGGCA AGAATTCCGG GAAAAACTGA CGTTCTATCT GGTTACCCTT 900 GAGCAAGCGC AGGAACAACA G 921

(2) INFORMATION FOR SEQ ID NO: 244:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 244:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 660

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900

CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 1020

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080

TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1110

(2) INFORMATION FOR SEQ ID NO: 245:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 245:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCA AATCTGCAAG ACGAGGAGCT GTGCGGGGGC 660

CTCTGGCGGC TGGTCCTGGC ACAGCGCTGG ATGGAGCGGC TCAAGACTGT CGCTGGGTCC 720

AAGATGCAAG GCTTGCTGGA GCGCGTGAAC ACGGAGATAC ACTTTGTCAC CAAATGTGCC 780

TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC GTCCAGATCA ACATCTCCCG CCTCCTGCAG 840

GAGACCTCCG AGCAGCTGGT GGCGCTGAAG CCCTGGATCA CTCGCCAGAA CTTCTCCCGG 900

TGCCTGGAGC TGCAGTGTCA GCCCGACTCC TCAACCCTGG GCGGTGGGTC AGGAGGTGGG 960

TCAGGAGGTG GATCCGGAGG TGGCTCAGGG GGAGGTAGTG GTACCCAGGA CTGCTCCTTC 1020

CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 1080

CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 1110

(2) INFORMATION FOR SEQ ID NO: 246:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 660

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 720

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 780

GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT 840

GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 900

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 960

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 1020

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 1080

CACTTTGTCA CCAAATGTGC CTTTCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 247:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 247:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT CTGCAGGATG AGGAACTGTG CGGCGGCCTC 660

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 720

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 780

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 840

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 900

CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 960

GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA GGTAGTGGTA CCCAGGACTG CTCCTTCCAA 1020

CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 1080

CAAGATTACC CAGTCACCGT GGCCTCCAAC 1110

(2) INFORMATION FOR SEQ ID NO: 248: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 248:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT CAAGATGAAG AGCTGTGTGG TGGTCTCTGG 660

CGGCTGGTCC TGGCACAGCG CTGGATGGAG CGGCTCAAGA CTGTCGCTGG GTCCAAGATG 720

CAAGGCTTGC TGGAGCGCGT GAACACGGAG ATACACTTTG TCACCAAATG TGCCTTTCAG 780

CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 840

TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 900

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 960

GGTGGATCCG GAGGTGGCTC AGGGGGAGGT AGTGGTACCC AGGACTGCTC CTTCCAACAC 1020

AGCCCCATCT CCTCCGACTT CGCTGTCAAA ATCCGTGAGC TGTCTGACTA CCTGCTTCAA 1080

GATTACCCAG TCACCGTGGC CTCCAACCTG 1110

(2) INFORMATION FOR SEQ ID NO: 249:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 249:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GAAGAACTGT GTGGTGGTCT GTGGCGGCTG 660

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 720

TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 780

CCCAGCTGTC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 840

CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 900

CAGTGTCAGC CCGACTCCTC AACCCTGGGC GGTGGGTCAG GAGGTGGGTC AGGAGGTGGA 960

TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 1020

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 1080

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC 1110

(2) INFORMATION FOR SEQ ID NO: 250:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:250:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300 GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GAGCTGTGTG GTGGCCTGTG GCGTCTGGTC 660

CTGGCACAGC GCTGGATGGA GCGGCTCAAG ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG 720

CTGGAGCGCG TGAACACGGA GATACACTTT GTCACCAAAT GTGCCTTTCA GCCCCCCCCC 780

AGCTGTCTTC GCTTCGTCCA GACCAACATC TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG 840

CTGGTGGCGC TGAAGCCCTG GATCACTCGC CAGAACTTCT CCCGGTGCCT GGAGCTGCAG 900

TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT GGGTCAGGAG GTGGGTCAGG AGGTGGATCC 960

GGAGGTGGCT CAGGGGGAGG TAGTGGTACC CAGGACTGCT CCTTCCAACA CAGCCCCATC 1020

TCCTCCGACT TCGCTGTCAA AATCCGTGAG CTGTCTGACT ACCTGCTTCA AGATTACCCA 1080

GTCACCGTGG CCTCCAACCT GCAGGACGAG 1110

(2) INFORMATION FOR SEQ ID NO: 251:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:251:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT CTGTGCGGTG GTCTGTGGCG TCTGGTCCTG 660

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 720

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 780

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 840

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 900

CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 960

GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 1020

TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 1080

ACCGTGGCCT CCAACCTGCA GGACGAGGAG 1110

(2) INFORMATION FOR SEQ ID NO: 252:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 252:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG GCTGTGGCGG 660

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900

CTGCAGTGTC AGCCCGACTC CTCAACCCTG CCGCCACCGT GGAGCCCGCG TCCACTCGGC 960

GCCACCGCAC CGACCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 1020

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 1080

TCCAACCTGC AG 1092 (2) INFORMATION FOR SEQ ID NO: 253:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1134 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:253:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG GCTGTGGCGG 660

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900

CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGCGGT 960

GGTTCTGGCG GAGGATCCGG CGGCGGAAGC GGAGGTGGCT CTGGGGGAGG TAGTGGTACC 1020

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 1080

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAG 1134

(2) INFORMATION FOR SEQ ID NO: 254:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 254:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG GCTGTGGCGG 660

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900

CTGCAGTGTC AGCCCGACTC CTCAACCCTG CCGCCACCGT GGAGCCCGCG TCCACTCGGC 960

GCCACCGCAC CGACCGCTGG ACAACCGCCT CTGACCCAGG ACTGCTCCTT CCAACACAGC 1020

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080

TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1110

(2) INFORMATION FOR SEQ ID NO: 255:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:255:

GCCGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 60

TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACTGTCGC TGGGTCCAAG 120

ATGCAAGGCT TGCTGGAGCG CGTGAACACG GAGATACACT TTGTCACCAA ATGTGCCTTT 180

CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC CAGACCAACA TCTCCCGCCT CCTGCAGGAG 240 -?

ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC TGGATCACTC GCCAGAACTT CTCCCGGTGC 300 CTGGAGCTGC AGTGTCAGCC CGACTCCTCA ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA 360 GGAGGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AACACAGCCC CATCTCCTCC 420 GACTTCGCTG TCAAAATCCG TGAGCTGTCT GACTACCTGC TTCAA 465

(2) INFORMATION FOR SEQ ID NO: 256:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID O: 256 :

GCCGCCTCCA ACCTGCAGGA CGAGGAGCTC TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA 60 CAGCGCTGGA TGGAGCGGCT CAAGACTGTC GCTGGGTCCA AGATGCAAGG CTTGCTGGAG 120 CGCGTGAACA CGGAGATACA CTTTGTCACC AAATGTGCCT TTCAGCCCCC CCCCAGCTGT 180 CTTCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 240 GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 300 CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT 360 GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 420 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTG 465

(2) INFORMATION FOR SEQ ID NO: 257:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 257:

GCCGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 60 GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 120 TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 180 CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 240 GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCA CCCAGGACTG CTCCTTCCAA 300 CACAGCCCCA TCTCCTCCGA CTTCGCTGTC AAAATCCGTG AGCTGTCTGA CTACCTGCTT 360 CAAGATTACC CAGTCACCGT GGCCTCCAAC CTGCAGGACG AGGAGCTCTG CGGGGGCCTC 420 TGGCGGCTGG TCCTGGCACA GCGCTGGATG GAGCGGCTCA AGACT 465

(2) INFORMATION FOR SEQ ID NO: 258:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 258:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60 TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240 GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGG 465

(2) INFORMATION FOR SEQ ID NO: 259:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 259: GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 180

GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 240

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 300

GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 360

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 420

GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCC 465

(2) INFORMATION FOR SEQ ID NO: 260:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 260:

GCCCGCTTCG TCCAGACCAA CATCTCCCGC CTCCTGCAGG AGACCTCCGA GCAGCTGGTG 60

GCGCTGAAGC CCTGGATCAC TCGCCAGAAC TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG 120

CCCGACTCCT CAACCCTGGG CGGTGGGTCA GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT 180

GGCACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 240

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 300

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 360

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 420

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTT 465

(2) INFORMATION FOR SEQ ID NO: 261:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 465 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:261:

GCCACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 60

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 120

ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC 180

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 240

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC 300

TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC 360

GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC 420

AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAG 465

(2) INFORMATION FOR SEQ ID NO: 262:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 262:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTGGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 263:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 263:

GCAGATGAAG AACTGTGTGG GGGACTGTGG CGTCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 264:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1062 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 264:

GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGCCGCCAC CGTGGAGCCC GCGTCCACTC GGCGCCACCG CACCGACCGC TGGACAACCG 360

CCTCTGACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 540

ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 600

GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG 660

CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 720

CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 780

GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 840

CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 900

ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 960

GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 1020

CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG 1062

(2) INFORMATION FOR SEQ ID NO: 265:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1089 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 265:

GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180 ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA 360

AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 420

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 480

CCAGTCACCG TGGCCTCCAA CCTGCAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGGT 540

GGTTCTGGCG GCGGCTCCAA CATGGCTACA CCATTGGGCC CTGCCAGCTC CCTGCCCCAG 600

AGCTTCCTGC TCAAGTCTTT AGAGCAAGTG AGGAAGATCC AGGGCGATGG CGCAGCGCTC 660

CAGGAGAAGC TGTGTGCCAC CTACAAGCTG TGCCACCCCG AGGAGCTGGT GCTGCTCGGA 720

CACTCTCTGG GCATCCCCTG GGCTCCCCTG AGCTCCTGCC CCAGCCAGGC CCTGCAGCTG 780

GCAGGCTGCT TGAGCCAACT CCATAGCGGC CTTTTCCTCT ACCAGGGGCT CCTGCAGGCC 840

CTGGAAGGGA TATCCCCCGA GTTGGGTCCC ACCTTGGACA CACTGCAGCT GGACGTCGCC 900

GACTTTGCCA CCACCATCTG GCAGCAGATG GAAGAACTGG GAATGGCCCC TGCCCTGCAG 960

CCCACCCAGG GTGCCATGCC GGCCTTCGCC TCTGCTTTCC AGCGCCGGGC AGGAGGGGTC 1020

CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT ACGCCACCTT 1080

GCGCAGCCG 1089

(2) INFORMATION FOR SEQ ID NO: 266:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1044 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:266:

GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGCCGCCAC CGTGGAGCCC GCGTCCACTC GGCGCCACCG CACCGACCAC CCAGGACTGC 360

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGTACGTAGA GGGCGGTGGA 480

GGCTCCCCGG GTGGTGGTTC TGGCGGCGGC TCCAACATGG CTACACCATT GGGCCCTGCC 540

AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGRAA GATCCAGGGC 600

GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG 660

CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC 720

CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG 780

GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GTCCCACCTT GGACACACTG 840

CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGAATG 900

GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC 960

CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGT GTCGTACCGC 1020

GTTCTACGCC ACCTTGCGCA GCCG 1044

(2) INFORMATION FOR SEQ ID NO: 267:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1077 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:267:

GCGGATGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAGGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGATCCGGA GGTACCCAGG ACTGCTCCTT CCAACACAGC 360

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 420

TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 480

GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 540

TCTCCAAACA TGGCTACACC ATTAGGCCCT GCCAGCTCCC TGCCCCAGAG CTTCCTGCTC 600

AAGTGCTTAG AGCAAGTGAG GAAGATCCAG GGCGATGGCG CAGCGCTCCA GGAGAAGCTG 660

TGTGCCACCT ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC 720

ATCCCCTGGG CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG 780

AGCCAACTCC ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA 840

TCCCCCGAGT TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC 900

ACCATCTGGC AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT 960

GCCATGCCGG CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC 1020

CATCTGCAGA GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCC 1077 (2) INFORMATION FOR SEQ ID NO: 268:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 268:

GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCAC CCAGGACTGC 360

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600

CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660

CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020

GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080

CTTGCGCAGC CC 1092

(2) INFORMATION FOR SEQ ID NO: 269:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:269:

GCAGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTG TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 270:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 270:

GCCCCCCCCA GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC 60

TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG 120

GAGCTGCAGT GTCAGCCCGA CTCCTCAACC CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA 180

GGTGGATCCG GAGGTGGCAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 240 TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 300

GCCTCCAACC TGCAGGACGA GGAGCTCTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 360

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 420

GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCGTGCCC 600

CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660

CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020

GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TATACGCCAC 1080

CTTGCGCAGC CC 1092

(2) INFORMATION FOR SEQ ID NO: 271:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:271:

GCTTCAAATC TGCAGGATGA AGAGCTGTGC GGGGGCCTCT GGCGGCTGGT CCTGGCACAG 60

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 120

GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 180

CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 240

CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 300

GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC 360

TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 420

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 480

GCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC ATCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 272:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 272:

GCTAATCTGC AAGATGAGGA GCTGTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 60

TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 120

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 180

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 240

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 300

TCCTCAACCC TGGGCGGTGG GTCAGGAGGT GGGTCAGGAG GTGGATCCGG AGGTGGCTCA 360

GGGGGAGGTA GTGGTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 420

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 480

TCCTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTA TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 273:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:273:

GCGCTGCAGG ATGAAGAGCT GTGTGGCGGC CTCTGGCGGC TGGTCCTGGC ACAGCGCTTG 60

ATGGAGCGGC TCAAGACTGT CGCTGGGTCC AAGATGCAAG GCTTGCTGGA GCGCGTGAAC 120

ACGGAGATAC ACTTTGTCAC CAAATGTGCC TTTCAGCCCC CCCCCAGCTG TCTTCGCTTC 180

GTCCAGACCA ACATCTCCCG CCTCCTGCAG GAGACCTCCG AGCAGCTGGT GGCGCTGAAG 240

CCCTGGATCA CTCGCCAGAA CTTCTCCCGG TGCCTGGAGC TGCAGTGTCA GCCCGACTCC 300

TCAACCCTGG GCGGTGGGTC AGGAGGTGGG TCAGGAGGTG GATCCGGAGG TGGCTCAGGG 360

GGAGGTAGTG GTACCCAGGA CTGCTCCTTC CAACACAGCC CCATCTCCTC CGACTTCGCT 420

GTCAAAATCC GTGAGCTGTC TGACTACCTG CTTCAAGATT ACCCAGTCAC CGTGGCCTCC 480

AACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 274:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 274:

GCACTGTGCG GTGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240

CAGAACTTCT CCCGGTGCCT GGAGCTACAG TGTCAGCCCG ACTCCTCAAC CCTGGGCGGT 300

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCGACT TCGCTGTCAA AATCCGTGAG 420

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 275:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:275:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60

TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120

CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240

GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600

CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660

CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020

GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080

CTTGCGCAGC CC 1092

(2) INFORMATION FOR SEQ ID NO: 276:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 276:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60

TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120

CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180

TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240

GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360

CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600

CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660

CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020

GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080

CTTGCGCAGC CC 1092

(2) INFORMATION FOR SEQ ID NO: 277:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 277:

GCGCTGTGTG GTGGTCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120

GTCACCAAAT GTGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT 300

GGGTCAGGAG GTGGGTCAGG AGGTGGATCC GGAGGTGGCT CAGGGGGAGG TAGTGGTACC 360

CAGGACTGCT CCTTCCAACA CAGCCCCATC TCCTCCAACT TCGCTGTCAA GATCCGTGAG 420

CTGTCTGACT ACCTGCTTCA AGATTACCCA GTCACCGTGG CCTCCAACCT GCAGGACGAG 480

GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT TTTTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080 TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110 (2) INFORMATION FOR SEQ ID NO: 278:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:278:

GCTGAACTGT GTGGTGGTCT GTGGCGTCTG GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC 60

AAGACTGTCG CTGGGTCCAA GATGCAAGGC TTGCTGGAGC GCGTGAACAC GGAGATACAC 120

TTTGTCACCA AATGTGCCTT TCAGCCCCCC CCCAGCTGTC TTCGCTTCGT CCAGACCAAC 180

ATCTCCCGCC TCCTGCAGGA GACCTCCGAG CAGCTGGTGG CGCTGAAGCC CTGGATCACT 240

CGCCAGAACT TCTCCCGGTG CCTGGAGCTG CAGTGTCAGC CCGACTCCTC AACCCTGGGC 300

GGTGGGTCAG GAGGTGGGTC AGGAGGTGGA TCCGGAGGTG GCTCAGGGGG AGGTAGTGGT 360

ACCCAGGACT GCTCCTTCCA ACACAGCCCC ATCTCCTCCG ACTTCGCTGT CAAAATCCGT 420

GAGCTGTCTG ACTACCTGCT TCAAGATTAC CCAGTCACCG TGGCCTCCAA CCTGCAGGAC 480

GAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 279:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 279:

GCTGAAGAAC TGTGTGGTGG CCTGTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 60

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 120

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 180

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 240

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 300

GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT GGATCCGGAG GTGGCTCAGG GGGAGGTAGT 360

GGTACCCAGG ACTGCTCCTT CCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 420

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 480

GACTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 280:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 280:

GCTCAGGACG AGGAACTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120 /17810 L _/,, O9nD PCT7US97/20037

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300

ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA 360

GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420

AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480

CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 281:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:281:

GCCACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 60

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 120

ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CACCCAGGAC 180

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTTGCTG TCAAAATCCG TGAGCTGTCT 240

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGCAGGA CGAGGAGCTC 300

TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC 360

GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC 420

AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600

CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660

CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020

GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080

CTTGCGCAGC CC 1092

(2) INFORMATION FOR SEQ ID NO: 282:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1065 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 282:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 600

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 660

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 720

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 780

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 840

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 900

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 960

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 1020 TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 1065 (2) INFORMATION FOR SEQ ID NO: 283:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:283:

GCTCAAGATG AAGAACTGTG CGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300

ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGCGGAT CCGGAGGTGG CTCAGGGGGA 360

GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTCCGCTGTC 420

AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480

CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 284:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1098 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:284:

GCGCTGTGTG GTGGCCTGTG GCGTCTGGTC CTGGCACAGC GCTGGATGGA GCGGCTCAAG 60

ACTGTCGCTG GGTCCAAGAT GCAAGGCTTG CTGGAGCGCG TGAACACGGA GATACACTTT 120

GTCACCAAAT ATGCCTTTCA GCCCCCCCCC AGCTGTCTTC GCTTCGTCCA GACCAACATC 180

TCCCGCCTCC TGCAGGAGAC CTCCGAGCAG CTGGTGGCGC TGAAGCCCTG GATCACTCGC 240

CAGAACTTCT CCCGGTGCCT GGAGCTGCAG TGTCGGCCCG ACTCCTCAAC CCTGGGCGGT 300

GGGTCAGGAG GTGGATCCGG AGGTGGCTCA GGGGGAGGTA GTGGTACCCA GGACTGCTCC 360

TTCCAACACA GCCCCATCTC CTCCGACTTC GCTGTCAAGA TCCGTGAGCT GTCTGACTAC 420

CTGCTTCAAG ATTACCCAGT CACCGTGGCC TCCAACCTGC AGGACGAGGA GTACGTAGAG 480

GGCGGTGGAG GCTCCCCGGG TGAACCGTCT GGTCCAATCT CTACTATCAA CCCGTCTCCT 540

CCGTCTAAAG AATCTCATAA ATCTCCAAAC ATGGCTACAC CATTAGGCCC TGCCAGCTCC 600

CTGCCCCAGA GCTTCCTGCT CAAGTGCTTA GAGCAAGTGA GGAAGATCCA GGGCGATGGC 660

GCAGCGCTCC AGGAGAAGCT GTGTGCCACC TACAAGCTGT GCCACCCCGA GGAGCTGGTG 720

CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC 780

CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC 840

CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 900

GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 960

GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 1020

GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 1080

CGCCACCTTG CGCAGCCC 1098

(2) INFORMATION FOR SEQ ID NO: 285:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 285:

GCCTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 60

TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 120 CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 180 TTCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTGGGCGG TGGGTCAGGA 240 GGTGGGTCAG GAGGTGGATC CGGAGGTGGC ACCCAGGACT GCTCCTTCCA ACACAGCCCC 300 ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 360 CCAGTCACCG TGGCCTCCAA CCTGCAGGAC GAGGAGCTCT GCGGGGGCCT CTGGCGGCTG 420 GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGCTACGT AGAGGGCGGT 480 GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540 AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600 CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660 CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720 GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780 CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840 GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900 GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960 CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080 CTTGCGCAGC CC 1092

(2) INFORMATION FOR SEQ ID NO: 286:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1134 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:286:

GCTCAAGACG AAGAACTGTG TGGTGGTCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300

ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGCGGTGGTT CTGGCGGAGG ATCCGGCGGC 360

GGAAGCGGAG GTGGCTCTGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 420

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 480

TACCCAGTCA CCGTGGCCTC CAACCTGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540

CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600

CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660

TGCTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720

GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780

CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840

CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900

CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960

ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020

ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080

CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134

(2) INFORMATION FOR SEQ ID NO: 287:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1092 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 287:

GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300

ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CACCCAGGAC 360

TGCTCCTTCC AACACAGCCC CATCTCCTCC GACTTCGCTG TCAAAATCCG TGAGCTGTCT 420

GACTACCTGC TTCAAGATTA CCCAGTCACC GTGGCCTCCA ACCTGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT ACACCATTAG GCCCTGCCAG CTCCCTGCCC 600

CAGAGCTTCC TGCTCAAGTG CTTAGAGCAA GTGAGGAAGA TCCAGGGCGA TGGCGCAGCG 660

CTCCAGGAGA AGCTGTGTGC CACCTACAAG CTGTGCCACC CCGAGGAGCT GGTGCTGCTC 720

GGACACTCTC TGGGCATCCC CTGGGCTCCC CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG 780

CTGGCAGGCT GCTTGAGCCA ACTCCATAGC GGCCTTTTCC TCTACCAGGG GCTCCTGCAG 840

GCCCTGGAAG GGATATCCCC CGAGTTGGGT CCCACCTTGG ACACACTGCA GCTGGACGTC 900

GCCGACTTTG CCACCACCAT CTGGCAGCAG ATGGAAGAAC TGGGAATGGC CCCTGCCCTG 960

CAGCCCACCC AGGGTGCCAT GCCGGCCTTC GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG 1020 GTCCTGGTTG CTAGCCATCT GCAGAGCTTC CTGGAGGTGT CGTACCGCGT TCTACGCCAC 1080

CTTGCGCAGC CC 1092

(2) INFORMATION FOR SEQ ID NO: 288:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:288:

GCCCAAGATG AAGAACTGTG TGGTGGCCTC TGGCGGCTGG TCCTGGCACA GCGCTGGATG 60

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 120

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 180

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 240

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 300

ACCCTGCCGC CACCGTGGAG CCCGCGTCCA CTCGGCGCCA CCGCACCGAC CGCTGGACAA 360

CCGCCTCTGA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 420

AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 480

CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO: 289:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1134 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 289:

GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA 360

AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 420

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 480

CCAGTCACCG TGGCCTCCAA CCTGCAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540

CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600

CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660

TGCTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720

GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780

CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840

CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900

CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960

ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020

ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080

CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134

(2) INFORMATION FOR SEQ ID NO: 290:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1134 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 290:

GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCCCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGC GGTGGTTCTG GCGGAGGATC CGGCGGCGGA 360

AGCGGAGGTG GCTCTGGGGG AGGTAGTGGT ACCCAGGACT GCTCCTTCCA ACACAGCCCC 420

ATCTCCTCCG ACTTCGCTGT CAAAATCCGT GAGCTGTCTG ACTACCTGCT TCAAGATTAC 480

CCAGTCACCG TGGCCTCCAA CCTGCAGTAC GTAGAGGGCG GTGGAGGCTC CCCGGGTGAA 540

CCGTCTGGTC CAATCTCTAC TATCAACCCG TCTCCTCCGT CTAAAGAATC TCATAAATCT 600

CCAAACATGG CTACACCATT AGGCCCTGCC AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG 660

TGCTTAGAGC AAGTGAGGAA GATCCAGGGC GATGGCGCAG CGCTCCAGGA GAAGCTGTGT 720

GCCACCTACA AGCTGTGCCA CCCCGAGGAG CTGGTGCTGC TCGGACACTC TCTGGGCATC 780

CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC 840

CAACTCCATA GCGGCCTTTT CCTCTACCAG GGGCTCCTGC AGGCCCTGGA AGGGATATCC 900

CCCGAGTTGG GTCCCACCTT GGACACACTG CAGCTGGACG TCGCCGACTT TGCCACCACC 960

ATCTGGCAGC AGATGGAAGA ACTGGGAATG GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC 1020

ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT 1080

CTGCAGAGCT TCCTGGAGGT GTCGTACCGC GTTCTACGCC ACCTTGCGCA GCCC 1134

(2) INFORMATION FOR SEQ ID NO: 291:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 291:

GCGGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGCCGCCAC CGTGGAGCCC GCGTCCACTC GGCGCCACCG CACCGACCGC TGGACAACCG 360

CCTCTGACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCACCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 600

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 660

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 720

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 780

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 840

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 900

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 960

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1020

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1080

TACCGCGTTC TACGCCACCT TGCGCAGCCC 1110

(2) INFORMATION FOR SEQ ID NO:292:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1041 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:292:

GCTGATGAGG AGCTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGT AGAGACGGTG 300

TTTCACCGTG TCAGCCAGGA TGGTCTAGAT CTCCTGACCT CGACCCAGGA CTGCTCCTTC 360

CAACACAGCC CCATCTCCTC CGACTTCGCT GTCAAAATCC GTGAGCTGTC TGACTACCTG 420

CTTCAAGATT ACCCAGTCAC CGTGGCCTCC AACCTGCAGT ACGTAGAGGG CGGTGGAGGC 480

TCCCCGGGTG GTGGTTCTGG CGGCGGCTCC AACATGGCTA CACCATTGGG CCCTGCCAGC 540

TCCCTGCCCC AGAGCTTCCT GCTCAAGTCT TTAGAGCAAG TGAGAAAGAT CCAGGGCGAT 600

GGCGCAGCGC TCCAGGAGAA GCTGTGTGCC ACTAACAAGC TGTGCCACCC CGAGGAGCTG 660

GTGCTGCTCG GACACTCTCT GGGCATCCCC TGGGCTCCCC TGAGCTCCTG CCCCAGCCAG 720

GCCCTGCAGC TGGCAGGCTG CTTGAGCCAA CTCCATAGCG GCCTTTTCCT CTACCAGGGG 780

CTCCTGCAGG CCCTGGAAGG GATATCCCCC GAGTTGGGTC CCACCTTGGA CACACTGCAG 840

CTGGACGTCG CCGACTTTGC CACCACCATC TGGCAGCAGA TGGAAGAACT GGGAATGGCC 900

CCTGCCCTGC AGCCCACCCA GGGTGCCATG CCGGCCTTCG CCTCTGCTTT CCAGCGCCGG 960 GCAGGAGGGG TCCTGGTTGC TAGCCATCTG CAGAGCTTCC TGGAGGTGTC GTACCGCGTT 1020

CTACGCCACC TTGCGCAGCC G 1041

(2) INFORMATION FOR SEQ ID NO: 293:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1152 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:293:

GCTGATGAAG AACTGTGTGG TGGGCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 360

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTGGGC 420

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTCTT TAGAGCAAGT GAGAAAGATC 480

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 540

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 600

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 660

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 720

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 780

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 840

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 900

TACCGCGTTC TACGCCACCT TGCGCAGCCC TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 960

GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 1020

TCTCCAAACA TGGCAACCCA GGACTGCTCT TTTCAACACA GCCCCATCTC CTCCGACTTC 1080

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 1140

TCCAACCTGC AG 1152

(2) INFORMATION FOR SEQ ID NO: 294:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1047 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:294:

GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GAGCCGAAGA GCCCGGACAC CCATACTAGT CCGCCATCTC CGACACCATT AGGCCCTGCC 180

AGCTCCCTGC CCCAGAGCTT CCTGCTCAAG TCTTTAGAGC AAGTGAGAAA GATCCAGGGC 240

GATGGCGCAG CGCTCCAGGA GAAGCTGTGT GCCACCTACA AGCTGTGCCA CCCCGAGGAG 300

CTGGTGCTGC TCGGACACTC TCTGGGCATC CCCTGGGCTC CCCTGAGCTC CTGCCCCAGC 360

CAGGCCCTGC AGCTGGCAGG CTGCTTGAGC CAACTCCATA GCGGCCTTTT CCTCTACCAG 420

GGGCTCCTGC AGGCCCTGGA AGGGATATCC CCCGAGTTGG GCCCCACCTT GGACACACTG 480

CAGCTGGACG TCGCCGACTT TGCCACCACC ATCTGGCAGC AGATGGAAGA ACTGGGAATG 540

GCCCCTGCCC TGCAGCCCAC CCAGGGTGCC ATGCCGGCCT TCGCCTCTGC TTTCCAGCGC 600

CGGGCAGGAG GGGTCCTGGT TGCTAGCCAT CTGCAGAGCT TCCTGGAGGT GTCGTACCGC 660

GTTCTACGCC ACCTTGCGCA GCCCTCTGCA GAACCGAAAT CTCCGGATAC TCATACCAGC 720

CCGCCATCCC CGGGTTCTAA TCTGCAAGAT GAAGAGCTGT GCGGGGGCCT CTGGCGGCTG 780

GTCCTGGCAC AGCGCTGGAT GGAGCGGCTC AAGACTGTCG CTGGGTCCAA GATGCAAGGC 840

TTGCTGGAGC GCGTGAACAC GGAGATACAC TTTGTCACCA AATGTGCCTT TCAGCCCCCC 900

CCCAGCTGCC TTCGCTTCGT CCAGACCAAC ATCTCCCGCC TCCTGCAGGA GACCTCCGAG 960

CAGCTGGTGG CGCTGAAGCC CTGGATCACT CGCCAGAACT TCTCCCGGTG CCTGGAGCTG 1020

CAGTGTCAGC CCGACTCCTC AACCCTG 1047

(2) INFORMATION FOR SEQ ID NO: 295:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1043 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 295:

GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60 CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTGGCAGG GGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCCGAAG AGCCCGGACA CCCATACTAG TCCGCCATCT 300

CCGGGTACAC CATTGGGCCC TGCCAGCTCC CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA 360

GAGCAAGTGA GAAAGATCCA GGGCGATGGC GCAGCGCTCC AGGAGAAGCT GTGTGCCACT 420

ACAAGCTGTG CCACCCCGAG GAGCTGGTGC TGCTCGGACA CTCTCTGGGC ATCCCCTGGG 480

CTCCCCTGAG CTCCTGCCCC AGCCAGGCCC TGCAGCTGGC AGGCTGCTTG AGCCAACTCC 540

ATAGCGGCCT TTTCCTCTAC CAGGGGCTCC TGCAGGCCCT GGAAGGGATA TCCCCCGAGT 600

TGGGTCCCAC CTTGGACACA CTGCAGCTGG ACGTCGCCGA CTTTGCCACC ACCATCTGGC 660

AGCAGATGGA AGAACTGGGA ATGGCCCCTG CCCTGCAGCC CACCCAGGGT GCCATGCCGG 720

CCTTCGCCTC TGCTTTCCAG CGCCGGGCAG GAGGGGTCCT GGTTGCTAGC CATCTGCAGA 780

GCTTCCTGGA GGTGTCGTAC CGCGTTCTAC GCCACCTTGC GCAGCCCTCT GCAGAACCGA 840

AATCTCCGGA TACTCATACC AGCCCGCCAT CCCCGGGTAA GGCCTTTCAG CCCCCCCCCA 900

GCTGTCTTCG CTTCGTCCAG ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC 960

TGGTGGCGCT GAAGCCCTGG ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT 1020

GTCAGCCCGA CTCCTCAACC CTG 1043

(2) INFORMATION FOR SEQ ID NO: 296:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1065 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 296:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATC TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTCCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 600

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACTAAC 660

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 720

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 780

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 840

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 900

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 960

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 1020

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 1065

(2) INFORMATION FOR SEQ ID NO: 297:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 297:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 660

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATCTGC CTTTCAGCCC 780

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900

CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTCCTCCTT CCAACACAGC 1020

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGCGAGCTGT CTGACTACCT GCTTCAAGAT 1080 TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1110 (2) INFORMATION FOR SEQ ID NO: 298:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1065 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:298:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTCTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTA GAGCTGCAGT CTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 600

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACTAAC 660

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 720

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 780

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 840

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 900

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 960

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 1020

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCG 1065

(2) INFORMATION FOR SEQ ID NO: 299:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1110 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 299:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCA GATGAAGAAC TGTGTGGGGG CCTGTGGCGG 660

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780

CCCCCCAGCT CTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900

CTGCAGTCTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACTCAGG ACTGTTCTTT TCAACACAGC 1020

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080

TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1110

(2) INFORMATION FOR SEQ ID NO: 300:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1002 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:300:

GCCACTCAGG ACTCCTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180 CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATCTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420

TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 480

ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 540

GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACTAACAAG 600

CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 660

CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 720

GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 780

CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 840

ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 900

GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 960

CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG 1002

(2) INFORMATION FOR SEQ ID NO: 301:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1002 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:301:

GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT CTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTCTC AGCCCGACTC CTCAACCCTG 420

TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 480

ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 540

GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG 600

CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 660

CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 720

GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 780

CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 840

ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 900

GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 960

CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG 1002

(2) INFORMATION FOR SEQ ID NO: 302:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 978 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:302:

GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTACG TAGAGGGCGG TGGAGGCTCC 420

CCGGGTGGTG GTTCTGGCGG CGGCTCCAAC ATGGCTACAC CATTGGGCCC TGCCAGCTCC 480

CTGCCCCAGA GCTTCCTGCT CAAGTCTTTA GAGCAAGTGA GAAAGATCCA GGGCGATGGC 540

GCAGCGCTCC AGGAGAAGCT GTGTGCCACT AACAAGCTGT GCCACCCCGA GGAGCTGGTG 600

CTGCTCGGAC ACTCTCTGGG CATCCCCTGG GCTCCCCTGA GCTCCTGCCC CAGCCAGGCC 660

CTGCAGCTGG CAGGCTGCTT GAGCCAACTC CATAGCGGCC TTTTCCTCTA CCAGGGGCTC 720

CTGCAGGCCC TGGAAGGGAT ATCCCCCGAG TTGGGTCCCA CCTTGGACAC ACTGCAGCTG 780

GACGTCGCCG ACTTTGCCAC CACCATCTGG CAGCAGATGG AAGAACTGGG AATGGCCCCT 840

GCCCTGCAGC CCACCCAGGG TGCCATGCCG GCCTTCGCCT CTGCTTTCCA GCGCCGGGCA 900

GGAGGGGTCC TGGTTGCTAG CCATCTGCAG AGCTTCCTGG AGGTGTCGTA CCGCGTTCTA 960

CGCCACCTTG CGCAGCCG 978

(2) INFORMATION FOR SEQ ID NO: 303:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1002 base pairs (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 303:

GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTCTC AGCCCGACTC CTCAACCCTG 420

TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 480

ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 540

GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG 600

CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 660

CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 720

GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 780

CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 840

ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 900

GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 960

CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC CG 1002

(2) INFORMATION FOR SEQ ID NO: 304:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1001 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 304:

GCCACTCAGG ACTGTTCTTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GCGCCTGGAG CTGCAGTCTC AGCCCGACTC CTCAACCCTG 420

TACGTAGAGG GCGGTGGAGG CTCCCCGGGT GGTGGTTCTG GCGGCGGCTC CAACATGGCT 480

ACACCATTGG GCCCTGCCAG CTCCCTGCCC CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 540

GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACTAACAAG 600

CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 660

CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 720

GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 780

CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 840

ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCACCC AGGGTGCCAT GCCGGCCTTC 900

GCCTCTGCTT TCCAGCGCCG GGCAGGAGGG GTCCTGGTTG CTAGCCATCT GCAGAGCTTC 960

CTGGAGGTGT CGTACCGCGT TCTACGCCAC CTTGCGCAGC C 1001

(2) INFORMATION FOR SEQ ID NO: 305:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1056 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:305:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540

GCTACTCAAG GTGCTATGCC AGCTTTTGCT TCTGCTTTTC AACGTCGTGC AGGTGGTGTT 600

CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT ACGCCACCTT 660

GCGCAGCCCT CTGGCGGCTC TGGCGGCTCT CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 720 GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG 780

CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 840

CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 900

GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 960

CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 1020

ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCC 1056

(2) INFORMATION FOR SEQ ID NO: 306:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1101 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 306:

GCTACTCAAG GTGCTATGCC AGCTTTTGCT TCTGCTTTTC AACGTCGTGC AGGTGGTGTT 60

CTGGTTGCTA GCCATCTGCA GAGCTTCCTG GAGGTGTCGT ACCGCGTTCT ACGCCACCTT 120

GCGCAGCCCT CTGGCGGCTC TGGCGGCTCT CAGAGCTTCC TGCTCAAGTC TTTAGAGCAA 180

GTGAGAAAGA TCCAGGGCGA TGGCGCAGCG CTCCAGGAGA AGCTGTGTGC CACCTACAAG 240

CTGTGCCACC CCGAGGAGCT GGTGCTGCTC GGACACTCTC TGGGCATCCC CTGGGCTCCC 300

CTGAGCTCCT GCCCCAGCCA GGCCCTGCAG CTGGCAGGCT GCTTGAGCCA ACTCCATAGC 360

GGCCTTTTCC TCTACCAGGG GCTCCTGCAG GCCCTGGAAG GGATATCCCC CGAGTTGGGT 420

CCCACCTTGG ACACACTGCA GCTGGACGTC GCCGACTTTG CCACCACCAT CTGGCAGCAG 480

ATGGAAGAAC TGGGAATGGC CCCTGCCCTG CAGCCCTACG TAGAGGGCGG TGGAGGCTCC 540

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 600

CATAAATCTC CAAACATGGC CGACGAGGAG CTCTGCGGGG GCCTCTGGCG GCTGGTCCTG 660

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 720

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 780

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 840

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 900

CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 960

GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 1020

TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 1080

ACCGTGGCCT CCAACCTGCA G 1101

(2) INFORMATION FOR SEQ ID NO: 307:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1032 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:307:

GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCC GACGAGGAGC TCTGCGGGGG CCTCTGGCGG 600

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 660

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 720

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 780

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 840

CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 900

GGATCCGGAG GTGGCACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 960

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 1020

TCCAACCTGC AG 1032

(2) INFORMATION FOR SEQ ID NO: 308:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1005 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:308:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 540

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC CCAGGACTGC 600

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 660

TACCTGCTTC AAAATTACCC AGTCACCGTG GCCTCCAACC TGCAGGACGA GGAGCTCTGC 720

GGGGGCCTCT GGCGGCTGGT CCTGGCACAG CGCTGGATGG AGCGGCTCAA GACTGTCGCT 780

GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC GTGAACACGG AGATACACTT TGTCACCAAA 840

TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT CGCTTCGTCC AGACCAACAT CTCCCGCCTC 900

CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG CTGAAGCCCT GGATCACTCG CCAGAACTTC 960

TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC GACTCCTCAA CCCTG 1005

(2) INFORMATION FOR SEQ ID NO: 309:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1650 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:309:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 600

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 660

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 720

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 780

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 840

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 900

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 960

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 1020

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 1080

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 1140

AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 1200

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 1260

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 1320

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 1380

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 1440

CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 1500

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 1560

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1620

TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1650

(2) INFORMATION FOR SEQ ID NO: 310:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1632 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:310:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360 CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 660

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900

CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 1020

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080

TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 1140

GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 1200

TCTCCAAACA TGGCTACCCA GGACTGCTCC TTCCAACACA GCCCCATCTC CTCCGACTTC 1260

GCTGTCAAAA TCCGTGAGCT GTCTGACTAC CTGCTTCAAG ATTACCCAGT CACCGTGGCC 1320

TCCAACCTGC AGGACGAGGA GCTCTGCGGG GGCCTCTGGC GGCTGGTCCT GGCACAGCGC 1380

TGGATGGAGC GGCTCAAGAC TGTCGCTGGG TCCAAGATGC AAGGCTTGCT GGAGCGCGTG 1440

AACACGGAGA TACACTTTGT CACCAAATGT GCCTTTCAGC CCCCCCCCAG CTGTCTTCGC 1500

TTCGTCCAGA CCAACATCTC CCGCCTCCTG CAGGAGACCT CCGAGCAGCT GGTGGCGCTG 1560

AAGCCCTGGA TCACTCGCCA GAACTTCTCC CGGTGCCTGG AGCTGCAGTG TCAGCCCGAC 1620

TCCTCAACCC TG 1632

(2) INFORMATION FOR SEQ ID NO: 311:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1695 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 311:

GCTACACCAT TGGGCCCTGC CAGCTCCCTG CCCCAGAGCT TCCTGCTCAA GTCTTTAGAG 60

CAAGTGAGAA AGATCCAGGG CGATGGCGCA GCGCTCCAGG AGAAGCTGTG TGCCACCTAC 120

AAGCTGTGCC ACCCCGAGGA GCTGGTGCTG CTCGGACACT CTCTGGGCAT CCCCTGGGCT 180

CCCCTGAGCT CCTGCCCCAG CCAGGCCCTG CAGCTGGCAG GCTGCTTGAG CCAACTCCAT 240

AGCGGCCTTT TCCTCTACCA GGGGCTCCTG CAGGCCCTGG AAGGGATATC CCCCGAGTTG 300

GGTCCCACCT TGGACACACT GCAGCTGGAC GTCGCCGACT TTGCCACCAC CATCTGGCAG 360

CAGATGGAAG AACTGGGAAT GGCCCCTGCC CTGCAGCCCA CCCAGGGTGC CATGCCGGCC 420

TTCGCCTCTG CTTTCCAGCG CCGGGCAGGA GGGGTCCTGG TTGCTAGCCA TCTGCAGAGC 480

TTCCTGGAGG TGTCGTACCG CGTTCTACGC CACCTTGCGC AGCCCTACGT AGAGGGCGGT 540

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 600

AAAGAATCTC ATAAATCTCC AAACATGGCT GATGAAGAAC TGTGTGGTGG TCTGTGGCGG 660

CTGGTCCTGG CACAGCGCTG GATGGAGCGG CTCAAGACTG TCGCTGGGTC CAAGATGCAA 720

GGCTTGCTGG AGCGCGTGAA CACGGAGATA CACTTTGTCA CCAAATGTGC CTTTCAGCCC 780

CCCCCCAGCT GTCTTCGCTT CGTCCAGACC AACATCTCCC GCCTCCTGCA GGAGACCTCC 840

GAGCAGCTGG TGGCGCTGAA GCCCTGGATC ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG 900

CTGCAGTGTC AGCCCGACTC CTCAACCCTG GGCGGTGGGT CAGGAGGTGG GTCAGGAGGT 960

GGATCCGGAG GTGGCTCAGG GGGAGGTAGT GGTACCCAGG ACTGCTCCTT CCAACACAGC 1020

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1080

TACCCAGTCA CCGTGGCCTC CAACCTGCAG TACGTAGAGG GCGGTGGAGG CTCCCCGGGT 1140

GAACCGTCTG GTCCAATCTC TACTATCAAC CCGTCTCCTC CGTCTAAAGA ATCTCATAAA 1200

TCTCCAAACA TGGCTGATGA AGAACTGTGT GGTGGTCTGT GGCGGCTGGT CCTGGCACAG 1260

CGCTGGATGG AGCGGCTCAA GACTGTCGCT GGGTCCAAGA TGCAAGGCTT GCTGGAGCGC 1320

GTGAACACGG AGATACACTT TGTCACCAAA TGTGCCTTTC AGCCCCCCCC CAGCTGTCTT 1380

CGCTTCGTCC AGACCAACAT CTCCCGCCTC CTGCAGGAGA CCTCCGAGCA GCTGGTGGCG 1440

CTGAAGCCCT GGATCACTCG CCAGAACTTC TCCCGGTGCC TGGAGCTGCA GTGTCAGCCC 1500

GACTCCTCAA CCCTGGGCGG TGGGTCAGGA GGTGGGTCAG GAGGTGGATC CGGAGGTGGC 1560

TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC 1620

TTCGCTGTCA AAATCCGTGA GCTGTCTGAC TACCTGCTTC AAGATTACCC AGTCACCGTG 1680

GCCTCCAACC TGCAG 1695

(2) INFORMATION FOR SEQ ID NO: 312:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1506 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 312:

GCTAACTGCT CTATAATGAT CGATGAAATT ATACATCACT TAAAGAGACC ACCTGCACCT 60

TTGCTGGACC CGAACAACCT CAATGACGAA GACGTCTCTA TCCTGATGGA CCGAAACCTT 120 CGACTTCCAA ACCTGGAGAG CTTCGTAAGG GCT tG/T3C3AAGA ACTTAGAAAA TGCATCAGGT 180

ATTGAGGCAA TTCTTCGTAA TCTCCAACCA TGTCTGCCCT CTGCCACGGC CGCACCCTCT 240

CGACATCCAA TCATCATCAA GGCAGGTGAC TGGCAAGAAT TCCGGGAAAA ACTGACGTTC 300

TATCTGGTTA CCCTTGAGCA AGCGCAGGAA CAACAGTACG TAGAGGGCGG TGGAGGCTCC 360

CCGGGTGAAC CGTCTGGTCC AATCTCTACT ATCAACCCGT CTCCTCCGTC TAAAGAATCT 420

CATAAATCTC CAAACATGGC TGATGAAGAA CTGTGTGGTG GTCTGTGGCG GCTGGTCCTG 480

GCACAGCGCT GGATGGAGCG GCTCAAGACT GTCGCTGGGT CCAAGATGCA AGGCTTGCTG 540

GAGCGCGTGA ACACGGAGAT ACACTTTGTC ACCAAATGTG CCTTTCAGCC CCCCCCCAGC 600

TGTCTTCGCT TCGTCCAGAC CAACATCTCC CGCCTCCTGC AGGAGACCTC CGAGCAGCTG 660

GTGGCGCTGA AGCCCTGGAT CACTCGCCAG AACTTCTCCC GGTGCCTGGA GCTGCAGTGT 720

CAGCCCGACT CCTCAACCCT GGGCGGTGGG TCAGGAGGTG GGTCAGGAGG TGGATCCGGA 780

GGTGGCTCAG GGGGAGGTAG TGGTACCCAG GACTGCTCCT TCCAACACAG CCCCATCTCC 840

TCCGACTTCG CTGTCAAAAT CCGTGAGCTG TCTGACTACC TGCTTCAAGA TTACCCAGTC 900

ACCGTGGCCT CCAACCTGCA GTACGTAGAG GGCGGTGGAG GCTCCCCGGG TGAACCGTCT 960

GGTCCAATCT CTACTATCAA CCCGTCTCCT CCGTCTAAAG AATCTCATAA ATCTCCAAAC 1020

ATGGCTGATG AAGAACTGTG TGGTGGTCTG TGGCGGCTGG TCCTGGCACA GCGCTGGATG 1080

GAGCGGCTCA AGACTGTCGC TGGGTCCAAG ATGCAAGGCT TGCTGGAGCG CGTGAACACG 1140

GAGATACACT TTGTCACCAA ATGTGCCTTT CAGCCCCCCC CCAGCTGTCT TCGCTTCGTC 1200

CAGACCAACA TCTCCCGCCT CCTGCAGGAG ACCTCCGAGC AGCTGGTGGC GCTGAAGCCC 1260

TGGATCACTC GCCAGAACTT CTCCCGGTGC CTGGAGCTGC AGTGTCAGCC CGACTCCTCA 1320

ACCCTGGGCG GTGGGTCAGG AGGTGGGTCA GGAGGTGGAT CCGGAGGTGG CTCAGGGGGA 1380

GGTAGTGGTA CCCAGGACTG CTCCTTCCAA CACAGCCCCA TCTCCTCCGA CTTCGCTGTC 1440

AAAATCCGTG AGCTGTCTGA CTACCTGCTT CAAGATTACC CAGTCACCGT GGCCTCCAAC 1500

CTGCAG 1506

(2) INFORMATION FOR SEQ ID NO: 313:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1674 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 313:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 600

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 660

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 720

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 780

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 840

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 900

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 960

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 1020

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGGTGGTT CTGGCGGCGG CTCCAACATG 540

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 600

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 660

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 720

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 780

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 840

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 900

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 960

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 1020

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 1080

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCTAC ACCATTAGGC 1140

CCTGCCAGCT CCCTGCCCCA GAGCTTCCTG CTCAAGTGCT TAGAGCAAGT GAGGAAGATC 1200

CAGGGCGATG GCGCAGCGCT CCAGGAGAAG CTGTGTGCCA CCTACAAGCT GTGCCACCCC 1260

GAGGAGCTGG TGCTGCTCGG ACACTCTCTG GGCATCCCCT GGGCTCCCCT GAGCTCCTGC 1320

CCCAGCCAGG CCCTGCAGCT GGCAGGCTGC TTGAGCCAAC TCCATAGCGG CCTTTTCCTC 1380

TACCAGGGGC TCCTGCAGGC CCTGGAAGGG ATATCCCCCG AGTTGGGTCC CACCTTGGAC 1440

ACACTGCAGC TGGACGTCGC CGACTTTGCC ACCACCATCT GGCAGCAGAT GGAAGAACTG 1500

GGAATGGCCC CTGCCCTGCA GCCCACCCAG GGTGCCATGC CGGCCTTCGC CTCTGCTTTC 1560

CAGCGCCGGG CAGGAGGGGT CCTGGTTGCT AGCCATCTGC AGAGCTTCCT GGAGGTGTCG 1620

TACCGCGTTC TACGCCACCT TGCGCAGCCC TGATAAGGAT CCGAATTCGG CAGC 1674

(2) INFORMATION FOR SEQ ID NO: 314:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1470 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 314: GCCGACGAGG AGCTGTGCGG TGGCCTCTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60 CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGAAC CCAGGACTGC 360

TCCTTCCAAC ACAGCCCCAT CTCCTCCGAC TTCGCTGTCA AAATCCGTGA GCTGTCTGAC 420

TACCTGCTTC AAGATTACCC AGTCACCGTG GCCTCCAACC TGCAGTACGT AGAGGGCGGT 480

GGAGGCTCCC CGGGTGAACC GTCTGGTCCA ATCTCTACTA TCAACCCGTC TCCTCCGTCT 540

AAAGAATCTC ATAAATCTCC AAACATGGCT AACTGCTCTA TAATGATCGA TGAAATTATA 600

CATCACTTAA AGAGACCACC TAACCCTTTG CTGGACCCGA ACAACCTCAA TTCTGAAGAC 660

ATGGATATCC TGATGGAACG AAACCTTCGA ACTCCAAACC TGCTCGCATT CGTAAGGGCT 720

GTCAAGCACT TAGAAAATGC ATCAGGTATT GAGGCAATTC TTCGTAATCT CCAACCATGT 780

CTGCCCTCTG CCACGGCCGC ACCCTCTCGA CATCCAATCA TCATCAAGGC AGGTGACTGG 840

CAAGAATTCC GGGAAAAACT GACGTTCTAT CTGGTTACCC TTGAGCAAGC GCAGGAACAA 900

CAGTACGTAG AGGGCGGTGG AGGCTCCCCG GGTGAACCGT CTGGTCCAAT CTCTACTATC 960

AACCCGTCTC CTCCGTCTAA AGAATCTCAT AAATCTCCAA ACATGGCCGA CGAGGAGCTC 1020

TGCGGGGGCC TCTGGCGGCT GGTCCTGGCA CAGCGCTGGA TGGAGCGGCT CAAGACTGTC 1080

GCTGGGTCCA AGATGCAAGG CTTGCTGGAG CGCGTGAACA CGGAGATACA CTTTGTCACC 1140

AAATGTGCCT TTCAGCCCCC CCCCAGCTGT CTTCGCTTCG TCCAGACCAA CATCTCCCGC 1200

CTCCTGCAGG AGACCTCCGA GCAGCTGGTG GCGCTGAAGC CCTGGATCAC TCGCCAGAAC 1260

TTCTCCCGGT GCCTGGAGCT GCAGTGTCAG CCCGACTCCT CAACCCTGGG CGGTGGGTCA 1320

GGAGGTGGGT CAGGAGGTGG ATCCGGAGGT GGCACCCAGG ACTGCTCCTT CCAACACAGC 1380

CCCATCTCCT CCGACTTCGC TGTCAAAATC CGTGAGCTGT CTGACTACCT GCTTCAAGAT 1440

TACCCAGTCA CCGTGGCCTC CAACCTGCAG 1470

(2) INFORMATION FOR SEQ ID NO: 315:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1194 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 315:

GCTGATGAAG AACTGTGTGG TGGTCTGTGG CGGCTGGTCC TGGCACAGCG CTGGATGGAG 60

CGGCTCAAGA CTGTCGCTGG GTCCAAGATG CAAGGCTTGC TGGAGCGCGT GAACACGGAG 120

ATACACTTTG TCACCAAATG TGCCTTTCAG CCCCCCCCCA GCTGTCTTCG CTTCGTCCAG 180

ACCAACATCT CCCGCCTCCT GCAGGAGACC TCCGAGCAGC TGGTGGCGCT GAAGCCCTGG 240

ATCACTCGCC AGAACTTCTC CCGGTGCCTG GAGCTGCAGT GTCAGCCCGA CTCCTCAACC 300

CTGGGCGGTG GGTCAGGAGG TGGGTCAGGA GGTGGATCCG GAGGTGGCTC AGGGGGAGGT 360

AGTGGTACCC AGGACTGCTC CTTCCAACAC AGCCCCATCT CCTCCGACTT CGCTGTCAAA 420

ATCCGTGAGC TGTCTGACTA CCTGCTTCAA GATTACCCAG TCACCGTGGC CTCCAACCTG 480

CAGGAATTCA AGCTTGAGCC CAGAGGGCCC ACAATCAAGC CCTGTCCTCC ATGCAAATGC 540

CCAGCACCTA ACCTCTTGGG TGGACCATCC GTCTTCATCT TCCCTCCAAA GATCAAGGAT 600

GTACTCATGA TCTCCCTGAG CCCCATAGTC ACATGTGTGG TGGTGGATGT GAGCGAGGAT 660

GACCCAGATG TCCAGATCAG CTGGTTTGTG AACAACGTGG AAGTACACAC AGCTCAGACA 720

CAAACCCATA GAGAGGATTA CAACAGTACT CTCCGGGCGG TCAGTGCCCT CCCCATCCAG 780

CACCAGGACT GGATGAGTGG CAAGGAGTTC AAATGCAAGG TCAACAACAA AGACCTCCCA 840

GCGCCCATCG AGAGAACCAT CTCAAAACCC AAAGGGTCAG TAAGAGCTCC ACAGGTATAT 900

GTCTTGCCTC CACCAGAAGA AGAGATGACT AAGAAACAGG TCACTCTGAC CTGCATGGTC 960

ACAGACTTCA TGCCTGAAGA CATTTACGTG GAGTGGACCA ACAACGGGAA AACAGAGCTA 1020

AACTACAAGA ACACTGAACC AGTCCTGGAC TCTGATGGTT CTTACTTCAT GTACAGCAAG 1080

CTGAGAGTGG AAAAGAAGAA CTGGGTGGAA AGAAATAGCT ACTCCTGTTC AGTGGTCCAC 1140

GAGGGTCTGC ACAATCACCA CACGACTAAG AGCTTCTCCC GGACTCCGGG TAAA 1194

(2) INFORMATION FOR SEQ ID NO: 316:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1131 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 316:

GCCACCCAGG ACTGCTCCTT TCAACACAGC CCCATCTCCT CCGACTTCGC TGTCAAAATC 60

CGTGAGCTGT CTGACTACCT GCTTCAAGAT TACCCAGTCA CCGTGGCCTC CAACCTGCAG 120

GACGAGGAGC TCTGCGGGGG CCTCTGGCGG CTGGTCCTGG CACAGCGCTG GATGGAGCGG 180

CTCAAGACTG TCGCTGGGTC CAAGATGCAA GGCTTGCTGG AGCGCGTGAA CACGGAGATA 240

CACTTTGTCA CCAAATGTGC CTTTCAGCCC CCCCCCAGCT GTCTTCGCTT CGTCCAGACC 300

AACATCTCCC GCCTCCTGCA GGAGACCTCC GAGCAGCTGG TGGCGCTGAA GCCCTGGATC 360

ACTCGCCAGA ACTTCTCCCG GTGCCTGGAG CTGCAGTGTC AGCCCGACTC CTCAACCCTG 420

GAATTCAAGC TTGAGCCCAG AGGGCCCACA ATCAAGCCCT GTCCTCCATG CAAATGCCCA 480

GCACCTAACC TCTTGGGTGG ACCATCCGTC TTCATCTTCC CTCCAAAGAT CAAGGATGTA 540 CTCATGATCT CCCTGAGCCC CATAGTCACA TGTGTGGTGG TGGATGTGAG CGAGGATGAC 600 CCAGATGTCC AGATCAGCTG GTTTGTGAAC AACGTGGAAG TACACACAGC TCAGACACAA 660 ACCCATAGAG AGGATTACAA CAGTACTCTC CGGGCGGTCA GTGCCCTCCC CATCCAGCAC 720 CAGGACTGGA TGAGTGGCAA GGAGTTCAAA TGCAAGGTCA ACAACAAAGA CCTCCCAGCG 780 CCCATCGAGA GAACCATCTC AAAACCCAAA GGGTCAGTAA GAGCTCCACA GGTATATGTC 840 TTGCCTCCAC CAGAAGAAGA GATGACTAAG AAACAGGTCA CTCTGACCTG CATGGTCACA 900 GACTTCATGC CTGAAGACAT TTACGTGGAG TGGACCAACA ACGGGAAAAC AGAGCTAAAC 960 TACAAGAACA CTGAACCAGT CCTGGACTCT GATGGTTCTT ACTTCATGTA CAGCAAGCTG 1020 AGAGTGGAAA AGAAGAACTG GGTGGAAAGA AATAGCTACT CCTGTTCAGT GGTCCACGAG 1080 GGTCTGCACA ATCACCACAC GACTAAGAGC TTCTCCCGGA CTCCGGGTAA A 1131

(2) INFORMATION FOR SEQ ID NO: 317:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 317: ACGTCCATGG CNTCNCCNGC NCCNCCTGCT TGTGCACTCC GAGTC 45

(2) INFORMATION FOR SEQ ID NO: 318:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 318: ATGCACGAAT TCCCTGACGC AGAGGGTGGA 30

(2) INFORMATION FOR SEQ ID NO: 319:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:319: TGACAAGCTT ACCTGACGCA GAGGGTGGAC CCT 33

(2) INFORMATION FOR SEQ ID NO: 320:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:320: AATTCGGCAA 10

(2) INFORMATION FOR SEQ ID NO: 321:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:321: CATGTTGCCG 10

(2) INFORMATION FOR SEQ ID NO: 322: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 322: AATTCGGCGG CAA 13

(2) INFORMATION FOR SEQ ID NO: 323:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 323: CATGTTGCCG CCG 13

(2) INFORMATION FOR SEQ ID NO: 324:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:324: AATTCGGCGG CAACGGCGGC AA 22

(2) INFORMATION FOR SEQ ID NO: 325:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:325: CATGTTGCCG CCGTTGCCGC CG 22

(2) INFORMATION FOR SEQ ID NO: 326:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 326: CGATCCATGG AGGTTCACCC TTTGCCT 27

(2) INFORMATION FOR SEQ ID NO: 327:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:327: GATCAAGCTT ATGGGCACTG GCTCAGTCT 29 (2) INFORMATION FOR SEQ ID NO: 328:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 328: CGATACATGT TGCCTACACC TGTCCTG 27

(2) INFORMATION FOR SEQ ID NO: 329:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 329: GATCAAGCTT AAGGGTGAAC CTCTGGGCA 29

(2) INFORMATION FOR SEQ ID NO: 330:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:330: CGATCCATGG TCCTGCTGCC TGCTGTG 27

(2) INFORMATION FOR SEQ ID NO: 331:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:331: GATCAAGCTT AAGGTGTAGG CAAAGGGTG 29

(2) INFORMATION FOR SEQ ID NO: 332:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 332: CGATCCATGG CTGTGGACTT TAGCTTGGGA 30

(2) INFORMATION FOR SEQ ID NO: 333:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 333: GATCAAGCTT AAGGCAGCAG GACAGGTGT 29 98/17810 M ιΛ<l PCT/US97/20037

(2) INFORMATION FOR SEQ ID NO: 334:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 334: CGATCCATGG ACTTTAGCTT GGGAGAA 27

(2) INFORMATION FOR SEQ ID NO: 335:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:335: GATCAAGCTT ACACAGCAGG CAGCAGGAC 29

(2) INFORMATION FOR SEQ ID NO:336:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:336: CGATCCATGG GAGAATGGAA AACCCAG 27

(2) INFORMATION FOR SEQ ID NO: 337:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 337: GATCAAGCTT ACAAGCTAAA GTCCACAGC 29

(2) INFORMATION FOR SEQ ID NO: 338:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:338: CGATCCATGG GACCCACTTG CCTCTCA 27

(2) INFORMATION FOR SEQ ID NO: 339:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 339: GATCAAGCTT ACAGTTGTCC CCGTGCTGC 29

(2) INFORMATION FOR SEQ ID NO: 340:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 340: CAGTCCATGG GAACCCAGCT TCCTCCA 27

(2) INFORMATION FOR SEQ ID NO: 341:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 341: GATCAAGCTT AAAGGAGGCT CTGCAGGGC 29

(2) INFORMATION FOR SEQ ID NO: 342:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:342: CGATCCATGG GCAGGACCAC AGCTCAC 27

(2) INFORMATION FOR SEQ ID NO: 343:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:343: GATCAAGCTT ACTGTGGAGG AAGCTGGGTT 30

(2) INFORMATION FOR SEQ ID NO: 344:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 344: CGATCCATGG CTCACAAGGA TCCCAATGCC 30

(2) INFORMATION FOR SEQ ID NO: 345:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 345: GATCAAGCTT ATGTGGTCCT GCCCTGTGG 29

(2) INFORMATION FOR SEQ ID NO: 346:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 346: CGATCCATGG ATCCCAATGC CATCTTCCTG 30

(2) INFORMATION FOR SEQ ID NO: 347:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 347: GATCAAGCTT ACTTGTGAGC TGTGGTCCT 29

(2) INFORMATION FOR SEQ ID NO: 348:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 348: CGATCCATGG CCATCTTCCT GAGCTTCCAA 30

(2) INFORMATION FOR SEQ ID NO: 349:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 349: GATCAAGCTT AATTGGGATC CTTGTGAGCT GT 32

(2) INFORMATION FOR SEQ ID NO: 350:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 83 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 350:

AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT 60 ACGTAGAGGG CGGTGGAGGC TCC 83

(2) INFORMATION FOR SEQ ID NO: 351:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 83 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:351:

CCGGGGAGCC TCCACCGCCC TCTACGTACT GTTGAGCCTG CGCGTTCTCC AAGGTTTTCA 60 GATAGAAGGT CAGTTTACGA CGG 83

(2) INFORMATION FOR SEQ ID NO: 352:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:352: GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTAACTGCTC TATAATGAT 59 (2) INFORMATION FOR SEQ ID NO: 353:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 56 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:353: CGATCATTAT AGAGCAGTTA GAGCCACCAC CCTGTTGTTC CTGCGCTTGC TCAAGG 56

(2) INFORMATION FOR SEQ ID NO: 354:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 83 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 354:

GTTACCCTTG AGCAAGCGCA GGAACAACAG GGTGGTGGCT CTGGCGGTGG CAGCGGCGGC 60 GGTTCTAACT GCTCTATAAT GAT 83

(2) INFORMATION FOR SEQ ID NO: 355:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 80 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 355:

CGATCATTAT AGAGCAGTTA GAACCGCCGC CGCTGCCACC GCCAGAGCCA CCACCCTGTT 60 GTTCCTGCGC TTGCTCAAGG 80

(2) INFORMATION FOR SEQ ID NO: 356:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 356:

GATCGACCAT GGCTCTGGAC CCGAACAACC TC 32

(2) INFORMATION FOR SEQ ID NO: 357:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 357: CTCGATTACG TACAAAGGTG CAGGTGGT 28

(2) INFORMATION FOR SEQ ID NO: 358:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 358: GATCGACCAT GGCTAATGCA TCAGGTATTG AG 32

(2) INFORMATION FOR SEQ ID NO: 359:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:359: CTCGATTACG TATTCTAAGT TCTTGACA 28

(2) INFORMATION FOR SEQ ID NO: 360:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 360: GATCGACCAT GGCTGCACCC TCTCGACATC CA 32

(2) INFORMATION FOR SEQ ID NO: 361:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 361: CTCGATTACG TAGGCCGTGG CAGAGGGC 28

(2) INFORMATION FOR SEQ ID NO: 362:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 362: GATCGACCAT GGCTGCAGGT GACTGGCAAG AA 32

(2) INFORMATION FOR SEQ ID NO: 363: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:363: CTCGATTACG TACTTGATGA TGATTGGA 28

(2) INFORMATION FOR SEQ ID NO: 364:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 54 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:364: GCTCTGAGAG CCGCCAGAGC CGCCAGAGGG CTGCGCAAGG TGGCGTAGAA CGCG 54

(2) INFORMATION FOR SEQ ID NO: 365:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 54 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 365: CAGCCCTCTG GCGGCTCTGG CGGCTCTCAG AGCTTCCTGC TCAAGTCTTT AGAG 54

(2) INFORMATION FOR SEQ ID NO: 366:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 366: GGGCTGCGCA AGGTGGCG 18

(2) INFORMATION FOR SEQ ID NO: 367:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:367: ACACCATTGG GCCCTGCCAG C 21

(2) INFORMATION FOR SEQ ID NO: 368:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 368: GATCGACCAT GGCTTACAAG CTGTGCCACC CC 32

(2) INFORMATION FOR SEQ ID NO: 369: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 369: CGATCGAAGC TTATTAGGTG GCACACAGCT TCTCCT 36

(2) INFORMATION FOR SEQ ID NO: 370:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 370: GATCGACCAT GGCTCCCGAG TTGGGTCCCA CC 32

(2) INFORMATION FOR SEQ ID NO: 371:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 371: CGATCGAAGC TTATTAGGAT ATCCCTTCCA GGGCCT 36

(2) INFORMATION FOR SEQ ID NO: 372:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:372: GATCGACCAT GGCTATGGCC CCTGCCCTGC AG 32

(2) INFORMATION FOR SEQ ID NO: 373:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 373: CGATCGAAGC TTATTATCCC AGTTCTTCCA TCTGCT 36

(2) INFORMATION FOR SEQ ID NO: 374:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 374: GATCGACCAT GGCTACCCAG GGTGCCATGC CG 32

(2) INFORMATION FOR SEQ ID NO: 375: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 375: CGATCGAAGC TTATTAGGGC TGCAGGGCAG GGGCCA 36

(2) INFORMATION FOR SEQ ID NO: 376:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:376: GATCGACCAT GGCTTCTGCT TTCCAGCGCC GG 32

(2) INFORMATION FOR SEQ ID NO: 377:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 377: CGATCGAAGC TTATTAGGCG AAGGCCGGCA TGGCAC 36

(2) INFORMATION FOR SEQ ID NO: 378:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:378: GTAGAGGGCG GTGGAGGCTC C 21

(2) INFORMATION FOR SEQ ID NO: 379:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 379: CCGGGGAGCC TCCACCGCCC TCTAC 25

(2) INFORMATION FOR SEQ ID NO: 380:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 380: TTCTACGCCA CCTTGCGCAG CCCGGCGGCG GCTCTGACAT GTCTACACCA TTG 53 (2) INFORMATION FOR SEQ ID NO: 381:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:381: CAATGGTGTA GACATGTCAG AGCCGCCGCC GGGCTGCGCA AGGTGGCGTA GAA 53

(2) INFORMATION FOR SEQ ID NO:382:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 382: GTCAGACCAT GGCCGATTAC CCAGTCACCG TGGCCTC 37

(2) INFORMATION FOR SEQ ID NO: 383:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:383: GTCAGCCCAT GGCCGCCTCC AACCTGCAGG ACGAGGA 37

(2) INFORMATION FOR SEQ ID NO: 384:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 384: GTCAGACCAT GGCCGTCGCT GGGTCCAAGA TGCAAGGC 38

(2) INFORMATION FOR SEQ ID NO: 385:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 385: GTCAGACCAT GGCCCGCTTC GTCCAGACCA ACATCTCC 38

(2) INFORMATION FOR SEQ ID NO: 386:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:386: GTCAGACCAT GGCCACCAAC ATCTCCCGCC TCCTGCAG 38 (2) INFORMATION FOR SEQ ID NO: 387:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 387: TCTGACAAGC TTATTGAAGC AGGTAGTCAG ACAGCTCAC 39

(2) INFORMATION FOR SEQ ID NO: 388:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:388: TCTGACAAGC TTACACGGTG ACTGGGTAAT CTTGAAGC 38

(2) INFORMATION FOR SEQ ID NO: 389:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:389: TCTGACAAGC TTAAGTCTTG AGCCGCTCCA TCCAGCG 37

(2) INFORMATION FOR SEQ ID NO: 390:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 390: GTCAAGAAGC TTACGGCTGA AAGGCACATT TG 32

(2) INFORMATION FOR SEQ ID NO: 391:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 391: TCTGACAAGC TTAAAGACAG CTGGGGGGGG GCTGAA 36

(2) INFORMATION FOR SEQ ID NO: 392:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 392: CTCGACAAGC TTACTGGACG AAGCGAAGAC AGCTGGG 37

(2) INFORMATION FOR SEQ ID NO: 393:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:393: GTTGCCATGG CNTCNAAYCT GCARGAYGAR GARCTGTGCG GGGGCCTCTG GCGGCTG 57 (2) INFORMATION FOR SEQ ID NO: 394:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:394: GTTGCCATGG CNAAYCTGCA RGAYGARGAR CTGTGYGGGG GCCTCTGGCG GCTGGTC 57 (2) INFORMATION FOR SEQ ID NO: 395:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 395: GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGGCGGCT GGTCCTG 57 (2) INFORMATION FOR SEQ ID NO: 396:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 396: GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GGCGGCTGGT CCTGGCA 57 (2) INFORMATION FOR SEQ ID NO: 397:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 397: GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCCT GGCACAG 57 (2) INFORMATION FOR SEQ ID NO: 398:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 398: GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGGCGGC TGGTCCTGGC ACAGCGC 57 (2) INFORMATION FOR SEQ ID NO: 399:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 399: GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG 57 (2) INFORMATION FOR SEQ ID NO: 400:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:400: GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCACAGCG CTGGATG 57 (2) INFORMATION FOR SEQ ID NO: 401:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 42 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 401: GTTGCCATGG CWGATGAAGA ACTGTGTGGN GGNCTGTGGC GG 42

(2) INFORMATION FOR SEQ ID NO: 402:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 402: TATGCAAGCT TAGGCCACGG TGACTGGGTA 30

(2) INFORMATION FOR SEQ ID NO: 403:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:403: TATGCAAGCT TAGGAGGCCA CGGTGACTGG 30

(2) INFORMATION FOR SEQ ID NO: 404:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 404: TATGCAAGCT TAGTTGGAGG CCACGGTGAC 30

(2) INFORMATION FOR SEQ ID NO: 405:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 405: TATGCAAGCT TACAGGTTGG AGGCCACGGT 30

(2) INFORMATION FOR SEQ ID NO: 406:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 406: TATGCAAGCT TAGTCCAGGT TGGAGGCCAC 30

(2) INFORMATION FOR SEQ ID NO: 407:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 407: TATGCAAGCT TACTCGTCCA GGTTGGAGGC 30

(2) INFORMATION FOR SEQ ID NO: 408:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 408: TATGCAAGCT TACTCCTCGT CCAGGTTGGA 30

(2) INFORMATION FOR SEQ ID NO: 409:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 44 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 409: GACTAGCCAT GGCNGAYGAR GARCTGTGYG GTGGCCTCTG GCGG 44

(2) INFORMATION FOR SEQ ID NO: 410:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 410: GACTAGTACG TACTGCAGGT TGGAGGCCAC GG 32

(2) INFORMATION FOR SEQ ID NO: 411:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 411: GCAGGTTACG TATTGAAGCA GGTAGTCAGA CAGCTC 36

(2) INFORMATION FOR SEQ ID NO: 412:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 412: GCAGGTTACG TACACGGTGA CTGGGTAATC TTGAAG 36

(2) INFORMATION FOR SEQ ID NO: 413:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 413: GCAGGTTACG TAAGTCTTGA GCCGCTCCAT CCAGC 35

(2) INFORMATION FOR SEQ ID NO: 414:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 414: GCAGGTTACG TAGCCAGCGA CAGTCTTGAG CCGCTC 36

(2) INFORMATION FOR SEQ ID NO: 415:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 49 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 415: GTCAAGCCAT GGCNCCRCCR AGCTGTCTRC GCTTCGTTCA GACCAACTC 49

(2) INFORMATION FOR SEQ ID NO: 416:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear £ 2/

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 416:^" GCAGGTTACG TACGGCTGAA AGGCACATTT GGTGACAA 38

(2) INFORMATION FOR SEQ ID NO: 417:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 417: GCAGGTTACG TAAAGACAGC TGGGGGGGGG 30

(2) INFORMATION FOR SEQ ID NO: 418:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 34 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 418: GCAGGTTACG TACTGGACGA AGCGAAGACA GCTG 34

(2) INFORMATION FOR SEQ ID NO: 419:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: TATGCTACGT AGGCCACGGT GACTGGGTA 29

(2) INFORMATION FOR SEQ ID NO: 420:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 420: TATGCTACGT AGGAGGCCAC GGTGACTGG 29

(2) INFORMATION FOR SEQ ID NO: 421:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 421: TATGCTACGT AGTTGGAGGC CACGGTGAC 29

(2) INFORMATION FOR SEQ ID NO: 422:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 422: TATGCTACGT ACAGGTTGGA GGCCACGGT 29

(2) INFORMATION FOR SEQ ID NO: 423:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 423: TATGCTACGT AGTCCAGGTT GGAGGCCAC 29

(2) INFORMATION FOR SEQ ID NO: 424:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 424: TATGCTACGT ACTCGTCCAG GTTGGAGGC 29

(2) INFORMATION FOR SEQ ID NO: 425:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 425: TATGCTACGT ACTCCTCGTC CAGGTTGGA 29

(2) INFORMATION FOR SEQ ID NO: 426:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:426: TCAGTTGGAT CCGGCGGCGG AAGCGGAGGT GGCTCTGGGG GAGGTA 46

(2) INFORMATION FOR SEQ ID NO: 427:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 427: TCAGTTGGAT CCTCCGCCAG AACCACCGCC TGACCCACCT CCTGACCC 48

(2) INFORMATION FOR SEQ ID NO: 428:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 base pairs

(B) TYPE: nucleic acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:428: GTCTGAGGCG CCACCGCACC GACCGCTGGA CAACCGCCTC TGACCCAGGA CTGCTCCTTC 60 (2) INFORMATION FOR SEQ ID NO: 429:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 429: GTCTGAGGCG CCACCGCACC GACCACCCAG GACTGCTCCT TCCAAC 46

(2) INFORMATION FOR SEQ ID NO: 430:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:430: GTCTGAGGCG CCGAGTGGAC GCGGGCTCCA CGGTGGCGGC AGGGTTGAGG AGTCGGGCTG 60 (2) INFORMATION FOR SEQ ID NO: 431:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 431: GTTGCCATGG CNTCNAAYCT GCARGAYGAR GARCTGTGCG GGGGCCTCTG GCGGCTG 57 (2) INFORMATION FOR SEQ ID NO: 432:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 432: GTTGCCATGG CNAAYCTGCA RGAYGARGAR CTGTGYGGGG GCCTCTGGCG GCTGGTC 57 (2) INFORMATION FOR SEQ ID NO: 433:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:433:

GTTGCCATGG CNCTGCARGA YGARGARCTG TGYGGYGGCC TCTGGCGGCT GGTCCTG 57

(2) INFORMATION FOR SEQ ID NO: 434: ■

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 434: GTTGCCATGG CNCARGAYGA RGARCTGTGY GGYGGYCTCT GGCGGCTGGT CCTGGCA 57 (2) INFORMATION FOR SEQ ID NO: 435:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 435: GTTGCCATGG CNGAYGARGA RCTGTGYGGY GGYCTCTGGC GGCTGGTCCT GGCACAG 57 (2) INFORMATION FOR SEQ ID NO: 436:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:436: GTTGCCATGG CNGARGARCT GTGYGGYGGY CTCTGGCGGC TGGTCCTGGC ACAGCGC 57 (2) INFORMATION FOR SEQ ID NO:437:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 437: GTTGCCATGG CNGARCTGTG YGGYGGYCTG TGGCGYCTGG TCCTGGCACA GCGCTGG 57 (2) INFORMATION FOR SEQ ID NO: 438:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 438: GTTGCCATGG CNCTGTGYGG YGGYCTGTGG CGYCTGGTCC TGGCACAGCG CTGGATG 57 (2) INFORMATION FOR SEQ ID NO: 439:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 439: TATGCAAGCT TAGGCCACGG TGACTGGGTA 30

(2) INFORMATION FOR SEQ ID NO: 440: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 440: TATGCAAGCT TAGGAGGCCA CGGTGACTGG 30

(2) INFORMATION FOR SEQ ID NO: 441:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 441: TATGCAAGCT TAGTTGGAGG CCACGGTGAC 30

(2) INFORMATION FOR SEQ ID NO: 442:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 442: TATGCAAGCT TACAGGTTGG AGGCCACGGT 30

(2) INFORMATION FOR SEQ ID NO: 443:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 443: TATGCAAGCT TACTGCAGGT TGGAGGCCAC 30

(2) INFORMATION FOR SEQ ID NO: 444:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 444: TATGCAAGCT TAGTCCTGCA GGTTGGAGGC 30

(2) INFORMATION FOR SEQ ID NO: 445:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 445: TATGCAAGCT TACTCGTCCT GCAGGTTGGA 30

(2) INFORMATION FOR SEQ ID NO: 446: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 446: TATGCAAGCT TACTCCTCGT CCTGCAGGTT 30

(2) INFORMATION FOR SEQ ID NO: 447:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 447: GCTACGTCTA GATCTCCTGA CCTCGACCCA GGACTGCTCC TTCCAAC 47

(2) INFORMATION FOR SEQ ID NO: 448:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 68 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 448:

GCTAGTTCTA GACCATCCTG GCTGACACGG TGAAACACCG TCTCTACGGG CTGACACTGC 60 AGCTCCAG 68

(2) INFORMATION FOR SEQ ID NO: 449:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 56 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 449: GTCAGTACTA GTATGGGTGT CCGGGCTCTT CGGCTCCTGC AGGTTGGAGG CCACGG 56

(2) INFORMATION FOR SEQ ID NO: 450:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 450: GTCAGTACTA GTCCGCCATC TCCGACACCA TTAGGCCCTG CCAGC 45

(2) INFORMATION FOR SEQ ID NO: 451:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 49 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 451: GTCAGTTCCG GAGATTTCGG TTCTGCAGAG GGCTGCGCAA GGTGGCGTA 49 (2) INFORMATION FOR SEQ ID NO: 452:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 452:

GTCAGTTCCG GATACTCATA CCAGCCCGCC ATCCCCGGGT TCTAATCTGC AAGATGAAGA 60 GCTG 64

(2) INFORMATION FOR SEQ ID NO: 453:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 61 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 453:

GTCAGTACTA GTATGGGTGT CCGGGCTCTT CGGAAAGGCA CATTTGGTGA CAAAGTGTAT 60 C 61

(2) INFORMATION FOR SEQ ID NO: 454:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 454: GTCAGTACTA GTCCGCCATC TCCGGGTACA CCATTAGGCC CTGCCAGC 48

(2) INFORMATION FOR SEQ ID NO: 455:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 63 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 455:

GTCAGTTCCG GATACTCATA CCAGCCCGCC ATCCCCGGGT AAGGCCTTTC AGCCCCCCCC 60 CAG 63

(2) INFORMATION FOR SEQ ID NO: 456:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:456: GTCAGACCAT GGCCACTCAG GACTCCTCTT TTC 33

(2) INFORMATION FOR SEQ ID NO: 457:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 457: CACTTTGTCA CCAAATCTGC CTTTCAG 27

(2) INFORMATION FOR SEQ ID NO: 458:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 458: CTGAAAGGCA GATTTGGTGA CAAAGTG 27

(2) INFORMATION FOR SEQ ID NO: 459:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 459: GCCCCCCCCC AGCTCTCTTC G 21

(2) INFORMATION FOR SEQ ID NO: 460:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 460: CGAAGAGAGC TGGGGGGGGG C 21

(2) INFORMATION FOR SEQ ID NO: 461:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 41 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 461: GTCAGTTACG TACAGGGTTG AAGGAGTCGG GCTGAGACTG C 41

(2) INFORMATION FOR SEQ ID NO: 462:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 462: GTCAGTCCAT GGCTACTCAA GGTGCTATGC 30

(2) INFORMATION FOR SEQ ID NO: 463:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:463: GTAGCATACG TAGGGCTGCA GGGCAGGGGC C 31

(2) INFORMATION FOR SEQ ID NO: 464:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 166 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 464:

Ala Pro Pro Arg Leu lie Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu

1 5 10 15

Leu Glu Ala Lys Glu Ala Glu Asn lie Thr Thr Gly Cys Ala Glu His

20 25 30

Cys Ser Leu Asn Glu Asn lie Thr Val Pro Asp Thr Lys Val Asn Phe

35 40 45

Tyr Ala Trp Lys Arg Met Glu Val Gly Gin Gin Ala Val Glu Val Trp

50 55 60

Gin Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gin Ala Leu 65 70 75 80

Leu Val Asn Ser Ser Gin Pro Trp Glu Pro Leu Gin Leu His Val Asp

85 90 95

Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu

100 105 110

Gly Ala Gin Lys Glu Ala lie Ser Pro Pro Asp Ala Ala Ser Ala Ala

115 120 125

Pro Leu Arg Thr lie Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val

130 135 140

Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala 145 150 155 160

Cys Arg Thr Gly Asp Arg 165

(2) INFORMATION FOR SEQ ID NO: 465:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 165 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:465:

Glu Gly lie Cys Arg Asn Arg Val Thr Asn Asn Val Lys Asp Val Thr

1 5 10 15

Lys Leu Val Ala Asn Leu Pro Lys Asp Tyr Met lie Thr Leu Lys Tyr

20 25 30

Val Pro Gly Met Asp Val Leu Pro Ser His Cys Trp lie Ser Glu Met

35 40 45

Val Val Gin Leu Ser Asp Ser Leu Thr Asp Leu Leu Asp Lys Phe Ser

50 55 60

Asn lie Ser Glu Gly Leu Ser Asn Tyr Ser lie lie Asp Lys Leu Val 65 70 75 80

Asn He Val Asp Asp Leu Val Glu Cys Val Lys Glu Asn Ser Ser Lys

85 90 95

Asp Leu Lys Lys Ser Phe Lys Ser Pro Glu Pro Arg Leu Phe Thr Pro

100 105 110

Glu Glu Phe Phe Arg He Phe Asn Arg Ser He Asp Ala Phe Lys Asp

115 120 125

Phe Val Val Ala Ser Glu Thr Ser Asp Cys Val Val Ser Ser Thr Leu

130 135 140

Ser Pro Glu Lys Asp Ser Arg Val Ser Val Thr Lys Pro Phe Met Leu 145 150 155 160

Pro Pro Val Ala Ala 165

(2) INFORMATION FOR SEQ ID NO: 466: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 139 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 466:

Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala

1 5 10 15

Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val

20 25 30

Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp

35 40 45

Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala

50 55 60

Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His 65 70 75 80

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

85 90 95

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

100 105 110

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

115 120 125

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135

(2) INFORMATION FOR SEQ ID NO: 467:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 467:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

100 105 110

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe

115 120 125

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe 145 150 155

(2) INFORMATION FOR SEQ ID NO: 468:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 468:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

100 105 110

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe

115 120 125

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala 145 150 155 160

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

165 170 175

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

180 185 190

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

195 200 205

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

210 215 220

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 225 230 235 240

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

245 250 255

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Gly

260 265 270

Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin

275 280 285

His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser

290 295 300

Thr Leu Cys Val Arg 305

(2) INFORMATION FOR SEQ ID NO: 469:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 312 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 469:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

100 105 110

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe

115 120 125

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser 145 150 155 160

Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg

165 170 175

Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His

180 185 190

Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly

195 200 205

Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly 210 215 220

Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu 225 230 235 240

Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val

245 250 255

Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro

260 265 270

Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu

275 280 285

Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val

290 295 300

Gly Gly Ser Thr Leu Cys Val Arg 305 310

(2) INFORMATION FOR SEQ ID NO: 470:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 313 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 470:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

100 105 110

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe

115 120 125

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala 145 150 155 160

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

165 170 175

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

180 185 190

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

195 200 205

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

210 215 220

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 225 230 235 240

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

245 250 255

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

260 265 270

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe

275 280 285

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

290 295 300

Val Gly Gly Ser Thr Leu Cys Val Arg 305 310

(2) INFORMATION FOR SEQ ID NO: 471:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 316 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 471:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

100 105 110

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe

115 120 125

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly 145 150 155 160

Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser

165 170 175

Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys

180 185 190

Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp

195 200 205

Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin

210 215 220

Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala 225 230 235 240

Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu

245 250 255

Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly

260 265 270

Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn

275 280 285

Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe

290 295 300

Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg 305 310 315

(2) INFORMATION FOR SEQ ID NO: 472:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 302 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 472:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly

130 135 140

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 145 150 155 160

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 165 170 175 Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

180 185 190

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

195 200 205

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin

210 215 220

Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 225 230 235 240

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val

245 250 255

Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly

260 265 270

Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He

275 280 285

Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr 290 295 300

(2) INFORMATION FOR SEQ ID NO: 473:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 317 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 473:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 145 150 155 160

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

165 170 175

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

180 185 190

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

195 200 205

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr

210 215 220

He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 225 230 235 240

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala

245 250 255

Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser

260 265 270

Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly

275 280 285

Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin

290 295 300

Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr 305 310 315

(2) INFORMATION FOR SEQ ID NO: 474:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 302 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 474:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp

130 135 140

Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly 145 150 155 160

Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala

165 170 175

Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu

180 185 190

Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin

195 200 205

Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu

210 215 220

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 225 230 235 240

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu

245 250 255

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

260 265 270

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

275 280 285

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser 290 295 300

(2) INFORMATION FOR SEQ ID NO: 475:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 317 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:475:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val 145 150 155 160

Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met 165 170 175

Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser

180 185 190

Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin

195 200 205

Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

210 215 220

Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu 225 230 235 240

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu

245 250 255

Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly

260 265 270

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

275 280 285

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe

290 295 300

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser 305 310 315

(2) INFORMATION FOR SEQ ID NO: 476:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 302 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:476:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro

130 135 140

Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala 145 150 155 160

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His

165 170 175

Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu

180 185 190

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

195 200 205

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

210 215 220

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser 225 230 235 240

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His

245 250 255

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

260 265 270

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

275 280 285

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly 290 295 300

(2) INFORMATION FOR SEQ ID NO: 477:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 317 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 477:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 145 150 155 160

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser

165 170 175

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu

180 185 190

Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys

195 200 205

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin

210 215 220

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 225 230 235 240

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

245 250 255

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser

260 265 270

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

275 280 285

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

290 295 300

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly 305 310 315

(2) INFORMATION FOR SEQ ID NO: 478:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 302 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 478:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin 130 135 140 Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu 145 150 155 160

Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly

165 170 175

Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg

180 185 190

Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr

195 200 205

Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu

210 215 220

Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin 225 230 235 240

Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin

245 250 255

Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr

260 265 270

Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp

275 280 285

Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 290 295 300

(2) INFORMATION FOR SEQ ID NO: 479:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 317 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:479:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 145 150 155 160

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

165 170 175

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser

180 185 190

Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys

195 200 205

He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr

210 215 220

Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly 225 230 235 240

He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu

245 250 255

Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly

260 265 270

Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu

275 280 285

Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin

290 295 300

Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315

(2) INFORMATION FOR SEQ ID NO: 480:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 302 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 480:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala

130 135 140

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 145 150 155 160

Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu

165 170 175

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

180 185 190

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

195 200 205

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

210 215 220

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 225 230 235 240

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

245 250 255

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

260 265 270

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

275 280 285

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala 290 295 300

(2) INFORMATION FOR SEQ ID NO: 481:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 317 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:481:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn SSΛ

130 135 140

Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser 145 150 155 160

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu

165 170 175

Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys

180 185 190

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin

195 200 205

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val

210 215 220

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys 225 230 235 240

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser

245 250 255

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

260 265 270

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

275 280 285

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro

290 295 300

Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala 305 310 315

(2) INFORMATION FOR SEQ ID NO: 482:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 482:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly

130 135 140

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 145 150 155 160

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe

165 170 175

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

180 185 190

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

195 200 205

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin

210 215 220

Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 225 230 235 240

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val

245 250 255

Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro

260 265 270

Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

275 280 285

Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala

290 295 300

Thr 305 (2) INFORMATION FOR SEQ ID NO: 483:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 320 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:483:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 145 150 155 160

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

165 170 175

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

180 185 190

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

195 200 205

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr

210 215 220

He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 225 230 235 240

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala

245 250 255

Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser

260 265 270

Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala

275 280 285

Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg

290 295 300

Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr 305 310 315 320

(2) INFORMATION FOR SEQ ID NO: 484:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 484:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys 85 90 95 98/17810 ._., „ PCT/US97/20037

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp

130 135 140

Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly 145 150 155 160

Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala

165 170 175

Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu

180 185 190

Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin

195 200 205

Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

210 215 220

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu 225 230 235 240

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

245 250 255

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

260 265 270

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His

275 280 285

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

290 295 300

Ser 305

(2) INFORMATION FOR SEQ ID NO: 485:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 320 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 485:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val 145 150 155 160

Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met

165 170 175

Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser

180 185 190

Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin

195 200 205

Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

210 215 220

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys 225 230 235 240

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin

245 250 255

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val

260 265 270

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys 275 280 285 Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser

290 295 300

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

305 310 315 320

(2) INFORMATION FOR SEQ ID NO: 486:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:486:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30 lie Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro

130 135 140

Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala 145 150 155 160

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His

165 170 175

Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

180 185 190

Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

195 200 205

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro

210 215 220

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro 225 230 235 240

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

245 250 255

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

260 265 270

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

275 280 285

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu

290 295 300

Gly 305

(2) INFORMATION FOR SEQ ID NO: 487:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 320 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 487:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu 50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 145 150 155 160

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser

165 170 175

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu

180 185 190

Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe

195 200 205

Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala

210 215 220

Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu 225 230 235 240

Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu

245 250 255

Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin

260 265 270

Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu

275 280 285

Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp

290 295 300

Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly 305 310 315 320

(2) INFORMATION FOR SEQ ID NO: 488:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:488:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin

130 135 140

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu 145 150 155 160

Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu

165 170 175

Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu

180 185 190

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu

195 200 205

Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly

210 215 220

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 225 230 235 240

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe 245 250 255

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

260 265 270

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

275 280 285

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin

290 295 300

Pro 305

(2) INFORMATION FOR SEQ ID NO: 489:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 320 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 489:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 145 150 155 160

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

165 170 175

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro Leu Gly

180 185 190

Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin

195 200 205

Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

210 215 220

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 225 230 235 240

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

245 250 255

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

260 265 270

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

275 280 285

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr

290 295 300

He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315 320

(2) INFORMATION FOR SEQ ID NO: 490:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 490:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro 1 5 10 15 Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser

115 120 125

Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala

130 135 140

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His 145 150 155 160

Leu Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

165 170 175

Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

180 185 190

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro

195 200 205

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

210 215 220

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser 225 230 235 240

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

245 250 255

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

260 265 270

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu

275 280 285

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

290 295 300

Ala 305

(2) INFORMATION FOR SEQ ID NO: 491:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 320 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:491:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr

100 105 110

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

115 120 125

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

130 135 140

Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser 145 150 155 160

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu

165 170 175

Ala Gin Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe

180 185 190

Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala 195 200 205 Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu

210 215 220

Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu 225 230 235 240

Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin

245 250 255

Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu

260 265 270

Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp

275 280 285

Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly

290 295 300

Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala 305 310 315 320

(2) INFORMATION FOR SEQ ID NO: 492:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 321 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 492:

Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp

1 5 10 15

Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys

20 25 30

Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin

35 40 45

Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He

50 55 60

He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr 65 70 75 80

Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn

85 90 95

Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro

100 105 110

Ala Pro Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser

115 120 125

Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His

130 135 140

Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160

Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin

165 170 175

Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

180 185 190

Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu

195 200 205

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu

210 215 220

Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

245 250 255

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe

260 265 270

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

275 280 285

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

290 295 300

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320

Pro

(2) INFORMATION FOR SEQ ID NO: 493:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 321 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:493:

Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu

1 5 10 15

Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala

20 25 30

Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

35 40 45

Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser He

50 55 60

Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu 65 70 75 80

Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp

85 90 95

Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys

100 105 110

Asn Leu Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser

115 120 125

Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His

130 135 140

Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160

Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin

165 170 175

Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

180 185 190

Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu

195 200 205

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu

210 215 220

Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

245 250 255

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe

260 265 270

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

275 280 285

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

290 295 300

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320

Pro

(2) INFORMATION FOR SEQ ID NO: 494:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 321 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 494:

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

1 5 10 15

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

20 25 30

Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He

35 40 45

He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn

50 55 60

Leu Asn Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu 65 70 75 80

Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala

85 90 95

Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser

100 105 110

Ala Thr Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser

115 120 125

Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His 130 135 140

Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160

Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin

165 170 175

Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

180 185 190

Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu

195 200 205

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu

210 215 220

Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

245 250 255

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe

260 265 270

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

275 280 285

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

290 295 300

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320

Pro

(2) INFORMATION FOR SEQ ID NO: 495:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 321 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 495:

Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

1 5 10 15

Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Asn Cys Ser

20 25 30

He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro

35 40 45

Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met

50 55 60

Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val 65 70 75 80

Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu

85 90 95

Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He

100 105 110

He He Lys Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser

115 120 125

Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His

130 135 140

Lys Ser Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser 145 150 155 160

Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin

165 170 175

Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro

180 185 190

Ser Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu

195 200 205

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu

210 215 220

Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

245 250 255

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe

260 265 270

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

275 280 285

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

290 295 300

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 15 320

Pro

(2) INFORMATION FOR SEQ ID NO: 496:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 496:

Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He Leu Met Asp

1 5 10 15

Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys

20 25 30

Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin

35 40 45

Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He

50 55 60

He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr 65 70 75 80

Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly

85 90 95

Gly Gly Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He

100 105 110

He His His Leu Lys Arg Pro Pro Ala Pro Leu Tyr Val Glu Gly Gly

115 120 125

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

130 135 140

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin 145 150 155 160

Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly

165 170 175

Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

180 185 190

Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin

195 200 205

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp

210 215 220

Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala

245 250 255

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

260 265 270

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

275 280 285

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

290 295 300

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu 305 310 315 320

Leu Gly Met Ala Pro Ala Leu Gin Pro 325

(2) INFORMATION FOR SEQ ID NO: 497:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 497:

Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu

1 5 10 15

Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala

20 25 30

Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr 35 40 45 Leu Glu Gin Ala Gin Glu Gin Gin Gly Giy Gly Ser Gly Gly Gly Ser

50 55 60

Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His His 65 70 75 80

Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp

85 90 95

Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu

100 105 110

Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Tyr Val Glu Gly Gly

115 120 125

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

130 135 140

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin 145 150 155 160

Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly

165 170 175

Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

180 185 190

Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin

195 200 205

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp

210 215 220

Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala

245 250 255

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

260 265 270

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

275 280 285

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

290 295 300

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu 305 310 315 320

Leu Gly Met Ala Pro Ala Leu Gin Pro 325

(2) INFORMATION FOR SEQ ID NO: 498:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 498:

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

1 5 10 15

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

20 25 30

Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asn

35 40 45

Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro

50 55 60

Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser He 65 70 75 80

Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg

85 90 95

Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg

100 105 110

Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Tyr Val Glu Gly Gly

115 120 125

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

130 135 140

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin 145 150 155 160

Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly

165 170 175

Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

180 185 190

Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin

195 200 205

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp 210 215 220 Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala

245 250 255

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

260 265 270

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

275 280 285

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

290 295 300

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu 305 310 315 320

Leu Gly Met Ala Pro Ala Leu Gin Pro 325

(2) INFORMATION FOR SEQ ID NO: 499:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 499:

Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

1 5 10 15

Thr Leu Glu Gin Ala Gin Glu Gin Gin Gly Gly Gly Ser Gly Gly Gly

20 25 30

Ser Gly Gly Gly Ser Asn Cys Ser He Met He Asp Glu He He His

35 40 45

His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn

50 55 60

Asp Glu Asp Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn 65 70 75 80

Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly

85 90 95

He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

100 105 110

Ala Ala Pro Ser Arg His Pro He He He Lys Tyr Val Glu Gly Gly

115 120 125

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

130 135 140

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin 145 150 155 160

Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly

165 170 175

Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg

180 185 190

Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly Gly Ser Gin

195 200 205

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp

210 215 220

Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala

245 250 255

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

260 265 270

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

275 280 285

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

290 295 300

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu 305 310 315 320

Leu Gly Met Ala Pro Ala Leu Gin Pro 325

(2) INFORMATION FOR SEQ ID NO: 500:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:500:

Met Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

1 5 10 15

Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

20 25 30

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser

35 40 45

Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala

50 55 60

He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80

Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg

85 90 95

Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

130 135 140

Pro Asn Met Ala Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 145 150 155 160

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

165 170 175

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

180 185 190

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

195 200 205

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

210 215 220

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 225 230 235 240

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg

245 250 255

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

260 265 270

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Gly Gly Gly Ser

275 280 285

Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe

290 295 300

Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala 305 310 315 320

Ala Leu Gin Glu Lys Leu Cys Ala Thr 325

(2) INFORMATION FOR SEQ ID NO: 501:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 501:

Met Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

1 5 10 15

Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

20 25 30

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser

35 40 45

Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala

50 55 60

He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80

Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg

85 90 95

Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 130 135 140

Pro Asn Met Ala Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu 145 150 155 160

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu

165 170 175

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

180 185 190

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

195 200 205

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

210 215 220

Gin Pro Gly Gly Gly Ser Asp Met Ala Thr Pro Leu Gly Pro Ala Ser 225 230 235 240

Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys

245 250 255

He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr

260 265 270

Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly

275 280 285

He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu

290 295 300

Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly 305 310 315 320

Leu Leu Gin Ala Leu Glu Gly He Ser 325

(2) INFORMATION FOR SEQ ID NO: 502:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 502:

Met Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

1 5 10 15

Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

20 25 30

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser

35 40 45

Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala

50 55 60

He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80

Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg

85 90 95

Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

130 135 140

Pro Asn Met Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val 145 150 155 160

Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg

165 170 175

His Leu Ala Gin Pro Gly Gly Gly Ser Asp Met Ala Thr Pro Leu Gly

180 185 190

Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin

195 200 205

Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

210 215 220

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 225 230 235 240

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

245 250 255

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

260 265 270

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

275 280 285

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr

290 295 300

He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315 320

Thr Gin Gly Ala Met Pro Ala Phe Ala 325

(2) INFORMATION FOR SEQ ID NO: 503:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 503:

Met Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

1 5 10 15

Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

20 25 30

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser

35 40 45

Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala

50 55 60

He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80

Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg

85 90 95

Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

130 135 140

Pro Asn Met Ala Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met 145 150 155 160

Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val

165 170 175

Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg

180 185 190

His Leu Ala Gin Pro Gly Gly Gly Ser Asp Met Ala Thr Pro Leu Gly

195 200 205

Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin

210 215 220

Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 225 230 235 240

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His

245 250 255

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

260 265 270

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

275 280 285

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

290 295 300

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320

He Trp Gin Gin Met Glu Glu Leu Gly 325

(2) INFORMATION FOR SEQ ID NO: 504:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 329 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:504:

Met Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

1 5 10 15

Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

20 25 30

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser 35 40 45 Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala

50 55 60

He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro 65 70 75 80

Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg

85 90 95

Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

130 135 140

Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

165 170 175

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Gly Gly

180 185 190

Gly Ser Asp Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin

195 200 205

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp

210 215 220

Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His 225 230 235 240

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala

245 250 255

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

260 265 270

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

275 280 285

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

290 295 300

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu 305 310 315 320

Leu Gly Met Ala Pro Ala Leu Gin Pro 325

(2) INFORMATION FOR SEQ ID NO: 505:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 319 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 505:

Met Ala Asn Cys Ser Asn Met He Asp Glu He He Thr His Leu Lys

1 5 10 15

Gin Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp

20 25 30

Gin Asp He Leu Met Asp Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

35 40 45

Phe Asn Arg Ala Val Lys Ser Leu Gin Asn Ala Ser Ala He Glu Ser

50 55 60

He Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80

Thr Arg His Pro He His He Lys Asp Gly Asp Trp Asn Glu Phe Arg

85 90 95

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

130 135 140

Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

165 170 175

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly

180 185 190

Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

195 200 205

Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala 210 215 220 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser 225 230 235 240

Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu

245 250 255

Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr

260 265 270

Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro

275 280 285

Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He

290 295 300

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315

(2) INFORMATION FOR SEQ ID NO: 506:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 322 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 506:

Met Ala Asn Cys Ser Asn Met He Asp Glu He He Thr His Leu Lys

1 5 10 15

Gin Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp

20 25 30

Gin Asp He Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

35 40 45

Phe Asn Arg Ala Val Lys Ser Leu Gin Asn Ala Ser Ala He Glu Ser

50 55 60

He Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80

Thr Arg His Pro He He He Arg Asp Gly Asp Trp Asn Glu Phe Arg

85 90 95

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

130 135 140

Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

165 170 175

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

210 215 220

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro

(2) INFORMATION FOR SEQ ID NO: 507:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 319 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 507:

Met Ala Asn Cys Ser Asn Met He Asp Glu He He Thr His Leu Lys

1 5 10 15

Gin Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp

20 25 30

Gin Asp He Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

35 40 45

Phe Asn Arg Ala Val Lys Ser Leu Gin Asn Ala Ser Ala He Glu Ser

50 55 60

He Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80

Thr Arg His Pro He He He Arg Asp Gly Asp Trp Asn Glu Phe Arg

85 90 95

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

130 135 140

Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

165 170 175

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly

180 185 190

Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val

195 200 205

Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala

210 215 220

Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser 225 230 235 240

Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu

245 250 255

Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr

260 265 270

Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro

275 280 285

Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He

290 295 300

Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 305 310 315

(2) INFORMATION FOR SEQ ID NO: 508:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 322 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 508:

Met Ala Asn Cys Ser Asn Met He Asp Glu He He Thr His Leu Lys

1 5 10 15

Gin Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp

20 25 30

Gin Asp He Leu Met Asp Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala

35 40 45

Phe Asn Arg Ala Val Lys Ser Leu Gin Asn Ala Ser Ala He Glu Ser

50 55 60

He Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro 65 70 75 80

Thr Arg His Pro He His He Lys Asp Gly Asp Trp Asn Glu Phe Arg

85 90 95

Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gin Ala Gin

100 105 110

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

115 120 125

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

130 135 140

Pro Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe 145 150 155 160

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 165 170 175

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

210 215 220

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro

(2) INFORMATION FOR SEQ ID NO: 509:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:509:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160

Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala

165 170 175

Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala

180 185 190

Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin

195 200 205

Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu

210 215 220

Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro 225 230 235 240

Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg

245 250 255

Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly

260 265 270

Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu

275 280 285

Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin

290 295 300

Cys Pro 305

(2) INFORMATION FOR SEQ ID NO:510: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 510:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 145 150 155 160

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

165 170 175

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin

180 185 190

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

195 200 205

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

210 215 220

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe 225 230 235 240

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

245 250 255

Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala

260 265 270

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

275 280 285

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

290 295 300

His Pro 305

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 511:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 55Zs

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys 145 150 155 160

Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr

165 170 175

Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr

180 185 190

Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu

195 200 205

Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly

210 215 220

Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin 225 230 235 240

His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser

245 250 255

Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro

260 265 270

Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His

275 280 285

Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro

290 295 300

Thr Pro 305

(2) INFORMATION FOR SEQ ID NO: 512:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 512:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 145 150 155 160

Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu

165 170 175

Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser

180 185 190

Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu

195 200 205

Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala

210 215 220

His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg 225 230 235 240

Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val

245 250 255

Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp

260 265 270

Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser

275 280 285

Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu 290 295 300 555

Leu Pro 305

(2) INFORMATION FOR SEQ ID NO: 513:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 513:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr 145 150 155 160

Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val

165 170 175

Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu

180 185 190

Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser

195 200 205

Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys

210 215 220

Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys 225 230 235 240

Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu

245 250 255

Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg

260 265 270

Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu

275 280 285

Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro

290 295 300

Ala Val 305

(2) INFORMATION FOR SEQ ID NO: 514:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 514:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp 145 150 155 160

He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg

165 170 175

Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser

180 185 190

Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr

195 200 205

Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala

210 215 220

He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240

Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn

245 250 255

Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys

260 265 270

Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro

275 280 285

Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe

290 295 300

Ser Leu 305

(2) INFORMATION FOR SEQ ID NO: 515:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 515:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly 145 150 155 160

Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin

165 170 175

Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He

180 185 190

Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met

195 200 205

Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met

210 215 220

Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu 225 230 235 240

Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu

245 250 255

Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser 260 265 270

Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He

275 280 285

Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly

290 295 300

Gin Leu 305

(2) INFORMATION FOR SEQ ID NO: 516:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 516:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys 145 150 155 160

Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys

165 170 175

Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu

180 185 190

Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg

195 200 205

Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu

210 215 220

Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro 225 230 235 240

Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr

245 250 255

Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val

260 265 270

Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu

275 280 285

Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser

290 295 300

Leu Leu 305

(2) INFORMATION FOR SEQ ID NO: 517:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 517:

Ala Asn Cys Ser lie Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30 Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu 145 150 155 160

Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val

165 170 175

Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala Ser

180 185 190

Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg

195 200 205

Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His

210 215 220

Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly 225 230 235 240

Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly

245 250 255

Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu

260 265 270

Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val

275 280 285

Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro

290 295 300

Pro Gin 305

(2) INFORMATION FOR SEQ ID NO: 518:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 518:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin His 145 150 155 160

Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr

165 170 175

Leu Cys Val Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro

180 185 190

Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val

195 200 205

Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr 210 215 220 Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr 225 230 235 240

Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu

245 250 255

Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys

260 265 270

Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu

275 280 285

Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg

290 295 300

Thr Thr 305

(2) INFORMATION FOR SEQ ID NO: 519:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 519:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg 145 150 155 160

Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val

165 170 175

Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp

180 185 190

Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser

195 200 205

Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu

210 215 220

Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 225 230 235 240

Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu

245 250 255

Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser

260 265 270

Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu

275 280 285

Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala

290 295 300

His Lys 305

(2) INFORMATION FOR SEQ ID NO: 520:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 306 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 520: 55 ?

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val 145 150 155 160

Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe

165 170 175

Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val

180 185 190

Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser

195 200 205

Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala

210 215 220

Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys 225 230 235 240

Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met

245 250 255

Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly

260 265 270

Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu

275 280 285

Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp

290 295 300

Pro Asn 305

(2) INFORMATION FOR SEQ ID NO: 521:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 521:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160

Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala

165 170 175

Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala 180 185 190

Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin

195 200 205

Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu

210 215 220

Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro 225 230 235 240

Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg

245 250 255

Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly

260 265 270

Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser

275 280 285

Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys

290 295 300

Pro 305

(2) INFORMATION FOR SEQ ID NO: 522:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 522:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 145 150 155 160

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

165 170 175

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin

180 185 190

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

195 200 205

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

210 215 220

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe 225 230 235 240

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

245 250 255

Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser

260 265 270

Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg

275 280 285

Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His

290 295 300

Pro 305

(2) INFORMATION FOR SEQ ID NO: 523:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 523:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys 145 150 155 160

Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr

165 170 175

Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr

180 185 190

Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu

195 200 205

Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly

210 215 220

Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin 225 230 235 240

His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser

245 250 255

Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pro

260 265 270

Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val

275 280 285

Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr

290 295 300

Pro 305

(2) INFORMATION FOR SEQ ID NO: 524:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 524:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro- Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Val Asp Phe Ser Leu Gly Glu' Trp Lys Thr Gin Met Glu 145 150 155 160

Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu

165 170 175

Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser

180 185 190

Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu

195 200 205

Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala

210 215 220

His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg 225 230 235 240

Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val

245 250 255

Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu

260 265 270

Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg

275 280 285

Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu

290 295 300

Pro 305

(2) INFORMATION FOR SEQ ID NO: 525:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 525:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr 145 150 155 160

Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val

165 170 175

Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu

180 185 190

Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser

195 200 205

Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys

210 215 220

Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys 225 230 235 240

Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu

245 250 255

Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val

260 265 270

Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser

275 280 285

Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala

290 295 300

Val 305

(2) INFORMATION FOR SEQ ID NO: 526: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 526:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp 145 150 155 160

He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg

165 170 175

Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser

180 185 190

Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr

195 200 205

Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala

210 215 220

He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240

Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met

245 250 255

Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu

260 265 270

Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu

275 280 285

Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser

290 295 300

Leu 305

(2) INFORMATION FOR SEQ ID NO: 527:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 527:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly 145 150 155 160

Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin

165 170 175

Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He

180 185 190

Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met

195 200 205

Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala

210 215 220

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 225 230 235 240

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

245 250 255

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

260 265 270

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

275 280 285

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin

290 295 300

Leu 305

(2) INFORMATION FOR SEQ ID NO: 528:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 528:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys 145 150 155 160

Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys

165 170 175

Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu

180 185 190

Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val

195 200 205

Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser

210 215 220

Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala 225 230 235 240

Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys

245 250 255

Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met

260 265 270

Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly

275 280 285

Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu 290 295 300

Leu 305

(2) INFORMATION FOR SEQ ID NO: 529:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 529:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu 145 150 155 160

Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val

165 170 175

Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser Pro

180 185 190

Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp

195 200 205

Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro

210 215 220

Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu 225 230 235 240

Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala

245 250 255

Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly

260 265 270

Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg

275 280 285

Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro

290 295 300

Gin 305

(2) INFORMATION FOR SEQ ID NO: 530:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 530:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He 50 55 60 Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser'Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin His 145 150 155 160

Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr

165 170 175

Leu Cys Val Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala

180 185 190

Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu

195 200 205

His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro

210 215 220

Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin 225 230 235 240

Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu

245 250 255

Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu

260 265 270

Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly

275 280 285

Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr

290 295 300

Thr 305

(2) INFORMATION FOR SEQ ID NO: 531:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 531:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg 145 150 155 160

Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val

165 170 175

Arg Glu Phe Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu

180 185 190

Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg

195 200 205

Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu

210 215 220

Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu 225 230 235 240

Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly 245 250 255 Val Met Ala Ser Leu

Leu Gly Gin Leu Gin

275

Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His

290 295 300

Lys 305

(2) INFORMATION FOR SEQ ID NO: 532:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:532:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val 145 150 155 160

Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe

165 170 175

Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu

180 185 190

Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin

195 200 205

Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val

210 215 220

Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala 225 230 235 240

Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala

245 250 255

Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin

260 265 270

Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu

275 280 285

Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro

290 295 300

Asn 305

(2) INFORMATION FOR SEQ ID NO: 533:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 533:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val 20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val 145 150 155 160

Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala

165 170 175

Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala

180 185 190

Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin

195 200 205

Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu

210 215 220

Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro 225 230 235 240

Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg

245 250 255

Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly

260 265 270

Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu

275 280 285

Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg

290 295 300

Leu Ser Gin Cys Pro 305

(2) INFORMATION FOR SEQ ID NO: 534:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 534:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 145 150 155 160

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

165 170 175

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin

180 185 190

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

195 200 205

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu 210 215 220

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe 225 230 235 240

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

245 250 255

Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly

260 265 270

Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser

275 280 285

Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys

290 295 300

Pro Glu Val His Pro 305

(2) INFORMATION FOR SEQ ID NO: 535:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:535:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys 145 150 155 160

Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr

165 170 175

Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr

180 185 190

Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu

195 200 205

Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly

210 215 220

Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin 225 230 235 240

His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser

245 250 255

Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser

260 265 270

Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg

275 280 285

Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His

290 295 300

Pro Leu Pro Thr Pro 305

(2) INFORMATION FOR SEQ ID NO: 536:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None St.?

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 536:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 145 150 155 160

Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu

165 170 175

Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser

180 185 190

Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu

195 200 205

Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala

210 215 220

His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg 225 230 235 240

Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val

245 250 255

Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro

260 265 270

Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val

275 280 285

Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr

290 295 300

Pro Val Leu Leu Pro 305

(2) INFORMATION FOR SEQ ID NO: 537:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 537:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr 145 150 155 160

Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val 165 170 175 Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu

180 185 190

Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser

195 200 205

Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys

210 215 220

Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys 225 230 235 240

Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu

245 250 255

Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys

260 265 270

Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His

275 280 285

Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val

290 295 300

Leu Leu Pro Ala Val 305

(2) INFORMATION FOR SEQ ID NO: 538:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 538:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp 145 150 155 160

He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg

165 170 175

Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser

180 185 190

Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr

195 200 205

Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala

210 215 220

He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu 225 230 235 240

Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn

245 250 255

Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val

260 265 270

Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser

275 280 285

Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala

290 295 300

Val Asp Phe Ser Leu 305

(2) INFORMATION FOR SEQ ID NO: 539:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 539:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly 145 150 155 160

Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin

165 170 175

Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He

180 185 190

Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met

195 200 205

Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly

210 215 220

Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu 225 230 235 240

Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin

245 250 255

Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val

260 265 270

Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala

275 280 285

Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala

290 295 300

Ala Arg Gly Gin Leu 305

(2) INFORMATION FOR SEQ ID NO: 540:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:540:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140

Asn Met Gly Thr Gin Leu Pro Pro Gin Gly Arg Thr Thr Ala His Lys 145 150 155 160

Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys

165 170 175

Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu

180 185 190

Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys

195 200 205

Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His

210 215 220

Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val 225 230 235 240

Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met

245 250 255

Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu

260 265 270

Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser

275 280 285

Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala

290 295 300

Leu Gin Ser Leu Leu 305

(2) INFORMATION FOR SEQ ID NO: 541:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 541:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu 145 150 155 160

Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val

165 170 175

Gly Gly Ser Thr Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn

180 185 190

Met Ala Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys

195 200 205

Leu Leu Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro

210 215 220

Glu Val His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe 225 230 235 240

Ser Leu Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp

245 250 255

He Leu Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg

260 265 270

Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser

275 280 285

Gly Gin Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr

290 295 300

Gin Leu Pro Pro Gin 305 (2) INFORMATION FOR SEQ ID NO: 542:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 542:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin His 145 150 155 160

Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr

165 170 175

Leu Cys Val Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro

180 185 190

Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp

195 200 205

Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro

210 215 220

Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu 225 230 235 240

Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala

245 250 255

Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly

260 265 270

Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg

275 280 285

Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro

290 295 300

Gin Gly Arg Thr Thr 305

(2) INFORMATION FOR SEQ ID NO: 543:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 543:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu 85 90 95 Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg 145 150 155 160

Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val

165 170 175

Arg Glu Phe Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro

180 185 190

Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val

195 200 205

Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr

210 215 220

Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr 225 230 235 240

Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu

245 250 255

Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys

260 265 270

Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu

275 280 285

Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu Pro Pro Gin Gly Arg

290 295 300

Thr Thr Ala His Lys 305

(2) INFORMATION FOR SEQ ID NO: 544:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 309 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 544:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala He Phe Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val 145 150 155 160

Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val Arg Glu Phe

165 170 175

Gly Gly Asn Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp

180 185 190

Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser

195 200 205

Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu

210 215 220

Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 225 230 235 240

Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu

245 250 255

Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser

260 265 270

Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu 275 280 285 Gin Ser Leu Leu Gly Thr Gin Leu Pro 5 Pro Gin Gly Arg Thr Thr Ala

290 295 300

His Lys Asp Pro Asn 305

(2) INFORMATION FOR SEQ ID NO: 545:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 302 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 545:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Asp Pro Asn Ala He Phe Leu Ser Phe Gin His Leu Leu Arg 145 150 155 160

Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser Thr Leu Cys Val

165 170 175

Arg Glu Phe Gly Gly Asn Met Ala Ser Pro Ala Pro Pro Ala Cys Asp

180 185 190

Leu Arg Val Leu Ser Lys Leu Leu Arg Asp Ser His Val Leu His Ser

195 200 205

Arg Leu Ser Gin Cys Pro Glu Val His Pro Leu Pro Thr Pro Val Leu

210 215 220

Leu Pro Ala Val Asp Phe Ser Leu Gly Glu Trp Lys Thr Gin Met Glu 225 230 235 240

Glu Thr Lys Ala Gin Asp He Leu Gly Ala Val Thr Leu Leu Leu Glu

245 250 255

Gly Val Met Ala Ala Arg Gly Gin Leu Gly Pro Thr Cys Leu Ser Ser

260 265 270

Leu Leu Gly Gin Leu Ser Gly Gin Val Arg Leu Leu Leu Gly Ala Leu

275 280 285

Gin Ser Leu Leu Gly Thr Gin Gly Arg Thr Thr Ala His Lys 290 295 300

(2) INFORMATION FOR SEQ ID NO: 546:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 153 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 546:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

100 105 110

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe

115 120 125

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg 145 150

(2) INFORMATION FOR SEQ ID NO: 547:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 149 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Gly

100 105 110

Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe Leu Ser Phe Gin

115 120 125

His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu Val Gly Gly Ser

130 135 140

Thr Leu Cys Val Arg 145

(2) INFORMATION FOR SEQ ID NO: 548:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 153 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

( i) SEQUENCE DESCRIPTION: SEQ ID NO: 548:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu

1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val

20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu

35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu

50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin

85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Leu

100 105 110

Pro Pro Gin Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe

115 120 125

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu

130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg 145 150 (2) INFORMATION FOR SEQ ID NO: 549:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 135 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 549:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Ala Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro 130 135

(2) INFORMATION FOR SEQ ID NO: 550:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 140 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 550:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140

(2) INFORMATION FOR SEQ ID NO: 551:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 122 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

( ii ) MOLECULE TYPE : None

(xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 551 :

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe 1 5 10 15 Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Glu Thr Ser Glu Gin Leu Val

85 90 95

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu

100 105 110

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 115 120

(2) INFORMATION FOR SEQ ID NO: 552:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 135 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 552:

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro 130 135

(2) INFORMATION FOR SEQ ID NO: 553:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 140 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 553:

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140 (2) INFORMATION FOR SEQ ID NO: 554:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 135 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 554:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro 130 135

(2) INFORMATION FOR SEQ ID NO: 555:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 140 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 555:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140

(2) INFORMATION FOR SEQ ID NO: 556:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 556:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser

100 105 110

Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155

(2) INFORMATION FOR SEQ ID NO: 557:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 557:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr

100 105 110

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

115 120 125

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

130 135 140

Val Ala Ser Asn Leu Gin 145 150

(2) INFORMATION FOR SEQ ID NO: 558:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 145 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:558:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe 100 105 110 Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

115 120 125

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

130 135 140

Gin 145

(2) INFORMATION FOR SEQ ID NO: 559:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 559:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 65 70 75 80

Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe

85 90 95

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

100 105 110

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

115 120 125

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

130 135 140

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 145 150 155

(2) INFORMATION FOR SEQ ID NO: 560:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 560:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 65 70 75 80

Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

85 90 95

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

100 105 110

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu

115 120 125

Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg

130 135 140

Leu Lys Thr Val Ala Gly 145 150

(2) INFORMATION FOR SEQ ID NO: 561:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 145 amino acids (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 561:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly 65 70 75 80

Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala

85 90 95

Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val

100 105 110

Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp

115 120 125

Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala

130 135 140

Gly 145

(2) INFORMATION FOR SEQ ID NO: 562:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 562:

Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu

1 5 10 15

Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr

20 25 30

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

35 40 45

Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly

50 55 60

Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp 65 70 75 80

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

85 90 95

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

100 105 110

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

115 120 125

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu

130 135 140

He His Phe Val Thr Lys Cys Ala Phe Gin Pro 145 150 155

(2) INFORMATION FOR SEQ ID NO: 563:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 563:

Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu

1 5 10 15

Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr 20 25 30

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

35 40 45

Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp

50 55 60

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He 65 70 75 80

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

85 90 95

Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

100 105 110

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys

115 120 125

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

130 135 140

Lys Cys Ala Phe Gin Pro 145 150

(2) INFORMATION FOR SEQ ID NO: 564:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 145 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 564:

Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu

1 5 10 15

Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr

20 25 30

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

35 40 45

Ser Thr Leu Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His

50 55 60

Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp 65 70 75 80

Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp

85 90 95

Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp

100 105 110

Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu

115 120 125

Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin

130 135 140

Pro 145

(2) INFORMATION FOR SEQ ID NO: 565:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 565:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser 100 105 110 Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155

(2) INFORMATION FOR SEQ ID NO: 566:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 566:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Thr

100 105 110

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

115 120 125

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

130 135 140

Val Ala Ser Asn Leu Gin 145 150

(2) INFORMATION FOR SEQ ID NO:567:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 145 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 567:

Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

1 5 10 15

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

20 25 30

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

35 40 45

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

50 55 60

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

85 90 95

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

100 105 110

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

115 120 125

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

130 135 140

Ser 145

(2) INFORMATION FOR SEQ ID NO: 568:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 143 amino acids (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 568:

Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

1 5 10 15

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

20 25 30

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys

35 40 45

Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu

50 55 60

Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn 65 70 75 80

Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser

85 90 95

Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr

100 105 110

Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe

115 120 125

Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140

(2) INFORMATION FOR SEQ ID NO: 569:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 149 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 569:

Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

1 5 10 15

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

20 25 30

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

35 40 45

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

50 55 60

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

85 90 95

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

100 105 110

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

115 120 125

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

130 135 140

Ser Gly Gly Gly Ser 145

(2) INFORMATION FOR SEQ ID NO: 570:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 144 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 570:

Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

1 5 10 15

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

20 25 30

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu

Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg

50 55 60

Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 65 70 75 80

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

85 90 95

Ser Cys Leu Arg Phe Val Gin Thr Asn lie Ser Arg Leu Leu Gin Glu

100 105 110

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

115 120 125

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 130 135 140

(2) INFORMATION FOR SEQ ID NO: 571:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 153 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 571:

Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

1 5 10 15

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

20 25 30

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

35 40 45

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

50 55 60

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 65 70 75 80

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

85 90 95

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

100 105 110

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

115 120 125

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

130 135 140

Ser Gly Gly Gly Ser Gly Gly Gly Ser 145 150

(2) INFORMATION FOR SEQ ID NO: 572:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 572:

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser

1 5 10 15

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

20 25 30

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn

35 40 45

Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

50 55 60

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 65 70 75 80

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

85 90 95

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

100 105 110

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

115 120 125

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin 130 135 140 98/17810 S _f<ri. PCT/US97/20037

Pro Asp Ser Ser Thr Leu 145 150

(2) INFORMATION FOR SEQ ID NO: 573:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 146 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:573:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser

100 105 110

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

115 120 125

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn

130 135 140

Leu Gin 145

(2) INFORMATION FOR SEQ ID NO: 574:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 147 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 574:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys

100 105 110

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

115 120 125

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser

130 135 140

Asn Leu Gin 145

(2) INFORMATION FOR SEQ ID NO: 575:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 575:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr

100 105 110

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

115 120 125

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

130 135 140

Val Ala Ser Asn Leu Gin 145 150

(2) INFORMATION FOR SEQ ID NO: 576:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 153 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 576:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

115 120 125

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

130 135 140

Pro Val Thr Val Ala Ser Asn Leu Gin 145 150

(2) INFORMATION FOR SEQ ID NO: 577:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 577:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155

(2) INFORMATION FOR SEQ ID NO: 578:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 161 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:578:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin

(2) INFORMATION FOR SEQ ID NO: 579:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 281 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:579:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser 145 150 155 160

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

165 170 175

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly

180 185 190

Ala Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys

195 200 205

Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

210 215 220

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240

Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

245 250 255

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

260 265 270

Arg Cys Leu Glu Leu Gin Cys Gin Pro 275 280

(2) INFORMATION FOR SEQ ID NO: 580:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 286 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 580:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser 145 150 155 160

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

165 170 175

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly

180 185 190

Ala Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys

195 200 205

Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

210 215 220

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240

Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

245 250 255

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

260 265 270

Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 275 280 285

(2) INFORMATION FOR SEQ ID NO: 581:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:581:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn

245 250 255

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

260 265 270

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

275 280 285

Val Thr Val Ala Ser Asn Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 582:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:582:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn

245 250 255

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

260 265 270

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

275 280 285

Val Thr Val Ala Ser Asn Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO:583:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 291 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 583:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly

210 215 220

Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp 225 230 235 240

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

245 250 255

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

260 265 270

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

275 280 285

Val Ala Gly 290

(2) INFORMATION FOR SEQ ID NO:584:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 584:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly

210 215 220

Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser 225 230 235 240

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

245 250 255

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu

260 265 270

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

275 280 285

Glu Arg Leu Lys Thr Val Ala Gly 290 295

(2) INFORMATION FOR SEQ ID NO: 585:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 585:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 165 170 175 Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn

245 250 255

Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

260 265 270

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

275 280 285

Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 586:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 291 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 586:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe

195 200 205

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

210 215 220

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 225 230 235 240

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

245 250 255

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

260 265 270

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

275 280 285

Phe Gin Pro 290

(2) INFORMATION FOR SEQ ID NO: 587:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None 5 5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 587:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr

195 200 205

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

210 215 220

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240

Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

245 250 255

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

260 265 270

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

275 280 285

Val Thr Lys Cys Ala Phe Gin Pro 290 295

(2) INFORMATION FOR SEQ ID NO: 588:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 588:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 180 185 190

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser

195 200 205

Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

210 215 220

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin 225 230 235 240

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys

245 250 255

Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu

260 265 270

Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn

275 280 285

Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295 300

(2) INFORMATION FOR SEQ ID NO: 589:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 281 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 589:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser 145 150 155 160

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

165 170 175

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly

180 185 190

Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys

195 200 205

Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

210 215 220

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240

Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

245 250 255

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

260 265 270

Arg Cys Leu Glu Leu Gin Cys Gin Pro 275 280

(2) INFORMATION FOR SEQ ID NO: 590:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 286 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:590: Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser 145 150 155 160

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

165 170 175

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly

180 185 190

Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys

195 200 205

Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

210 215 220

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240

Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

245 250 255

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

260 265 270

Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 275 280 285

(2) INFORMATION FOR SEQ ID NO: 591:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 591:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 210 215 220 59?

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn

245 250 255

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

260 265 270

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

275 280 285

Val Thr Val Ala Ser Asn Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 592:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 592:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn

245 250 255

Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

260 265 270

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

275 280 285

Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 593:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 291 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 593:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 5^"39 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly

210 215 220

Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp 225 230 235 240

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

245 250 255

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

260 265 270

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

275 280 285

Val Ala Gly 290

(2) INFORMATION FOR SEQ ID NO: 594:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:594:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly

210 215 220

Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser bθO

225 230 235 240

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

245 250 255

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu

260 265 270

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

275 280 285

Glu Arg Leu Lys Thr Val Ala Gly 290 295

(2) INFORMATION FOR SEQ ID NO: 595:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 595:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly

210 215 220

Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr Gin Asp Cys 225 230 235 240

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

245 250 255

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser

260 265 270

Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu

275 280 285

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 290 295 300

(2) INFORMATION FOR SEQ ID NO: 596:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 291 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:596:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met 20 25 30 Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr lie Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe

195 200 205

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

210 215 220

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 225 230 235 240

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

245 250 255

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

260 265 270

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

275 280 285

Phe Gin Pro 290

(2) INFORMATION FOR SEQ ID NO: 597:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 597:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr lie Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Thr

195 200 205

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

210 215 220

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240 Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

245 250 255

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

260 265 270

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

275 280 285

Val Thr Lys Cys Ala Phe Gin Pro 290 295

(2) INFORMATION FOR SEQ ID NO: 598:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:598:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser

195 200 205

Gly Gly Asn Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

210 215 220

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin 225 230 235 240

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys

245 250 255

Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu

260 265 270

Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn

275 280 285

Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295 300

(2) INFORMATION FOR SEQ ID NO: 599:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 599:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe 35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser

245 _ 250 255

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

260 265 270

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

275 280 285

Val Thr Val Ala Ser Asn Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 600:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 600:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Ser Gly Gly Ser Gly Ser Gly Gly Ser 245 250 255

Gly Ser Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

260 265 270

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

275 280 285

Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 601:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 281 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:601:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro

130 135 140

Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser 145 150 155 160

Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys Ser He Met He

165 170 175

Asp Glu lie He His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp

180 185 190

Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu Met Glu Arg Asn

195 200 205

Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu

210 215 220

Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys 225 230 235 240

Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys

245 250 255

Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val

260 265 270

Thr Leu Glu Gin Ala Gin Glu Gin Gin 275 280

(2) INFORMATION FOR SEQ ID NO: 602:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 286 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 602:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 50 55 60 foeo

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn 145 150 155 160

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn

165 170 175

Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro

180 185 190

Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He

195 200 205

Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg

210 215 220

Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg 225 230 235 240

Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His

245 250 255

Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu

260 265 270

Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 275 280 285

(2) INFORMATION FOR SEQ ID NO: 603:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 268 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:603:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Pro His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser 145 150 155 160

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

165 170 175

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly

180 185 190

Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys

195 200 205

Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

210 215 220

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Glu Thr Ser Glu Gin 225 230 235 240

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

245 250 255

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 260 265

(2) INFORMATION FOR SEQ ID NO: 604: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 604:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Thr Gin Asp

245 250 255

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

260 265 270

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

275 280 285

Ser Asn Leu Gin 290

(2) INFORMATION FOR SEQ ID NO: 605:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 293 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 605:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Gin

245 250 255

Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys

260 265 270

He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val

275 280 285

Ala Ser Asn Leu Gin 290

(2) INFORMATION FOR SEQ ID NO: 606:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 606:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly

245 250 255

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

260 265 270

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

275 280 285

Val Thr Val Ala Ser Asn Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 607: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 299 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 607:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly

245 250 255

Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

260 265 270

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

275 280 285

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 608:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 608:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly

245 250 255

Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

260 265 270

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

275 280 285

Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 609:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 609:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly

245 250 255

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys

260 265 270

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

275 280 285

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser

290 295 300

Asn Leu Gin 305

(2) INFORMATION FOR SEQ ID NO: 610: <£>40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 610:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

210 215 220

Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser 225 230 235 240

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

245 250 255

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly

260 265 270

Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys

275 280 285

Thr Val Ala Gly 290

(2) INFORMATION FOR SEQ ID NO: 611:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 293 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 611:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

210 215 220

Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser 225 230 235 240

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

245 250 255

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys

260 265 270

Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu

275 280 285

Lys Thr Val Ala Gly 290

(2) INFORMATION FOR SEQ ID NO: 612:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 612:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

210 215 220

Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser 225 230 235 240

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

245 250 255

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu

260 265 270

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

275 280 285

Glu Arg Leu Lys Thr Val Ala Gly 290 295

(2) INFORMATION FOR SEQ ID NO: 613: 8/17810 _{(σ AZι} PCT/US97/20037

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 299 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 613:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

210 215 220

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 225 230 235 240

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

245 250 255

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

260 265 270

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

275 280 285

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 290 295

(2) INFORMATION FOR SEQ ID NO: 614:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 614:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

210 215 220

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys 225 230 235 240

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

245 250 255

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser

260 265 270

Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu

275 280 285

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 290 295 300

(2) INFORMATION FOR SEQ ID NO: 615:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 615:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 145 150 155 160

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

165 170 175

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu

180 185 190

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

195 200 205

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly

210 215 220

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 225 230 235 240

Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

245 250 255

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

260 265 270

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

275 280 285

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

290 295 300

Val Ala Gly 305

(2) INFORMATION FOR SEQ ID NO: 616: it

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 616:

Ala Asn Cys Ser lie Met lie Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175 lie Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser

195 200 205

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

210 215 220

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 225 230 235 240

Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

245 250 255

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

260 265 270

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

275 280 285

Ala Phe Gin Pro 290

(2) INFORMATION FOR SEQ ID NO: 617:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 293 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 617:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He ⁽oAS

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys

195 200 205

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

210 215 220

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 225 230 235 240

Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu

245 250 255

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

260 265 270

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

275 280 285

Cys Ala Phe Gin Pro 290

(2) INFORMATION FOR SEQ ID NO: 618:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 618:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr

195 200 205

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

210 215 220

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240

Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

245 250 255

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

260 265 270

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

275 280 285

Val Thr Lys Cys Ala Phe Gin Pro 290 295

(2) INFORMATION FOR SEQ ID NO: 619: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 299 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 619:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

195 200 205

Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

210 215 220

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 225 230 235 240

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

245 250 255

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

260 265 270

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu

275 280 285

He His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295

(2) INFORMATION FOR SEQ ID NO: 620:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 620:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

195 200 205

Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

210 215 220

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin 225 230 235 240

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys

245 250 255

Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu

260 265 270

Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn

275 280 285

Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro 290 295 300

(2) INFORMATION FOR SEQ ID NO: 621:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:621:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 145 150 155 160

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

165 170 175

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

180 185 190

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

195 200 205

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

210 215 220

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu 225 230 235 240

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

245 250 255

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

260 265 270

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

275 280 285

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

290 295 300

Phe Gin Pro 305

(2) INFORMATION FOR SEQ ID NO: 622: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 622:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

165 170 175

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

180 185 190

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

195 200 205

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

210 215 220

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

245 250 255

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys

260 265 270

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

275 280 285

Glu Leu Ser Asp Tyr Leu Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 623:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 623:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

165 170 175

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

180 185 190

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

195 200 205

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

210 215 220

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

245 250 255

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

260 265 270

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

275 280 285

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 624:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 624:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

165 170 175

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

180 185 190

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

195 200 205

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

210 215 220

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

260 265 270

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

275 280 285

Leu Gin Asp Tyr Pro Val Thr Val 290 295

(2) INFORMATION FOR SEQ ID NO: 625: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 625:

Ala Asn Cys Ser He Met lie Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

165 170 175

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

180 185 190

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

195 200 205

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

210 215 220

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser

260 265 270

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

275 280 285

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 290 295 300

(2) INFORMATION FOR SEQ ID NO: 626:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 626:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 b2

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe 225 230 235 240

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

245 250 255

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

260 265 270

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

275 280 285

Arg Trp Met Glu Arg Leu Lys Thr 290 295

(2) INFORMATION FOR SEQ ID NO: 627:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 627:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 225 230 235 240

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

245 250 255

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

260 265 270

Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

275 280 285

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 290 295 300

(2) INFORMATION FOR SEQ ID NO: 628:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 628:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 145 150 155 160

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

165 170 175

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe

195 200 205

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

210 215 220

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 225 230 235 240

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

245 250 255

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

260 265 270

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

275 280 285

Phe Gin Pro Pro Pro Ser Cys Leu 290 295

(2) INFORMATION FOR SEQ ID NO: 629:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 629:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140

Asn Met Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 145 150 155 160

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

165 170 175

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr

195 200 205

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

210 215 220

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240

Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

245 250 255

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

260 265 270

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

275 280 285

Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 290 295 300

(2) INFORMATION FOR SEQ ID NO: 630:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 630:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

165 170 175

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

180 185 190

Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

195 200 205

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

210 215 220

Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu 225 230 235 240

Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu

245 250 255

Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg

260 265 270

Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro

275 280 285

Pro Ser Cys Leu Arg Phe Val Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 631:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 301 amino acids b/

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 631:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

165 170 175

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser

195 200 205

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

210 215 220

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 225 230 235 240

Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

245 250 255

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

260 265 270

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

275 280 285

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 632:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:632:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

165 170 175

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

180 185 190

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

195 200 205

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

210 215 220

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

245 250 255

Thr Leu Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His

260 265 270

Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp

275 280 285

Tyr Leu Leu Gin 290

(2) INFORMATION FOR SEQ ID NO: 633:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 293 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 633:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

165 170 175

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

180 185 190

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

195 200 205

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

210 215 220

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

245 250 255

Thr Leu Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin

260 265 270

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

275 280 285

Asp Tyr Leu Leu Gin 290

(2) INFORMATION FOR SEQ ID NO: 634:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 299 amino acids

(B) TYPE: amino acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 634:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

165 170 175

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

180 185 190

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

195 200 205

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

210 215 220

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

245 250 255

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr

260 265 270

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

275 280 285

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 635:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 635:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 225 230 235 240

Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

245 250 255

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

260 265 270

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu

275 280 285

Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg

290 295 300

Leu Lys Thr 305

(2) INFORMATION FOR SEQ ID NO: 636:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 636:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

165 170 175

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

180 185 190

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

195 200 205

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

210 215 220

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

245 250 255

Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

260 265 270

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

275 280 285

Pro Val Thr Val 290

(2) INFORMATION FOR SEQ ID NO: 637:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 293 amino acids (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 637:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

165 170 175

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

180 185 190

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

195 200 205

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

210 215 220

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

245 250 255

Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser

260 265 270

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

275 280 285

Tyr Pro Val Thr Val 290

(2) INFORMATION FOR SEQ ID NO: 638:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 299 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 638:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140 Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

165 170 175

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

180 185 190

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

195 200 205

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

210 215 220

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

260 265 270

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

275 280 285

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 290 295

(2) INFORMATION FOR SEQ ID NO: 639:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 639:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

165 170 175

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

180 185 190

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

195 200 205

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

210 215 220

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

260 265 270

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

275 280 285

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

290 295 300

Val Thr Val 305

(2) INFORMATION FOR SEQ ID NO: 640:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 292 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 640:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro 225 230 235 240

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

245 250 255

Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu

260 265 270

Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu

275 280 285

Arg Leu Lys Thr 290

(2) INFORMATION FOR SEQ ID NO: 641:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 293 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 641:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser 225 230 235 240

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

245 250 255

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu

260 265 270

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

275 280 285

Glu Arg Leu Lys Thr 290

(2) INFORMATION FOR SEQ ID NO: 642:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 299 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 642:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp 225 230 235 240

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

245 250 255

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

260 265 270

Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

275 280 285

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 290 295

(2) INFORMATION FOR SEQ ID NO: 643:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 307 amino acids (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 643:

Ala Asn Cys Ser He Met He Asp Glu lie He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 225 230 235 240

Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

245 250 255

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

260 265 270

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu

275 280 285

Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg

290 295 300

Leu Lys Thr 305

(2) INFORMATION FOR SEQ ID NO: 644:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 644:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 145 150 155 160

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

165 170 175

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

180 185 190

Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

195 200 205

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

210 215 220

Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu 225 230 235 240

Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu

245 250 255

Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg

260 265 270

Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro

275 280 285

Pro Ser Cys Leu 290

(2) INFORMATION FOR SEQ ID NO: 645:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 293 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 645:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 145 150 155 160

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

165 170 175

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

180 185 190

Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser

195 200 205

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

210 215 220

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 225 230 235 240

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

245 250 255

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

260 265 270

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

275 280 285

Pro Pro Ser Cys Leu 290

(2) INFORMATION FOR SEQ ID NO: 646:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 299 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 646:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 145 150 155 160

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

165 170 175

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp

195 200 205

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

210 215 220

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 225 230 235 240

Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

245 250 255

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys

260 265 270

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

275 280 285

Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 290 295

(2) INFORMATION FOR SEQ ID NO: 647:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 647:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 130 135 140

Asn Met Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 145 150 155 160

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

165 170 175

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

195 200 205

Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

210 215 220

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu 225 230 235 240

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu

245 250 255

Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg

260 265 270

Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val

275 280 285

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

290 295 300

Ser Cys Leu 305

(2) INFORMATION FOR SEQ ID NO: 648:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 648:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

165 170 175

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

180 185 190

Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

195 200 205

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

210 215 220

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly 225 230 235 240

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

245 250 255

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu

260 265 270

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

275 280 285

Arg Phe Val Gin 290

(2) INFORMATION FOR SEQ ID NO: 649: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 293 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 649:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

165 170 175

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

180 185 190

Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser

195 200 205

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

210 215 220

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly 225 230 235 240

Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys

245 250 255

Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

260 265 270

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys

275 280 285

Leu Arg Phe Val Gin 290

(2) INFORMATION FOR SEQ ID NO: 650:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 299 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 650:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He 115 120 125 Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

165 170 175

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

195 200 205

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

210 215 220

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 225 230 235 240

Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg

245 250 255

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

260 265 270

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

275 280 285

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 651:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 651:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

165 170 175

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

195 200 205

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

210 215 220

Ala Val Lys lie Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 225 230 235 240

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

245 250 255

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

260 265 270

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

275 280 285

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

290 295 300

Phe Val Gin 305

(2) INFORMATION FOR SEQ ID NO: 652: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 749 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 652:

Gly Ser Thr Met Ser Arg Leu Pro Val Leu Leu Leu Leu Gin Leu Leu

1 5 10 15

Val Arg Pro Ala Met Ser Thr Asn Gin Asp Leu Pro Val He Lys Cys

20 25 30

Val Leu He Asn His Lys Asn Asn Asp Ser Ser Val Gly Lys Ser Ser

35 40 45

Ser Tyr Pro Met Val Ser Glu Ser Pro Glu Asp Leu Gly Cys Ala Leu

50 55 60

Arg Pro Gin Ser Ser Gly Thr Val Tyr Glu Ala Ala Ala Val Glu Val 65 70 75 80

Asp Val Ser Ala Ser He Thr Leu Gin Val Leu Val Asp Ala Pro Gly

85 90 95

Asn He Ser Cys Leu Trp Val Phe Lys His Ser Ser Leu Asn Cys Gin

100 105 110

Pro His Phe Asp Leu Gin Asn Arg Gly Val Val Ser Met Val He Leu

115 120 125

Lys Met Thr Glu Thr Gin Ala Gly Glu Tyr Leu Leu Phe He Gin Ser

130 135 140

Glu Ala Thr Asn Tyr Thr He Leu Phe Thr Val Ser He Arg Asn Thr 145 150 155 160

Leu Leu Tyr Thr Leu Arg Arg Pro Tyr Phe Arg Lys Met Glu Asn Gin

165 170 175

Asp Ala Leu Val Cys He Ser Glu Ser Val Pro Glu Pro He Val Glu

180 185 190

Trp Val Leu Cys Asp Ser Gin Gly Glu Ser Cys Lys Glu Glu Ser Pro

195 200 205

Ala Val Val Lys Lys Glu Glu Lys Val Leu His Glu Leu Phe Gly Met

210 215 220

Asp He Arg Cys Cys Ala Arg Asn Glu Leu Gly Arg Glu Cys Thr Arg 225 230 235 240

Leu Phe Thr He Asp Leu Asn Gin Thr Pro Gin Thr Thr Leu Pro Gin

245 250 255

Leu Phe Leu Lys Val Gly Glu Pro Leu Trp He Arg Cys Lys Ala Val

260 265 270

His Val Asn His Gly Phe Gly Leu Thr Trp Glu Leu Glu Asn Lys Ala

275 280 285

Leu Glu Glu Gly Asn Tyr Phe Glu Met Ser Thr Tyr Ser Thr Asn Arg

290 295 300

Thr Met He Arg He Leu Phe Ala Phe Val Ser Ser Val Ala Arg Asn 305 310 315 320

Asp Thr Gly Tyr Tyr Thr Cys Ser Ser Ser Lys His Pro Ser Gin Ser

325 330 335

Ala Leu Val Thr He Val Glu Lys Gly Phe He Asn Ala Thr Asn Ser

340 345 350

Ser Glu Asp Tyr Glu He Asp Gin Tyr Glu Glu Phe Cys Phe Ser Val

355 360 365

Arg Phe Lys Ala Tyr Pro Gin He Arg Cys Thr Trp Thr Phe Ser Arg

370 375 380

Lys Ser Phe Pro Cys Glu Gin Lys Gly Leu Asp Asn Gly Tyr Ser He 385 390 395 400

Ser Lys Phe Cys Asn His Lys His Gin Pro Gly Glu Tyr He Phe His

405 410 415

Ala Glu Asn Asp Asp Ala Gin Phe Thr Lys Met Phe Thr Leu Asn He

420 425 430

Arg Arg Lys Pro Gin Val Leu Ala Glu Ala Ser Ala Ser Gin Ala Ser

435 440 445

Cys Phe Ser Asp Gly Tyr Pro Leu Pro Ser Trp Thr Trp Lys Lys Cys

450 455 460

Ser Asp Lys Ser Pro Asn Cys Thr Glu Glu He Thr Glu Gly Val Trp 465 470 475 480

Asn Arg Lys Ala Asn Arg Lys Val Phe Gly Gin Trp Val Ser Ser Ser

485 490 495

Thr Leu Asn Met Ser Glu Ala He Lys Gly Phe Leu Val Lys Cys Cys

500 505 510

Ala Tyr Asn Ser Leu Gly Thr Ser Cys Glu Thr He Leu Leu Asn Ser 515 520 525 Pro Gly Pro Phe Pro Phe He Gin Asp Asn Glu Phe He He Leu Gly

530 535 540

Leu Phe Gly Leu Leu Leu Leu Leu Thr Cys Leu Cys Gly Thr Ala Trp 545 550 555 560

Leu Cys Cys Ser Pro Asn Arg Lys Asn Pro Leu Trp Pro Ser Val Pro

565 570 575

Asp Pro Ala His Ser Ser Leu Gly Ser Trp Val Pro Thr He Met Glu

580 585 590

Glu Asp Ala Phe Gin Leu Pro Gly Leu Gly Thr Pro Pro He Thr Lys

595 600 605

Leu Thr Val Leu Glu Glu Asp Glu Lys Lys Pro Val Pro Trp Glu Ser

610 615 620

His Asn Ser Ser Glu Thr Cys Gly Leu Pro Thr Leu Val Gin Thr Tyr 625 630 635 640

Val Leu Gin Gly Asp Pro Arg Ala Val Ser Thr Gin Pro Gin Ser Gin

645 650 655

Ser Gly Thr Ser Asp Gin Val Leu Tyr Gly Gin Leu Leu Gly Ser Pro

660 665 670

Thr Ser Pro Gly Pro Gly His Tyr Leu Arg Cys Asp Ser Thr Gin Pro

675 680 685

Leu Leu Ala Gly Leu Thr Pro Ser Pro Lys Ser Tyr Glu Asn Leu Trp

690 695 700

Phe Gin Ala Ser Pro Leu Gly Thr Leu Val Thr Pro Ala Pro Ser Gin 705 710 715 720

Glu Asp Asp Cys Val Phe Gly Pro Leu Leu Asn Phe Pro Leu Leu Gin

725 730 735

Gly He Arg Val His Gly Met Glu Ala Leu Gly Ser Phe 740 745

(2) INFORMATION FOR SEQ ID NO: 653:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 349 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 653:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

210 215 220

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 225 230 235 240

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

245 250 255

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

260 265 270

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu 275 280 285 Mo

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

290 295 300

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu 305 310 315 320

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

325 330 335

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 340 345

(2) INFORMATION FOR SEQ ID NO: 654:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 314 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 654:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys lie Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn 145 150 155 160

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr

165 170 175

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

180 185 190

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

195 200 205

Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

210 215 220

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 225 230 235 240

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

245 250 255

Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val

260 265 270

Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val

275 280 285

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu

290 295 300

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 305 310

(2) INFORMATION FOR SEQ ID NO: 655:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 349 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 655:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro 20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn 145 150 155 160

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr

165 170 175

Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys

180 185 190

Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu

195 200 205

Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu

210 215 220

Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro 225 230 235 240

Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly

245 250 255

Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro

260 265 270

Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe

275 280 285

Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala

290 295 300

Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin 305 310 315 320

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu

325 330 335

Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 340 345

(2) INFORMATION FOR SEQ ID NO: 656:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 523 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 656:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser 180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

210 215 220

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 225 230 235 240

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

245 250 255

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

260 265 270

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu

275 280 285

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

290 295 300

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu 305 310 315 320

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

325 330 335

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu

340 345 350

Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He

355 360 365

Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala

370 375 380

Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala 385 390 395 400

Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val

405 410 415

Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp

420 425 430

Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala

435 440 445

Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

450 455 460

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 465 470 475 480

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

485 490 495

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

500 505 510

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 515 520

(2) INFORMATION FOR SEQ ID NO: 657:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 460 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 657:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser 145 150 155 160

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 165 170 175

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly

180 185 190

Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys

195 200 205

Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

210 215 220

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys 225 230 235 240

Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

245 250 255

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

260 265 270

Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val

275 280 285

Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro lie Ser Thr

290 295 300

He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met 305 310 315 320

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

325 330 335

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

340 345 350

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

355 360 365

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

370 375 380

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 385 390 395 400

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

405 410 415

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

420 425 430

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

435 440 445

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 450 455 460

(2) INFORMATION FOR SEQ ID NO: 658:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 523 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 658:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn 145 150 155 160

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr

165 170 175

Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser

180 185 190

Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu

195 200 205

Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu 210 215 220

Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro 225 230 235 240

Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly

245 250 255

Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro

260 265 270

Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe

275 280 285

Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala

290 295 300

Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin 305 310 315 320

Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu

325 330 335

Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr Val Glu

340 345 350

Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He

355 360 365

Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala

370 375 380

Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala 385 390 395 400

Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val

405 410 415

Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp

420 425 430

Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala

435 440 445

Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

450 455 460

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe 465 470 475 480

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

485 490 495

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

500 505 510

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 515 520

(2) INFORMATION FOR SEQ ID NO: 659:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 334 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 659:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

165 170 175

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin

180 185 190

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 195 200 205

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

210 215 220

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

245 250 255

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

260 265 270

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro

275 280 285

Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

290 295 300

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330

(2) INFORMATION FOR SEQ ID NO: 660:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 660:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

165 170 175

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

180 185 190

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

195 200 205

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn lie Ser Arg Leu Leu

210 215 220

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

245 250 255

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys

260 265 270

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

275 280 285

Glu Leu Ser Asp Tyr Leu Leu Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 661:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 661:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

165 170 175

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

180 185 190

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

195 200 205

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

210 215 220

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 225 230 235 240

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

245 250 255

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

260 265 270

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

275 280 285

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 662:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 662:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val 165 170 175 Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

180 185 190

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

195 200 205

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

210 215 220

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

260 265 270

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

275 280 285

Leu Gin Asp Tyr Pro Val Thr Val 290 295

(2) INFORMATION FOR SEQ ID NO: 663:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 663:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu 145 150 155 160

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

165 170 175

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He

180 185 190

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

195 200 205

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

210 215 220

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys 225 230 235 240

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser

260 265 270

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

275 280 285

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 290 295 300

(2) INFORMATION FOR SEQ ID NO: 664:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 664:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe 225 230 235 240

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys lie Arg Glu Leu

245 250 255

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

260 265 270

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

275 280 285

Arg Trp Met Glu Arg Leu Lys Thr 290 295

(2) INFORMATION FOR SEQ ID NO: 665:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 665:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 145 150 155 160

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

165 170 175

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 180 185 190

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

195 200 205

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

210 215 220

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr 225 230 235 240

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

245 250 255

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

260 265 270

Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

275 280 285

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 290 295 300

(2) INFORMATION FOR SEQ ID NO: 666:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 666:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 145 150 155 160

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

165 170 175

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe

195 200 205

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

210 215 220

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 225 230 235 240

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

245 250 255

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

260 265 270

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

275 280 285

Phe Gin Pro Pro Pro Ser Cys Leu 290 295

(2) INFORMATION FOR SEQ ID NO: 667:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 667:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 145 150 155 160

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

165 170 175

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr

195 200 205

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

210 215 220

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr 225 230 235 240

Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

245 250 255

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

260 265 270

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

275 280 285

Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 290 295 300

(2) INFORMATION FOR SEQ ID NO: 668:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 668:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Ser Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

165 170 175

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser 180 185 190 Gly Gly Gly Ser Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro

195 200 205

He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu

210 215 220

Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu 225 230 235 240

Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu

245 250 255

Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg

260 265 270

Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro

275 280 285

Pro Ser Cys Leu Arg Phe Val Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 669:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 669:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin 145 150 155 160

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

165 170 175

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser

180 185 190

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser

195 200 205

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

210 215 220

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 225 230 235 240

Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

245 250 255

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

260 265 270

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

275 280 285

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 670:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 670: Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp 145 150 155 160

Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala

165 170 175

Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

180 185 190

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

195 200 205

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

210 215 220

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu 225 230 235 240

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly

245 250 255

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly

260 265 270

Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala

275 280 285

Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val

290 295 300

Thr Val Ala 305

(2) INFORMATION FOR SEQ ID NO: 671:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:671:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 145 150 155 160

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

165 170 175

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe 180 185 190

Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val

195 200 205

Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val

210 215 220

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 225 230 235 240

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly

245 250 255

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr

260 265 270

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

275 280 285

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

290 295 300

Val Ala Ser 305

(2) INFORMATION FOR SEQ ID NO: 672:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 672:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu 145 150 155 160

Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser

165 170 175

Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val

180 185 190

Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin

195 200 205

Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala

210 215 220

Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu 225 230 235 240

Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly

245 250 255

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin

260 265 270

Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys

275 280 285

He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val

290 295 300

Ala Ser Asn 305

(2) INFORMATION FOR SEQ ID NO: 673:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 673:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 145 150 155 160

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys

165 170 175

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

180 185 190

Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr

195 200 205

Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu

210 215 220

Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin 225 230 235 240

Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp

260 265 270

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

275 280 285

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

290 295 300

Ser Asn Leu 305

(2) INFORMATION FOR SEQ ID NO: 674:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 305 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 674:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg

35 40 45

Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg

50 55 60

Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His 65 70 75 80

Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu

85 90 95

Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val

100 105 110

Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr

115 120 125

He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met 130 135 140 Ala Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 145 150 155 160

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

165 170 175

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

180 185 190

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg

195 200 205

Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He

210 215 220

Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 225 230 235 240

Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

260 265 270

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

275 280 285

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin

290 295 300

Asp 305

(2) INFORMATION FOR SEQ ID NO: 675:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 675:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin 145 150 155 160

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

165 170 175

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

180 185 190

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

195 200 205

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

210 215 220

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 225 230 235 240

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

245 250 255

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

260 265 270

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

275 280 285

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

290 295 300

Gin Asp Glu 305

(2) INFORMATION FOR SEQ ID NO: 676: b%

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 676:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 145 150 155 160

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

165 170 175

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

180 185 190

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg

195 200 205

Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He

210 215 220

Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 225 230 235 240

Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

260 265 270

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

275 280 285

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin

290 295 300

Asp Glu Glu 305

(2) INFORMATION FOR SEQ ID NO: 677:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 677:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp 145 150 155 160

Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala

165 170 175

Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

180 185 190

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

195 200 205

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

210 215 220

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu 225 230 235 240

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly

245 250 255

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly

260 265 270

Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Ser Ala

275 280 285

Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val

290 295 300

Thr Val Ala 305

(2) INFORMATION FOR SEQ ID NO: 678:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 678:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val 145 150 155 160

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys

165 170 175

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

180 185 190

Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr

195 200 205

Asn He Ser Arg Leu Leu Arg Glu Thr Ser Glu Gin Pro Val Ala Leu

210 215 220

Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin 225 230 235 240

Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp

260 265 270

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

275 280 285

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 290 295 300

Ser Asn Leu 305

(2) INFORMATION FOR SEQ ID NO: 679:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 679:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg 145 150 155 160

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

165 170 175

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

180 185 190

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg

195 200 205

Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He

210 215 220

Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Arg Pro Asp 225 230 235 240

Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

245 250 255

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

260 265 270

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

275 280 285

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin

290 295 300

Asp Glu Glu 305

(2) INFORMATION FOR SEQ ID NO: 680:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 302 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 680:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser 50 55 60 Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Tyr Val Glu Gly 145 150 155 160

Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn

165 170 175

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn

180 185 190

Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro

195 200 205

Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He

210 215 220

Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg 225 230 235 240

Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg

245 250 255

Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His

260 265 270

Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu

275 280 285

Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 681:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 681:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Arg Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr

100 105 110

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

115 120 125

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

130 135 140

Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 145 150 155 160

Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys

165 170 175

Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys Ser He Met He Asp

180 185 190

Glu He He His His Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro

195 200 205

Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu Met Glu Arg Asn Leu

210 215 220

Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys His Leu Glu 225 230 235 240

Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu

245 250 255

Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala 260 265 270 (ebO

Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr

275 280 285

Leu Glu Gin Ala Gin Glu Gin Gin 290 295

(2) INFORMATION FOR SEQ ID NO: 682:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 682:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 683:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 683:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp lie Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 684:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 684:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Leu Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys lie Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 685:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 685:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Gly Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 686:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 302 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 686:

Met Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu

1 5 10 15

Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu

20 25 30

Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg 35 40 45 Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro

50 55 60

Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin 65 70 75 80

Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin

85 90 95

Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr

100 105 110

Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

115 120 125

Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala

130 135 140

Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Tyr Val Glu Gly 145 150 155 160

Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn

165 170 175

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn

180 185 190

Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro

195 200 205

Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He

210 215 220

Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg 225 230 235 240

Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg

245 250 255

Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His

260 265 270

Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu

275 280 285

Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 687:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 687:

Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

1 5 10 15

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

20 25 30

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

35 40 45

Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val

50 55 60

Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 65 70 75 80

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu

85 90 95

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin

115 120 125

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

130 135 140

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp lie Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala lie Leu Arg Asn 245 250 255 Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 688:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 688:

Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

1 5 10 15

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys

20 25 30

Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

35 40 45

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

50 55 60

Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly 65 70 75 80

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp

85 90 95

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

100 105 110

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

115 120 125

Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

130 135 140

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 689:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 689:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu 50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe

85 90 95

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

100 105 110

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

115 120 125

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

130 135 140

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 690:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 690:

Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu

1 5 10 15

Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr

20 25 30

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

35 40 45

Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly

50 55 60

Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp 65 70 75 80

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

85 90 95

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

100 105 110

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

115 120 125

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu

130 135 140

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro 260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 691:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 691:

Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val

1 5 10 15

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu

20 25 30

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly

35 40 45

Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin

50 55 60

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 65 70 75 80

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin

85 90 95

Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg

100 105 110

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

115 120 125

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

130 135 140

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 692:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 692:

Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

1 5 10 15

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

20 25 30

Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly

35 40 45

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp 50 55 60 Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He 65 70 75 80

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

85 90 95

Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

100 105 110

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys

115 120 125

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

130 135 140

Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Phe Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 693:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 693:

Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu

1 5 10 15

Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser

20 25 30

Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val

35 40 45

Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin

50 55 60

Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala 65 70 75 80

Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu

85 90 95

Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin

115 120 125

Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys

130 135 140

He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 145 150 155 160

Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala 260 265 270 Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 694:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 694:

Ala Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

1 5 10 15

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys

20 25 30

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

35 40 45

Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr

50 55 60

Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu 65 70 75 80

Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin

85 90 95

Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser

100 105 110

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp

115 120 125

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

130 135 140

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 145 150 155 160

Ser Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 695:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 695:

Ala Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu

1 5 10 15

Ala Gin Arg Leu Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

20 25 30

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys 35 40 45

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

50 55 60

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 65 70 75 80

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys

85 90 95

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly

100 105 110

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys

115 120 125

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

130 135 140

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 145 150 155 160

Asn Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 696:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 696:

Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

35 40 45

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser

115 120 125

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

130 135 140

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160

Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 697:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 697:

Ala Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg

1 5 10 15

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

20 25 30

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

35 40 45

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg

50 55 60

Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He 65 70 75 80

Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp

85 90 95

Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

100 105 110

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

115 120 125

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

130 135 140

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 160

Asp Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 698:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 698: Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

1 5 10 15

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

20 25 30

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

35 40 45

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

50 55 60

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 75 80

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

85 90 95

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser

115 120 125

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

130 135 140

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 699:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 699:

Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

1 5 10 15

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

20 25 30

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

35 40 45

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

50 55 60

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 75 80

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

85 90 95

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser

115 120 125

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

130 135 140

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 700:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 700:

Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

1 5 10 15

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

20 25 30

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

35 40 45

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

50 55 60

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 75 80

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Arg Pro Asp Ser Ser

85 90 95

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser

115 120 125

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

130 135 140

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 701:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:701:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe

85 90 95

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

100 105 110

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

115 120 125

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

130 135 140

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 702:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 315 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:702:

Ala Gin Asp Asp Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

35 40 45

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

115 120 125

Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser

130 135 140

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 145 150 155 160

Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly Gly Gly 165 170 175

Ser Pro Gly Glu Pro Ser Gly Pro lie Ser Thr He Asn Pro Ser Pro

180 185 190

Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys Ser He

195 200 205

Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn Pro Leu

210 215 220

Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu Met Glu 225 230 235 240

Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys

245 250 255

His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin

260 265 270

Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He

275 280 285

He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr

290 295 300

Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 305 310 315

(2) INFORMATION FOR SEQ ID NO: 703:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 301 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:703:

Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

35 40 45

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly

100 105 110

Ala Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

115 120 125

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

130 135 140

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 290 295 300

(2) INFORMATION FOR SEQ ID NO: 704:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 307 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:704:

Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

35 40 45

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly

100 105 110

Ala Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser

115 120 125

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

130 135 140

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160

Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Asn Cys Ser He Met He Asp Glu He He His His

195 200 205

Leu Lys Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser

210 215 220

Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu 225 230 235 240

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He

245 250 255

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala

260 265 270

Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu

275 280 285

Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin

290 295 300

Glu Gin Gin 305

(2) INFORMATION FOR SEQ ID NO: 705:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 705:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala 130 135 140 Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

210 215 220

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

245 250 255

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

290 295 300

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser

325 330 335

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

340 345 350

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn

355 360 365

Leu Gin 370

(2) INFORMATION FOR SEQ ID NO: 706:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 706:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu

210 215 220

Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser 225 230 235 240

Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val

245 250 255

Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 260 265 270 He Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala

275 280 285

Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu

290 295 300

Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly 305 310 315 320

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin

325 330 335

Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys

340 345 350

He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val

355 360 365

Ala Ser 370

(2) INFORMATION FOR SEQ ID NO: 707:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:707:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg

210 215 220

Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He 225 230 235 240

Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp

245 250 255

Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

260 265 270

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

275 280 285

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

290 295 300

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 305 310 315 320

Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg

325 330 335

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

340 345 350

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 708: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 708:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

210 215 220

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys 225 230 235 240

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

245 250 255

Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr

260 265 270

Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu

275 280 285

Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin

290 295 300

Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser 305 310 315 320

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp

325 330 335

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

340 345 350

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

355 360 365

Ser Asn 370

(2) INFORMATION FOR SEQ ID NO: 709:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:709:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu 35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu

210 215 220

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met 225 230 235 240

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

245 250 255

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

260 265 270

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

275 280 285

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys

290 295 300

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly 305 310 315 320

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys

325 330 335

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

340 345 350

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser

355 360 365

Asn Leu 370

(2) INFORMATION FOR SEQ ID NO: 710:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 710:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr 165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

210 215 220

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly 225 230 235 240

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

245 250 255

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

260 265 270

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp

275 280 285

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

290 295 300

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 305 310 315 320

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

325 330 335

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

340 345 350

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

355 360 365

Gin Asp 370

(2) INFORMATION FOR SEQ ID NO: 711:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:711:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg

210 215 220

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu 225 230 235 240

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

245 250 255

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg

260 265 270

Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He

275 280 285

Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp 290 295 300

Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 305 310 315 320

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

325 330 335

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

340 345 350

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin

355 360 365

Asp Glu 370

(2) INFORMATION FOR SEQ ID NO: 712:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 712:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr lie Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp

210 215 220

Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu 225 230 235 240

Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin

245 250 255

Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu

260 265 270

Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr

275 280 285

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

290 295 300

Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 305 310 315 320

Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His

325 330 335

Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp

340 345 350

Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp

355 360 365

Glu Glu 370

(2) INFORMATION FOR SEQ ID NO: 713:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 364 amino acids (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:713:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

210 215 220

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

245 250 255

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

290 295 300

Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 305 310 315 320

Ala Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

325 330 335

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

340 345 350

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 355 360

(2) INFORMATION FOR SEQ ID NO: 714:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 378 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 714:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

210 215 220

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

245 250 255

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

290 295 300

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

325 330 335

Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser

340 345 350

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

355 360 365

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 370 375

(2) INFORMATION FOR SEQ ID NO: 715:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:715:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn 195 200 205 Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

210 215 220

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

245 250 255

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

290 295 300

Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 305 310 315 320

Ala Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser

325 330 335

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

340 345 350

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn

355 360 365

Leu Gin 370

(2) INFORMATION FOR SEQ ID NO: 716:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:716:

Ala Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu

1 5 10 15

Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg

20 25 30

Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val

35 40 45

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

50 55 60

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu 65 70 75 80

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

85 90 95

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu

100 105 110

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr

115 120 125

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

130 135 140

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin 145 150 155

(2) INFORMATION FOR SEQ ID NO: 717:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 717:

Ala Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

1 5 10 15

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

20 25 30

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

35 40 45

Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val

50 55 60

Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val 65 70 75 80

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu

85 90 95

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin

115 120 125

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

130 135 140

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 145 150 155

(2) INFORMATION FOR SEQ ID NO:718:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:718:

Ala Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr

1 5 10 15

Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys

20 25 30

Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

35 40 45

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

50 55 60

Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly 65 70 75 80

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp

85 90 95

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

100 105 110

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

115 120 125

Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

130 135 140

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr 145 150 155

(2) INFORMATION FOR SEQ ID NO:719:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:719:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe

85 90 95

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

100 105 110

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

115 120 125

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

130 135 140

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly 145 150 155 (2) INFORMATION FOR SEQ ID NO: 720:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 720:

Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu

1 5 10 15

Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr

20 25 30

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

35 40 45

Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly

50 55 60

Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp 65 70 75 80

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

85 90 95

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

100 105 110

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

115 120 125

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu

130 135 140

He His Phe Val Thr Lys Cys Ala Phe Gin Pro 145 150 155

(2) INFORMATION FOR SEQ ID NO: 721:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:721:

Ala Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser

1 5 10 15

Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser

20 25 30

Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly

35 40 45

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp

50 55 60

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He 65 70 75 80

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala

85 90 95

Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

100 105 110

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys

115 120 125

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

130 135 140

Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu 145 150 155

(2) INFORMATION FOR SEQ ID NO: 722:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 155 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 713:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

210 215 220

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

245 250 255

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

290 295 300

Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly 305 310 315 320

Ala Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

325 330 335

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

340 345 350

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 355 360

(2) INFORMATION FOR SEQ ID NO:714:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 378 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 714:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80 Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 724:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 724:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 725:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 354 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 725:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala

100 105 110

Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly

165 170 175

Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

180 185 190

Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

195 200 205

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro

210 215 220

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro 225 230 235 240

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

245 250 255

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

260 265 270

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

275 280 285

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu

290 295 300

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe 305 310 315 320

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

325 330 335

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

340 345 350

Gin Pro

(2) INFORMATION FOR SEQ ID NO: 726:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 363 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 726:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 10 ) lib 120 125

Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

130 135 140

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 145 150 155 160

Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly

165 170 175

Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Pro Leu

180 185 190

Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu

195 200 205

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu

210 215 220

Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly 225 230 235 240

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin

245 250 255

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe

260 265 270

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

275 280 285

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

290 295 300

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin 305 310 315 320

Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

325 330 335

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val

340 345 350

Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360

(2) INFORMATION FOR SEQ ID NO: 727:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 348 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 727:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala

100 105 110

Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly Gly 145 150 155 160

Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Pro

165 170 175

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu

180 185 190

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

195 200 205

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu

210 215 220

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser 225 230 235 240

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

245 250 255

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu 260 265 270

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

275 280 285

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu

290 295 300

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg 305 310 315 320

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

325 330 335

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 340 345

(2) INFORMATION FOR SEQ ID NO: 728:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 359 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:728:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Arg Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Thr

100 105 110

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

115 120 125

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

130 135 140

Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 145 150 155 160

Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys

165 170 175

Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser

180 185 190

Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys

195 200 205

He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr

210 215 220

Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly 225 230 235 240

He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu

245 250 255

Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly

260 265 270

Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu

275 280 285

Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin

290 295 300

Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly 305 310 315 320

Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val

325 330 335

Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val

340 345 350

Leu Arg His Leu Ala Gin Pro 355

(2) INFORMATION FOR SEQ ID NO: 729:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 729:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

210 215 220

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg

325 330 335

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

340 345 350

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360

(2) INFORMATION FOR SEQ ID NO: 730:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:730:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95 Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Val Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO:731:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 731:

Ala Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu

1 5 10 15

Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr

20 25 30

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

35 40 45

Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly

50 55 60

Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp 65 70 75 80

Phe Ala Val Lys lie Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

85 90 95

Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

100 105 110

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

115 120 125

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu

130 135 140

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Val Pro Gin Ser Phe Leu Leu Lys Cys Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys 210 215 220 Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg

325 330 335

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

340 345 350

Val Ser Tyr Arg Val He Arg His Leu Ala Gin Pro 355 360

(2) INFORMATION FOR SEQ ID NO: 732:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:732:

Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu

1 5 10 15

Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser

20 25 30

Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val

35 40 45

Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin

50 55 60

Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala 65 70 75 80

Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu

85 90 95

Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin

115 120 125

Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys

130 135 140

He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 145 150 155 160

Ala Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser His Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala 355 360 365 Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 733:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:733:

Ala Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val

1 5 10 15

Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys

20 25 30

Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr

35 40 45

Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr

50 55 60

Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu 65 70 75 80

Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin

85 90 95

Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser

100 105 110

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp

115 120 125

Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He

130 135 140

Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala 145 150 155 160

Ser Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val He Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 734:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 734: Ala Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 1 5 10 15

Ala Gin Arg Leu Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

20 25 30

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

35 40 45

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

50 55 60

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys 65 70 75 80

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys

85 90 95

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly

100 105 110

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys

115 120 125

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

130 135 140

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser 145 150 155 160

Asn Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 735:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 735:

Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

1 5 10 15

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

20 25 30

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

35 40 45

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

50 55 60

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 75 80

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

85 90 95

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser

115 120 125

Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr 130 135 140

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 736:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 736:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe

85 90 95

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

100 105 110

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

115 120 125

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

130 135 140

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

210 215 220

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu 260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg

325 330 335

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

340 345 350

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360

(2) INFORMATION FOR SEQ ID NO: 737:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 737:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe

85 90 95

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

100 105 110

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

115 120 125

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

130 135 140

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

210 215 220

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg

325 330 335

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

340 345 350

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360

(2) INFORMATION FOR SEQ ID NO: 738:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 370 amino acids (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 738:

Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

1 5 10 15

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

20 25 30

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro

35 40 45

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

50 55 60

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 75 80

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Arg Pro Asp Ser Ser

85 90 95

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser

115 120 125

Pro He Ser Ser Asn Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr

130 135 140

Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu 145 150 155 160

Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Phe Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 739:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 739:

Ala Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp

1 5 10 15

Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu

20 25 30

Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin

35 40 45

Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu 50 55 60 Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr 65 70 75 80

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

85 90 95

Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly

100 105 110

Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His

115 120 125

Ser Pro lie Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp

130 135 140

Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp 145 150 155 160

Glu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 740:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 740:

Ala Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg

1 5 10 15

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

20 25 30

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

35 40 45

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg

50 55 60

Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He 65 70 75 80

Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp

85 90 95

Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

100 105 110

Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin

115 120 125

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

130 135 140

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 145 150 155 160

Asp Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 741:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:741:

Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

35 40 45

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser

115 120 125

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

130 135 140

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160

Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320 Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 742:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 742:

Ala Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val

1 5 10 15

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu

20 25 30

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly

35 40 45

Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin

50 55 60

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser 65 70 75 80

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin

85 90 95

Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg

100 105 110

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

115 120 125

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

130 135 140

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

210 215 220

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg

325 330 335

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

340 345 350

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360

(2) INFORMATION FOR SEQ ID NO: 743:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 355 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 743:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly

165 170 175

Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin

180 185 190

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp

195 200 205

Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His

210 215 220

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala 225 230 235 240

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

245 250 255

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

260 265 270

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

275 280 285

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu

290 295 300

Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 305 310 315 320

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser

325 330 335

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu

340 345 350

Ala Gin Pro 355

(2) INFORMATION FOR SEQ ID NO: 744:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 744:

Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

35 40 45

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn lie

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser 115 120 125

Phe Gin His Ser Pro He Ser Ser Asp Ser Ala Val Lys He Arg Glu

130 135 140

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160

Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 745:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 366 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 745:

Ala Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

1 5 10 15

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

20 25 30

Arg Val Asn Thr Glu He His Phe Val Thr Lys Tyr Ala Phe Gin Pro

35 40 45

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

50 55 60

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg 65 70 75 80

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Arg Pro Asp Ser Ser

85 90 95

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser

115 120 125

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp

130 135 140

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Tyr Val Glu 145 150 155 160

Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He

165 170 175

Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala

180 185 190

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

195 200 205

Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin

210 215 220

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val 225 230 235 240

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys 245 250 255

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser

260 265 270

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

275 280 285

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

290 295 300

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro 305 310 315 320

Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

325 330 335

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe

340 345 350

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360 365

(2) INFORMATION FOR SEQ ID NO: 746:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 746:

Ala Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His

1 5 10 15

Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

20 25 30

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu

35 40 45

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Phe Arg Cys Leu

50 55 60

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly 65 70 75 80

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe

85 90 95

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

100 105 110

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu

115 120 125

Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

130 135 140

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

210 215 220

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg

325 330 335

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

340 345 350

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360

(2) INFORMATION FOR SEQ ID NO: 747: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 378 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 747:

Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

35 40 45

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

100 105 110

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

115 120 125

Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser

130 135 140

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 145 150 155 160

Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly Gly Gly

165 170 175

Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro

180 185 190

Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly

195 200 205

Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin

210 215 220

Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 225 230 235 240

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His

245 250 255

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

260 265 270

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

275 280 285

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

290 295 300

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320

He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

325 330 335

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala

340 345 350

Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser

355 360 365

Tyr Arg Val Leu Arg His Leu Ala Gin Pro 370 375

(2) INFORMATION FOR SEQ ID NO: 748:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 364 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 748:

Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 35 40 45 Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly

100 105 110

Ala Thr Ala Pro Thr Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

115 120 125

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

130 135 140

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro

180 185 190

Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu

195 200 205

Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys

210 215 220

Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu 225 230 235 240

Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser

245 250 255

Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu

260 265 270

Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu

275 280 285

Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala

290 295 300

Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu 305 310 315 320

Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg

325 330 335

Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu

340 345 350

Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 355 360

(2) INFORMATION FOR SEQ ID NO: 749:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 749:

Ala Gin Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

1 5 10 15

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin

20 25 30

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

35 40 45

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

50 55 60

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro 65 70 75 80

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

85 90 95

Pro Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly

100 105 110

Ala Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser

115 120 125

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

130 135 140

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn 145 150 155 160

Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser 180 185 190 Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 750:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 378 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 750:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

115 120 125

Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

130 135 140

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 145 150 155 160

Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly

165 170 175

Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro

180 185 190

Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly

195 200 205

Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin

210 215 220

Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 225 230 235 240

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His

245 250 255

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

260 265 270

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

275 280 285

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

290 295 300

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320 He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

325 330 335

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala

340 345 350

Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser

355 360 365

Tyr Arg Val Leu Arg His Leu Ala Gin Pro 370 375

(2) INFORMATION FOR SEQ ID NO:751:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 378 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:751:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Pro Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

115 120 125

Ser Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

130 135 140

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr 145 150 155 160

Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly

165 170 175

Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro

180 185 190

Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly

195 200 205

Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin

210 215 220

Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys 225 230 235 240

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His

245 250 255

Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

260 265 270

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

275 280 285

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly

290 295 300

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr 305 310 315 320

He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro

325 330 335

Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala

340 345 350

Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser

355 360 365

Tyr Arg Val Leu Arg His Leu Ala Gin Pro 370 375

(2) INFORMATION FOR SEQ ID NO: 752:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:752:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala

100 105 110

Thr Ala Pro Thr Ala Gly Gin Pro Pro Leu Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Thr Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser

195 200 205

Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly

210 215 220

Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro 225 230 235 240

Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro

245 250 255

Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser

260 265 270

Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu

275 280 285

Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu

290 295 300

Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu 305 310 315 320

Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe

325 330 335

Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His

340 345 350

Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala

355 360 365

Gin Pro 370

(2) INFORMATION FOR SEQ ID NO: 753:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 347 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 753:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95

Val Glu Thr Val Phe His Arg Val Ser Gin Asp Gly Leu Asp Leu Leu

100 105 110

Thr Ser Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp

115 120 125

Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr

130 135 140

Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly 145 150 155 160

Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala Thr Pro Leu

165 170 175

Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu

180 185 190

Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu

195 200 205

Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly

210 215 220

His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin 225 230 235 240

Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe

245 250 255

Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu

260 265 270

Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr

275 280 285

Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin

290 295 300

Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg 305 310 315 320

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val

325 330 335

Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 340 345

(2) INFORMATION FOR SEQ ID NO: 754:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 384 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 754:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 lie Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu

100 105 110

Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu

115 120 125

Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser

130 135 140

Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He 145 150 155 160

Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys

165 170 175

Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He

180 185 190

Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

195 200 205

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

210 215 220

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp 225 230 235 240

Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin 245 250 255

Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala

260 265 270

Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu

275 280 285

Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu

290 295 300

Arg His Leu Ala Gin Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly 305 310 315 320

Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys

325 330 335

Glu Ser His Lys Ser Pro Asn Met Ala Thr Gin Asp Cys Ser Phe Gin

340 345 350

His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser

355 360 365

Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 370 375 380

(2) INFORMATION FOR SEQ ID NO: 755:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 349 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 755:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Glu Pro Lys Ser Pro Asp Thr His

35 40 45

Thr Ser Pro Pro Ser Pro Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro

50 55 60

Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly 65 70 75 80

Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys

85 90 95

His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp

100 105 110

Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys

115 120 125

Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin

130 135 140

Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu 145 150 155 160

Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu

165 170 175

Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro

180 185 190

Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala

195 200 205

Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His

210 215 220

Leu Ala Gin Pro Ser Ala Glu Pro Lys Ser Pro Asp Thr His Thr Ser 225 230 235 240

Pro Pro Ser Pro Gly Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly

245 250 255

Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr

260 265 270

Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu

275 280 285

He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu

290 295 300

Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu 305 310 315 320

Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg

325 330 335

Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 340 345

(2) INFORMATION FOR SEQ ID NO: 756: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 347 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:756:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Trp Gin Gly Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Pro Lys Ser Pro Asp Thr His Thr

85 90 95

Ser Pro Pro Ser Pro Gly Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro

100 105 110

Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly

115 120 125

Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Tyr Lys Leu Cys His

130 135 140

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala 145 150 155 160

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

165 170 175

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

180 185 190

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

195 200 205

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu

210 215 220

Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 225 230 235 240

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser

245 250 255

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu

260 265 270

Ala Gin Pro Ser Ala Glu Pro Lys Ser Pro Asp Thr His Thr Ser Pro

275 280 285

Pro Ser Pro Gly Lys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe

290 295 300

Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu 305 310 315 320

Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu

325 330 335

Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 340 345

(2) INFORMATION FOR SEQ ID NO: 757:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 355 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:757:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Ser Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80 He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Ser Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly

165 170 175

Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin

180 185 190

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp

195 200 205

Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His

210 215 220

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala 225 230 235 240

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

245 250 255

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

260 265 270

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

275 280 285

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu

290 295 300

Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 305 310 315 320

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser

325 330 335

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu

340 345 350

Ala Gin Pro 355

(2) INFORMATION FOR SEQ ID NO: 758:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:758:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 210 215 220 Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Ser

245 250 255

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

290 295 300

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Ser Ser

325 330 335

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

340 345 350

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn

355 360 365

Leu Gin 370

(2) INFORMATION FOR SEQ ID NO: 759:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 355 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 759:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Ser Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Ser Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly

165 170 175

Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin

180 185 190

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp

195 200 205

Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His

210 215 220

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala 225 230 235 240

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

245 250 255

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

260 265 270

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

275 280 285

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu

290 295 300

Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 305 310 315 320

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser

325 330 335

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu 340 345 350 Ala Gin Pro 355

(2) INFORMATION FOR SEQ ID NO: 760:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 370 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 760:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

210 215 220

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

245 250 255

Ala Phe Gin Pro Pro Pro Ser Ser Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Ser Gin

290 295 300

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser

325 330 335

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

340 345 350

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn

355 360 365

Leu Gin 370

(2) INFORMATION FOR SEQ ID NO: 761:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 334 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:761: Ala Thr Gin Asp Ser Ser Phe Gin His Ser Pro He Ser Ser Asp Phe 1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Ser Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

165 170 175

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin

180 185 190

Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val

195 200 205

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

210 215 220

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly lie Ser

245 250 255

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

260 265 270

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro

275 280 285

Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

290 295 300

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330

(2) INFORMATION FOR SEQ ID NO: 762:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 334 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:762:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Ser Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Ser Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

165 170 175

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin 180 185 190

Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val

195 200 205

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

210 215 220

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

245 250 255

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

260 265 270

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro

275 280 285

Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

290 295 300

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330

(2) INFORMATION FOR SEQ ID NO: 763:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 326 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 763:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly

130 135 140

Ser Gly Gly Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser 145 150 155 160

Leu Pro Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He

165 170 175

Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Asn Lys

180 185 190

Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He

195 200 205

Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

210 215 220

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu 225 230 235 240

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp

245 250 255

Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin

260 265 270

Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala

275 280 285

Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu

290 295 300

Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu 305 310 315 320

Arg His Leu Ala Gin Pro 325

(2) INFORMATION FOR SEQ ID NO: 764: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 334 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:764:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Ser Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

165 170 175

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin

180 185 190

Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val

195 200 205

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

210 215 220

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

245 250 255

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

260 265 270

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro

275 280 285

Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

290 295 300

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330

(2) INFORMATION FOR SEQ ID NO: 765:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 334 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:765:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg 85 90 95 Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Arg

115 120 125

Leu Glu Leu Gin Ser Gin Pro Asp Ser Ser Thr Leu Tyr Val Glu Gly

130 135 140

Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly Gly Ser Asn Met Ala 145 150 155 160

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu Lys

165 170 175

Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin

180 185 190

Glu Lys Leu Cys Ala Thr Asn Lys Leu Cys His Pro Glu Glu Leu Val

195 200 205

Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys

210 215 220

Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser 225 230 235 240

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser

245 250 255

Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp

260 265 270

Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro

275 280 285

Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe

290 295 300

Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe 305 310 315 320

Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro 325 330

(2) INFORMATION FOR SEQ ID NO: 766:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 352 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 766:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly

165 170 175

Gly Ser Asn Met Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

180 185 190

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser

195 200 205

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser

210 215 220

Gly Gly Ser Gly Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin 225 230 235 240

Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys

245 250 255

Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His 260 265 270 Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala

275 280 285

Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu

290 295 300

Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly 305 310 315 320

Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr

325 330 335

He Trp Gin Gin Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro 340 345 350

(2) INFORMATION FOR SEQ ID NO:767:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 367 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 767:

Ala Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg

1 5 10 15

Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser Phe Leu Glu Val

20 25 30

Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Ser Gly Gly Ser Gly

35 40 45

Gly Ser Gin Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He

50 55 60

Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys 65 70 75 80

Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He

85 90 95

Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

100 105 110

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

115 120 125

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp

130 135 140

Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin 145 150 155 160

Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Tyr Val Glu Gly

165 170 175

Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn

180 185 190

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asp

195 200 205

Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp

210 215 220

Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu 225 230 235 240

Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin

245 250 255

Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu

260 265 270

Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr

275 280 285

Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser

290 295 300

Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 305 310 315 320

Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe Gin His

325 330 335

Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp

340 345 350

Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 355 360 365

(2) INFORMATION FOR SEQ ID NO: 768:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 344 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:768:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asp Glu

180 185 190

Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met

195 200 205

Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu

210 215 220

Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro 225 230 235 240

Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu

245 250 255

Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg

260 265 270

Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser

275 280 285

Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly

290 295 300

Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe 305 310 315 320

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

325 330 335

Val Thr Val Ala Ser Asn Leu Gin 340

(2) INFORMATION FOR SEQ ID NO: 769:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 335 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 769:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe 115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro

165 170 175

He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser

180 185 190

Pro Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

195 200 205

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

210 215 220

Asn Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys 225 230 235 240

Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu

245 250 255

Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn

260 265 270

Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser

275 280 285

Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr

290 295 300

Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe 305 310 315 320

Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 325 330 335

(2) INFORMATION FOR SEQ ID NO:770:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 550 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 770:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly

165 170 175

Gly Ser Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin

180 185 190

Ser Phe Leu Leu Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp

195 200 205

Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His

210 215 220

Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala 225 230 235 240

Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu

245 250 255

Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala

260 265 270

Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin

275 280 285

Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu 290 295 300

Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala 305 310 315 320

Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser

325 330 335

His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu

340 345 350

Ala Gin Pro Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser

355 360 365

Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His

370 375 380

Lys Ser Pro Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg 385 390 395 400

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

405 410 415

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

420 425 430

Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val

435 440 445

Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val

450 455 460

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu 465 470 475 480

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly

485 490 495

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr

500 505 510

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val

515 520 525

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

530 535 540

Val Ala Ser Asn Leu Gin 545 550

(2) INFORMATION FOR SEQ ID NO: 771:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 544 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:771:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala

210 215 220

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys 245 250 255

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

290 295 300

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser

325 330 335

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

340 345 350

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn

355 360 365

Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly

370 375 380

Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys 385 390 395 400

Ser Pro Asn Met Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He

405 410 415

Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu

420 425 430

Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu

435 440 445

Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg

450 455 460

Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val 465 470 475 480

Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro

485 490 495

Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu

500 505 510

Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn

515 520 525

Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu 530 535 540

(2) INFORMATION FOR SEQ ID NO: 772:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 565 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 772:

Ala Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gin Ser Phe Leu Leu

1 5 10 15

Lys Ser Leu Glu Gin Val Arg Lys He Gin Gly Asp Gly Ala Ala Leu

20 25 30

Gin Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu

35 40 45

Val Leu Leu Gly His Ser Leu Gly He Pro Trp Ala Pro Leu Ser Ser

50 55 60

Cys Pro Ser Gin Ala Leu Gin Leu Ala Gly Cys Leu Ser Gin Leu His 65 70 75 80

Ser Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He

85 90 95

Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gin Leu Asp Val Ala

100 105 110

Asp Phe Ala Thr Thr He Trp Gin Gin Met Glu Glu Leu Gly Met Ala

115 120 125

Pro Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala

130 135 140

Phe Gin Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gin Ser 145 150 155 160

Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gin Pro Tyr

165 170 175

Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser

180 185 190

Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn

195 200 205

Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala 210 215 220

Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin 225 230 235 240

Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys

245 250 255

Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He

260 265 270

Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro

275 280 285

Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin

290 295 300

Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 305 310 315 320

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser

325 330 335

Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu

340 345 350

Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn

355 360 365

Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly

370 375 380

Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys 385 390 395 400

Ser Pro Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu

405 410 415

Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser

420 425 430

Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val

435 440 445

Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin

450 455 460

Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala 465 470 475 480

Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu

485 490 495

Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly

500 505 510

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin

515 520 525

Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys

530 535 540

He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val 545 550 555 560

Ala Ser Asn Leu Gin 565

(2) INFORMATION FOR SEQ ID NO: 773:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 502 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 773:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val

20 25 30

Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin

100 105 110

Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He

115 120 125

Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro

130 135 140

Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu 145 150 155 160

Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met

165 170 175

Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys

180 185 190

Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn

195 200 205

He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys

210 215 220

Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys 225 230 235 240

Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly

245 250 255

Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys

260 265 270

Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg

275 280 285

Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser

290 295 300

Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser 305 310 315 320

Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu Ser His

325 330 335

Lys Ser Pro Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg

340 345 350

Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly

355 360 365

Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe

370 375 380

Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val 385 390 395 400

Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val

405 410 415

Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu

420 425 430

Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly

435 440 445

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr

450 455 460

Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val 465 470 475 480

Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr

485 490 495

Val Ala Ser Asn Leu Gin 500

(2) INFORMATION FOR SEQ ID NO: 774:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 562 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 774:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Gly Gly Ser Gly Gly

165 170 175

Gly Ser Asn Met Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu

180 185 190

Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser

195 200 205

Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val

210 215 220

Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin 225 230 235 240

Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala

245 250 255

Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu

260 265 270

Gin Cys Gin Pro Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly

275 280 285

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin

290 295 300

Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys 305 310 315 320

He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val

325 330 335

Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly Gly Gly Ser Pro Gly Glu

340 345 350

Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro Ser Lys Glu

355 360 365

Ser His Lys Ser Pro Asn Met Ala Thr Pro Leu Gly Pro Ala Ser Ser

370 375 380

Leu Pro Gin Ser Phe Leu Leu Lys Cys Leu Glu Gin Val Arg Lys He 385 390 395 400

Gin Gly Asp Gly Ala Ala Leu Gin Glu Lys Leu Cys Ala Thr Tyr Lys

405 410 415

Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly He

420 425 430

Pro Trp Ala Pro Leu Ser Ser Cys Pro Ser Gin Ala Leu Gin Leu Ala

435 440 445

Gly Cys Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

450 455 460

Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu Asp 465 470 475 480

Thr Leu Gin Leu Asp Val Ala Asp Phe Ala Thr Thr He Trp Gin Gin

485 490 495

Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gin Pro Thr Gin Gly Ala

500 505 510

Met Pro Ala Phe Ala Ser Ala Phe Gin Arg Arg Ala Gly Gly Val Leu

515 520 525

Val Ala Ser His Leu Gin Ser Phe Leu Glu Val Ser Tyr Arg Val Leu

530 535 540

Arg His Leu Ala Gin Pro Ser Thr Pro Ser Thr Pro Gly Ser Glu Phe 545 550 555 560

Gly Ser

(2) INFORMATION FOR SEQ ID NO: 775:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 490 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 775:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro 85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly

100 105 110

Ser Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser

115 120 125

Ser Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin

130 135 140

Asp Tyr Pro Val Thr Val Ala Ser Asn Leu Gin Tyr Val Glu Gly Gly 145 150 155 160

Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He Asn Pro

165 170 175

Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala Asn Cys

180 185 190

Ser He Met He Asp Glu He lie His His Leu Lys Arg Pro Pro Asn

195 200 205

Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu

210 215 220

Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe Val Arg Ala 225 230 235 240

Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn

245 250 255

Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro

260 265 270

He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr

275 280 285

Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin Tyr Val Glu

290 295 300

Gly Gly Gly Gly Ser Pro Gly Glu Pro Ser Gly Pro He Ser Thr He 305 310 315 320

Asn Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro Asn Met Ala

325 330 335

Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin Arg

340 345 350

Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly Leu

355 360 365

Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala Phe

370 375 380

Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser Arg 385 390 395 400

Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp He

405 410 415

Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro Asp

420 425 430

Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

435 440 445

Gly Gly Gly Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser

450 455 460

Asp Phe Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp 465 470 475 480

Tyr Pro Val Thr Val Ala Ser Asn Leu Gin 485 490

(2) INFORMATION FOR SEQ ID NO: 776:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 398 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:776:

Ala Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gin

1 5 10 15

Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gin Gly

20 25 30

Leu Leu Glu Arg Val Asn Thr Glu He His Phe Val Thr Lys Cys Ala

35 40 45

Phe Gin Pro Pro Pro Ser Cys Leu Arg Phe Val Gin Thr Asn He Ser

50 55 60

Arg Leu Leu Gin Glu Thr Ser Glu Gin Leu Val Ala Leu Lys Pro Trp 65 70 75 80

He Thr Arg Gin Asn Phe Ser Arg Cys Leu Glu Leu Gin Cys Gin Pro

85 90 95

Asp Ser Ser Thr Leu Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 100 105 110

Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Thr Gin Asp Cys Ser Phe

115 120 125

Gin His Ser Pro He Ser Ser Asp Phe Ala Val Lys He Arg Glu Leu

130 135 140

Ser Asp Tyr Leu Leu Gin Asp Tyr Pro Val Thr Val Ala Ser Asn Leu 145 150 155 160

Gin Glu Phe Lys Leu Glu Pro Arg Gly Pro Thr He Lys Pro Cys Pro

165 170 175

Pro Cys Lys Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe

180 185 190

He Phe Pro Pro Lys He Lys Asp Val Leu Met He Ser Leu Ser Pro

195 200 205

He Val Thr Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val

210 215 220

Gin He Ser Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gin Thr 225 230 235 240

Gin Thr His Arg Glu Asp Tyr Asn Ser Thr Leu Arg Ala Val Ser Ala

245 250 255

Leu Pro He Gin His Gin Asp Trp Met Ser Gly Lys Glu Phe Lys Cys

260 265 270

Lys Val Asn Asn Lys Asp Leu Pro Ala Pro He Glu Arg Thr He Ser

275 280 285

Lys Pro Lys Gly Ser Val Arg Ala Pro Gin Val Tyr Val Leu Pro Pro

290 295 300

Pro Glu Glu Glu Met Thr Lys Lys Gin Val Thr Leu Thr Cys Met Val 305 310 315 320

Thr Asp Phe Met Pro Glu Asp He Tyr Val Glu Trp Thr Asn Asn Gly

325 330 335

Lys Thr Glu Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp

340 345 350

Gly Ser Tyr Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp

355 360 365

Val Glu Arg Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His

370 375 380

Asn His His Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys 385 390 395

(2) INFORMATION FOR SEQ ID NO: 777:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 377 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 777:

Ala Thr Gin Asp Cys Ser Phe Gin His Ser Pro He Ser Ser Asp Phe

1 5 10 15

Ala Val Lys He Arg Glu Leu Ser Asp Tyr Leu Leu Gin Asp Tyr Pro

20 25 30

Val Thr Val Ala Ser Asn Leu Gin Asp Glu Glu Leu Cys Gly Gly Leu

35 40 45

Trp Arg Leu Val Leu Ala Gin Arg Trp Met Glu Arg Leu Lys Thr Val

50 55 60

Ala Gly Ser Lys Met Gin Gly Leu Leu Glu Arg Val Asn Thr Glu He 65 70 75 80

His Phe Val Thr Lys Cys Ala Phe Gin Pro Pro Pro Ser Cys Leu Arg

85 90 95

Phe Val Gin Thr Asn He Ser Arg Leu Leu Gin Glu Thr Ser Glu Gin

100 105 110

Leu Val Ala Leu Lys Pro Trp He Thr Arg Gin Asn Phe Ser Arg Cys

115 120 125

Leu Glu Leu Gin Cys Gin Pro Asp Ser Ser Thr Leu Glu Phe Lys Leu

130 135 140

Glu Pro Arg Gly Pro Thr He Lys Pro Cys Pro Pro Cys Lys Cys Pro 145 150 155 160

Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe He Phe Pro Pro Lys

165 170 175

He Lys Asp Val Leu Met He Ser Leu Ser Pro He Val Thr Cys Val

180 185 190

Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gin He Ser Trp Phe

195 200 205

Val Asn Asn Val Glu Val His Thr Ala Gin Thr Gin Thr His Arg Glu 210 215 220

Asp Tyr Asn Ser Thr Leu Arg Ala Val Ser Ala Leu Pro He Gin His 225 230 235 240

Gin Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys

245 250 255

Asp Leu Pro Ala Pro He Glu Arg Thr He Ser Lys Pro Lys Gly Ser

260 265 270

Val Arg Ala Pro Gin Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met

275 280 285

Thr Lys Lys Gin Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro

290 295 300

Glu Asp He Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn 305 310 315 320

Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met

325 330 335

Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser

340 345 350

Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr

355 360 365

Lys Ser Phe Ser Arg Thr Pro Gly Lys 370 375

(2) INFORMATION FOR SEQ ID NO: 778:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:778:

Gly Gly Gly Ser

1

(2) INFORMATION FOR SEQ ID NO: 779:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:779:

Gly Gly Gly Ser Gly Gly Gly Ser 1 5

(2) INFORMATION FOR SEQ ID NO: 780:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 780:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 1 5 10

(2) INFORMATION FOR SEQ ID NO: 781:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 781:

Ser Gly Gly Ser Gly Gly Ser 1 5

(2) INFORMATION FOR SEQ ID NO: 782:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 782:

Glu Phe Gly Asn Met 1 5

(2) INFORMATION FOR SEQ ID NO: 783:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:783:

Glu Phe Gly Gly Asn Met 1 5

(2) INFORMATION FOR SEQ ID NO: 784:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 784:

Glu Phe Gly Gly Asn Gly Gly Asn Met 1 5

(2) INFORMATION FOR SEQ ID NO: 785:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:785:

Gly Gly Ser Asp Met Ala Gly 1 5

(2) INFORMATION FOR SEQ ID NO: 786:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:786: Ser Gly Gly Asn Gly 1 5

(2) INFORMATION FOR SEQ ID NO:787:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:787:

Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly 1 5 10

(2) INFORMATION FOR SEQ ID NO: 788:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 788:

Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly Ser Gly Gly Asn Gly 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 789:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 789:

Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly 1 5 10

(2) INFORMATION FOR SEQ ID NO: 790:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:790:

Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly Ser Gly Gly Ser Gly 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 791:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 791:

Gly Gly Gly Ser Gly Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 792:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 792:

Gly Gly Gly Ser Gly Gly Gly 1 5

(2) INFORMATION FOR SEQ ID NO: 793:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:793:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 1 5 10

(2) INFORMATION FOR SEQ ID NO: 794:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:794:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly 1 5 10

(2) INFORMATION FOR SEQ ID NO: 795:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:795:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 796:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:796:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser

1 5 10 15

Gly Gly Gly Ser Gly 20 (2) INFORMATION FOR SEQ ID NO:797:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:797:

Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala Thr Ala Pro Thr Ala

1 5 10 15

Gly Gin Pro Pro Leu 20

(2) INFORMATION FOR SEQ ID NO: 798:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:798:

Pro Pro Pro Trp Ser Pro Arg Pro Leu Gly Ala Thr Ala Pro Thr 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 799:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 799:

Val Glu Thr Val Phe His Arg Val Ser Gin Asp Gly Leu Leu Thr Ser 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 800:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 800:

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Gly

1 5 10 15

Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser

20 25 30

Gly Gly Gly Ser 35

(2) INFORMATION FOR SEQ ID NO: 801:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 801:

He Ser Glu Pro Ser Gly Pro He Ser Thr He Asn Pro Ser Pro Pro

1 5 10 15

Ser Lys Glu Ser His Lys Ser Pro 20

(2) INFORMATION FOR SEQ ID NO: 802:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 802:

He Glu Gly Arg He Ser Glu Pro Ser Gly Pro He Ser Thr He Asn

1 5 10 15

Pro Ser Pro Pro Ser Lys Glu Ser His Lys Ser Pro 20 25

(2) INFORMATION FOR SEQ ID NO: 803:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 112 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 803:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu Asp Val

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110

(2) INFORMATION FOR SEQ ID NO: 804:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 112 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

( i) SEQUENCE DESCRIPTION: SEQ ID NO: 804:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

1 5 10 15

Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110 (2) INFORMATION FOR SEQ ID NO: 805:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 112 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 805:

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Val

1 5 10 15

Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu Asp Met

20 25 30

Asp He Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe

35 40 45

Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He

50 55 60

Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser 65 70 75 80

Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu

85 90 95

Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110

(2) INFORMATION FOR SEQ ID NO: 806:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 111 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: None

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 806:

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro

1 5 10 15

Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp Val Ser

20 25 30

He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val

35 40 45

Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu

50 55 60

Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg 65 70 75 80

His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys

85 90 95

Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin 100 105 110

(2) INFORMATION FOR SEQ ID NO: 807:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 807: CTGACCATGG CNACCCAGGA CTGCTCCTTC CAA 33

(2) INFORMATION FOR SEQ ID NO: 808:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 808: ACTGAAGCTT AGGGCTGACA CTGCAGCTCC AG 32

(2) INFORMATION FOR SEQ ID NO: 809:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 809: ACTGAAGCTT ACAGGGTTGA GGAGTCGGGC TG 32

(2) INFORMATION FOR SEQ ID NO: 810:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 810: GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC 46

(2) INFORMATION FOR SEQ ID NO: 811:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 811: GACTGCCATG GCNACYCAGG AYTGYTCYTT YCAACACAGC CCCATC 46

(2) INFORMATION FOR SEQ ID NO: 812:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 812: TGTCCAAACT CATCAATGTA TC 22

(2) INFORMATION FOR SEQ ID NO: 813:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 813: CATGGCCATG GCCGACGAGG AGCTCTGCGG GGGCCTCT 38

(2) INFORMATION FOR SEQ ID NO: 814:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTIQN: SEQ ID NO: 814: GCTAGAAGCT TACTGCAGGT TGGAGGCCAC GGTGAC 36

(2) INFORMATION FOR SEQ ID NO: 815:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 815: CATGGCCATG GCCTCCAAGA TGCAAGGCTT GCTGGAGC 38

(2) INFORMATION FOR SEQ ID NO:816:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 816: GCTAGAAGCT TACCCAGCGA CAGTCTTGAG CCGCTC 36

(2) INFORMATION FOR SEQ ID NO: 817:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 817: CATGGCCATG GCCCCCCCCA GCTGTCTTCG CTTCGT 36

(2) INFORMATION FOR SEQ ID NO: 818:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 818: GCTAGAAGCT TAGGGCTGAA AGGCACATTT GGTGACA 37

(2) INFORMATION FOR SEQ ID NO: 819:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 42 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 819: CCCTGTCTGG CGGCAACGGC ACCCAGGACT GCTCCTTCCA AC 42

(2) INFORMATION FOR SEQ ID NO: 820:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 820: GCGGTAACGG CAGTGGAGGT AATGGCACCC AGGACTGCTC CTTCCAAC 48

(2) INFORMATION FOR SEQ ID NO:821:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 57 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 821: ACGGCAGTGG TGGCAATGGG AGCGGCGGAA ATGGAACCCA GGACTGCTCC TTCCAAC 57 (2) INFORMATION FOR SEQ ID NO: 822:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 822: GTGCCGTTGC CGCCAGACAG GGTTGAGGAG TCGGGCTG 38

(2) INFORMATION FOR SEQ ID NO: 823:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 823: ATTACCTCCA CTGCCGTTAC CGCCTGACAG GGTTGAGGAG TCGGGCTG 48

(2) INFORMATION FOR SEQ ID NO: 824:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 54 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 824: GCTCCCATTG CCACCACTGC CGTTACCTCC AGACAGGGTT GAGGAGTCGG GCTG 54

(2) INFORMATION FOR SEQ ID NO: 825:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 825: GATGAGGATC CGGTGGCAAT GGGAGCGGCG GAAATGGAAC CCAGGACTGC TCCTTCCACC 60 (2) INFORMATION FOR SEQ ID NO: 826:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 826: GATGACGGAT CCGTTACCTC CAGACAGGGT TGAGGAGTCG GGCTG 45

(2) INFORMATION FOR SEQ ID NO: 827:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 46 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 827: GATGACGGAT CCGGAGGTAA TGGCACCCAG GACTGCTCCT TCCAAC 46

(2) INFORMATION FOR SEQ ID NO: 828:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 828: GACTGCCATG GCCGACGAGG AGCTCTGCG 29

(2) INFORMATION FOR SEQ ID NO: 829:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 829: GACTCAAGCT TACTGCAGGT TGGAGGCC 28

(2) INFORMATION FOR SEQ ID NO: 830:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 830: GACTCGGGAT CCGGAGGTTC TGGCACCCAG GACTGCTCC 39

(2) INFORMATION FOR SEQ ID NO: 831:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 41 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 831: GACTGGGATC CGGTGGCAGT GGGAGCGGCG GATCTGGAAC C 41

(2) INFORMATION FOR SEQ ID NO: 832:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:832: GACTTGGGAT CCACTACCTC CAGACAGGGT TGAGGAGTC 39

(2) INFORMATION FOR SEQ ID NO: 833:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 833: ACTGACGGAT CCACCGCCCA GGGTTGAGGA GTCGGGCTG 39

(2) INFORMATION FOR SEQ ID NO: 834:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 834: ACTGACGGAT CCACCTCCTG ACCCACCGCC CAGGGTTGAG GAGTCGGGCT G 51

(2) INFORMATION FOR SEQ ID NO: 835:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 63 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 835:

ACTGACGGAT CCACCTCCTG ACCCACCTCC TGACCCACCG CCCAGGGTTG AGGAGTCGGG 60 CTG 63

(2) INFORMATION FOR SEQ ID NO: 836:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 836: ACGTAAAGCT TACAGGGTTG AGGAGTCG 28

(2) INFORMATION FOR SEQ ID NO: 837:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 837: GTCAGTGGAT CCGGAGGTAC CCAGGACTGC TCCTTCCAAC 40

(2) INFORMATION FOR SEQ ID NO: 838: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 838: GTCAGTGGAT CCGGAGGTGG CACCCAGGAC TGCTCCTTCC AAC 43

(2) INFORMATION FOR SEQ ID NO: 839:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 60 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 839: TCAGTGGATC CGGAGGTGGC TCAGGGGGAG GTAGTGGTAC CCAGGACTGC TCCTTCCAAC 60 (2) INFORMATION FOR SEQ ID NO: 840:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 840: TAGTCCATGG CCACCCAGGA CTGCTCC 27

(2) INFORMATION FOR SEQ ID NO: 841:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 841: GCATTACGTA GGGCTGACAC TGCAGCTCCA G 31

(2) INFORMATION FOR SEQ ID NO: 842:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 31 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 842: GCATTACGTA CAGGGTTGAG GAGTCGGGCT G 31

(2) INFORMATION FOR SEQ ID NO: 843:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 843: GTCAGACCAT GGCCGATTAC CCAGTCACCG TGGCCTC 37

(2) INFORMATION FOR SEQ ID NO: 844: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 844: TCTGACAAGC TTATTGAAGC AGGTAGTCAG ACAGCTCAC 39

(2) INFORMATION FOR SEQ ID NO: 845:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 845: GTCAGCCCAT GGCCGCCTCC AACCTGCAGG ACGAGGA 37

(2) INFORMATION FOR SEQ ID NO: 846:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 846: TCTGACAAGC TTACACGGTG ACTGGGTAAC TTGAAGC 37

(2) INFORMATION FOR SEQ ID NO: 847:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 847: GTCAGACCAT GGCCGTCGCT GGGTCCAAGA TGCAAGGC 38

(2) INFORMATION FOR SEQ ID NO: 848:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 848: TCTGACAAGC TTAAGTCTTG AGCCGCTCCA TCCAGCG 37

(2) INFORMATION FOR SEQ ID NO: 849:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 849: GTCAGACCAT GGCCCGCTTC GTCCAGACCA ACATCTCC 38

(2) INFORMATION FOR SEQ ID NO: 850: (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 850: TCTGACAAGC TTAAAGACAG CTGGGGGGGG GCTGAA 36

(2) INFORMATION FOR SEQ ID NO: 851:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 851: GTCAGACCAT GGCCACCAAC ATCTCCCGCC TCCTGCAG 38

(2) INFORMATION FOR SEQ ID NO: 852:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:852: CTCGACAAGC TTACTGGACG AAGCGAAGAC AGCTGGG 37

(2) INFORMATION FOR SEQ ID NO: 853:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 33 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 853: GATCACATGT CTACAAATCA AGATCTGCCT GTG 33

(2) INFORMATION FOR SEQ ID NO: 854:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 854: GATCGAATTC GTTGTCTTGG ATGAAAGGGA 30

(2) INFORMATION FOR SEQ ID NO: 855:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 855: ACTTGAATTC ATCATCCTGG GCCTGTTCGG GC 32 (2) INFORMATION FOR SEQ ID NO: 856:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 30 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 856: ACTCAAGCTT AGAAGCTCCC CAGCGCCTCC 30

(2) INFORMATION FOR SEQ ID NO: 857:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 64 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 857:

GGATCCACCA TGAGCCGCCT GCCCGTCCTG CTCCTGCTCC AACTCCTGGT CCGCCCCGCC 60 ATGG 64

(2) INFORMATION FOR SEQ ID NO : 858:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 174 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 1

(D) OTHER INFORMATION: /note= "Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATIONS

(D) OTHER INFORMATION: /note= "Xaa at position 2 is Pro or Leu; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 3

(D) OTHER INFORMATION: /note= "Xaa at position 3 is Leu, Arg, Tyr or Ser;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 13

(D) OTHER INFORMATION: /note= "Xaa at position 13 is Phe, Ser, His, Thr or Pro;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 16

(D) OTHER INFORMATION : /note= "Xaa at position 16 is Lys, Pro, Ser, thr or His;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 17

(D) OTHER INFORMATION: /note= "Xaa at position 17 is Cys, Ser, Gly, Ala, He, Tyr or Arg,-"

(ix) FEATURE:

(A) NAME/KEY: Modified-site (B) LOCATION: 18

(D) OTHER INFORMATION: /note= "Xaa at position 18 is Leu, Thr, Pro, His, He or Cys;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 22

(D) OTHER INFORMATION: /note= "Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 24

(D) OTHER INFORMATION: /note= "Xaa at position 24 is He, Pro , Tyr or Leu ; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 27

(D) OTHER INFORMATION: /note= "Xaa at position 27 is Asp, or Gly; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 30

(D) OTHER INFORMATION: /note= "Xaa at position 30 is Ala, He, Leu or Gly; "

( ix) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 34

(D) OTHER INFORMATION: /note= "Xaa at position 34 is Lys or Ser; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 36

(D) OTHER INFORMATION: /note= "Xaa at position 36 is Cys or Ser; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 42

(D) OTHER INFORMATION: /note= "Xaa at position 42 is Cys or Ser; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 43

(D) OTHER INFORMATION: /note= "Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 44

(D) OTHER INFORMATION: /note= "Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin, or Thr;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 46

(D) OTHER INFORMATION: /note= "Xaa at position 46 is Glu, Arg, Phe, Arg, He or Ala; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 47

(D) OTHER INFORMATION: /note= "Xaa at position 47 is Leu or Thr; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 49

(D) OTHER INFORMATION: /note= "Xaa at position 49 is Leu, Phe, Arg or Ser; "

(ix) FEATURE: (A) NAME/KEY: Modified-site

(B) LOCATION: 50

(D) OTHER INFORMATION: /note= "Xaa at position 50 is Leu, He, His, Pro or Tyr;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 54

(D) OTHER INFORMATION:/note= "Xaa at position 54 is Leu or His; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 64

(D) OTHER INFORMATION: /note= "Xaa at position 64 is Cys or Ser; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 67

(D) OTHER INFORMATION: /note= "Xaa at position 67 is Gin, Lys , Leu or Cys ; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 70

(D) OTHER INFORMATION: /note= "Xaa at position 70 is Gin, Pro, Leu, Arg or Ser;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 74

(D) OTHER INFORMATION: /note= "Xaa at position 74 is Cys or Ser; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 104

(D) OTHER INFORMATION: /note= "Xaa at position 104 is Asp, Gly or Val ; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 108

(D) OTHER INFORMATION: /note= "Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gin or Gly;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 115

(D) OTHER INFORMATION: /note= "Xaa at position 115 is Thr, His, Leu or Ala;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 120

(D) OTHER INFORMATION: /note= "Xaa at position 120 is Gin, Gly, Arg, Lys or His"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 123

(D) OTHER INFORMATION: /note= "Xaa at position 123 is Glu, Arg, Phe or Thr"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 144

(D) OTHER INFORMATION: /note= "Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gin or Glu;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 146

(D) OTHER INFORMATION: /note= "Xaa at positionl46 is Arg or Gin; " (ix) FEATURE:

(A) NAME/KEY: Modi ied-site

(B) LOCATION: 147

(D) OTHER INFORMATION: /note= "Xaa ap position 147 is Arg or Gin; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 156

(D) OTHER INFORMATION: /note= "Xaa at position 156 is His, Gly or Ser; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 159

(D) OTHER INFORMATION: /note= "Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 162

(D) OTHER INFORMATION: /note= "Xaa at position 162 is Glu, Leu, Gly or Trp; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 163

(D) OTHER INFORMATION:/note= "Xaa at position 163 is Val, Gly, Arg or Ala; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 169

(D) OTHER INFORMATION:/note= "Xaa at position 169 is Arg, Ser, Leu, Arg or Cys;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 170

(D) OTHER INFORMATION: /note= "Xaa at position 170 is His, Arg or Ser; "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 858: Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser Xaa Leu Leu Xaa

Xaa Xaa Glu Gin Val Xaa Lys Xaa Gin Gly Xaa Gly Ala Xaa Leu Gin 20 25 30

Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa Xaa Glu Xaa Xaa Val 35 40 45

Xaa Xaa Gly His Ser Xaa Gly He Pro Trp Ala Pro Leu Ser Ser Xaa 50 55 60

Pro Ser Xaa Ala Leu Xaa Leu Ala Gly Xaa Leu Ser Gin Leu His Ser 65 70 75 80

Gly Leu Phe Leu Tyr Gin Gly Leu Leu Gin Ala Leu Glu Gly He Ser 85 90 95

Pro Glu Leu Gly Pro Thr Leu Xaa Thr Leu Gin Xaa Asp Val Ala Asp 100 105 110

Phe Ala Xaa Thr He Trp Gin Gin Met Glu Xaa Xaa Gly Met Ala Pro 115 120 125

Ala Leu Gin Pro Thr Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa 130 135 140

Gin Xaa Xaa Ala Gly Gly Val Leu Val Ala Ser Xaa Leu Gin Xaa Phe 145 150 155 160

Leu Xaa Xaa Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gin Pro (2) INFORMATION FOR SEQ ID NO : 859:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 133 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 17

(D) OTHER INFORMATION: /note= "Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 18

(D) OTHER INFORMATION: /note= "Xaa at position 18 is Asn, His, Leu, He, Phe, Arg, or Gin;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 19

(D) OTHER INFORMATION: /note= "Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala, or Cys;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 20

(D) OTHER INFORMATION: /note= "Xaa at position 20 is He, Cys, Gin, Glu, Arg, Pro, or Ala;"

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 21

(D) OTHER INFORMATION: /note= "Xaa at position 21 is Asp,

Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser or Val;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 22

(D) OTHER INFORMATION: /note= "Xaa at position 22 is Glu,

Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val or Gly;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 23

(D) OTHER INFORMATION: /note= "Xaa at position 23 is He, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 24

(D) OTHER INFORMATION: /note= "Xaa at position 24 is He, Gly, Val, Arg, Ser, Phe, Leu;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 25

(D) OTHER INFORMATION: /note= "Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro, or Ala;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 26

(D) OTHER INFORMATION: /note= "Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, Trp;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 27

(D) OTHER INFORMATION: /note= "Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala; " 98/17810 __-. . PCT/US97/20037

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 28

(D) OTHER INFORMATION: /note= "Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 29

(D) OTHER INFORMATION: /note= "Xaa at position 29 is Gin, Asn, Leu, Pro, Arg, or Val;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 30

(D) OTHER INFORMATION: /note= "Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leu, or L..."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 31

(D) OTHER INFORMATION: /note- "Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gin; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 32

(D) OTHER INFORMATION: /note= "Xaa at position 32 is Leu, Val, Arg, Gin, Asn, Gly, Ala, or Glu;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 33

(D) OTHER INFORMATION: /note= "Xaa at position 33 is Pro, Leu, Gin, Ala, Thr, or Glu; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 34

(D) OTHER INFORMATION: /note= "Xaa at position 34 is Leu,

Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, He or

Met;

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 35

(D) OTHER INFORMATION: /note= "Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 36

(D) OTHER INFORMATION: /note= "Xaa at position 36 is Asp, Leu, or Val; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 37

(D) OTHER INFORMATION: /note= "Xaa at position 37 is Phe, Ser, Pro, Trp, or He;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 38

(D) OTHER INFORMATION: /note= "Xaa at position 38 is Asn, or Ala; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 40

(D) OTHER INFORMATION: /note= "Xaa at position 40 is Leu, Trp, or Arg; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 41 (D) OTHER INFORMATION: /note= "Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or pro;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 42

(D) OTHER INFORMATION:/note= "Xaa at position 42 is Gly,

Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 43

(D) OTHER INFORMATION: /note= "Xaa at position 43 is Glu,

Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gin, Arg, Thr, Gly, or Ser; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 44

(D) OTHER INFORMATION: /note= "Xaa at position 44 is Asp,

Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala or Pro; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 45

(D) OTHER INFORMATION: /note= "Xaa at position 45 is Gin,

Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 46

(D) OTHER INFORMATION: /note= "Xaa at position 46 is Asp,

Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, He, Val or Gly; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 47

(D) OTHER INFORMATION: /note= "Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro, or His;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 48

(D) OTHER INFORMATION: /note= "Xaa at position 48 is Leu,

Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or

Asn; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 49

(D) OTHER INFORMATION: /note- "Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 50

(D) OTHER INFORMATION: /note= "Xaa at position 50 is Glu,

Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe,

Met or Gin; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 51

(D) OTHER INFORMATION: /note= "Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or his;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 52 (D) OTHER INFORMATION: /note= "Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 53

(D) OTHER INFORMATION: /note= "Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or M... "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 54

(D) OTHER INFORMATION: /note= "Xaa at position 54 is Arg,

Asp, He, Ser, Val, Thr, Gin, Asn, Lys, His, Ala or Leu;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 55

(D) OTHER INFORMATION: /note= "Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 56

(D) OTHER INFORMATION: /note= "Xaa at position 56 is Pro,

Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu,

Val or Lys ; "

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 57

(D) OTHER INFORMATION: /note= "Xaa at position 57 is Asn or Gly; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 58

(D) OTHER INFORMATION: /note= "Xaa at position 58 is Leu, Ser, Asp, Arg, Gin, Val, or Cys;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 59

(D) OTHER INFORMATION: /note= "Xaa at position 59 is Glu, Tyr, His, Leu, Pro, or Arg;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 60

(D) OTHER INFORMATION: /note= "Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;"

( i ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 61

(D) OTHER INFORMATION: /note= "Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 62

(D) OTHER INFORMATION: /note= "Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or He;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 63

(D) OTHER INFORMATION: /note= "Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 64

(D) OTHER INFORMATION:/note= "Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;" (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 65

(D) OTHER INFORMATION: /note= "Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 66

(D) OTHER INFORMATION:/no e= "Xaa at position 66 is Lys, He, Arg, Val, Asn, Glu, or Ser;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 67

(D) OTHER INFORMATION: /note= "Xaa at postion 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro, or His;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 68

(D) OTHER INFORMATION :/note= "Xaa at position 68 is Leu, Val, Trp, Ser, He, Phe, Thr, or His;"

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 69

(D) OTHER INFORMATION: /note= "Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or L..."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 70

(D) OTHER INFORMATION: /note= "Xaa at position 70 is Asn, Leu, Val, Trp, pro, or Ala;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 71

(D) OTHER INFORMATION: /note= "Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp, or Asn; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 72

(D) OTHER INFORMATION: /note= "Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 73

(D) OTHER INFORMATION: /note= "Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 74

(D) OTHER INFORMATION: /note= "Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 75

(D) OTHER INFORMATION: /note= "Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin, or Leu;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 76

(D) OTHER INFORMATION: /note= "Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or A..."

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 77

(D) OTHER INFORMATION :/note= "Xaa at position 77 is He, Ser, Arg, Thr, or Leu; " ΨS5

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 78

(D) OTHER INFORMATION: /note= "Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 79

(D) OTHER INFORMATION: /note= "Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly, or Asp; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 80

(D) OTHER INFORMATION: /note= "Xaa position at 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;"

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 81

(D) OTHER INFORMATION: /note- "Xaa at position 81 is Leu, Gin, Gly, Ala, Trp, Arg, Val, or Lys;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 82

(D) OTHER INFORMATION: /note= "Xaa at position 82 is Leu,

Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 83

(D) OTHER INFORMATION: /note= "Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met; "

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 84

(D) OTHER INFORMATION: /note= "Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 85

(D) OTHER INFORMATION: /note= "Xaa at position 85 is Leu, Asn, Val, or Gin;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 86

(D) OTHER INFORMATION: /note= "Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 87

(D) OTHER INFORMATION: /note= "Xaa at position 87 is Leu, Ser, Trp, or Gly;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 88

(D) OTHER INFORMATION: /note= "Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 89

(D) OTHER INFORMATION: /note= "Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or S..."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 90 (D) OTHER INFORMATION: /note= "Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He, or ,Met;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 91

(D) OTHER INFORMATION: /note= "Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 92

(D) OTHER INFORMATION: /note= "Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 93

(D) OTHER INFORMATION: /note= "Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 94

(D) OTHER INFORMATION: /note= "Xaa at position 94 is Arg,

He, Ser, Glu, Leu, Val, Gin, Lys, His, Ala, or Pro;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 95

(D) OTHER INFORMATION: /note= "Xaa at position 95 is His,

Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, He, or Tyr; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 96

(D) OTHER INFORMATION: /note= "Xaa at position 96 is Pro, Lys, Tyr, Gly, He, or Thr;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 97

(D) OTHER INFORMATION: /note= "Xaa at position 97 is He, Val, Lys, Ala, or Asn;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 98

(D) OTHER INFORMATION: /note= "Xaa at position 98 is His,

He, Asn, Leu, Asp, Ala, Thr, Glu, Gin, Ser, Phe, Met, Val, Lys , Arg , Tyr , or Pro ; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 99

(D) OTHER INFORMATION: /note= "Xaa at position 99 is He,

Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe, or His;"

( ix) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 100

(D) OTHER INFORMATION: /note= "Xaa at position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gin, or ..."

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 101

(D) OTHER INFORMATION: /note= "Xaa at position is Asp,

Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu, or Gin; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 102

(D) OTHER INFORMATION: /note= "Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;" (ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 103

(D) OTHER INFORMATION: /note= "Xaa at position 103 is Asp, or Ser; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 104

(D) OTHER INFORMATION: /note= "Xaa at position 104 is Trp,

Val, Cys, Tyr, Thr, Met, Pro, Leu, Gin, Lys, Ala, Phe, or

Gly; "

FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 105

(D) OTHER INFORMATION: /note= "Xaa at position 105 is Asn,

Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, He, Asp,

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 106

(D) OTHER INFORMATION: /note= "Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly, or Pro;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 108

(D) OTHER INFORMATION: /note= "Xaa at position 108 is Arg,

Lys, Asp, Leu, Thr, He, Gin, His, Ser, Ala or Pro;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 109

(D) OTHER INFORMATION: /note= "Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; "

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 110

(D) OTHER INFORMATION: /note= "Xaa at position 110 is Lys,

Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser, or Trp;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 111

(D) OTHER INFORMATION: /note= "Xaa at position 111 is Leu, He, Arg, Asp, or Met; "

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 112

(D) OTHER INFORMATION: /note= "Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 113

(D) OTHER INFORMATION: /note= "Xaa at position 113 is Phe,

Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or

Asn;

( ix ) FEATURE :

(A) NAME/KEY: Modified-site

(B) LOCATION: 114

(D) OTHER INFORMATION: /note= "Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 115

(D) OTHER INFORMATION: /note= "Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;"

(ix) FEATURE: 17810 J - - ft PCT/US97/20037

(A) NAME/KEY: Modified-site

(B) LOCATION: 116

(D) OTHER INFORMATION: /note= "Xaa at position 116 is Lys,

Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or He;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 117

(D) OTHER INFORMATION: /note= "Xaa at position 117 is Thr, Ser, Asn, He, Trp, Lys, or Pro;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 118

(D) OTHER INFORMATION:/note= "Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 119

(D) OTHER INFORMATION: /note= "Xaa at position 119 is Glu, Ser, Lys, Pro, leu, Thr, Tyr, or Arg;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 120

(D) OTHER INFORMATION :/note= "Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 121

(D) OTHER INFORMATION: /note= "Xaa at position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp, or Gly;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 122

(D) OTHER INFORMATION: /note= "Xaa at position 122 is Gin,

Ser, Met, Trp, Arg, Phe, Pro, His, He, Tyr, or Cys;"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 123

(D) OTHER INFORMATION: /note= "Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 859:

Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys 1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa 100 105 110

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gin Gin Thr Thr Leu 115 120 125

Ser Leu Ala He Phe 130 f-55

(2) INFORMATION FOR SEQ ID NO: 860:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 153 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: unknown

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 112

(D) OTHER INFORMATION: /note= "position 112 is deleted or Leu, Ala,VAl, He, Pro, Phe, Trp or Met"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 113

(D) OTHER INFORMATION: /note= "positoin 113 is deleted or Pro, Phe, Ala, Val, Leu, He, Trp or Met"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 114

(D) OTHER INFORMATION: /note= "position 114 is deleted or Pro, Phe, Ala, Val, Leu, He, Trp or Met"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 115

(D) OTHER INFORMATION: /note= "positon 115 is deleted or Gin, Gly, Ser, Thr, Tyr, or Asn"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 860:

Ser Pro Ala Pro Pro Ala Cys Asp Leu Arg Val Leu Ser Lys Leu Leu 1 5 10 15

Arg Asp Ser His Val Leu His Ser Arg Leu Ser Gin Cys Pro Glu Val 20 25 30

His Pro Leu Pro Thr Pro Val Leu Leu Pro Ala Val Asp Phe Ser Leu 35 40 45

Gly Glu Trp Lys Thr Gin Met Glu Glu Thr Lys Ala Gin Asp He Leu 50 55 60

Gly Ala Val Thr Leu Leu Leu Glu Gly Val Met Ala Ala Arg Gly Gin 65 70 75 80

Leu Gly Pro Thr Cys Leu Ser Ser Leu Leu Gly Gin Leu Ser Gly Gin 85 90 95

Val Arg Leu Leu Leu Gly Ala Leu Gin Ser Leu Leu Gly Thr Gin Xaa 100 105 110

Xaa Xaa Xaa Gly Arg Thr Thr Ala His Lys Asp Pro Asn Ala He Phe 115 120 125

Leu Ser Phe Gin His Leu Leu Arg Gly Lys Val Arg Phe Leu Met Leu 130 135 140

Val Gly Gly Ser Thr Leu Cys Val Arg 145 150

(2) INFORMATION FOR SEQ ID NO: 861:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1 amino acids

(B) TYPE: amino acid (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1

(D) OTHER INFORMATION: /note= "where x= (glyglyglyser ) n and where n is an integer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO : 861:

Xaa

1

(2) INFORMATION FOR SEQ ID NO : 862:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION :1

(D) OTHER INFORMATION: /note= "where x= (glyglyglyglyser ) n and where n is an integer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 862:

Xaa 1

(2) INFORMATION FOR SEQ ID NO : 863:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION :1

(D) OTHER INFORMATION: /note= "where x=

(glyglyglyglyglyser)n and where n is an integer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 863:

Xaa 1

(2) INFORMATION FOR SEQ ID NO : 864:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein (B) LOCATION: 1

(D) OTHER INFORMATION: /note= "where x= (gly n serin and where n is an integer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 864:

Xaa

1

(2) INFORMATION FOR SEQ ID NO: 865:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

( ix) FEATURE :

(A) NAME/KEY: Protein

(B) LOCATION :1

(D) OTHER INFORMATION: /note= "where x= (alaglyser ) n and where n is an integer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 865: Xaa

Claims

WHAT IS CLAIMED IS:

1. A hematopoietic protein comprising; an amino acid sequence of the formula:

R_j—L_j^—R₂, R₂—L^—R_χ R_j—R₂ or R₂—R_x

wherein R_λ and R₂ are independently selected from the group consisting of ;

( I ) A human EPO receptor agonist polypeptide , comprising; a modif ied EPO amino acid sequence of the Formula : AlaProProArg euIleCysAspSerArgVal euGluArgTyr euLeuGluAlaLys

10 20

GluAlaGluAsnlleThrThrGlyCysAlaGluHisCysSerLeuAsnGluAsnlleThr

30 40

ValProAspThrLysValAsnPheTyrAlaTrpLysArgMetGluValGlyGlnGlnAla

50 60

ValGluValTrpGlnGly euAlaLeu euSerGluAlaVal euArgGlyGlnAlaLeu 70 80 euValAsnSerSerGlnProTrpGluProLeuGlnLeuHisValAsp ysAlaValSer

90 100 GlyLeuArgSerLeuThrThrLeuLeuArgAlaLeuGlyAlaGlnLysGluAlalleSer

110 120

ProProAspAlaAlaSerAlaAlaProLeuArgThrlleThrAlaAspThrPheArgLys

130 140 euPheArgValTyrSerAsnPheLeuArgGlyLysLeuLysLeuTyrThrGlyGluAla

150 160

CysArgThrGlyAspArg SEQ ID NO: 464 166

wherein 1-6 amino acids from the N-terminus and/or 1-5 from the C-terminus are optionally deleted from said EPO receptor agonist polypeptide;

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

23 -24 47-48 109-110 24 -25 48-49 110-111 25 -26 49-50 111-112 26-27 50-51 112-113 27 -28 51-52 113-114 28-29 52-53 114-115 29 -30 53-54 115-116 30 -31 54-55 116-117 31-32 55-56 117-118 32 -33 56-57 118-119 33 -34 57-58 119-120 34-35 77-78 120-121 35-36 78-79 121-122 36-37 79-80 122-123 37 -38 80-81 123-124 38-39 81-82 124-125 39-40 82-83 125-126 40-41 84-85 126-127 41-42 85-86 127-128 42 -43 86-87 128-129 43 -44 87-88 129-130 44 -45 88-89 130-131 45-46 108-109 131-132 46-47 respectively;

(II) A human stem cell factor receptor agonist polypeptide, comprising; a modified stem cell factor amino acid sequence of the Formula:

GluGlylleCysArgAsnArgValThrAsnAsnValLysAspValThrLys euValAla

10 20

AsnLeuProLysAspTyrMetlleThr euLysTyrValProGlyMetAspValLeuPro 30 40

SerHisCysTrpIleSerGluMetValValGln euSerAspSer euThrAspLeu eu 50 60

Asp ysPheSerAsnlleSerGluGlyLeuSerAsnTyrSerllelleAsp ysLeuVal

70 80

AsnlleValAspAsp euValGluCysValLysGluAsnSerSer ysAspLeuLysLys

90 100

SerPhe ysSerProGluProArgLeuPheThrProGluGluPhePheArgllePheAsn 110 120

ArgSerlleAspAlaPheLysAspPheValValAlaSerGluThrSerAspCysValVal

130 140 SerSerThrLeuSerProGluLysAspSerArgValSerValThrLysProPheMet eu

150 160

ProProValAlaAla SEQ ID NO: 465 165

wherein 1-23 amino acids are optionally deleted from the C-terminus of said stem cell factor receptor agonist polypeptide; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

23-24 39-40 96-97

24-25 40-41 97-98

25-26 64-65 98-99

26-27 65-66 99-100

27-28 66-67 100-101

28-29 67-68 101-102

29-30 68-69 102-103

30-31 69-70 103-104

31-32 70-71 104-105

32-33 89-90 105-106

33-34 90-91 106-107

34-35 91-92 107-108

35-36 92-93 108-109

36-37 93-94 109-110 37 -38 94 -95 110 - 111

38 -39 95 -96 respectively;

( III ) A human flt-3 receptor agonist polypeptide , comprising ; a modi f ied f lt-3 ligand amino acid sequence of the Formula :

ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg

10 20 GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp

30 40

GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu

50 60

LysThrValAlaGlySer ysMetGlnGly euLeuGluArgValAsnThrGluIleHis

70 80

PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 90 100

IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr

110 120 ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu

130 SEQ ID NO:466

wherein 1-7 amino acids are optionally deleted from the C-terminus of said flt3 receptor agonist polypeptide; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

28-29 42-43 93-94

29-30 64-65 94-95

30-31 65-66 95-96

31-32 66-67 96-97

32-33 86-87 97-98

34-35 87-88 98-99

36-37 88-89 99-100

37-38 89-90 100-101 38-39 90-91 101-102

39-40 91-92 102-103

40-41 92-93 respectively;

41-42

(IV) A polypeptide comprising; a modified human G-

CSF amino acid sequence of the formula:

1 10

Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser Xaa

20 Leu Leu Xaa Xaa Xaa Glu Gin Val Xaa Lys Xaa Gin Gly Xaa Gly

30 40

Ala Xaa Leu Gin Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa 50

Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly lie Pro Trp

60 70

Ala Pro Leu Ser Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly

80 Xaa Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

90 100 Leu Gin Ala Leu Glu Gly lie Ser Pro Glu Leu Gly Pro Thr Leu

110

Xaa Thr Leu Gin Xaa Asp Val Ala Asp Phe Ala Xaa Thr lie Trp 120 130

Gin Gin Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gin Pro Thr

140

Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa Gin Xaa Xaa Ala

150 160

Gly Gly Val Leu Val Ala Ser Xaa Leu Gin Xaa Phe Leu Xaa Xaa

170 Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gin Pro SEQ ID NO: 858

wherein

Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly; Xaa at position 2 is Pro or Leu;

Xaa at position 3 is Leu, Arg, Tyr or Ser;

Xaa at position 13 is Phe, Ser, His, Thr or Pro;

Xaa at position 16 is Lys, Pro, Ser, Thr or His;

Xaa at position 17 is Cys, Ser, Gly, Ala, lie, Tyr or &?

Arg ;

Xaa at position 18 is Leu, Thr, Pro, His, lie or Cys;

Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala;

Xaa at position 24 is lie, Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly;

Xaa at position 30 is Ala, lie, Leu or Gly;

Xaa at position 34 is Lys or Ser;

Xaa at position 36 is Cys or Ser;

Xaa at position 42 is Cys or Ser; Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu;

Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin, or Thr;

Xaa at position 46 is Glu, Arg, Phe, Arg, lie or Ala; Xaa at position 47 is Leu or Thr;

Xaa at position 49 is Leu, Phe, Arg or Ser;

Xaa at position 50 is Leu, lie, His, Pro or Tyr;

Xaa at position 54 is Leu or His;

Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gin, Lys, Leu or Cys;

Xaa at position 70 is Gin, Pro, Leu, Arg or Ser;

Xaa at position 74 is Cys or Ser;

Xaa at position 104 is Asp, Gly or Val;

Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gin or Gly;

Xaa at position 115 is Thr, His, Leu or Ala;

Xaa at position 120 is Gin, Gly, Arg, Lys or His

Xaa at position 123 is Glu, Arg, Phe or Thr

Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gin or Glu;

Xaa at position 146 is Arg or Gin;

Xaa at position 147 is Arg or Gin;

Xaa at position 156 is His, Gly or Ser;

Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly; Xaa at position 162 is Glu, Leu, Gly or Trp;

Xaa at position 163 is Val, Gly, Arg or Ala;

Xaa at position 169 is Arg, Ser, Leu, Arg or Cys;

Xaa at position 170 is His, Arg or Ser;

wherein 1-11 amino acids from the N-terminus and/or 1-5 amino acids from the C-terminus are optionally deleted from said modified human G-CSF amino acid sequence; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

38-39 62-63 123-124 39-40 63-64 124-125 40-41 64-65 125-126 41-42 65-66 126-127 42-43 66-67 128-129

43-44 67-68 128-129

45-46 68-69 129-130

48-49 69-70 130-131 49-50 70-71 131-132

52-53 71-72 132-133

53-54 91-92 133-134

54-55 92-93 134-135

55-56 93-94 135-136 56-57 94-95 136-137

57-58 95-96 137-138

58-59 96-97 138-139

59-60 97-98 139-140

60-61 98-99 140-141 61-62 99-100 141-142 or 142-143 respectively;

(V) A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula:

Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100 105 ²*?

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120

Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala He Phe SEQ ID NO: 859 125 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg;

Xaa at position 18 is Asn, His, Leu, He, Phe, Arg, or Gin;

Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala, or Cys; Xaa at position 20 is He, Cys, Gin, Glu, Arg, Pro, or Ala;

Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val or Gly; Xaa at position 23 is He, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 24 is He, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp;

Xaa at position 29 is Gin, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leu, or Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gin;

Xaa at position 32 is Leu, Val, Arg, Gin, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gin, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr, Arg, Ala, Phe, He or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val;

Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or lie;

Xaa at position 38 is Asn, or Ala;

Xaa at position 40 is Leu, Trp, or Arg; Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;

Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,

Gin, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp,

Glu, Asn, Gin, Ala or Pro; Xaa at position 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Lys,

Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin,

Lys, His, Ala, Tyr, He, Val or Gly;

Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu,

Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser,

Ala, He, Val, His, Phe, Met or Gin; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;

Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or

Met;

Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gin, Asn, Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gin, Glu, Arg, His,

Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position 58 is Leu, Ser, Asp, Arg, Gin, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or lie; Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, He, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro, or His;

Xaa at position 68 is Leu, Val, Trp, Ser, He, Phe, Thr, or His; Xaa at position 69 is Gin, Ala, Pro , Thr , Glu , Arg , Trp , Gly , or

Leu ;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is He, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gin, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gin;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly; Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu;

Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gin, Lys, His, Ala, or Pro; Xaa at position 95 is His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn,

Lys, Ser, Ala, Trp, Phe, He, or Tyr;

Xaa at position 96 is Pro, Lys, Tyr, Gly, He, or Thr; Xaa at position 97 is He, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, He, Asn, Leu, Asp, Ala, Thr,

Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is He, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gin, or

Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val,

Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu, or Gin; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,

Gin, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr, Leu, Lys, He, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gin, His, Ser,

Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu,

Ser, or Trp; Xaa at position 111 is Leu, lie, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe; Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, He, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,

Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or lie;

Xaa at position 117 is Thr, Ser, Asn, He, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg; Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin; Xaa at position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp, or Gly; Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His,

He, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; wherein from 0 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 ; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) , capable of joining the N-terminus to the C-terminus and having new C- and N-termini at amino acids;

26-27 49-50 83-84

27-28 50-51 84-85

28-29 51-52 85-86

29-30 52-53 86-87

30-31 53-54 87-88

31-32 54-55 88-89

32-33 64-65 89-90

33-34 65-66 90-91

34-35 66-67 91-92

35-36 67-68 92-93

36-37 68-69 97-98

37-38 69-70 98-99

38-39 70-71 99-100

39-40 71-72 100-101

40-41 72-73 101-102

41-42 82-83 102-103 or 103-104 respectively;

(VI) A polypeptide comprising; a modified human c- mpl ligand amino acid sequence of the formula:

SerProAlaProProAlaCysAspLeuArgValLeuSerLysLeuLeuArgAspSer 1 5 10 15

HisValLeuHisSerArgLeuSerGlnCysProGluValHisProLeuProThrPro 20 25 30 35

ValLeuLeuProAlaValAspPheSerLeuGlyGluTrpLysThrGlnMetGluGlu 40 45 50 55 ThrLysAlaGlnAspHeLeuGlyAlaValThrLeuLeuLeuGluGlyValMetAla 60 65 70 75

AlaArgGlyGlnLeuGlyProThrCysLeuSerSerLeuLeuGlyGlnLeuSerGly 80 85 90 95

GlnValArgLeuLeuLeuGlyAlaLeuGlnSerLeuLeuGlyThrGlnXaaXaaXaa 100 105 110 XaaGlyArgThrThrAlaHisLysAspProAsnAlallePheLeuSerPheGlnHis 115 120 125 130

LeuLeuArgGlyLysValArgPheLeuMetLeuValGlyGlySerThrLeuCysVal 135 140 145 150

Arg SEQ ID NO: 860 153

wherein;

Xaa at position 112 is deleted or Leu, Ala, Val, lie,

Pro, Phe, Trp, or Met;

Xaa at position 113 is deleted or Pro, Phe, Ala, Val,

Leu, lie, Trp, or Met; Xaa at position 114 is deleted or Pro, Phe, Ala, Val,

Leu, lie, Trp, or Met;

Xaa at position 115 is deleted or Gin, Gly, Ser, Thr,

Tyr, or Asn; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

26-27 51-52 108-109

27-28 52-53 109-110

28-29 53-54 110-111

29-30 54-55 111-112

30-31 55-56 112-113

32-33 56-57 113-114

33-34 57-58 114-115

34-35 58-59 115-116

36-37 59-60 116-117

37-38 78-79 117-118

38-39 79-80 118-119

40-41 80-81 119-120

41-42 81-82 120-121

42-43 82-83 121-122 43 -44 83 -84 122 -123

44-45 84 -85 123 -124

46-47 85 -86 124 -125

47 -48 86-87 125-126

48 -49 87 -88 126-127

50-51 88-89 or 127 -128 respectively;

(VII ) A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula :

Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

95 100 105

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120

Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala He Phe SEQ ID NO: 859 125 130 wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg;

Xaa at position 18 is Asn, His, Leu, He, Phe, Arg, or Gin;

Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala, or Cys;

Xaa at position 20 is He, Cys, Gin, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin,

Leu, Val or Gly;

Xaa at position 23 is He, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 24 is He, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp;

Xaa at position 29 is Gin, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leu, or

Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gin; Xaa at position 32 is Leu, Val, Arg, Gin, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gin, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr,

Arg, Ala, Phe, He or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val; Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or lie; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala;

Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,

Gin, Arg, Thr, Gly or Ser;

Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala or Pro;

Xaa at position 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Lys,

Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, He, Val or Gly;

Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;

Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, He, Val, His, Phe, Met or Gin;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;

Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gin, Asn, Lys, His, Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gin, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;

Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gin, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or lie;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, He, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro, or His; Xaa at position 68 is Leu, Val, Trp, Ser, He, Phe, Thr, or His;

Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or

Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg; =&1

Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp ;

Xaa at position 77 is He, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly, or Asp;

Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg; Xaa at position 81 is Leu, Gin, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn,

His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;

Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val; Xaa at position 85 is Leu, Asn, Val, or Gin;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser ;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He, or Met;

Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;

Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu ; Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gin, Lys, His,

Ala, or Pro;

Xaa at position 95 is His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn,

Lys, Ser, Ala, Trp, Phe, He, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, He, or Thr;

Xaa at position 97 is He, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, He, Asn, Leu, Asp, Ala, Thr,

Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;

Xaa at position 99 is He, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gin, or Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val,

Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu, or Gin;

Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;

Xaa at position 103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,

Gin, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr,

Leu, Lys, He, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gin, His, Ser,

Ala or Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu,

Ser , or Trp ; Xaa at position 111 is Leu, He, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,

Lys, Leu, He, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,

Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,

Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or lie;

Xaa at position 117 is Thr, Ser, Asn, He, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin;

Xaa at position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, He, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 ; and

(VIII) a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor; and

wherein L₁ is a linker capable of linking R₁ to R₂;

said hematopoietic protein can optionally be immediately preceded by (methionine^-1) , (alanine^-1) or (methionine^-2, alanine^'1) ;

with the proviso that at least R₁ or R₂ is selected from the polypeptide of formula (I) , (II), or (III); and.

2. A hematopoietic protein comprising; an amino acid sequence of the formula:

R.-L^R., R--L.-R,_, R R_2ι or R₂-R_x

wherein R₁ and R₂ are independently selected from the group consisting of;

(I) A human EPO receptor agonist polypeptide, comprising; a modified EPO amino acid sequence of the Formula:

AlaProProArgLeuIleCysAspSerArgValLeuGluArgTyrLeuLeuGluAlaLys

10 20 GluAlaGluAsnlleThrThrGlyCysAlaGluHisCysSerLeuAsnGluAsnlleThr

30 40

ValProAspThr ysValAsnPheTyrAlaTrpLysArgMetGluValGlyGlnGlnAla

50 60

ValGluValTrpGlnGlyLeuAlaLeuLeuSerGluAlaValLeuArgGlyGlnAlaLeu

70 80 ?Ϊ4

LeuValAsnSerSerGlnProTrpGluProLeuGlnLeuHisValAspLysAlaValSer

90 100 GlyLeuArgSerLeuThrThrLeuLeuArgAlaLeuGlyAlaGlnLysGluAlalleSer

110 120

ProProAspAlaAlaSerAlaAlaProLeuArgThrlleThrAlaAspThrPheArgLys

130 140

LeuPheArgValTyrSerAsnPheLeuArgGlyLysLeuLysLeuTyrThrGlyGluAla

150 160

CysArgThrGlyAspArg SEQ ID NO: 464 166

wherein 1-6 amino acids from the N-terminus and/or 1-5 from the C-terminus are optionally deleted from said EPO receptor agonist polypeptide; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

23-24 47-48 109-110

24-25 48-49 110-111

25-26 49-50 111-112

26-27 50-51 112-113

27-28 51-52 113-114

28-29 52-53 114-115

29-30 53-54 115-116

30-31 54-55 116-117

31-32 55-56 117-118

32-33 56-57 118-119

33-34 57-58 119-120

34-35 77-78 120-121

35-36 78-79 121-122

36-37 79-80 122-123

37-38 80-81 123-124

38-39 81-82 124-125

39-40 82-83 125-126 40-41 84-85 126-127 41-42 85 -86 127 -128 42 -43 86-87 128 -129 43 -44 87 -88 129 -130 44-45 88-89 130 -131 45 -46 108-109 131-132 46-47 respectively;

( II ) A human stem cell factor receptor agonist polypeptide , comprising ; a modified stem cell factor amino acid sequence of the Formula :

GluGlylleCysArgAsnArgValThrAsnAsnValLysAspValThrLysLeuValAla

10 20

AsnLeuProLysAspTyrMetlleThrLeuLysTyrValProGlyMetAspValLeuPro

30 40

SerHisCysTrpHeSerGluMetValValGlnLeuSerAspSerLeuThrAspLeuLeu 50 60

AspLysPheSerAsnlleSerGluGlyLeuSerAsnTyrSerllelleAspLysLeuVal

70 80 AsnlleValAspAspLeuValGluCysValLysGluAsnSerSerLysAspLeuLysLys

90 100

SerPheLysSerProGluProArgLeuPheThrProGluGluPhePheArgllePheAsn

110 120

ArgSerlleAspAlaPheLysAspPheValValAlaSerGluThrSerAspCysValVal

130 140

SerSerThrLeuSerProGluLysAspSerArgValSerValThrLysProPheMetLeu 150 160

ProProValAlaAla SEQ ID NO: 465 165

wherein 1-23 amino acids are optionally deleted from the C-terminus of said stem cell factor receptor agonist polypeptide; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

23-24 39-40 96-97

24-25 40-41 97-98

25-26 64-65 98-99

26-27 65-66 99-100

27-28 66-67 100-101

28-29 67-68 101-102

29-30 68-69 102-103

30-31 69-70 103-104

31-32 70-71 104-105

32-33 89-90 105-106

33-34 90-91 106-107

34-35 91-92 107-108

35-36 92-93 108-109

36-37 93-94 109-110

37-38 94-95 110-111

38-39 95-96 respectively;

(III) A human flt-3 receptor agonist polypeptide, comprising a modified flt-3 ligand amino acid sequence of the Formula:

ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg

10 20 GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp

30 40

GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu

50 60

LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis

70 80

PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn 90 100

IleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThr 110 120

ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu

130 SEQ ID N0:466

wherein 1-7 amino acids are optionally deleted from the C-terminus of said flt3 receptor agonist polypeptide; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L2) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

28-29 42-43 93-94

29-30 64-65 94-95

30-31 65-66 95-96

31-32 66-67 96-97

32-33 86-87 97-98

34-35 87-88 98-99

36-37 88-89 99-100

37-38 89-90 100-101

38-39 90-91 101-102

39-40 91-92 102-103

40-41 92-93 respectively;

41-42

(IV) A polypeptide comprising; a modified human IL-3 amino acid sequence of the formula:

Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

50 55 60 *5^"

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

80 85 90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

95 100 105

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120

Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala He Phe SEQ ID NO: 859 125 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg; Xaa at position 18 is Asn, His, Leu, He, Phe, Arg, or Gin; Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala, or Cys; Xaa at position 20 is He, Cys, Gin, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn,

Thr, Ser or Val; Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin, Leu, Val or Gly; Xaa at position 23 is He, Val, Ala, Gly, Trp, Lys, Phe,

Leu, Ser, or Arg;

Xaa at position 24 is He, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp; Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;

Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp;

Xaa at position 29 is Gin, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leu, or

Lys; Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gin; Xaa at position 32 is Leu, Val, Arg, Gin, Asn, Gly, Ala, or Glu; Xaa at position 33 is Pro, Leu, Gin, Ala, Thr, or Glu; Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr,

Arg, Ala, Phe, He or Met; Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val; Xaa at position 36 is Asp, Leu, or Val; Xaa at position 37 is Phe, Ser, Pro, Trp, or lie; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala;

Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,

Gin, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp,

Glu, Asn, Gin, Ala or Pro; Xaa at position 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Lys,

Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His; Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin,

Lys, His, Ala, Tyr, He, Val or Gly; Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro, or His; Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu,

Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp; Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser,

Ala, He, Val, His, Phe, Met or Gin; Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr; Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or

Met; Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gin, Asn, Lys, His, Ala or Leu;

Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gin, Glu, Arg, His,

Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly; Xaa at position 58 is Leu, Ser, Asp, Arg, Gin, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg; Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr; Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or lie;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;

Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys; Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, He, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro, or

His;

Xaa at position 68 is Leu, Val, Trp, Ser, He, Phe, Thr, or His; Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp, or Asn; Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin, or Leu; Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;

Xaa at position 77 is He, Ser, Arg, Thr, or Leu;

Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;

Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;

Xaa at position 81 is Leu, Gin, Gly, Ala, Trp, Arg, Val, or Lys;

Xaa at position 82 is Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn,

His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val;

Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;

Xaa at position 85 is Leu, Asn, Val, or Gin;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;

Xaa at position 87 is Leu, Ser, Trp, or Gly;

Xaa at position 88 is Ala, Lys, Arg, Val, or Trp; Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He, or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu; Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg; Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gin, Lys, His,

Ala, or Pro; Xaa at position 95 is His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn,

Lys, Ser, Ala, Trp, Phe, He, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, He, or Thr; Xaa at position 97 is He, Val, Lys, Ala, or Asn;

Xaa at position 98 is His, He, Asn, Leu, Asp, Ala, Thr,

Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is He, Leu, Arg, Asp, Val, Pro, Gin,

Gly, Ser, Phe, or His; Xaa at position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gin, or

Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val,

Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu, or Gin; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser;

Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu,

Gin, Lys, Ala, Phe, or Gly; Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr,

Leu, Lys, He, Asp, or His; Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly, or Pro;

Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gin, His, Ser,

Ala or Pro; Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly; Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu, Ser, or Trp;

Xaa at position 111 is Leu, He, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,

Lys, Leu, He, Val or Asn; Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;

Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,

Trp, or Met; Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,

Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or lie;

Xaa at position 117 is Thr, Ser, Asn, He, Trp, Lys, or Pro;

Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr; Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin;

Xaa at position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His,

He, Tyr, or Cys; Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids are optionally deleted from the C-terminus of said modified human IL-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 ;

(V) a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an inter leukin, and a hematopoietic growth factor;

wherein L₁ is a linker capable of linking R₁ to R₂; and

wherein said hematopoietic protein can optionally be immediately preceded by (methionine^-1) , (alanine^-1) or (methionine^-2, alanine^-1) ;

with the proviso that at least R₁ or R₂ is selected from the polypeptide of formula (I) , (II) , or (III) .

3. The hematopoietic protein as recited in claim 2 wherein the polypeptide of (IV) is selected from the from the group consisting of;

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu

Asp Val Asp He Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu

Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly

He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp

Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu

Glu Gin Ala Gin Glu Gin Gin SEQ ID NO : 803;

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu

Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala

Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp

Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu

Glu Gin Ala Gin Glu Gin Gin SEQ ID NO: 804;

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu

Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly

He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala

Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp

Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu

Glu Gin Ala Gin Glu Gin Gin SEQ ID NO: 805; and

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg

Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr

Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin SEQ ID NO: 806.

4. A hematopoietic protein comprising; an amino acid sequence of the formula:

R₁-L₁-R₂, R₂-L₁-R₁ R_x-R₂ or

wherein R^_^ is a polypeptide, comprising; a modified flt-3 ligand amino acid sequence of the Formula:

ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg

10 20

GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp 30 40

GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu

50 60 LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis

70 80

PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn

90 100

HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr

110 120

ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeu 130 SEQ ID N0:466

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

28-29 42-43 93-94

29-30 64-65 94-95

30-31 65-66 95-96

31-32 66-67 96-97

32-33 86-87 97-98

34-35 87-88 98-99

36-37 88-89 99-100

37-38 89-90 100-101

38-39 90-91 101-102

39-40 91-92 102-103

40-41 92-93 respectively; 41-42 ?32s

wherein R₂ is a polypeptide comprising; a modified human IL-3 amino acid sequence of the formula:

Ala Pro Met Thr Gin Thr Thr Ser Leu Lys Thr Ser Trp Val Asn 1 5 10 15

Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 80 85 90

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 95 100 105

Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 115 120

Xaa Xaa Xaa Gin Gin Thr Thr Leu Ser Leu Ala He Phe SEQ ID NO: 859

125 130

wherein Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gin, or Arg; Xaa at position 18 is Asn, His, Leu, He, Phe, Arg, or Gin; Xaa at position 19 is Met, Phe, He, Arg, Gly, Ala, or Cys; Xaa at position 20 is He, Cys, Gin, Glu, Arg, Pro, or Ala; Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gin, Asn, Thr, Ser or Val;

Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gin,

Leu, Val or Gly;

Xaa at position 23 is He, Val, Ala, Gly, Trp, Lys, Phe, Leu, Ser, or Arg;

Xaa at position 24 is He, Gly, Val, Arg, Ser, Phe, or Leu;

Xaa at position 25 is Thr, His, Gly, Gin, Arg, Pro, or Ala;

Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;

Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala; Xaa at position 28 is Lys, Arg, Leu, Gin, Gly, Pro, Val or Trp;

Xaa at position 29 is Gin, Asn, Leu, Pro, Arg, or Val;

Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gin, Ser, Leu, or

Lys;

Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gin; Xaa at position 32 is Leu, Val, Arg, Gin, Asn, Gly, Ala, or Glu;

Xaa at position 33 is Pro, Leu, Gin, Ala, Thr, or Glu;

Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gin, Thr,

Arg, Ala, Phe, He or Met;

Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gin, or Val; Xaa at position 36 is Asp, Leu, or Val;

Xaa at position 37 is Phe, Ser, Pro, Trp, or lie; Xaa at position 38 is Asn, or Ala; Xaa at position 40 is Leu, Trp, or Arg;

Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro; Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, He, Met or Ala; Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys,

Gin, Arg, Thr, Gly or Ser; Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gin, Ala or Pro;

Xaa at position 45 is Gin, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, He, Glu or His;

Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gin, Lys, His, Ala, Tyr, He, Val or Gly; Xaa at position 47 is He, Gly, Val, Ser, Arg, Pro, or His;

Xaa at position 48 is Leu, Ser, Cys, Arg, He, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn; Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;

Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser,

Ala, He, Val, His, Phe, Met or Gin;

Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His; Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;

Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or

Met;

Xaa at position 54 is Arg, Asp, He, Ser, Val, Thr, Gin, Asn,

Lys, His, Ala or Leu; Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;

Xaa at position 56 is Pro, Gly, Cys, Ser, Gin, Glu, Arg, His,

Thr, Ala, Tyr, Phe, Leu, Val or Lys; Xaa at position 57 is Asn or Gly;

Xaa at position 58 is Leu, Ser, Asp, Arg, Gin, Val, or Cys; Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;

Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;

Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;

Xaa at position 62 is Asn, His, Val, Arg, Pro, Thr, Asp, or lie;

Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val; Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;

Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;

Xaa at position 66 is Lys, He, Arg, Val, Asn, Glu, or Ser;

Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, He, Pro, or

His; Xaa at position 68 is Leu, Val, Trp, Ser, He, Phe, Thr, or His;

Xaa at position 69 is Gin, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or

Leu;

Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;

Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gin, Trp, or Asn;

Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;

Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;

Xaa at position 74 is He, Met, Thr, Pro, Arg, Gly, Ala;

Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gin, or Leu;

Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp; Xaa at position 77 is He, Ser, Arg, Thr, or Leu; Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg; Xaa at position 79 is Lys, Thr, Asn, Met, Arg, He, Gly, or Asp; Xaa at position 80 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg; Xaa at position 81 is Leu, Gin, Gly, Ala, Trp, Arg, Val, or Lys ; Xaa at position 82 is Leu, Gin, Lys, Trp, Arg, Asp, Glu, Asn,

His, Thr, Ser, Ala, Tyr, Phe, He, Met or Val; Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met; Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val; Xaa at position 85 is Leu, Asn, Val, or Gin;

Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys; Xaa at position 87 is Leu, Ser, Trp, or Gly; Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;

Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;

Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, He, or Met; Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His; Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, He or Leu; Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;

Xaa at position 94 is Arg, He, Ser, Glu, Leu, Val, Gin, Lys, His,

Ala, or Pro; Xaa at position 95 is His, Gin, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, He, or Tyr; Xaa at position 96 is Pro, Lys, Tyr, Gly, He, or Thr; Xaa at position 97 is He, Val, Lys, Ala, or Asn; Xaa at position 98 is His, He, Asn, Leu, Asp, Ala, Thr,

Glu, Gin, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro; Xaa at position 99 is He, Leu, Arg, Asp, Val, Pro, Gin, Gly, Ser, Phe, or His;

Xaa at position 100 is Lys, Tyr, Leu, His, Arg, He, Ser, Gin, or

Pro; Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, He, Leu, or Gin; Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro; Xaa at position 103 is Asp, or Ser; Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, b

Gin, Lys, Ala, Phe, or Gly;

Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gin, Tyr,

Leu, Lys, He, Asp, or His;

Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, He, Gly, or Pro; Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, He, Gin, His, Ser,

Ala or Pro;

Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;

Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gin, His, Glu,

Ser, or Trp; Xaa at position 111 is Leu, He, Arg, Asp, or Met;

Xaa at position 112 is Thr, Val, Gin, Tyr, Glu, His, Ser, or Phe;

Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp,

Lys, Leu, He, Val or Asn;

Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu; Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr,

Trp, or Met;

Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu,

Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gin, or lie;

Xaa at position 117 is Thr, Ser, Asn, He, Trp, Lys, or Pro; Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;

Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;

Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gin;

Xaa at position 121 is Ala, Ser, He, Asn, Pro, Lys, Asp, or Gly;

Xaa at position 122 is Gin, Ser, Met, Trp, Arg, Phe, Pro, His, He, Tyr, or Cys;

Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;

wherein from 1 to 14 amino acids are optionally deleted from the N-terminus and/or from 1 to 15 amino acids optionally deleted from the C-terminus of said modified human interleukin-3 amino acid sequence; and wherein from 1 to 44 of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; and

wherein L₁ is a linker capable of linking R_λ to R₂; and 73?

said hematopoietic protein can optionally be immediately preceded by (methionine^-1) , (alanine^-1) or (methionine^-2, alanine^-1) .

5. The hematopoeitic protein of claim 4 wherein R₂ is selected from the group consisting of;

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Ala Glu

Asp Val Asp He Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu Glu Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly

He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala

Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp

Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin SEQ ID NO: 803;

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys

Arg Pro Pro Asn Pro Leu Leu Asp Pro Asn Asn Leu Asn Ser Glu Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Thr Pro Asn Leu

Leu Ala Phe Val Arg Ala Val Lys His Leu Glu Asn Ala Ser Gly

He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala

Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp

Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu Gin Ala Gin Glu Gin Gin SEQ ID NO : 804;

Ala Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Val Pro Pro Ala Pro Leu Leu Asp Ser Asn Asn Leu Asn Ser Glu

Asp Met Asp He Leu Met Glu Arg Asn Leu Arg Leu Pro Asn Leu

Leu Ala Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly

He Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala

Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu

Glu Gin Ala Gin Glu Gin Gin SEQ ID NO: 805; and

Asn Cys Ser He Met He Asp Glu He He His His Leu Lys Arg Pro Pro Ala Pro Leu Leu Asp Pro Asn Asn Leu Asn Asp Glu Asp

Val Ser He Leu Met Asp Arg Asn Leu Arg Leu Pro Asn Leu Glu

Ser Phe Val Arg Ala Val Lys Asn Leu Glu Asn Ala Ser Gly He

Glu Ala He Leu Arg Asn Leu Gin Pro Cys Leu Pro Ser Ala Thr Ala Ala Pro Ser Arg His Pro He He He Lys Ala Gly Asp Trp

Gin Glu Phe Arg Glu Lys Leu Thr Phe Tyr Leu Val Thr Leu Glu

Gin Ala Gin Glu Gin Gin SEQ ID NO: 806.

6. A hematopoietic protein comprising; an amino acid sequence of the formula:

^Rι^~Lι-^R ₂' R2-L1-R1, ^Rι-^R ₂, or R₂-R₁

wherein R₁ is a polypeptide comprising; a modified flt-3 ligand amino acid sequence of the Formula:

ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg

10 20

GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp

30 40

GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu 50 60

LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis

70 80 PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn

90 100

HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr

110 120

ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsrSerSerThrLeu

130 SEQ ID NO: 466

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

28-29 42-43 93-94 29-30 64-65 94-95

30-31 65-66 95-96

31-32 66-67 96-97

32-33 86-87 97-98

34-35 87-88 98-99

36-37 88-89 99-100

37-38 89-90 100-101

38-39 90-91 101-102

39-40 91-92 102-103

40-41 92-93 respectively;

41-42

wherein R₂ is a factor selected from the group consisting of: a colony stimulating factor, a cytokine, a lymphokine, an interleukin, and a hematopoietic growth factor;

wherein L₂ is a linker capable of linking R₁ to R₂; and

said hematopoietic protein can optionally be immediately preceded by (methionine^-1) , (alanine^-1) or (methionine^-2, alanine^-1) .

7. A hematopoietic protein comprising; an amino acid sequence of the formula:

R₂-L₁-R₁, R₁-R₂. or R₂-R,

wherein R_χ is a polypeptide comprising; a modified flt-3 ligand amino acid sequence of the Formula :

ThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArg 10 20

GluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAsp

30 40 GluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeu

50 60

LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHis

70 80 PheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsn

90 100

HeSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThr

110 120

ArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAsrSerSerThrLeu

130 SEQ ID N0:466

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

28-29 42 -43 93-94 29-30 64-65 94-95 30-31 65-66 95-96 31-32 66-67 96-97 32 -33 86-87 97-98 34-35 87 -88 98-99 36-37 88-89 99-100 37 -38 89 -90 100-101 38-39 90-91 101-102 39 -40 91-92 102-103 40-41 92 -93 respectively; 41-42

wherein R₂ is a polypeptide, comprising; a modified human G-CSF amino acid sequence of the formula:

1 10

Xaa Xaa Xaa Gly Pro Ala Ser Ser Leu Pro Gin Ser Xaa

20 Leu Leu Xaa Xaa Xaa Glu Gin Val Xaa Lys Xaa Gin Gly Xaa Gly

30 40

Ala Xaa Leu Gin Glu Xaa Leu Xaa Ala Thr Tyr Lys Leu Xaa Xaa 50

Xaa Glu Xaa Xaa Val Xaa Xaa Gly His Ser Xaa Gly He Pro Trp

60 70

Ala Pro Leu Ser Ser Xaa Pro Ser Xaa Ala Leu Xaa Leu Ala Gly

80 Xaa Leu Ser Gin Leu His Ser Gly Leu Phe Leu Tyr Gin Gly Leu

90 100 Leu Gin Ala Leu Glu Gly He Ser Pro Glu Leu Gly Pro Thr Leu

110

Xaa Thr Leu Gin Xaa Asp Val Ala Asp Phe Ala Xaa Thr He Trp

120 130

Gin Gin Met Glu Xaa Xaa Gly Met Ala Pro Ala Leu Gin Pro Thr

140 Gin Gly Ala Met Pro Ala Phe Ala Ser Ala Xaa Gin Xaa Xaa Ala

150 160

Gly Gly Val Leu Val Ala Ser Xaa Leu Gin Xaa Phe Leu Xaa Xaa 170

Ser Tyr Arg Val Leu Xaa Xaa Leu Ala Gin Pro SEQ ID NO: 858

wherein Xaa at position 1 is Thr, Ser, Arg, Tyr or Gly;

Xaa at position 2 is Pro or Leu;

Xaa at position 3 is Leu, Arg, Tyr or Ser;

Xaa at position 13 is Phe, Ser, His, Thr or Pro;

Xaa at position 16 is Lys, Pro, Ser, Thr or His; Xaa at position 17 is Cys, Ser, Gly, Ala, lie, Tyr or Arg;

Xaa at position 18 is Leu, Thr, Pro, His, lie or Cys;

Xaa at position 22 is Arg, Tyr, Ser, Thr or Ala;

Xaa at position 24 is lie, Pro, Tyr or Leu; Xaa at position 27 is Asp, or Gly;

Xaa at position 30 is Ala, lie, Leu or Gly;

Xaa at position 34 is Lys or Ser;

Xaa at position 36 is Cys or Ser;

Xaa at position 42 is Cys or Ser; Xaa at position 43 is His, Thr, Gly, Val, Lys, Trp, Ala, Arg, Cys, or Leu;

Xaa at position 44 is Pro, Gly, Arg, Asp, Val, Ala, His, Trp, Gin, or Thr;

Xaa at position 46 is Glu, Arg, Phe, Arg, lie or Ala; Xaa at position 47 is Leu or Thr;

Xaa at position 49 is Leu, Phe, Arg or Ser;

Xaa at position 50 is Leu, lie, His, Pro or Tyr;

Xaa at position 54 is Leu or His;

Xaa at position 64 is Cys or Ser; Xaa at position 67 is Gin, Lys, Leu or Cys;

Xaa at position 70 is Gin, Pro, Leu, Arg or Ser;

Xaa at position 74 is Cys or Ser;

Xaa at position 104 is Asp, Gly or Val;

Xaa at position 108 is Leu, Ala, Val, Arg, Trp, Gin or Gly;

Xaa at position 115 is Thr, His, Leu or Ala;

Xaa at position 120 is Gin, Gly, Arg, Lys or His

Xaa at position 123 is Glu, Arg, Phe or Thr

Xaa at position 144 is Phe, His, Arg, Pro, Leu, Gin or Glu;

Xaa at position 146 is Arg or Gin; Xaa at position 147 is Arg or Gin;

Xaa at position 156 is His, Gly or Ser;

Xaa at position 159 is Ser, Arg, Thr, Tyr, Val or Gly;

Xaa at position 162 is Glu, Leu, Gly or Trp; Xaa at position 163 is Val, Gly, Arg or Ala;

Xaa at position 169 is Arg, Ser, Leu, Arg or Cys;

Xaa at position 170 is His, Arg or Ser;

wherein 1-11 amino acids from the N-terminus and/or 1-5 amino acids from the C-terminus are optionally deleted from said modified human G-CSF amino acid sequence; and

wherein the N-terminus is joined to the C-terminus directly or through a linker (L₂) capable of joining the N-terminus to the C-terminus and having new C- and N- termini at amino acids;

38-39 62-63 123-124 39-40 63-64 124-125

40-41 64-65 125-126

41-42 65-66 126-127

42-43 66-67 128-129

43-44 67-68 128-129 45-46 68-69 129-130

48-49 69-70 130-131

49-50 70-71 131-132

52-53 71-72 132-133

53-54 91-92 133-134 54-55 92-93 134-135

55-56 93-94 135-136

56-57 94-95 136-137

57-58 95-96 137-138

58-59 96-97 138-139 59-60 97-98 139-140

60-61 98-99 140-141

61-62 99-100 141-142 or 142-143 respectively;

wherein L_x is a linker capable of linking R_λ to R₂; and

said hematopoietic protein can optionally be immediately preceded by (methionine^-1) , (alanine^-1) or (methionine^-2, alanine^-1) .

8. The hematopoietic protein as recited in claim

1, 2, 3, 4, 5, 6 or 7 wherein said linker (L₂) is selected from the group consisting of; Ser; Asn

Gly

Thr

GlySer;

AlaAla; GlySerGly

GlyGlyGly

GlyAsnGly

GlyAlaGly

GlyThrGly AlaSerAla

AlaAlaAla;

GlyGlyGlySer SEQ ID NO: 778;

GlyGlyGlySerGlyGlyGlySer SEQ ID NO : 779;

GlyGlyGlySerGlyGlyGlySerGlyG±yGlySer SEQ ID NO : 780; SerGlyGlySerGlyGlySer SEQ ID NO : 781;

GluPheGlyAsnMet SEQ ID NO : 782;

GluPheGlyGlyAsnMet SEQ ID NO: 783;

GluPheGlyGlyAsnGlyGlyAsnMet SEQ ID NO : 784;

GlyGlySerAspMetAlaGly SEQ ID NO: 785; SerGlyGlyAsnGly SEQ ID NO : 786;

SerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO : 787; SerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGlyAsnGly SEQ ID NO : 788; SerGlyGlySerGlySerGlyGlySerGly SEQ ID NO : 789; SerGlyGlySerGlySerGlyGlySerGlySerGlyGlySerGly

SEQ ID NO : 790;

GlyGlyGlySerGlyGly SEQ ID NO : 791; GlyGlyGlySerGlyGlyGly SEQ ID NO : 792; GlyGlyGlySerGlyGlyGlySerGlyGly SEQ ID NO: 793; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGly SEQ ID NO : 794; GlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGly SEQ ID NO : 795 ;

GlyGlyGlySerGlyGlyGlySerGlyGlyG ySerGlyGlyG±ySerGly GlyGlySerGly SEQ ID NO: 796,•

ProProProTrpSerProArgProLeuGlyAlaThrAlaProThrAlaGly GlnProProLeu SEQ ID NO: 797;

ProProProTrpSerProArgProLeuGlyAlaThrAlaProThr SEQ ID NO: 798; and

ValGluThrValPheHisArgValSerGlnAspGlyLeuLeuThrSer SEQ ID NO: 799.

9. The hematopoietic protein as recited in claim 1 wherein said protein is selected from the group consisting of;

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe

TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID

NO : 581;

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro

LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer

ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAsp CysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGluLeuSer AspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 582; 3oS

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAsp PheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrVal AlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGln ArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO : 583;

AlaAsnCysSerlleMetHeAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe

TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaSerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGln ThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrp

HeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThr LeuSerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSer ProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAsp TyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SEQ ID NO : 584;

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIle lelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeu AlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeu GluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSer CysLeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeu ValAlaLeuLysProTrpHeThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCys GlnProAspSerSerThrLeuSerGlyGlyAsnGlySerGlyGlyAsnGlySerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu Gin SEQ ID NO: 585; AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLys HeArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeu GlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGlu ArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGlu HeHisPheValThrLysCysAlaPheGlnPro SEQ ID NO : 586;

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly IleGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHisSerProIleSerSer AspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProValThr ValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAla GlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeuLeuGlu ArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnPro SEQ ID NO : 587;

AlaAsnCysSerlleMetlleAspGluIlelleHisHisLeuLysArgProProAlaPro LeuLeuAspProAsnAsnLeuAsnAspGluAspValSerlleLeuMetAspArgAsnLeu ArgLeuProAsnLeuGluSerPheValArgAlaValLysAsnLeuGluAsnAlaSerGly HeGluAlalleLeuArgAsnLeuGlnProCysLeuProSerAlaThrAlaAlaProSer ArgHisProIlellelleLysAlaGlyAspTrpGlnGluPheArgGluLysLeuThrPhe TyrLeuValThrLeuGluGlnAlaGlnGluGlnGlnTyrValGluGlyGlyGlyGlySer ProGlyGluProSerGlyProIleSerThrlleAsnProSerProProSerLysGluSer HisLysSerProAsnMetAlaProProSerCysLeuArgPheValGlnThrAsnlleSer ArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpHeThrArgGln AsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSerThrLeuSerGlyGly AsnGlySerGlyGlyAsnGlySerGlyGlyAsnGlyThrGlnAspCysSerPheGlnHis SerProIleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGln AspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeuCysGlyGlyLeuTrp ArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMet GlnGlyLeuLeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGln Pro SEQ ID NO: 588; AlaAspGluGluLeuCysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArg eu LysThrValAlaGlySerLysMetGlnGlyLeuLeuGluArgValAsnThrGluIleHisPheVal Thr ysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeuLeuGlnAspTyrProVal ThrValAlaSerAsn euGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGly GlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSer LeuGluGlnValArgLysIleGlnGlyAspGlyAlaAla euGlnGluLysLeuCysAlaThrTyr LysLeuCysHisProGluGluLeuVal euLeuGlyHisSerLeuGlylleProTrpAlaProLeu SerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGly eu euGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThr euGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAla ProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHisLeu AlaGlnPro SEQ ID NO: 743;

AlaThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu LeuSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGlnAspGluGluLeu

CysGlyGlyLeuTrpArgLeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGly SerLysMetGlnGly euLeuGluArgValAsnThrGluIleHisPheValThr ysCysAlaPhe GlnProProProSerCys euArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSer GluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArgCysLeuGlu euGln CysGlnProAspSerSerThrLeuTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGly GlyGlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLys SerLeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLysLeuCysAlaThr Tyr ys euCysHisProGluGluLeuValLeuLeuGlyHisSerLeuGlylleProTrpAlaPro euSerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeu PheLeuTyrGlnGlyLeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThr euAsp

ThrLeuGlnLeuAspValAlaAspPheAlaT rThrlleTrpGlnGlnMetGluGluLeuGlyMet AlaProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAla GlyGlyValLeuValAlaSerHisLeuGlnSerPheLeuGluValSerTyrArgValLeuArgHis LeuAlaGlnPro SEQ ID NO: 659;

AlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSerLeuGluGlnVal Arg ysIleGlnGlyAspGlyAlaAlaLeuGlnGlu ys euCysAlaThrTyrLysLeuCysHis ProGluGluLeuValLeuLeuGlyHisSer euGlylleProTrpAlaProLeuSerSerCysPro SerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPheLeuTyrGlnGly LeuLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThr euAspThrLeuGln euAsp ValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAlaProAlaLeuGln ProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGlyGlyValLeuVal AlaSerHis euGlnSerPheLeuGluValSerTyrArgValLeuArgHis euAlaGlnProTyr ValGluGlyGlyGlyGlySerProGlyGluProSerGlyProIleSerThrlleAsnProSerPro ProSerLysGluSerHisLysSerProAsnMetAlaAspGluGluLeuCysGlyGlyLeuTrpArg LeuValLeuAlaGlnArgTrpMetGluArgLeuLysThrValAlaGlySerLysMetGlnGlyLeu LeuGluArgValAsnThrGluIleHisPheValThrLysCysAlaPheGlnProProProSerCys LeuArgPheValGlnThrAsnlleSerArgLeuLeuGlnGluThrSerGluGlnLeuValAlaLeu LysProTrpIleThrArgGlnAsnPheSerArgCysLeuGluLeuGlnCysGlnProAspSerSer ThrLeuGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySerGlyGlyGlySer GlyThrGlnAspCysSerPheGlnHisSerProIleSerSerAspPheAlaValLysIleArgGlu euSerAspTyrLeuLeuGlnAspTyrProValThrValAlaSerAsnLeuGln SEQ ID NO: 705; AlaAspGluGluLeuCysGlyGlyLeuTrpArg euValLeuAlaGlnArgTrpMetGluArgLeu LysThrValAlaGlySerLysMetGlnGly eu euGluArgValAsnThrGluIleHisPheVal ThrLysCysAlaPheGlnProProProSerCysLeuArgPheValGlnThrAsnlleSerArgLeu LeuGlnGluThrSerGluGlnLeuValAlaLeuLysProTrpIleThrArgGlnAsnPheSerArg CysLeuGluLeuGlnCysGlnProAspSerSerThrLeuGlyGlyGlySerGlyGlyGlySerGly GlyGlySerGlyGlyGlySerGlyGlyGlySerGlyThrGlnAspCysSerPheGlnHisSerPro IleSerSerAspPheAlaValLysIleArgGluLeuSerAspTyrLeu euGlnAspTyrProVal ThrValAlaSerAsnLeuGlnTyrValGluGlyGlyGlyGlySerProGlyGlyGlySerGlyGly GlySerAsnMetAlaThrProLeuGlyProAlaSerSerLeuProGlnSerPheLeuLeuLysSer LeuGluGlnValArgLysIleGlnGlyAspGlyAlaAlaLeuGlnGluLys euCysAlaThrTyr LysLeuCysHisProGluGluLeuValLeu euGlyHisSerLeuGlylleProTrpAlaPro eu SerSerCysProSerGlnAlaLeuGlnLeuAlaGlyCysLeuSerGlnLeuHisSerGlyLeuPhe LeuTyrGlnGly euLeuGlnAlaLeuGluGlylleSerProGluLeuGlyProThrLeuAspThr LeuGlnLeuAspValAlaAspPheAlaThrThrlleTrpGlnGlnMetGluGluLeuGlyMetAla ProAlaLeuGlnProThrGlnGlyAlaMetProAlaPheAlaSerAlaPheGlnArgArgAlaGly GlyValLeuValAlaSerHisLeuGlnSerPhe euGluValSerTyrArgValLeuArgHisLeu AlaGlnPro SEQ ID NO: 743.

11. The hematopoietic protein of claim 1, 2 or 6 , wherein said colony stimulating factor is selected from

17 the group consisting of GM-CSF, G-CSF, G-CSF Ser , c- mpl ligand (TPO), M-CSF, erythropoietin (EPO), IL-1, IL- 4, IL-2, IL-3, IL-5, IL 6, IL-7, IL-8, IL-9, IL-10, IL- 11, IL-12, IL-13, IL-15, LIF, flt3/flk2 ligand, human growth hormone, B-cell growth factor, B-cell differentiation factor, eosinophil differentiation factor and stem cell factor (SCF) .

12. The hematopoietic protein of claim 11 wherein said colony stimulating factor is selected from the

1 _, 17 group consisting of G-CSF, G-CSF Ser , G-CSF Ala and c-mpl ligand (TPO) .

13. A nucleic acid molecule encoding said hematopoietic protein of claim 1.

14. A nucleic acid molecule encoding said hematopoietic protein of claim 2.

15. A nucleic acid molecule encoding said hematopoietic protein of claim 3. ?cβ

16. A nucleic acid molecule encoding said hematopoietic protein of claim 4.

17. A nucleic acid molecule encoding said hematopoietic protein of claim 5.

18. A nucleic acid molecule encoding said hematopoietic protein of claim 6.

19. A nucleic acid molecule encoding said hematopoietic protein of claim 7.

20. A nucleic acid molecule encoding said hematopoietic protein of claim 8.

21. A nucleic acid molecule encoding said hematopoietic protein of claim .

22. A nucleic acid molecule encoding said hematopoietic protein of claim 10.

23. A nucleic acid molecule encoding said hematopoietic protein of claim 11.

24. The nucleic acid molecule according to claim 13 selected from group consisting of;

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG

TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO : 121;

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCGACGAGGAG CTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCG GCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGA ACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT

AACGGATCCGGTGGCAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG CAG SEQ ID NO: 122;

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG

CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGCGGCAACGGCACGCAGGACTGCTCCTTCCAAC

ACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGAC TACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGA GGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGG AGCGGCTCAAGACTGTCGCTGGG SEQ ID NO : 123;

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG ?//

TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGAGGTAATGGCACCCAGG ACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATC CGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTC CAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGG CACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGG SEQ ID NO : 124;

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCTCCAAGATG CAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATG TGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCT CCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGG ATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGA CTCCTCAACCCTGTCTGGAGGTAACGGATCCGGTGGCAATGGGAGCGGCG GAAATGGAACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGAC

TTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCC AGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCT GGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCT GGG SEQ ID NO : 125;

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC

TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGCGGC AACGGCACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTT CGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAG

TCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTCTGCGGGGGCCTCTGG CGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTG TCACCAAATGTGCCTTTCAGCCC SEQ ID NO : 126;

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA

TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCAGGCGGT AACGGCAGTGGAGGTAATGGCACCCAGGACTGCTCCTTCCAACACAGCCC CATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGC TTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCTC TGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCT CAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACA CGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCC SEQ ID NO: 127;

GCTAACTGCTCTATAATGATCGATGAAATTATACATCACTTAAAGAGACC ACCTGCACCTTTGCTGGACCCGAACAACCTCAATGACGAAGACGTCTCTA TCCTGATGGACCGAAACCTTCGACTTCCAAACCTGGAGAGCTTCGTAAGG GCTGTCAAGAACTTAGAAAATGCATCAGGTATTGAGGCAATTCTTCGTAA TCTCCAACCATGTCTGCCCTCTGCCACGGCCGCACCCTCTCGACATCCAA TCATCATCAAGGCAGGTGACTGGCAAGAATTCCGGGAAAAACTGACGTTC TATCTGGTTACCCTTGAGCAAGCGCAGGAACAACAGTACGTAGAGGGCGG TGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGT CTCCTCCGTCTAAAGAATCTCATAAATCTCCAAACATGGCCCCCCCCAGC TGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC

CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCC GGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGTCTGGAGGT AACGGCAGTGGTGGTAATGGGAGCGGCGGAAATGGAACCCAGGACTGCTC CTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGC TGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTG

CAGGACGAGGAGCTCTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCG CTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGC TGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAG CCC SEQ ID NO : 128;

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTAC AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCC CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT GCGCAGCCG SEQ ID NO : 282;

GGCCACTCAGGACTGCTCTTTTCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGA GCTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAGGACGAGGAGCT

CTGCGGGGGCCTCTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGG ?/3

GTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTT TCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTC CGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCA GTGTCAGCCCGACTCCTCAACCCTGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGG CGGCGGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAA GTCTTTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCAC CTACAAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCC CCTGAGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCT TTTCCTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGA CACACTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAAT GGCCCCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGC AGGAGGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCA CCTTGCGCAGCCG SEQ ID NO: 198; GCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCTTTAGAGCAAGTG AGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTACAAGCTGTGCCAC CCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTGAGCTCCTGCCCC AGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTCCTCTACCAGGGG CTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACACTGCAGCTGGAC GTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCCCCTGCCCTGCAG

CCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGAGGGGTCCTGGTT GCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTTGCGCAGCCCTAC GTAGAGGGCGGTGGAGGCTCCCCGGGTGAACCGTCTGGTCCAATCTCTACTATCAACCCGTCTCCT CCGTCTAAAGAATCTCATAAATCTCCAAACATGGCTGATGAAGAACTGTGTGGTGGTCTGTGGCGG CTGGTCCTGGCACAGCGCTGGATGGAGCGGCTCAAGACTGTCGCTGGGTCCAAGATGCAAGGCTTG CTGGAGCGCGTGAACACGGAGATACACTTTGTCACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGT CTTCGCTTCGTCCAGACCAACATCTCCCGCCTCCTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTG AAGCCCTGGATCACTCGCCAGAACTTCTCCCGGTGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCA ACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGAGGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGT GGTACCCAGGACTGCTCCTTCCAACACAGCCCCATCTCCTCCGACTTCGCTGTCAAAATCCGTGAG

CTGTCTGACTACCTGCTTCAAGATTACCCAGTCACCGTGGCCTCCAACCTGCAG SEQ ID NO: 244;

GCTGATGAAGAACTGTGTGGTGGTCTGTGGCGGCTGGTCCTGGCACAGCGCTGGATGGAGCGGCTC AAGACTGTCGCTGGGTCCAAGATGCAAGGCTTGCTGGAGCGCGTGAACACGGAGATACACTTTGTC ACCAAATGTGCCTTTCAGCCCCCCCCCAGCTGTCTTCGCTTCGTCCAGACCAACATCTCCCGCCTC CTGCAGGAGACCTCCGAGCAGCTGGTGGCGCTGAAGCCCTGGATCACTCGCCAGAACTTCTCCCGG TGCCTGGAGCTGCAGTGTCAGCCCGACTCCTCAACCCTGGGCGGTGGGTCAGGAGGTGGGTCAGGA GGTGGATCCGGAGGTGGCTCAGGGGGAGGTAGTGGTACCCAGGACTGCTCCTTCCAACACAGCCCC ATCTCCTCCGACTTCGCTGTCAAAATCCGTGAGCTGTCTGACTACCTGCTTCAAGATTACCCAGTC ACCGTGGCCTCCAACCTGCAGTACGTAGAGGGCGGTGGAGGCTCCCCGGGTGGTGGTTCTGGCGGC GGCTCCAACATGGCTACACCATTGGGCCCTGCCAGCTCCCTGCCCCAGAGCTTCCTGCTCAAGTCT TTAGAGCAAGTGAGAAAGATCCAGGGCGATGGCGCAGCGCTCCAGGAGAAGCTGTGTGCCACCTAC AAGCTGTGCCACCCCGAGGAGCTGGTGCTGCTCGGACACTCTCTGGGCATCCCCTGGGCTCCCCTG AGCTCCTGCCCCAGCCAGGCCCTGCAGCTGGCAGGCTGCTTGAGCCAACTCCATAGCGGCCTTTTC CTCTACCAGGGGCTCCTGCAGGCCCTGGAAGGGATATCCCCCGAGTTGGGTCCCACCTTGGACACA CTGCAGCTGGACGTCGCCGACTTTGCCACCACCATCTGGCAGCAGATGGAAGAACTGGGAATGGCC CCTGCCCTGCAGCCCACCCAGGGTGCCATGCCGGCCTTCGCCTCTGCTTTCCAGCGCCGGGCAGGA GGGGTCCTGGTTGCTAGCCATCTGCAGAGCTTCCTGGAGGTGTCGTACCGCGTTCTACGCCACCTT GCGCAGCCG SEQ ID NO: 282.

25. A method of producing a hematopoietic protein comprising: growing under suitable nutrient conditions, a host cell transformed or transfected with a replicable vector comprising a nucleic acid molecule of claim 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 in a manner allowing expression of said hematopoietic protein and recovering said hematopoietic protein.

26. A pharmaceutical composition comprising; the hematopoietic protein according to claim 1, 2, 3, 4, 5, 6, 7, 9, or 10; and a pharmaceutically acceptable carrier.

27. A method of stimulating the production of hematopoietic cells in a patient comprising the step of; administering an effective amount of the hematopoietic protein as recited in claim 1, 2, 3, 4, 5, 6, 7, 9 or 10 to said patient .

28. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of; (a) culturing said hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1; and

(b) harvesting said cultured cells.

29. A method for selective ex vivo expansion of hematopoietic cells, comprising the steps of;

(a) separating hematopoietic cells from other cells;

(b) culturing said separated hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1; and

(c) harvesting said cultured cells.

30. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of;

(a) removing hematopoietic cells from said patient; (b) culturing said hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1;

(c) harvesting said cultured cells; and

(d) transplanting said cultured cells into said patient.

31. A method for treatment of a patient having a hematopoietic disorder, comprising the steps of; (a) removing hematopoietic cells from said patient;

(b) separating hematopoietic cells from other cells;

(c) culturing said separated hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1;

(d) harvesting said cultured cells; and

(e) transplanting said cultured cells into said patient .

32. A method of human gene therapy, comprising the steps of;

(a) removing hematopoietic cells from a patient;

(b) separating said hematopoietic cells from other cells; (c) culturing said separated hematopoietic cells in a culture medium comprising; the hematopoietic protein of claim 1;

(d) introducing DNA into said cultured cells;

(e) harvesting said transduced cells; and (f) transplanting said transduced cells into said patient .

33. The method according to claim 28, 29, 30, 31 or 32 wherein said hematopoietic cells are CD34+ cells.

34. The method according to claim 28, 29, or 30, 31 or 32 wherein said hematopoietic cells are peripheral blood cells.

35. A method for the production of dendritic cells comprising the steps of;

a) separating hematopoietic progenitor cells or CD34+ cells from other cells; and

b) culturing said hematopoietic progenitor cells or CD34+ cells in a growth medium, comprising the hematopoietic protein of claim 1, 2, 3 or 4.

36. The method of claim 35, further comprising the step of; c) pulsing said culturing hematopoietic progenitor cells or CD34+ cells with an antigen.

37. The method of claim 35, wherein said growth medium, further comprises; one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

38. The method of claim 36, wherein said growth medium, further comprises; one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

39. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of; administering the hematopoietic protein of claim 1, 2, 3, or 4, to said human.

40. The method of claim 39, further comprising; administrating one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

41. The method of claim 39, further comprising the step of; administering an antigen to said patient.

42. The method of claim 40, further comprising the step of; administering an antigen to said patient.

43. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of; a) mobilizing dendritic cell progenitors or mature dendritic cells by administering the hematopoietic protein of claim 1 to said human;

b) removing said dendritic cell precursors or mature dendritic cells by a blood draw or pheresis;

c) pulsing said dendritic cell precursors or mature dendritic cells with an antigen; and

d) returning said antigen pulsed dendritic cell precursors or mature dendritic cells to said human.

44. The method of claim 43, further comprising; administering in step a) , one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

45. The method of claim 43, further comprising the step of; culturing said dendritic cell precursors or mature dendritic cells from step b) , in a growth medium, comprising; the hematopoietic protein of claim 1, 2, 3 or 4.

46. The method of claim 44, further comprising the step of; culturing said dendritic cell precursors or mature dendritic cells from step b) , in a growth medium, comprising; the hematopoietic protein of claim 1, 2, 3 or 4.

47. The method of claim 45, wherein said growth medium, further comprises one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

48. The method of claim 46, wherein said growth medium, further comprises one or more factor selected from the group consisting of; GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

49. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of; a) removing hematopoietic progenitor cells or CD34+ cells from said human by a blood draw or pheresis;

b) culturing said hematopoietic progenitor cells or CD34+ cells in a growth medium, comprising the 7

hematopoietic protein of claim 1 to produce dendritic cell precursors or mature dendritic cells;

c) returning said dendritic cell precursors or mature dendritic cells to said human.

50. A method for treating a human having a tumor, infection or auto-immune disease, comprising the step of;

a) removing hematopoietic progenitor cells or CD34+ cells from said patient by a blood draw or pheresis;

b) culturing said hematopoietic progenitor cells or CD34+ cells in a growth medium, comprising; the hematopoietic protein of claim 1 to produce dendritic cell precursors or mature dendritic cells;

c) pulsing said dendritic cell precursors or mature dendritic cells with an antigen; and

d) returning said antigen pulsed dendritic cell precursors or mature dendritic cells to said human.

51. The method of claim 49, further comprising the step of; separating said hematopoietic progenitor cells or CD34+ cells from other cells prior to culturing.

52. The method of claim 50, further comprising the step of; separating said hematopoietic progenitor cells or CD34+ cells from other cells prior to culturing.

53. The method of claim 51, wherein said culture medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

54. The method of claim 50, wherein said culture medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

55. The method of claim 51, wherein said culture medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.

56. The method of claim 52, wherein said culture medium further comprises; one or more factor selected from the group consisting of: GM-CSF, IL-4, TNF-α, stem cell factor (SCF), flt-3 ligand, IL-3, an IL-3 variant, an IL-3 variant fusion protein, and a multi-functional receptor agonist.